{"cells":[{"cell_type":"code","source":["dbutils.fs.ls (\"/FileStore/tables/\")"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"39ee4f9a-5165-433b-a9a7-f9d769396ee4"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[30]: [FileInfo(path='dbfs:/FileStore/tables/Assignment_DFs_MRU.ipynb', name='Assignment_DFs_MRU.ipynb', size=32526, modificationTime=1646080082000),\n FileInfo(path='dbfs:/FileStore/tables/Assignment_DFs_MRU_1_-1.ipynb', name='Assignment_DFs_MRU_1_-1.ipynb', size=32526, modificationTime=1651570575000),\n FileInfo(path='dbfs:/FileStore/tables/Assignment_DFs_MRU_1_-2.ipynb', name='Assignment_DFs_MRU_1_-2.ipynb', size=32526, modificationTime=1651570604000),\n FileInfo(path='dbfs:/FileStore/tables/Assignment_DFs_MRU_1_.ipynb', name='Assignment_DFs_MRU_1_.ipynb', size=32526, modificationTime=1651570328000),\n FileInfo(path='dbfs:/FileStore/tables/accounts.zip', name='accounts.zip', size=5297592, modificationTime=1645020911000),\n FileInfo(path='dbfs:/FileStore/tables/character_counting.ipynb', name='character_counting.ipynb', size=25386, modificationTime=1645728848000),\n FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2019.csv', name='clinicaltrial_2019.csv', size=42400056, modificationTime=1651570063000),\n FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2019_csv', name='clinicaltrial_2019_csv', size=42400056, modificationTime=1651570054000),\n FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2019_csv.gz', name='clinicaltrial_2019_csv.gz', size=10060669, modificationTime=1647434452000),\n FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2020_csv.gz', name='clinicaltrial_2020_csv.gz', size=10981608, modificationTime=1647434439000),\n FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2021.csv', name='clinicaltrial_2021.csv', size=50359696, modificationTime=1651967260000),\n FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2021_csv.gz', name='clinicaltrial_2021_csv.gz', size=11921810, modificationTime=1647434422000),\n FileInfo(path='dbfs:/FileStore/tables/data_scrubbing_using_rdds__1_.ipynb', name='data_scrubbing_using_rdds__1_.ipynb', size=16994, modificationTime=1646080600000),\n FileInfo(path='dbfs:/FileStore/tables/devicestatus-1.zip', name='devicestatus-1.zip', size=23873574, modificationTime=1645373229000),\n FileInfo(path='dbfs:/FileStore/tables/json_activations-1.zip', name='json_activations-1.zip', size=8411369, modificationTime=1645008118000),\n FileInfo(path='dbfs:/FileStore/tables/json_activations-2.zip', name='json_activations-2.zip', size=8411369, modificationTime=1645276448000),\n FileInfo(path='dbfs:/FileStore/tables/json_activations.zip', name='json_activations.zip', size=8411369, modificationTime=1645006664000),\n FileInfo(path='dbfs:/FileStore/tables/letter_frequencies.txt', name='letter_frequencies.txt', size=2593894, modificationTime=1646068033000),\n FileInfo(path='dbfs:/FileStore/tables/logs.zip', name='logs.zip', size=18168065, modificationTime=1645020835000),\n FileInfo(path='dbfs:/FileStore/tables/mesh-1.csv', name='mesh-1.csv', size=5295548, modificationTime=1647434403000),\n FileInfo(path='dbfs:/FileStore/tables/mesh.csv', name='mesh.csv', size=5295548, modificationTime=1647434385000),\n FileInfo(path='dbfs:/FileStore/tables/pharma.csv', name='pharma.csv', size=678999, modificationTime=1647434406000),\n FileInfo(path='dbfs:/FileStore/tables/spark_sql.ipynb', name='spark_sql.ipynb', size=10821, modificationTime=1646508801000),\n FileInfo(path='dbfs:/FileStore/tables/webpage.zip', name='webpage.zip', size=1582, modificationTime=1646216400000)]","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[30]: [FileInfo(path='dbfs:/FileStore/tables/Assignment_DFs_MRU.ipynb', name='Assignment_DFs_MRU.ipynb', size=32526, modificationTime=1646080082000),\n FileInfo(path='dbfs:/FileStore/tables/Assignment_DFs_MRU_1_-1.ipynb', name='Assignment_DFs_MRU_1_-1.ipynb', size=32526, modificationTime=1651570575000),\n FileInfo(path='dbfs:/FileStore/tables/Assignment_DFs_MRU_1_-2.ipynb', name='Assignment_DFs_MRU_1_-2.ipynb', size=32526, modificationTime=1651570604000),\n FileInfo(path='dbfs:/FileStore/tables/Assignment_DFs_MRU_1_.ipynb', name='Assignment_DFs_MRU_1_.ipynb', size=32526, modificationTime=1651570328000),\n FileInfo(path='dbfs:/FileStore/tables/accounts.zip', name='accounts.zip', size=5297592, modificationTime=1645020911000),\n FileInfo(path='dbfs:/FileStore/tables/character_counting.ipynb', name='character_counting.ipynb', size=25386, modificationTime=1645728848000),\n FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2019.csv', name='clinicaltrial_2019.csv', size=42400056, modificationTime=1651570063000),\n FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2019_csv', name='clinicaltrial_2019_csv', size=42400056, modificationTime=1651570054000),\n FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2019_csv.gz', name='clinicaltrial_2019_csv.gz', size=10060669, modificationTime=1647434452000),\n FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2020_csv.gz', name='clinicaltrial_2020_csv.gz', size=10981608, modificationTime=1647434439000),\n FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2021.csv', name='clinicaltrial_2021.csv', size=50359696, modificationTime=1651967260000),\n FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2021_csv.gz', name='clinicaltrial_2021_csv.gz', size=11921810, modificationTime=1647434422000),\n FileInfo(path='dbfs:/FileStore/tables/data_scrubbing_using_rdds__1_.ipynb', name='data_scrubbing_using_rdds__1_.ipynb', size=16994, modificationTime=1646080600000),\n FileInfo(path='dbfs:/FileStore/tables/devicestatus-1.zip', name='devicestatus-1.zip', size=23873574, modificationTime=1645373229000),\n FileInfo(path='dbfs:/FileStore/tables/json_activations-1.zip', name='json_activations-1.zip', size=8411369, modificationTime=1645008118000),\n FileInfo(path='dbfs:/FileStore/tables/json_activations-2.zip', name='json_activations-2.zip', size=8411369, modificationTime=1645276448000),\n FileInfo(path='dbfs:/FileStore/tables/json_activations.zip', name='json_activations.zip', size=8411369, modificationTime=1645006664000),\n FileInfo(path='dbfs:/FileStore/tables/letter_frequencies.txt', name='letter_frequencies.txt', size=2593894, modificationTime=1646068033000),\n FileInfo(path='dbfs:/FileStore/tables/logs.zip', name='logs.zip', size=18168065, modificationTime=1645020835000),\n FileInfo(path='dbfs:/FileStore/tables/mesh-1.csv', name='mesh-1.csv', size=5295548, modificationTime=1647434403000),\n FileInfo(path='dbfs:/FileStore/tables/mesh.csv', name='mesh.csv', size=5295548, modificationTime=1647434385000),\n FileInfo(path='dbfs:/FileStore/tables/pharma.csv', name='pharma.csv', size=678999, modificationTime=1647434406000),\n FileInfo(path='dbfs:/FileStore/tables/spark_sql.ipynb', name='spark_sql.ipynb', size=10821, modificationTime=1646508801000),\n FileInfo(path='dbfs:/FileStore/tables/webpage.zip', name='webpage.zip', size=1582, modificationTime=1646216400000)]"]}}],"execution_count":0},{"cell_type":"code","source":["clinicaltrial_2021=\"/FileStore/tables/clinicaltrial_2021.csv\" #file location for clinicaltrial_2021 after uploading datasets\nmesh=\"/FileStore/tables/mesh.csv\"; #file location for mesh file after uploading datasets\npharma=\"/FileStore/tables/pharma.csv\"\n##file location for pharma file after uploading datasets"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"Loading the input data","showTitle":true,"inputWidgets":{},"nuid":"e1832c7e-2e06-4e8a-b43b-800223393a94"}},"outputs":[],"execution_count":0},{"cell_type":"code","source":["clinicrdd= sc.textFile(clinicaltrial_2021)  # read from text file words.txt on DBFS\nclinicrdd.take(5)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"66b79294-ffa3-4056-83cb-5107e594e467"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[32]: ['Id|Sponsor|Status|Start|Completion|Type|Submission|Conditions|Interventions',\n 'NCT02758028|The University of Hong Kong|Recruiting|Aug 2005|Nov 2021|Interventional|Apr 2016||',\n 'NCT02751957|Duke University|Completed|Jul 2016|Jul 2020|Interventional|Apr 2016|Autistic Disorder,Autism Spectrum Disorder|',\n 'NCT02758483|Universidade Federal do Rio de Janeiro|Completed|Mar 2017|Jan 2018|Interventional|Apr 2016|Diabetes Mellitus|',\n 'NCT02759848|Istanbul Medeniyet University|Completed|Jan 2012|Dec 2014|Observational|May 2016|Tuberculosis,Lung Diseases,Pulmonary Disease|']","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[32]: ['Id|Sponsor|Status|Start|Completion|Type|Submission|Conditions|Interventions',\n 'NCT02758028|The University of Hong Kong|Recruiting|Aug 2005|Nov 2021|Interventional|Apr 2016||',\n 'NCT02751957|Duke University|Completed|Jul 2016|Jul 2020|Interventional|Apr 2016|Autistic Disorder,Autism Spectrum Disorder|',\n 'NCT02758483|Universidade Federal do Rio de Janeiro|Completed|Mar 2017|Jan 2018|Interventional|Apr 2016|Diabetes Mellitus|',\n 'NCT02759848|Istanbul Medeniyet University|Completed|Jan 2012|Dec 2014|Observational|May 2016|Tuberculosis,Lung Diseases,Pulmonary Disease|']"]}}],"execution_count":0},{"cell_type":"code","source":["header = clinicrdd.first() #declared that header is the first row of the RDD \nclinicrdd1=clinicrdd.filter(lambda line: line != header) #filter() function was used to filter the rows from RDD that is not header (first row) to return a new RDD\nclinicrdd1.take(5) #take and display five rows of the new RDD"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"637030cf-b972-4431-9de4-1be8df5e1563"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[33]: ['NCT02758028|The University of Hong Kong|Recruiting|Aug 2005|Nov 2021|Interventional|Apr 2016||',\n 'NCT02751957|Duke University|Completed|Jul 2016|Jul 2020|Interventional|Apr 2016|Autistic Disorder,Autism Spectrum Disorder|',\n 'NCT02758483|Universidade Federal do Rio de Janeiro|Completed|Mar 2017|Jan 2018|Interventional|Apr 2016|Diabetes Mellitus|',\n 'NCT02759848|Istanbul Medeniyet University|Completed|Jan 2012|Dec 2014|Observational|May 2016|Tuberculosis,Lung Diseases,Pulmonary Disease|',\n 'NCT02758860|University of Roma La Sapienza|Active, not recruiting|Jun 2016|Sep 2020|Observational [Patient Registry]|Apr 2016|Diverticular Diseases,Diverticulum,Diverticulosis|']","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[33]: ['NCT02758028|The University of Hong Kong|Recruiting|Aug 2005|Nov 2021|Interventional|Apr 2016||',\n 'NCT02751957|Duke University|Completed|Jul 2016|Jul 2020|Interventional|Apr 2016|Autistic Disorder,Autism Spectrum Disorder|',\n 'NCT02758483|Universidade Federal do Rio de Janeiro|Completed|Mar 2017|Jan 2018|Interventional|Apr 2016|Diabetes Mellitus|',\n 'NCT02759848|Istanbul Medeniyet University|Completed|Jan 2012|Dec 2014|Observational|May 2016|Tuberculosis,Lung Diseases,Pulmonary Disease|',\n 'NCT02758860|University of Roma La Sapienza|Active, not recruiting|Jun 2016|Sep 2020|Observational [Patient Registry]|Apr 2016|Diverticular Diseases,Diverticulum,Diverticulosis|']"]}}],"execution_count":0},{"cell_type":"code","source":["meshrdd= sc.textFile(mesh)   # read from text file words.txt on DBFS \nmeshrdd.collect()"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"b9d94a5f-b0f7-4cc8-b031-923c4987b3a2"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[34]: ['term,tree',\n 'Calcimycin,D03.633.100.221.173',\n 'A-23187,D03.633.100.221.173',\n 'Temefos,D02.705.400.625.800',\n 'Temefos,D02.705.539.345.800',\n 'Temefos,D02.886.300.692.800',\n 'Abate,D02.705.400.625.800',\n 'Abate,D02.705.539.345.800',\n 'Abate,D02.886.300.692.800',\n 'Difos,D02.705.400.625.800',\n 'Difos,D02.705.539.345.800',\n 'Difos,D02.886.300.692.800',\n 'Abattoirs,J01.576.423.200.700.100',\n 'Abattoirs,J03.540.020',\n 'Abbreviations as Topic,L01.559.598.400.556.131',\n 'Acronyms as Topic,L01.559.598.400.556.131',\n 'Abdomen,A01.923.047',\n '\"Abdomen, Acute\",C23.888.592.612.054.200',\n '\"Abdomen, Acute\",C23.888.821.030.249',\n 'Abdominal Injuries,C26.017',\n 'Abdominal Neoplasms,C04.588.033',\n 'Abdominal Muscles,A02.633.567.050',\n 'Cremaster Muscle,A02.633.567.050',\n 'Pyramidalis Muscle,A02.633.567.050',\n 'Quadratus Abdominis,A02.633.567.050',\n 'Transversus Abdominis,A02.633.567.050',\n 'Abducens Nerve,A08.800.800.120.030',\n 'Abelson murine leukemia virus,B04.613.807.375.525.020',\n 'Abelson murine leukemia virus,B04.820.650.375.525.020',\n 'Abetalipoproteinemia,C16.320.565.398.500.440.500',\n 'Abetalipoproteinemia,C18.452.584.500.875.440.500',\n 'Abetalipoproteinemia,C18.452.648.398.500.440.500',\n 'Congenital Abnormalities,C16.131',\n 'Fetal Malformations,C16.131',\n 'Fetal Anomalies,C16.131',\n '\"Abnormalities, Drug-Induced\",C16.131.042',\n '\"Abnormalities, Multiple\",C16.131.077',\n '\"Abnormalities, Radiation-Induced\",C16.131.080',\n '\"Abnormalities, Radiation-Induced\",C26.733.031',\n '\"Abnormalities, Radiation-Induced\",G01.750.748.500.031',\n '\"Abnormalities, Radiation-Induced\",N06.850.460.350.850.500.031',\n '\"Abnormalities, Radiation-Induced\",N06.850.810.300.360.031',\n 'ABO Blood-Group System,D23.050.301.290.031',\n 'ABO Blood-Group System,D23.050.705.230.031',\n 'Blood Group H Type 1 Antigen,D23.050.301.290.031',\n 'Blood Group H Type 1 Antigen,D23.050.705.230.031',\n 'ABO Factors,D23.050.301.290.031',\n 'ABO Factors,D23.050.705.230.031',\n 'Abomasum,A13.869.106',\n 'Abortifacient Agents,D27.505.696.875.131',\n 'Abortifacient Agents,D27.505.954.705.131',\n 'Abortifacient Effect,D27.505.696.875.131',\n 'Abortifacient Effect,D27.505.954.705.131',\n '\"Abortifacient Agents, Nonsteroidal\",D27.505.696.875.131.100',\n '\"Abortifacient Agents, Nonsteroidal\",D27.505.954.705.131.100',\n '\"Abortifacient Agents, Steroidal\",D27.505.696.875.131.200',\n '\"Abortifacient Agents, Steroidal\",D27.505.954.705.131.200',\n '\"Abortion, Spontaneous\",C13.703.039',\n '\"Abortion, Spontaneous\",G08.686.784.769.496.125',\n 'Early Pregnancy Loss,C13.703.039',\n 'Early Pregnancy Loss,G08.686.784.769.496.125',\n 'Miscarriage,C13.703.039',\n 'Miscarriage,G08.686.784.769.496.125',\n '\"Abortion, Tubal\",C13.703.039',\n '\"Abortion, Tubal\",G08.686.784.769.496.125',\n 'Abortion Applicants,M01.050',\n '\"Abortion Seekers, Repeated\",M01.050',\n '\"Abortion Seekers, Refused\",M01.050',\n '\"Abortion, Criminal\",I01.198.240.089',\n '\"Abortion, Eugenic\",E04.520.050.050',\n '\"Abortion, Selective\",E04.520.050.050',\n '\"Abortion, Habitual\",C13.703.039.089',\n '\"Abortion, Incomplete\",C13.703.039.093',\n '\"Abortion, Induced\",E04.520.050',\n 'Abortion Rate,E04.520.050',\n 'Abortion Techniques,E04.520.050',\n '\"Abortion, Drug-Induced\",E04.520.050',\n 'Previous Abortion,E04.520.050',\n '\"Abortion, Saline-Solution\",E04.520.050',\n '\"Abortion, Soap-Solution\",E04.520.050',\n 'Anti-Abortion Groups,E04.520.050',\n 'Embryotomy,E04.520.050',\n '\"Fertility Control, Postconception\",E04.520.050',\n 'Abortion Failure,E04.520.050',\n '\"Abortion, Rivanol\",E04.520.050',\n '\"Abortion, Legal\",E04.520.050.055',\n 'Abortion on Demand,E04.520.050.055',\n '\"Abortion, Missed\",C13.703.039.173',\n '\"Abortion, Septic\",C01.674.173',\n '\"Abortion, Septic\",C13.703.039.256',\n '\"Abortion, Septic\",C13.703.700.173',\n '\"Abortion, Therapeutic\",E04.520.050.060',\n '\"Abortion, Threatened\",C13.703.090',\n '\"Abortion, Veterinary\",C13.703.039.422',\n '\"Abortion, Veterinary\",C22.021',\n 'Abreaction,F04.754.720.107',\n 'Abrin,D08.811.277.450.430.700.750.111',\n 'Abrin,D12.776.503.499.249',\n 'Abrin,D12.776.765.678.906.111',\n 'Abrin C,D08.811.277.450.430.700.750.111',\n 'Abrin C,D12.776.503.499.249',\n 'Abrin C,D12.776.765.678.906.111',\n 'Abrin A,D08.811.277.450.430.700.750.111',\n 'Abrin A,D12.776.503.499.249',\n 'Abrin A,D12.776.765.678.906.111',\n 'Abruptio Placentae,C13.703.420.078',\n 'Abruptio Placentae,C13.703.590.132',\n 'Abscess,C01.830.025',\n 'Abscess,C23.550.470.756.100',\n 'Peritonsillar Abscess,C01.748.561.750.500',\n 'Peritonsillar Abscess,C01.830.025.675',\n 'Peritonsillar Abscess,C07.550.781.750.500',\n 'Peritonsillar Abscess,C08.730.561.750.500',\n 'Peritonsillar Abscess,C09.775.649.750.500',\n 'Abscisic Acid,D02.241.223.268.034',\n 'Abscisic Acid,D02.455.326.271.665.202.061',\n 'Abscisic Acid,D02.455.426.392.368.367.379.249.024',\n 'Abscisic Acid,D02.455.849.131.061',\n 'Abscisic Acid,D02.455.849.765.521.500',\n '\"Abscisic Acid, (+,-)-Isomer\",D02.241.223.268.034',\n '\"Abscisic Acid, (+,-)-Isomer\",D02.455.326.271.665.202.061',\n '\"Abscisic Acid, (+,-)-Isomer\",D02.455.426.392.368.367.379.249.024',\n '\"Abscisic Acid, (+,-)-Isomer\",D02.455.849.131.061',\n '\"Abscisic Acid, (+,-)-Isomer\",D02.455.849.765.521.500',\n '\"Abscisic Acid, (Z,E)-Isomer\",D02.241.223.268.034',\n '\"Abscisic Acid, (Z,E)-Isomer\",D02.455.326.271.665.202.061',\n '\"Abscisic Acid, (Z,E)-Isomer\",D02.455.426.392.368.367.379.249.024',\n '\"Abscisic Acid, (Z,E)-Isomer\",D02.455.849.131.061',\n '\"Abscisic Acid, (Z,E)-Isomer\",D02.455.849.765.521.500',\n '\"Abscisic Acid, (E,Z)-(+,-)-Isomer\",D02.241.223.268.034',\n '\"Abscisic Acid, (E,Z)-(+,-)-Isomer\",D02.455.326.271.665.202.061',\n '\"Abscisic Acid, (E,Z)-(+,-)-Isomer\",D02.455.426.392.368.367.379.249.024',\n '\"Abscisic Acid, (E,Z)-(+,-)-Isomer\",D02.455.849.131.061',\n '\"Abscisic Acid, (E,Z)-(+,-)-Isomer\",D02.455.849.765.521.500',\n '\"Abscisic Acid, (R)-Isomer\",D02.241.223.268.034',\n '\"Abscisic Acid, (R)-Isomer\",D02.455.326.271.665.202.061',\n '\"Abscisic Acid, (R)-Isomer\",D02.455.426.392.368.367.379.249.024',\n '\"Abscisic Acid, (R)-Isomer\",D02.455.849.131.061',\n '\"Abscisic Acid, (R)-Isomer\",D02.455.849.765.521.500',\n '\"Abscisic Acid Monoammonium Salt, (R)-Isomer\",D02.241.223.268.034',\n '\"Abscisic Acid Monoammonium Salt, (R)-Isomer\",D02.455.326.271.665.202.061',\n '\"Abscisic Acid Monoammonium Salt, (R)-Isomer\",D02.455.426.392.368.367.379.249.024',\n '\"Abscisic Acid Monoammonium Salt, (R)-Isomer\",D02.455.849.131.061',\n '\"Abscisic Acid Monoammonium Salt, (R)-Isomer\",D02.455.849.765.521.500',\n '\"Abscisic Acid, (E,E)-(+-)-Isomer\",D02.241.223.268.034',\n '\"Abscisic Acid, (E,E)-(+-)-Isomer\",D02.455.326.271.665.202.061',\n '\"Abscisic Acid, (E,E)-(+-)-Isomer\",D02.455.426.392.368.367.379.249.024',\n '\"Abscisic Acid, (E,E)-(+-)-Isomer\",D02.455.849.131.061',\n '\"Abscisic Acid, (E,E)-(+-)-Isomer\",D02.455.849.765.521.500',\n 'Absenteeism,F02.784.692.107',\n 'Absorption,G01.015',\n 'Absorption,G02.010',\n 'Absorption,G03.015',\n 'Absorption,G03.787.024',\n 'Absorption,G07.690.725.015',\n 'Abstracting and Indexing,L01.453.245.100',\n 'Indexing,L01.453.245.100',\n 'Indexes as Topic,L01.453.245.100',\n 'Abstracting,L01.453.245.100',\n 'Dental Abutments,E06.780.346.500',\n 'Dental Abutments,E07.695.190.175',\n 'Acacia,B01.650.940.800.575.912.250.401.025',\n 'Acacia catechu,B01.650.940.800.575.912.250.401.025',\n 'Academic Medical Centers,N02.278.020',\n 'Academies and Institutes,N03.540.052',\n 'Institutes,N03.540.052',\n 'Research Institutes,N03.540.052',\n 'Academies,N03.540.052',\n 'Acanthamoeba,B01.046.500.100.075.080',\n 'Acanthocephala,B01.050.500.500.132',\n 'Acanthocytes,A11.118.290.330.100',\n 'Acanthocytes,A11.443.240.330.100',\n 'Acanthocytes,A15.145.229.334.330.100',\n 'Acantholysis,C17.800.865.070',\n 'Acantholysis,C23.550.035',\n 'Acanthosis Nigricans,C17.800.621.430.530.100',\n 'Acari,B01.050.500.131.166.132',\n 'Acceleration,G01.482.107',\n 'Accessory Nerve,A08.800.800.120.060',\n 'Accident Prevention,N06.850.135.060',\n 'Accident Proneness,F01.145.015',\n 'Accidental Falls,N06.850.135.122',\n 'Slip and Fall,N06.850.135.122',\n 'Accidents,N06.850.135',\n '\"Accidents, Aviation\",N06.850.135.185',\n '\"Accidents, Home\",N06.850.135.217',\n '\"Accidents, Occupational\",N06.850.135.240',\n '\"Accidents, Industrial\",N06.850.135.240',\n '\"Accidents, Traffic\",N06.850.135.392',\n 'Traffic Collisions,N06.850.135.392',\n 'Traffic Crashes,N06.850.135.392',\n 'Acclimatization,G07.025.133',\n 'Acclimatization,G16.012.500.133',\n '\"Accommodation, Ocular\",G14.010',\n '\"Accommodation, Lens\",G14.010',\n 'Accounting,N03.219.463.030',\n 'Oil and Gas Industry,J01.576.655.875.750',\n 'Petroleum Industry,J01.576.655.875.750',\n 'Oil Refinery,J01.576.655.875.750',\n 'Natural Gas Industry,J01.576.655.875.750',\n 'Coal Industry,J01.576.655.875.200',\n 'Driving Under the Influence,F01.145.250.250',\n 'Driving Under the Influence,F01.145.263.500',\n 'Driving Under the Influence,I01.880.735.223.250',\n 'Driving Under the Influence,I03.125.649',\n 'Drinking and Driving,F01.145.250.250',\n 'Drinking and Driving,F01.145.263.500',\n 'Drinking and Driving,I01.880.735.223.250',\n 'Drinking and Driving,I03.125.649',\n 'Human Embryonic Stem Cells,A11.872.700.250.750',\n 'Mouse Embryonic Stem Cells,A11.872.700.250.875',\n 'Embryonic Germ Cells,A11.497.124',\n 'Embryonic Germ Cells,A11.872.700.250.625',\n 'Work Performance,I03.946.675',\n 'Job Performance,I03.946.675',\n 'Criminal Behavior,F01.145.250',\n 'Clinical Decision-Making,E01.055',\n 'Cognitive Aging,G07.345.124.260',\n 'Cognitive Neuroscience,F04.096.628.255.500',\n 'Cognitive Neuroscience,H01.158.610.030',\n 'Social Neuroscience,F04.096.628.255.500',\n 'Social Neuroscience,H01.158.610.030',\n 'Emotional Adjustment,F01.058.144',\n 'Emotional Adjustment,F01.752.543.500.250',\n 'Facial Recognition,F02.463.593.524.250.500',\n 'Facial Recognition,F02.463.593.524.500.500',\n 'Facial Recognition,F02.463.593.932.622.500',\n 'Facial Emotion Recognition,F02.463.593.524.250.500',\n 'Facial Emotion Recognition,F02.463.593.524.500.500',\n 'Facial Emotion Recognition,F02.463.593.932.622.500',\n 'Grandparents,F01.829.263.403',\n 'Grandparents,I01.880.853.150.452',\n 'Grandparents,M01.264',\n 'Grandmother,F01.829.263.403',\n 'Grandmother,I01.880.853.150.452',\n 'Grandmother,M01.264',\n 'Grandfather,F01.829.263.403',\n 'Grandfather,I01.880.853.150.452',\n 'Grandfather,M01.264',\n 'Help-Seeking Behavior,F01.145.813.217',\n 'Heuristics,F02.463.425.725.500',\n 'Heuristics,F02.463.785.810.500',\n 'Intimate Partner Violence,I01.198.240.856.575',\n 'Intimate Partner Violence,I01.880.735.900.688',\n 'Dating Violence,I01.198.240.856.575',\n 'Dating Violence,I01.880.735.900.688',\n 'Neurological Rehabilitation,E02.760.169.063.500.477',\n 'Neurological Rehabilitation,E02.831.477',\n 'Neurological Rehabilitation,H02.403.680.600.750',\n 'Neurological Rehabilitation,N02.421.784.511',\n 'Physical Abuse,I01.198.240.856.688',\n 'Physical Abuse,I01.880.735.900.744',\n 'Problem Behavior,F01.145.126.972',\n 'Problem Behavior,F01.145.179.750',\n '\"Dysfunctional Behavior, Psychology\",F01.145.126.972',\n '\"Dysfunctional Behavior, Psychology\",F01.145.179.750',\n 'Disruptive Behavior,F01.145.126.972',\n 'Disruptive Behavior,F01.145.179.750',\n 'Underage Drinking,F01.145.022.750',\n 'Underage Drinking,F01.145.317.269.875',\n 'Underage Drinking,I01.880.735.878',\n 'Legal Drinking Age,F01.145.022.750',\n 'Legal Drinking Age,F01.145.317.269.875',\n 'Legal Drinking Age,I01.880.735.878',\n 'Ectopic Gene Expression,G05.308.202',\n 'Cell Plasticity,G04.356.250',\n 'Cell Self Renewal,G04.144.220.235',\n 'Cell Self Renewal,G04.161.750.500.375',\n 'Cell Self Renewal,G05.113.415',\n 'Cell Self Renewal,G07.345.249.410.750.500.625',\n 'Stem Cell Self-Renewal,G04.144.220.235',\n 'Stem Cell Self-Renewal,G04.161.750.500.375',\n 'Stem Cell Self-Renewal,G05.113.415',\n 'Stem Cell Self-Renewal,G07.345.249.410.750.500.625',\n 'Rehabilitation Research,H01.770.644.145.472',\n 'Orthodontists,M01.526.485.330.655',\n 'Orthodontists,N02.360.330.655',\n 'Dentofacial Orthopedists,M01.526.485.330.655',\n 'Dentofacial Orthopedists,N02.360.330.655',\n 'Oral and Maxillofacial Surgeons,M01.526.485.330.483',\n 'Oral and Maxillofacial Surgeons,N02.360.330.483',\n 'Exodontists,M01.526.485.330.483',\n 'Exodontists,N02.360.330.483',\n 'Neuroprotection,G11.561.645',\n '\"Diet, Food, and Nutrition\",G07.203',\n 'Triticale,B01.650.940.800.575.912.250.822.906',\n 'Critical Care Outcomes,N04.761.559.590.399.250',\n 'Critical Care Outcomes,N05.715.360.575.575.399.250',\n 'Simulation Training,I02.903.847',\n 'Interactive Learning,I02.903.847',\n 'Millets,B01.650.940.800.575.912.250.822.587',\n 'Biobehavioral Sciences,H01.770.644.108.687',\n 'Protein Corona,D12.776.642',\n 'Vegetarians,M01.928',\n 'Lacto-Ovo Vegetarians,M01.928',\n 'Vegans,M01.928.500',\n 'Accounts Payable and Receivable,N03.219.463.030.080',\n 'Accounts Payable,N03.219.463.030.080',\n 'Youth Sports,I03.450.642.845.987',\n 'Organized Youth Sports,I03.450.642.845.987',\n 'Literacy,F01.145.209.429',\n 'Literacy,N01.824.196.500',\n 'Illiteracy,F01.145.209.429',\n 'Illiteracy,N01.824.196.500',\n 'Severe Acute Malnutrition,C18.654.521.719',\n '\"Banking, Personal\",N03.219.463.030.100',\n 'Savings Accounts,N03.219.463.030.100',\n 'Checking Accounts,N03.219.463.030.100',\n 'Evidence-Based Facility Design,N02.278.200.252',\n '\"Physical Appearance, Body\",E01.370.600.115.450',\n '\"Physical Appearance, Body\",G07.100.175',\n 'Fruit and Vegetable Juices,G07.203.100.606',\n 'Fruit and Vegetable Juices,J02.200.606',\n 'Vegetable Juices,G07.203.100.606',\n 'Vegetable Juices,J02.200.606',\n 'Fruit Juices,G07.203.100.606',\n 'Fruit Juices,J02.200.606',\n 'Ghee,D10.212.302.199.500',\n 'Ghee,G07.203.300.350.100.500',\n 'Ghee,G07.203.300.375.200.500',\n 'Ghee,J02.500.350.100.500',\n 'Ghee,J02.500.375.200.500',\n 'Hydraulic Fracking,J01.576.655.875.750.500',\n 'Psychological Trauma,F03.950.750.375',\n 'Peer Influence,F01.829.316.483.750',\n 'Peer Pressure,F01.829.316.483.750',\n 'Vegetable Products,G07.203.300.850.450',\n 'Vegetable Products,J02.500.850.800',\n 'Direct-to-Consumer Advertising,J01.219.687.274.500',\n 'Direct-To-Consumer Screening and Testing,E01.370.398',\n 'Direct-To-Consumer Screening and Testing,N02.421.726.233.166',\n 'Extracellular Vesicles,A11.284.295.588',\n 'Exovesicles,A11.284.295.588',\n 'Apoptotic Bodies,A11.284.295.588',\n 'Fungal Viruses,B04.352',\n 'Telocytes,A11.329.830.750',\n 'Exoskeleton Device,E07.341',\n 'Robotic Exoskeleton,E07.341',\n 'Shellfish Hypersensitivity,C20.543.480.370.763',\n '\"Failure to Rescue, Health Care\",E01.789.800.760.500',\n '\"Failure to Rescue, Health Care\",H01.770.644.145.431.500',\n '\"Failure to Rescue, Health Care\",N04.761.559.590.800.760.500',\n '\"Failure to Rescue, Health Care\",N05.715.360.575.575.800.760.500',\n 'Psychiatric Rehabilitation,H02.403.680.600.875',\n 'Psychiatric Rehabilitation,N02.421.784.578',\n 'Psychosocial Care,H02.403.680.600.875',\n 'Psychosocial Care,N02.421.784.578',\n 'Symptom Flare Up,C23.550.291.937.500',\n 'Symptom Exacerbation,C23.550.291.937.500',\n 'Isolated Heart Preparation,E05.519',\n 'Isolated Heart Preparation,E05.598.750',\n 'Langendorff Perfused Heart,E05.519',\n 'Langendorff Perfused Heart,E05.598.750',\n 'Working Heart Preparation Technique,E05.519',\n 'Working Heart Preparation Technique,E05.598.750',\n 'Working Heart Preparation,E05.519',\n 'Working Heart Preparation,E05.598.750',\n 'Isolated Heart Preparation Technique,E05.519',\n 'Isolated Heart Preparation Technique,E05.598.750',\n '\"Diet, Vegan\",E02.642.249.300.750',\n '\"Diet, Vegan\",G07.203.650.240.300.750',\n 'Veganism,E02.642.249.300.750',\n 'Veganism,G07.203.650.240.300.750',\n 'Behavior Observation Techniques,E05.796.112',\n 'Behavior Observation Techniques,F04.669.112',\n 'Behavior Rating Scale,F04.711.271',\n 'Behavior Test,F04.711.271',\n 'Alcohol Drinking in College,F01.145.317.269.625',\n '\"Obesity, Metabolically Benign\",C18.654.726.500.650',\n '\"Obesity, Metabolically Benign\",C23.888.144.699.500.250',\n '\"Obesity, Metabolically Benign\",E01.370.600.115.100.160.120.699.500.375',\n '\"Obesity, Metabolically Benign\",G07.100.100.160.120.699.500.375',\n 'Whole Grains,G07.203.300.300.550.500',\n 'Whole Grains,G07.203.300.775.500.500',\n 'Whole Grains,J02.500.300.550.500',\n 'Whole Grains,J02.500.775.500.500',\n 'Whole Grain Cereals,G07.203.300.300.550.500',\n 'Whole Grain Cereals,G07.203.300.775.500.500',\n 'Whole Grain Cereals,J02.500.300.550.500',\n 'Whole Grain Cereals,J02.500.775.500.500',\n 'Transanal Endoscopic Surgery,E01.370.388.250.630.500',\n 'Transanal Endoscopic Surgery,E04.210.240.250.680.500',\n 'Transanal Endoscopic Surgery,E04.502.250.250.250.680.500',\n 'Transanal Endoscopic Surgery,E04.502.250.630.500',\n 'Transanal Minimally Invasive Surgery,E01.370.388.250.630.500',\n 'Transanal Minimally Invasive Surgery,E04.210.240.250.680.500',\n 'Transanal Minimally Invasive Surgery,E04.502.250.250.250.680.500',\n 'Transanal Minimally Invasive Surgery,E04.502.250.630.500',\n 'Transanal Endoscopic Microsurgery,E01.370.388.250.630.500.500',\n 'Transanal Endoscopic Microsurgery,E04.210.240.250.680.500.500',\n 'Transanal Endoscopic Microsurgery,E04.494.787',\n 'Transanal Endoscopic Microsurgery,E04.502.250.250.250.680.500.500',\n 'Transanal Endoscopic Microsurgery,E04.502.250.630.500.500',\n 'Cold Injury,C26.212',\n 'Personal Protective Equipment,E07.700.560',\n 'Personal Protective Equipment,J01.637.708.560',\n 'Nerve Agents,D27.720.599',\n 'Nerve Agents,D27.720.777.300.500',\n 'Nerve Gas,D27.720.599',\n 'Nerve Gas,D27.720.777.300.500',\n 'War-Related Injuries,C26.946',\n 'War-Related Injuries,I01.880.735.950.500.951.500',\n 'War-Related Injuries,N06.850.460.350.600.903.500',\n 'War-Related Trauma,C26.946',\n 'War-Related Trauma,I01.880.735.950.500.951.500',\n 'War-Related Trauma,N06.850.460.350.600.903.500',\n 'Abnormal Involuntary Movement Scale,E01.370.600.550.162',\n 'Blood Alcohol Content,D02.033.375.135',\n 'Social Communication Disorder,F03.625.374.250',\n 'Legal Services,I01.880.604.583.482',\n 'Defamation,I01.198.240.240',\n 'Defamation,I01.880.735.191.051',\n 'Slander,I01.198.240.240',\n 'Slander,I01.880.735.191.051',\n 'Libel,I01.198.240.240',\n 'Libel,I01.880.735.191.051',\n 'Anger Management Therapy,F04.754.137.087',\n '\"Psychology, Sports\",F04.096.628.914',\n 'War Exposure,I01.880.735.950.500.951',\n 'War Exposure,N06.850.460.350.600.903',\n 'Childhood-Onset Fluency Disorder,F03.625.374.125',\n 'No-Show Patients,F01.100.150.750.500.600.750',\n 'No-Show Patients,F01.145.488.887.500.600.750',\n 'No-Show Patients,M01.643.550',\n 'No-Show Patients,N04.452.758.635.500',\n 'No-Show Patients,N05.300.150.800.500.600.750',\n 'Cellular Reprogramming Techniques,E05.200.500.380',\n 'Cellular Reprogramming Techniques,E05.242.378',\n 'Cellular Reprogramming Techniques,E05.393.085',\n 'Directed Differentiation Techniques,E05.200.500.380',\n 'Directed Differentiation Techniques,E05.242.378',\n 'Directed Differentiation Techniques,E05.393.085',\n 'Direct Cell Reprogramming Techniques,E05.200.500.380',\n 'Direct Cell Reprogramming Techniques,E05.242.378',\n 'Direct Cell Reprogramming Techniques,E05.393.085',\n 'Metacognition,F02.463.188.756',\n 'Metacognitive Awareness,F02.463.188.756',\n 'Metacognitive Monitoring,F02.463.188.756',\n 'Metacognitive Control,F02.463.188.756',\n 'Metaemotion,F02.463.188.756',\n 'Metamemory,F02.463.188.756',\n 'Prescription Drug Overuse,E02.319.306.500.750',\n '\"Near Miss, Healthcare\",E02.319.529.750',\n '\"Near Miss, Healthcare\",N02.421.450.500.750',\n '\"Near Miss, Healthcare\",N02.421.450.550',\n '\"Near Miss, Healthcare\",N04.761.700.594',\n '\"Near Miss, Healthcare\",N05.700.513',\n 'RNAi Therapeutics,E02.095.301.250',\n 'Dynamic Light Scattering,E05.196.822.325',\n 'Quasi-Elastic Light Scattering (QELS),E05.196.822.325',\n '\"Time Out, Healthcare\",N04.761.700.635',\n '\"Time Out, Healthcare\",N05.700.739',\n 'Surgical Time Out,N04.761.700.635',\n 'Surgical Time Out,N05.700.739',\n 'Healthcare Failure Mode and Effect Analysis,E05.318.740.600.800.715.500',\n 'Healthcare Failure Mode and Effect Analysis,N04.452.871.715.400',\n 'Healthcare Failure Mode and Effect Analysis,N05.715.360.750.625.700.690.400',\n 'Healthcare Failure Mode and Effect Analysis,N06.850.505.715.500',\n 'Healthcare Failure Mode and Effect Analysis,N06.850.520.830.600.800.715.500',\n 'Failure Mode and Effect Analysis,E05.318.740.600.800.715.500',\n 'Failure Mode and Effect Analysis,N04.452.871.715.400',\n 'Failure Mode and Effect Analysis,N05.715.360.750.625.700.690.400',\n 'Failure Mode and Effect Analysis,N06.850.505.715.500',\n 'Failure Mode and Effect Analysis,N06.850.520.830.600.800.715.500',\n 'Spirit Possession,K01.844.619.500',\n '\"Crew Resource Management, Healthcare\",N04.590.254',\n 'Computer Heuristics,L01.224.050.375.095',\n 'Ataxins,D12.776.631.069',\n 'Ataxins,D12.776.660.075',\n 'Alarmins,D23.035',\n 'Dermal Fillers,D27.720.102.461',\n 'Action Spectrum,E05.196.867.826.150',\n 'Diplomacy,F01.829.316.171',\n 'Diplomacy,F02.463.785.373.520.500',\n 'Diplomacy,I01.738.305',\n 'Mutation Accumulation,G05.365.590.594',\n 'Spontaneous Mutation Accumulation,G05.365.590.594',\n 'Internal Ribosome Entry Sites,D13.444.735.790.878.942.250',\n 'Internal Ribosome Entry Sites,G02.111.570.080.689.687.093',\n 'Internal Ribosome Entry Sites,G05.360.080.689.687.093',\n 'Biological Mimicry,G16.012.750',\n 'Biological Camouflage,G16.012.750',\n 'Specific Learning Disorder,F03.625.562.700',\n 'Potentially Inappropriate Medication List,N04.761.700.615',\n 'Potentially Inappropriate Medication List,N05.700.594',\n 'Beers Criteria,N04.761.700.615',\n 'Beers Criteria,N05.700.594',\n 'STOPP (Screening Tool of Older Persons Potentially Inappropriate Prescriptions),N04.761.700.615',\n 'STOPP (Screening Tool of Older Persons Potentially Inappropriate Prescriptions),N05.700.594',\n 'Medication Appropriateness Index,N04.761.700.615',\n 'Medication Appropriateness Index,N05.700.594',\n 'Late Onset Disorders,C23.550.291.883',\n 'Phakopsora pachyrhizi,B01.300.179.113',\n 'Farmers,M01.526.390',\n 'Ranchers,M01.526.390',\n 'Culturally Appropriate Technology,J01.897.052',\n 'Intermediate Technology,J01.897.052',\n 'Soft Technology,J01.897.052',\n 'Social Learning,F02.784.629.529.663',\n 'Financial Statements,N03.219.463.030.140',\n '\"Assets, Financial\",N03.219.463.030.140',\n 'Cash Flow Statement,N03.219.463.030.140',\n 'Balance Sheet,N03.219.463.030.140',\n 'Expense Statement,N03.219.463.030.140',\n 'Income Statement,N03.219.463.030.140',\n '\"Equity, Financial\",N03.219.463.030.140',\n '\"Liabilities, Financial\",N03.219.463.030.140',\n 'Miners,M01.526.693',\n 'Chronopharmacokinetics,G07.690.725.249',\n '\"Administrative Claims, Healthcare\",N04.452.859.564.137',\n 'Child Health,N01.400.225',\n 'Child Well Being,N01.400.225',\n 'Interleukin-33,D12.644.276.374.465.850',\n 'Interleukin-33,D12.776.467.374.465.850',\n 'Interleukin-33,D23.529.374.465.850',\n 'S100A12 Protein,D12.776.157.125.750.875',\n 'Telopodes,A11.284.180.900',\n 'Telopodes,A11.329.830.750.500',\n 'Podomers,A11.284.180.900',\n 'Podomers,A11.329.830.750.500',\n 'Podoms,A11.284.180.900',\n 'Podoms,A11.329.830.750.500',\n 'Drosophila simulans,B01.050.500.131.617.720.500.500.750.310.250.750',\n 'Optimism,F01.100.787',\n 'Positive Attitude,F01.100.787',\n 'Positive Thinking,F01.100.787',\n 'Pessimism,F01.100.893',\n 'Ataxin-1,D12.776.631.069.500',\n 'Ataxin-1,D12.776.660.075.500',\n 'Adolescent Health,N01.400.075',\n 'Adolescent Well Being,N01.400.075',\n 'Ataxin-2,D12.776.157.725.452.125',\n 'Ataxin-2,D12.776.631.069.750',\n 'Ataxin-2,D12.776.660.075.750',\n 'Ataxin-2,D12.776.664.962.452.125',\n 'Ataxin-3,D08.811.037.250',\n 'Ataxin-3,D12.776.631.069.875',\n 'Ataxin-3,D12.776.660.075.875',\n 'Point-of-Care Testing,N04.590.874.500',\n 'Bedside Testing,N04.590.874.500',\n 'Ataxin-7,D12.776.631.069.901',\n 'Ataxin-7,D12.776.660.075.900',\n 'Ataxin-10,D12.776.631.069.950',\n 'Glucagon-Like Peptide Receptors,D12.776.543.750.695.021',\n 'Glucagon-Like Peptide Receptors,D12.776.543.750.750.360.100',\n 'Glucagon-Like Peptide-1 Receptor,D12.776.543.750.695.021.500',\n 'Glucagon-Like Peptide-1 Receptor,D12.776.543.750.750.360.100.500',\n 'Glucagon-Like Peptide-2 Receptor,D12.776.543.750.695.021.600',\n 'Glucagon-Like Peptide-2 Receptor,D12.776.543.750.750.360.100.600',\n 'Receptor for Advanced Glycation End Products,D12.776.543.750.615',\n 'RNA Recognition Motif Proteins,D12.776.157.725.813',\n 'RNA Recognition Motif Proteins,D12.776.664.962.813',\n 'ELAV-Like Protein 2,D12.776.157.725.813.500.500',\n 'ELAV-Like Protein 2,D12.776.631.520.500',\n 'ELAV-Like Protein 2,D12.776.664.962.813.500.500',\n 'ELAV-Like Protein 3,D12.776.157.725.813.500.750',\n 'ELAV-Like Protein 3,D12.776.631.520.750',\n 'ELAV-Like Protein 3,D12.776.664.962.813.500.750',\n 'ELAV-Like Protein 4,D12.776.157.725.813.500.875',\n 'ELAV-Like Protein 4,D12.776.631.520.875',\n 'ELAV-Like Protein 4,D12.776.664.962.813.500.875',\n 'ELAV-Like Protein 1,D12.776.157.725.813.500.250',\n 'ELAV-Like Protein 1,D12.776.664.962.813.500.250',\n 'Whey,A12.790.760',\n 'Whey,G07.203.100.700.750',\n 'Whey,G07.203.300.350.525.760',\n 'Whey,J02.200.700.750',\n 'Whey,J02.500.350.525.760',\n 'Whey Proteins,A12.790.520.500',\n 'Whey Proteins,A12.790.760.500',\n 'Whey Proteins,D12.776.256.159.750.816',\n 'Whey Proteins,G07.203.300.350.525.760.500',\n 'Whey Proteins,G07.203.300.428.159.812.500',\n 'Whey Proteins,J02.500.350.525.520.500',\n 'Whey Proteins,J02.500.350.525.760.500',\n 'Whey Proteins,J02.500.428.159.750.500',\n 'Hoarding Disorder,F03.080.600.250',\n 'Obsessive Hoarding,F03.080.600.250',\n 'Poly(ADP-ribose) Polymerase Inhibitors,D27.505.519.389.739',\n 'Poly(ADP-ribose) Polymerase Inhibitors,D27.505.954.248.692',\n 'Autism Spectrum Disorder,F03.625.164.113',\n 'CELF Proteins,D12.776.157.725.813.250',\n 'CELF Proteins,D12.776.664.962.813.250',\n 'CELF1 Protein,D12.776.157.725.813.250.500',\n 'CELF1 Protein,D12.776.664.962.813.250.500',\n 'Industrial Development,I01.261.262.500',\n 'Industrial Development,J01.576.519',\n 'Technology Development,I01.261.262.500',\n 'Technology Development,J01.576.519',\n 'Industrialization,I01.261.262.500',\n 'Industrialization,J01.576.519',\n 'Cloud Computing,L01.224.097',\n 'Natural Resources,G16.500.275.553',\n 'Natural Resources,J01.728',\n 'Natural Resources,N06.230.350',\n 'Land Supply,G16.500.275.553',\n 'Land Supply,J01.728',\n 'Land Supply,N06.230.350',\n 'Glycemic Load,G07.203.650.660.750',\n 'Glycemic Load,J01.576.423.850.730.750.750',\n 'Glycemic Load,N06.850.601.750.750',\n 'Adenylyl Cyclase Inhibitors,D27.505.519.389.108',\n 'RAW 264.7 Cells,A11.251.210.172.875',\n 'RAW 264.7 Cells,A11.733.397.815',\n 'Accreditation,N03.706.110.070',\n 'Accreditation,N05.700.200.100',\n 'Clostridiales,B03.353.625',\n 'Graphic Novel,V02.700.415',\n 'Comic Book,V02.700.415',\n 'South Sudan,Z01.058.290.120.745',\n 'Motor Disorders,F03.608',\n 'Maternal Health,N01.400.900.500',\n 'Seed Bank,N02.278.065.650',\n 'Germplasm Bank,N02.278.065.650',\n 'Trauma and Stressor Related Disorders,F03.950',\n 'Maternal-Child Health Services,N02.421.143.130.660',\n 'Maternal-Child Health Services,N02.421.143.620.275',\n 'Serine-Arginine Splicing Factors,D12.776.157.725.829.500',\n 'Serine-Arginine Splicing Factors,D12.776.664.962.829.500',\n 'Infant Health,N01.400.388',\n 'Newborn Health,N01.400.388',\n 'Bipolar and Related Disorders,F03.084',\n 'Gender Dysphoria,F03.835.550',\n 'Formative Feedback,F02.784.629.529.223',\n 'Aripiprazole,D03.383.606.170',\n 'Aripiprazole,D03.633.100.810.835.122',\n 'Abilify,D03.383.606.170',\n 'Abilify,D03.633.100.810.835.122',\n 'OPC 14597,D03.383.606.170',\n 'OPC 14597,D03.633.100.810.835.122',\n 'Prunus dulcis,B01.650.940.800.575.912.250.859.937.500.625.500',\n 'Almonds,B01.650.940.800.575.912.250.859.937.500.625.500',\n 'Albumin-Bound Paclitaxel,D02.455.426.392.368.242.888.777.500',\n 'Albumin-Bound Paclitaxel,D02.455.849.291.850.777.500',\n 'Albumin-Bound Paclitaxel,D12.776.034.073',\n 'Abraxane,D02.455.426.392.368.242.888.777.500',\n 'Abraxane,D02.455.849.291.850.777.500',\n 'Abraxane,D12.776.034.073',\n 'ABI007,D02.455.426.392.368.242.888.777.500',\n 'ABI007,D02.455.849.291.850.777.500',\n 'ABI007,D12.776.034.073',\n 'Child Protective Services,I01.409.418.500',\n 'Child Protective Services,N03.540.400.500',\n 'Social Workers,M01.526.919',\n 'Prunus africana,B01.650.940.800.575.912.250.859.937.500.625.250',\n 'Prunus armeniaca,B01.650.940.800.575.912.250.859.937.500.625.375',\n 'Apricot,B01.650.940.800.575.912.250.859.937.500.625.375',\n 'Prunus avium,B01.650.940.800.575.912.250.859.937.500.625.400',\n 'Prunus serotina,B01.650.940.800.575.912.250.859.937.500.625.400',\n 'Sweet Cherries,B01.650.940.800.575.912.250.859.937.500.625.400',\n 'Prunus cerasus,B01.650.940.800.575.912.250.859.937.500.625.400',\n 'Refugium,G16.500.275.683',\n 'Refugium,G16.500.819',\n 'Distance Counseling,F02.784.176.350',\n 'Distance Counseling,F04.408.413.437',\n 'Distance Counseling,N02.421.143.303.175',\n 'Distance Counseling,N02.421.461.363.437',\n 'Distance Counseling,N04.452.758.849.550.500',\n 'Lubiprostone,D10.251.355.325.050.500',\n 'RU 0211,D10.251.355.325.050.500',\n 'Amitiza,D10.251.355.325.050.500',\n 'SPI 0211,D10.251.355.325.050.500',\n 'Prunus persica,B01.650.940.800.575.912.250.859.937.500.625.750',\n 'Peach,B01.650.940.800.575.912.250.859.937.500.625.750',\n 'Data Anonymization,H01.770.644.205',\n 'Data Anonymization,L01.224.134.500',\n 'Data Anonymization,N03.706.437.650.124.160',\n 'Data Anonymization,N04.452.910.200.500',\n 'De-Identification,H01.770.644.205',\n 'De-Identification,L01.224.134.500',\n 'De-Identification,N03.706.437.650.124.160',\n 'De-Identification,N04.452.910.200.500',\n 'Data Masking,H01.770.644.205',\n 'Data Masking,L01.224.134.500',\n 'Data Masking,N03.706.437.650.124.160',\n 'Data Masking,N04.452.910.200.500',\n 'Personally Identifiable Information,I01.880.604.583.080.660',\n 'Prunus domestica,B01.650.940.800.575.912.250.859.937.500.625.450',\n 'Plum,B01.650.940.800.575.912.250.859.937.500.625.450',\n 'Prunus cerasifera,B01.650.940.800.575.912.250.859.937.500.625.450',\n 'Prunus salicina,B01.650.940.800.575.912.250.859.937.500.625.450',\n 'Darbepoetin alfa,D12.776.395.240.150.500',\n 'Aranesp,D12.776.395.240.150.500',\n 'KRN 321,D12.776.395.240.150.500',\n '\"Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination\",D02.705.429.906.125',\n '\"Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination\",D03.383.533.375',\n '\"Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination\",D03.383.742.680.245.500.600.125',\n '\"Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination\",D03.633.100.759.138.881.125',\n '\"Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination\",D26.310.375',\n 'Atripla,D02.705.429.906.125',\n 'Atripla,D03.383.533.375',\n 'Atripla,D03.383.742.680.245.500.600.125',\n 'Atripla,D03.633.100.759.138.881.125',\n 'Atripla,D26.310.375',\n 'Bevacizumab,D12.776.124.486.485.114.224.060.375',\n 'Bevacizumab,D12.776.124.790.651.114.224.060.438',\n 'Bevacizumab,D12.776.377.715.548.114.224.200.438',\n 'Mvasi,D12.776.124.486.485.114.224.060.375',\n 'Mvasi,D12.776.124.790.651.114.224.060.438',\n 'Mvasi,D12.776.377.715.548.114.224.200.438',\n 'Bevacizumab-awwb,D12.776.124.486.485.114.224.060.375',\n 'Bevacizumab-awwb,D12.776.124.790.651.114.224.060.438',\n 'Bevacizumab-awwb,D12.776.377.715.548.114.224.200.438',\n 'Avastin,D12.776.124.486.485.114.224.060.375',\n 'Avastin,D12.776.124.790.651.114.224.060.438',\n 'Avastin,D12.776.377.715.548.114.224.200.438',\n 'Giraffes,B01.050.150.900.649.313.500.380.443',\n 'Okapis,B01.050.150.900.649.313.500.380.443',\n 'Risedronic Acid,D02.705.429.500.872',\n 'Risedronic Acid,D03.383.725.836',\n '1-Hydroxy-2-(3-pyridyl)ethylidene diphosphonate,D02.705.429.500.872',\n '1-Hydroxy-2-(3-pyridyl)ethylidene diphosphonate,D03.383.725.836',\n 'Atelvia,D02.705.429.500.872',\n 'Atelvia,D03.383.725.836',\n 'Risedronate Sodium,D02.705.429.500.872',\n 'Risedronate Sodium,D03.383.725.836',\n '2-(3-pyridinyl)-1-hydroxyethylidene-bisphosphonate,D02.705.429.500.872',\n '2-(3-pyridinyl)-1-hydroxyethylidene-bisphosphonate,D03.383.725.836',\n '\"Risedronic Acid, Monosodium Salt\",D02.705.429.500.872',\n '\"Risedronic Acid, Monosodium Salt\",D03.383.725.836',\n 'Actonel,D02.705.429.500.872',\n 'Actonel,D03.383.725.836',\n 'Risedronate,D02.705.429.500.872',\n 'Risedronate,D03.383.725.836',\n 'Bisphosphonate Risedronate Sodium,D02.705.429.500.872',\n 'Bisphosphonate Risedronate Sodium,D03.383.725.836',\n 'Fluticasone-Salmeterol Drug Combination,D02.033.100.291.057.750.500',\n 'Fluticasone-Salmeterol Drug Combination,D02.092.063.291.057.750.500',\n 'Fluticasone-Salmeterol Drug Combination,D02.092.471.683.061.750.500',\n 'Fluticasone-Salmeterol Drug Combination,D04.210.500.054.079.129.114.500',\n 'Fluticasone-Salmeterol Drug Combination,D26.310.438',\n '\"Fluticasone Propionate, Salmeterol Xinafoate Drug Combination\",D02.033.100.291.057.750.500',\n '\"Fluticasone Propionate, Salmeterol Xinafoate Drug Combination\",D02.092.063.291.057.750.500',\n '\"Fluticasone Propionate, Salmeterol Xinafoate Drug Combination\",D02.092.471.683.061.750.500',\n '\"Fluticasone Propionate, Salmeterol Xinafoate Drug Combination\",D04.210.500.054.079.129.114.500',\n '\"Fluticasone Propionate, Salmeterol Xinafoate Drug Combination\",D26.310.438',\n 'Advair Diskus,D02.033.100.291.057.750.500',\n 'Advair Diskus,D02.092.063.291.057.750.500',\n 'Advair Diskus,D02.092.471.683.061.750.500',\n 'Advair Diskus,D04.210.500.054.079.129.114.500',\n 'Advair Diskus,D26.310.438',\n 'Seretide,D02.033.100.291.057.750.500',\n 'Seretide,D02.092.063.291.057.750.500',\n 'Seretide,D02.092.471.683.061.750.500',\n 'Seretide,D04.210.500.054.079.129.114.500',\n 'Seretide,D26.310.438',\n 'Advair HFA,D02.033.100.291.057.750.500',\n 'Advair HFA,D02.092.063.291.057.750.500',\n 'Advair HFA,D02.092.471.683.061.750.500',\n 'Advair HFA,D04.210.500.054.079.129.114.500',\n 'Advair HFA,D26.310.438',\n 'Advair,D02.033.100.291.057.750.500',\n 'Advair,D02.092.063.291.057.750.500',\n 'Advair,D02.092.471.683.061.750.500',\n 'Advair,D04.210.500.054.079.129.114.500',\n 'Advair,D26.310.438',\n 'Fluticasone,D04.210.500.054.079.129.114',\n 'Flonase,D04.210.500.054.079.129.114',\n 'Flovent HFA,D04.210.500.054.079.129.114',\n 'Cutivate,D04.210.500.054.079.129.114',\n 'Fluticasone Propionate,D04.210.500.054.079.129.114',\n 'Flixonase,D04.210.500.054.079.129.114',\n 'Flixotide,D04.210.500.054.079.129.114',\n 'Flovent,D04.210.500.054.079.129.114',\n 'Salmeterol Xinafoate,D02.033.100.291.057.750',\n 'Salmeterol Xinafoate,D02.092.063.291.057.750',\n 'Salmeterol Xinafoate,D02.092.471.683.061.750',\n 'Salmeterol,D02.033.100.291.057.750',\n 'Salmeterol,D02.092.063.291.057.750',\n 'Salmeterol,D02.092.471.683.061.750',\n 'Serevent,D02.033.100.291.057.750',\n 'Serevent,D02.092.063.291.057.750',\n 'Serevent,D02.092.471.683.061.750',\n '\"Parks, Recreational\",J03.925.680',\n 'National Parks,J03.925.680',\n 'Community Parks,J03.925.680',\n 'Green Space,J03.925.680',\n 'Urban Parks,J03.925.680',\n 'Warfare and Armed Conflicts,I01.880.735.950',\n 'Armed Conflicts,I01.880.735.950.250',\n 'Wars,I01.880.735.950.250',\n 'Everolimus,D02.540.505.760.500',\n 'RAD 001,D02.540.505.760.500',\n 'Afinitor,D02.540.505.760.500',\n 'Certican,D02.540.505.760.500',\n '\"Aspirin, Dipyridamole Drug Combination\",D02.455.426.559.389.657.410.595.176.500',\n '\"Aspirin, Dipyridamole Drug Combination\",D03.383.742.175.500',\n '\"Aspirin, Dipyridamole Drug Combination\",D26.310.125',\n 'TX 3301,D02.455.426.559.389.657.410.595.176.500',\n 'TX 3301,D03.383.742.175.500',\n 'TX 3301,D26.310.125',\n 'Extended-Release Dipyridamole-Aspirin,D02.455.426.559.389.657.410.595.176.500',\n 'Extended-Release Dipyridamole-Aspirin,D03.383.742.175.500',\n 'Extended-Release Dipyridamole-Aspirin,D26.310.125',\n 'Asasantin,D02.455.426.559.389.657.410.595.176.500',\n 'Asasantin,D03.383.742.175.500',\n 'Asasantin,D26.310.125',\n 'Asasantin Retard,D02.455.426.559.389.657.410.595.176.500',\n 'Asasantin Retard,D03.383.742.175.500',\n 'Asasantin Retard,D26.310.125',\n 'Aggrenox,D02.455.426.559.389.657.410.595.176.500',\n 'Aggrenox,D03.383.742.175.500',\n 'Aggrenox,D26.310.125',\n 'Self-Control,F01.145.813.595',\n 'Saline Waters,G16.500.275.725',\n 'Brackish Water,G16.500.275.725',\n 'Compassion Fatigue,C23.888.369.500.500',\n 'Compassion Fatigue,F01.145.126.937.500',\n 'Compassion Fatigue,F01.145.126.990.734.500',\n 'Compassion Fatigue,F02.830.900.666.750',\n 'Plantaginaceae,B01.650.940.800.575.912.250.583.700',\n 'Stemodia,B01.650.940.800.575.912.250.583.700',\n 'Globularia,B01.650.940.800.575.912.250.583.700',\n 'Lamiales,B01.650.940.800.575.912.250.583',\n 'Proboscidea Plant,B01.650.940.800.575.912.250.583',\n 'Clinical Study,V03.175',\n 'Surgical Clearance,E01.370.505',\n 'Pemetrexed,D03.633.100.759.758.399.454.650',\n 'Pemetrexed,D12.125.067.625.525',\n 'Pemetrexed,D12.125.119.409.525',\n 'Pemetrexed Disodium,D03.633.100.759.758.399.454.650',\n 'Pemetrexed Disodium,D12.125.067.625.525',\n 'Pemetrexed Disodium,D12.125.119.409.525',\n 'LY 231514,D03.633.100.759.758.399.454.650',\n 'LY 231514,D12.125.067.625.525',\n 'LY 231514,D12.125.119.409.525',\n 'Alimta,D03.633.100.759.758.399.454.650',\n 'Alimta,D12.125.067.625.525',\n 'Alimta,D12.125.119.409.525',\n 'Brimonidine Tartrate,D03.633.100.857.070',\n '\"Brimonidine Tartrate (1:1), (S-(R*,R*))-Isomer\",D03.633.100.857.070',\n 'Brimonidine Purite,D03.633.100.857.070',\n 'AGN 190342,D03.633.100.857.070',\n 'Sanrosa,D03.633.100.857.070',\n 'Alphagan,D03.633.100.857.070',\n 'Brimonidine,D03.633.100.857.070',\n 'Alphagan P,D03.633.100.857.070',\n '\"UK 14,304\",D03.633.100.857.070',\n 'Ratio-Brimonidine,D03.633.100.857.070',\n '\"UK 14,304-18\",D03.633.100.857.070',\n 'UK 14308,D03.633.100.857.070',\n '\"Brimonidine Tartrate, (R-(R*,R*))-Isomer\",D03.633.100.857.070',\n 'Brimonidine Tartrate (1:1),D03.633.100.857.070',\n 'Mirvaso,D03.633.100.857.070',\n 'Clinical Studies as Topic,E05.318.372.250',\n 'Clinical Studies as Topic,N05.715.360.330.250',\n 'Clinical Studies as Topic,N06.850.520.450.250',\n 'Beijing,Z01.252.474.164.225',\n 'Beijing,Z01.433.114',\n 'African Union,I01.615.500.125',\n 'African Union,N03.540.089',\n 'Firmicutes,B03.353',\n 'Dutasteride,D04.210.500.925.100.125',\n 'Avodart,D04.210.500.925.100.125',\n 'GG 745,D04.210.500.925.100.125',\n 'GI198745,D04.210.500.925.100.125',\n 'Calceolariaceae,B01.650.940.800.575.912.250.583.190',\n 'Jovellana,B01.650.940.800.575.912.250.583.190',\n 'Calceolaria,B01.650.940.800.575.912.250.583.190',\n 'Porodittia,B01.650.940.800.575.912.250.583.190',\n 'Interferon beta-1a,D12.644.276.374.440.890.275.500',\n 'Interferon beta-1a,D12.776.467.374.440.890.275.500',\n 'Interferon beta-1a,D23.529.374.440.890.275.500',\n 'Avonex Pen,D12.644.276.374.440.890.275.500',\n 'Avonex Pen,D12.776.467.374.440.890.275.500',\n 'Avonex Pen,D23.529.374.440.890.275.500',\n 'Rebif,D12.644.276.374.440.890.275.500',\n 'Rebif,D12.776.467.374.440.890.275.500',\n 'Rebif,D23.529.374.440.890.275.500',\n 'Avonex,D12.644.276.374.440.890.275.500',\n 'Avonex,D12.776.467.374.440.890.275.500',\n 'Avonex,D23.529.374.440.890.275.500',\n 'Olmesartan Medoxomil,D03.383.129.308.674',\n 'Olmesartan Medoxomil,D03.383.129.617.584',\n 'Benicar,D03.383.129.308.674',\n 'Benicar,D03.383.129.617.584',\n 'Olmetec,D03.383.129.308.674',\n 'Olmetec,D03.383.129.617.584',\n 'CS 866,D03.383.129.308.674',\n 'CS 866,D03.383.129.617.584',\n 'Votum,D03.383.129.308.674',\n 'Votum,D03.383.129.617.584',\n '\"Amlodipine Besylate, Olmesartan Medoxomil Drug Combination\",D03.383.129.308.674.500',\n '\"Amlodipine Besylate, Olmesartan Medoxomil Drug Combination\",D03.383.129.617.584.500',\n '\"Amlodipine Besylate, Olmesartan Medoxomil Drug Combination\",D03.383.725.203.065.500',\n '\"Amlodipine Besylate, Olmesartan Medoxomil Drug Combination\",D26.310.063',\n 'Azor,D03.383.129.308.674.500',\n 'Azor,D03.383.129.617.584.500',\n 'Azor,D03.383.725.203.065.500',\n 'Azor,D26.310.063',\n 'Interferon beta-1b,D12.644.276.374.440.890.275.750',\n 'Interferon beta-1b,D12.776.467.374.440.890.275.750',\n 'Interferon beta-1b,D23.529.374.440.890.275.750',\n 'Betaseron,D12.644.276.374.440.890.275.750',\n 'Betaseron,D12.776.467.374.440.890.275.750',\n 'Betaseron,D23.529.374.440.890.275.750',\n 'Extavia,D12.644.276.374.440.890.275.750',\n 'Extavia,D12.776.467.374.440.890.275.750',\n 'Extavia,D23.529.374.440.890.275.750',\n 'Betaferon,D12.644.276.374.440.890.275.750',\n 'Betaferon,D12.776.467.374.440.890.275.750',\n 'Betaferon,D23.529.374.440.890.275.750',\n 'Nebivolol,D02.033.100.291.491',\n 'Nebivolol,D02.092.063.291.503',\n 'Nebivolol,D03.383.663.283.755',\n 'Nebivolol,D03.633.100.150.755',\n 'Bystolic,D02.033.100.291.491',\n 'Bystolic,D02.092.063.291.503',\n 'Bystolic,D03.383.663.283.755',\n 'Bystolic,D03.633.100.150.755',\n 'Nebilet,D02.033.100.291.491',\n 'Nebilet,D02.092.063.291.503',\n 'Nebilet,D03.383.663.283.755',\n 'Nebilet,D03.633.100.150.755',\n 'Silostar,D02.033.100.291.491',\n 'Silostar,D02.092.063.291.503',\n 'Silostar,D03.383.663.283.755',\n 'Silostar,D03.633.100.150.755',\n 'Nebivolol Hydrochloride,D02.033.100.291.491',\n 'Nebivolol Hydrochloride,D02.092.063.291.503',\n 'Nebivolol Hydrochloride,D03.383.663.283.755',\n 'Nebivolol Hydrochloride,D03.633.100.150.755',\n 'R 67555,D02.033.100.291.491',\n 'R 67555,D02.092.063.291.503',\n 'R 67555,D03.383.663.283.755',\n 'R 67555,D03.633.100.150.755',\n 'Lobivon,D02.033.100.291.491',\n 'Lobivon,D02.092.063.291.503',\n 'Lobivon,D03.383.663.283.755',\n 'Lobivon,D03.633.100.150.755',\n 'Celecoxib,D02.065.884.247',\n 'Celecoxib,D02.886.590.700.247',\n 'Celecoxib,D03.383.129.539.160',\n 'Celebrex,D02.065.884.247',\n 'Celebrex,D02.886.590.700.247',\n 'Celebrex,D03.383.129.539.160',\n 'SC 58635,D02.065.884.247',\n 'SC 58635,D02.886.590.700.247',\n 'SC 58635,D03.383.129.539.160',\n 'Varenicline,D03.633.100.079.900',\n 'Varenicline,D03.633.100.857.942',\n 'Chantix,D03.633.100.079.900',\n 'Chantix,D03.633.100.857.942',\n 'Varenicline Tartrate,D03.633.100.079.900',\n 'Varenicline Tartrate,D03.633.100.857.942',\n 'Champix,D03.633.100.079.900',\n 'Champix,D03.633.100.857.942',\n 'Tadalafil,D03.383.725.150.500',\n 'Tadalafil,D03.633.100.473.155.500',\n 'Tadalafil,D03.633.300.154.672',\n 'IC351,D03.383.725.150.500',\n 'IC351,D03.633.100.473.155.500',\n 'IC351,D03.633.300.154.672',\n 'Cialis,D03.383.725.150.500',\n 'Cialis,D03.633.100.473.155.500',\n 'Cialis,D03.633.300.154.672',\n 'Certolizumab Pegol,D05.750.741.125',\n 'Certolizumab Pegol,D12.644.541.500.650.250',\n 'Certolizumab Pegol,D12.776.124.486.485.114.224.060.500',\n 'Certolizumab Pegol,D12.776.124.486.485.680.650.250',\n 'Certolizumab Pegol,D12.776.124.790.651.114.224.060.500',\n 'Certolizumab Pegol,D12.776.124.790.651.680.650.250',\n 'Certolizumab Pegol,D12.776.377.715.548.114.224.200.500',\n 'Certolizumab Pegol,D12.776.377.715.548.680.650.250',\n 'Cimzia,D05.750.741.125',\n 'Cimzia,D12.644.541.500.650.250',\n 'Cimzia,D12.776.124.486.485.114.224.060.500',\n 'Cimzia,D12.776.124.486.485.680.650.250',\n 'Cimzia,D12.776.124.790.651.114.224.060.500',\n 'Cimzia,D12.776.124.790.651.680.650.250',\n 'Cimzia,D12.776.377.715.548.114.224.200.500',\n 'Cimzia,D12.776.377.715.548.680.650.250',\n 'CDP870,D05.750.741.125',\n 'CDP870,D12.644.541.500.650.250',\n 'CDP870,D12.776.124.486.485.114.224.060.500',\n 'CDP870,D12.776.124.486.485.680.650.250',\n 'CDP870,D12.776.124.790.651.114.224.060.500',\n 'CDP870,D12.776.124.790.651.680.650.250',\n 'CDP870,D12.776.377.715.548.114.224.200.500',\n 'CDP870,D12.776.377.715.548.680.650.250',\n '\"Censorship, Research\",I01.880.604.238',\n '\"Censorship, Research\",K01.752.566.479.173.200',\n '\"Censorship, Research\",N05.350.670.250',\n 'Data Accuracy,E05.318.308.028',\n 'Data Accuracy,E05.318.370.725.250',\n 'Data Accuracy,L01.399.250.202',\n 'Data Accuracy,N05.715.360.300.202',\n 'Data Accuracy,N05.715.360.325.685.250',\n 'Data Quality,E05.318.308.028',\n 'Data Quality,E05.318.370.725.250',\n 'Data Quality,L01.399.250.202',\n 'Data Quality,N05.715.360.300.202',\n 'Data Quality,N05.715.360.325.685.250',\n '\"Brimonidine Tartrate, Timolol Maleate Drug Combination\",D02.033.100.624.915.500',\n '\"Brimonidine Tartrate, Timolol Maleate Drug Combination\",D02.033.755.624.915.500',\n '\"Brimonidine Tartrate, Timolol Maleate Drug Combination\",D02.092.063.624.915.500',\n '\"Brimonidine Tartrate, Timolol Maleate Drug Combination\",D02.886.675.867.768.500',\n '\"Brimonidine Tartrate, Timolol Maleate Drug Combination\",D03.383.129.708.867.768.500',\n '\"Brimonidine Tartrate, Timolol Maleate Drug Combination\",D03.633.100.857.070.500',\n '\"Brimonidine Tartrate, Timolol Maleate Drug Combination\",D26.310.312',\n ...]","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[34]: ['term,tree',\n 'Calcimycin,D03.633.100.221.173',\n 'A-23187,D03.633.100.221.173',\n 'Temefos,D02.705.400.625.800',\n 'Temefos,D02.705.539.345.800',\n 'Temefos,D02.886.300.692.800',\n 'Abate,D02.705.400.625.800',\n 'Abate,D02.705.539.345.800',\n 'Abate,D02.886.300.692.800',\n 'Difos,D02.705.400.625.800',\n 'Difos,D02.705.539.345.800',\n 'Difos,D02.886.300.692.800',\n 'Abattoirs,J01.576.423.200.700.100',\n 'Abattoirs,J03.540.020',\n 'Abbreviations as Topic,L01.559.598.400.556.131',\n 'Acronyms as Topic,L01.559.598.400.556.131',\n 'Abdomen,A01.923.047',\n '\"Abdomen, Acute\",C23.888.592.612.054.200',\n '\"Abdomen, Acute\",C23.888.821.030.249',\n 'Abdominal Injuries,C26.017',\n 'Abdominal Neoplasms,C04.588.033',\n 'Abdominal Muscles,A02.633.567.050',\n 'Cremaster Muscle,A02.633.567.050',\n 'Pyramidalis Muscle,A02.633.567.050',\n 'Quadratus Abdominis,A02.633.567.050',\n 'Transversus Abdominis,A02.633.567.050',\n 'Abducens Nerve,A08.800.800.120.030',\n 'Abelson murine leukemia virus,B04.613.807.375.525.020',\n 'Abelson murine leukemia virus,B04.820.650.375.525.020',\n 'Abetalipoproteinemia,C16.320.565.398.500.440.500',\n 'Abetalipoproteinemia,C18.452.584.500.875.440.500',\n 'Abetalipoproteinemia,C18.452.648.398.500.440.500',\n 'Congenital Abnormalities,C16.131',\n 'Fetal Malformations,C16.131',\n 'Fetal Anomalies,C16.131',\n '\"Abnormalities, Drug-Induced\",C16.131.042',\n '\"Abnormalities, Multiple\",C16.131.077',\n '\"Abnormalities, Radiation-Induced\",C16.131.080',\n '\"Abnormalities, Radiation-Induced\",C26.733.031',\n '\"Abnormalities, Radiation-Induced\",G01.750.748.500.031',\n '\"Abnormalities, Radiation-Induced\",N06.850.460.350.850.500.031',\n '\"Abnormalities, Radiation-Induced\",N06.850.810.300.360.031',\n 'ABO Blood-Group System,D23.050.301.290.031',\n 'ABO Blood-Group System,D23.050.705.230.031',\n 'Blood Group H Type 1 Antigen,D23.050.301.290.031',\n 'Blood Group H Type 1 Antigen,D23.050.705.230.031',\n 'ABO Factors,D23.050.301.290.031',\n 'ABO Factors,D23.050.705.230.031',\n 'Abomasum,A13.869.106',\n 'Abortifacient Agents,D27.505.696.875.131',\n 'Abortifacient Agents,D27.505.954.705.131',\n 'Abortifacient Effect,D27.505.696.875.131',\n 'Abortifacient Effect,D27.505.954.705.131',\n '\"Abortifacient Agents, Nonsteroidal\",D27.505.696.875.131.100',\n '\"Abortifacient Agents, Nonsteroidal\",D27.505.954.705.131.100',\n '\"Abortifacient Agents, Steroidal\",D27.505.696.875.131.200',\n '\"Abortifacient Agents, Steroidal\",D27.505.954.705.131.200',\n '\"Abortion, Spontaneous\",C13.703.039',\n '\"Abortion, Spontaneous\",G08.686.784.769.496.125',\n 'Early Pregnancy Loss,C13.703.039',\n 'Early Pregnancy Loss,G08.686.784.769.496.125',\n 'Miscarriage,C13.703.039',\n 'Miscarriage,G08.686.784.769.496.125',\n '\"Abortion, Tubal\",C13.703.039',\n '\"Abortion, Tubal\",G08.686.784.769.496.125',\n 'Abortion Applicants,M01.050',\n '\"Abortion Seekers, Repeated\",M01.050',\n '\"Abortion Seekers, Refused\",M01.050',\n '\"Abortion, Criminal\",I01.198.240.089',\n '\"Abortion, Eugenic\",E04.520.050.050',\n '\"Abortion, Selective\",E04.520.050.050',\n '\"Abortion, Habitual\",C13.703.039.089',\n '\"Abortion, Incomplete\",C13.703.039.093',\n '\"Abortion, Induced\",E04.520.050',\n 'Abortion Rate,E04.520.050',\n 'Abortion Techniques,E04.520.050',\n '\"Abortion, Drug-Induced\",E04.520.050',\n 'Previous Abortion,E04.520.050',\n '\"Abortion, Saline-Solution\",E04.520.050',\n '\"Abortion, Soap-Solution\",E04.520.050',\n 'Anti-Abortion Groups,E04.520.050',\n 'Embryotomy,E04.520.050',\n '\"Fertility Control, Postconception\",E04.520.050',\n 'Abortion Failure,E04.520.050',\n '\"Abortion, Rivanol\",E04.520.050',\n '\"Abortion, Legal\",E04.520.050.055',\n 'Abortion on Demand,E04.520.050.055',\n '\"Abortion, Missed\",C13.703.039.173',\n '\"Abortion, Septic\",C01.674.173',\n '\"Abortion, Septic\",C13.703.039.256',\n '\"Abortion, Septic\",C13.703.700.173',\n '\"Abortion, Therapeutic\",E04.520.050.060',\n '\"Abortion, Threatened\",C13.703.090',\n '\"Abortion, Veterinary\",C13.703.039.422',\n '\"Abortion, Veterinary\",C22.021',\n 'Abreaction,F04.754.720.107',\n 'Abrin,D08.811.277.450.430.700.750.111',\n 'Abrin,D12.776.503.499.249',\n 'Abrin,D12.776.765.678.906.111',\n 'Abrin C,D08.811.277.450.430.700.750.111',\n 'Abrin C,D12.776.503.499.249',\n 'Abrin C,D12.776.765.678.906.111',\n 'Abrin A,D08.811.277.450.430.700.750.111',\n 'Abrin A,D12.776.503.499.249',\n 'Abrin A,D12.776.765.678.906.111',\n 'Abruptio Placentae,C13.703.420.078',\n 'Abruptio Placentae,C13.703.590.132',\n 'Abscess,C01.830.025',\n 'Abscess,C23.550.470.756.100',\n 'Peritonsillar Abscess,C01.748.561.750.500',\n 'Peritonsillar Abscess,C01.830.025.675',\n 'Peritonsillar Abscess,C07.550.781.750.500',\n 'Peritonsillar Abscess,C08.730.561.750.500',\n 'Peritonsillar Abscess,C09.775.649.750.500',\n 'Abscisic Acid,D02.241.223.268.034',\n 'Abscisic Acid,D02.455.326.271.665.202.061',\n 'Abscisic Acid,D02.455.426.392.368.367.379.249.024',\n 'Abscisic Acid,D02.455.849.131.061',\n 'Abscisic Acid,D02.455.849.765.521.500',\n '\"Abscisic Acid, (+,-)-Isomer\",D02.241.223.268.034',\n '\"Abscisic Acid, (+,-)-Isomer\",D02.455.326.271.665.202.061',\n '\"Abscisic Acid, (+,-)-Isomer\",D02.455.426.392.368.367.379.249.024',\n '\"Abscisic Acid, (+,-)-Isomer\",D02.455.849.131.061',\n '\"Abscisic Acid, (+,-)-Isomer\",D02.455.849.765.521.500',\n '\"Abscisic Acid, (Z,E)-Isomer\",D02.241.223.268.034',\n '\"Abscisic Acid, (Z,E)-Isomer\",D02.455.326.271.665.202.061',\n '\"Abscisic Acid, (Z,E)-Isomer\",D02.455.426.392.368.367.379.249.024',\n '\"Abscisic Acid, (Z,E)-Isomer\",D02.455.849.131.061',\n '\"Abscisic Acid, (Z,E)-Isomer\",D02.455.849.765.521.500',\n '\"Abscisic Acid, (E,Z)-(+,-)-Isomer\",D02.241.223.268.034',\n '\"Abscisic Acid, (E,Z)-(+,-)-Isomer\",D02.455.326.271.665.202.061',\n '\"Abscisic Acid, (E,Z)-(+,-)-Isomer\",D02.455.426.392.368.367.379.249.024',\n '\"Abscisic Acid, (E,Z)-(+,-)-Isomer\",D02.455.849.131.061',\n '\"Abscisic Acid, (E,Z)-(+,-)-Isomer\",D02.455.849.765.521.500',\n '\"Abscisic Acid, (R)-Isomer\",D02.241.223.268.034',\n '\"Abscisic Acid, (R)-Isomer\",D02.455.326.271.665.202.061',\n '\"Abscisic Acid, (R)-Isomer\",D02.455.426.392.368.367.379.249.024',\n '\"Abscisic Acid, (R)-Isomer\",D02.455.849.131.061',\n '\"Abscisic Acid, (R)-Isomer\",D02.455.849.765.521.500',\n '\"Abscisic Acid Monoammonium Salt, (R)-Isomer\",D02.241.223.268.034',\n '\"Abscisic Acid Monoammonium Salt, (R)-Isomer\",D02.455.326.271.665.202.061',\n '\"Abscisic Acid Monoammonium Salt, (R)-Isomer\",D02.455.426.392.368.367.379.249.024',\n '\"Abscisic Acid Monoammonium Salt, (R)-Isomer\",D02.455.849.131.061',\n '\"Abscisic Acid Monoammonium Salt, (R)-Isomer\",D02.455.849.765.521.500',\n '\"Abscisic Acid, (E,E)-(+-)-Isomer\",D02.241.223.268.034',\n '\"Abscisic Acid, (E,E)-(+-)-Isomer\",D02.455.326.271.665.202.061',\n '\"Abscisic Acid, (E,E)-(+-)-Isomer\",D02.455.426.392.368.367.379.249.024',\n '\"Abscisic Acid, (E,E)-(+-)-Isomer\",D02.455.849.131.061',\n '\"Abscisic Acid, (E,E)-(+-)-Isomer\",D02.455.849.765.521.500',\n 'Absenteeism,F02.784.692.107',\n 'Absorption,G01.015',\n 'Absorption,G02.010',\n 'Absorption,G03.015',\n 'Absorption,G03.787.024',\n 'Absorption,G07.690.725.015',\n 'Abstracting and Indexing,L01.453.245.100',\n 'Indexing,L01.453.245.100',\n 'Indexes as Topic,L01.453.245.100',\n 'Abstracting,L01.453.245.100',\n 'Dental Abutments,E06.780.346.500',\n 'Dental Abutments,E07.695.190.175',\n 'Acacia,B01.650.940.800.575.912.250.401.025',\n 'Acacia catechu,B01.650.940.800.575.912.250.401.025',\n 'Academic Medical Centers,N02.278.020',\n 'Academies and Institutes,N03.540.052',\n 'Institutes,N03.540.052',\n 'Research Institutes,N03.540.052',\n 'Academies,N03.540.052',\n 'Acanthamoeba,B01.046.500.100.075.080',\n 'Acanthocephala,B01.050.500.500.132',\n 'Acanthocytes,A11.118.290.330.100',\n 'Acanthocytes,A11.443.240.330.100',\n 'Acanthocytes,A15.145.229.334.330.100',\n 'Acantholysis,C17.800.865.070',\n 'Acantholysis,C23.550.035',\n 'Acanthosis Nigricans,C17.800.621.430.530.100',\n 'Acari,B01.050.500.131.166.132',\n 'Acceleration,G01.482.107',\n 'Accessory Nerve,A08.800.800.120.060',\n 'Accident Prevention,N06.850.135.060',\n 'Accident Proneness,F01.145.015',\n 'Accidental Falls,N06.850.135.122',\n 'Slip and Fall,N06.850.135.122',\n 'Accidents,N06.850.135',\n '\"Accidents, Aviation\",N06.850.135.185',\n '\"Accidents, Home\",N06.850.135.217',\n '\"Accidents, Occupational\",N06.850.135.240',\n '\"Accidents, Industrial\",N06.850.135.240',\n '\"Accidents, Traffic\",N06.850.135.392',\n 'Traffic Collisions,N06.850.135.392',\n 'Traffic Crashes,N06.850.135.392',\n 'Acclimatization,G07.025.133',\n 'Acclimatization,G16.012.500.133',\n '\"Accommodation, Ocular\",G14.010',\n '\"Accommodation, Lens\",G14.010',\n 'Accounting,N03.219.463.030',\n 'Oil and Gas Industry,J01.576.655.875.750',\n 'Petroleum Industry,J01.576.655.875.750',\n 'Oil Refinery,J01.576.655.875.750',\n 'Natural Gas Industry,J01.576.655.875.750',\n 'Coal Industry,J01.576.655.875.200',\n 'Driving Under the Influence,F01.145.250.250',\n 'Driving Under the Influence,F01.145.263.500',\n 'Driving Under the Influence,I01.880.735.223.250',\n 'Driving Under the Influence,I03.125.649',\n 'Drinking and Driving,F01.145.250.250',\n 'Drinking and Driving,F01.145.263.500',\n 'Drinking and Driving,I01.880.735.223.250',\n 'Drinking and Driving,I03.125.649',\n 'Human Embryonic Stem Cells,A11.872.700.250.750',\n 'Mouse Embryonic Stem Cells,A11.872.700.250.875',\n 'Embryonic Germ Cells,A11.497.124',\n 'Embryonic Germ Cells,A11.872.700.250.625',\n 'Work Performance,I03.946.675',\n 'Job Performance,I03.946.675',\n 'Criminal Behavior,F01.145.250',\n 'Clinical Decision-Making,E01.055',\n 'Cognitive Aging,G07.345.124.260',\n 'Cognitive Neuroscience,F04.096.628.255.500',\n 'Cognitive Neuroscience,H01.158.610.030',\n 'Social Neuroscience,F04.096.628.255.500',\n 'Social Neuroscience,H01.158.610.030',\n 'Emotional Adjustment,F01.058.144',\n 'Emotional Adjustment,F01.752.543.500.250',\n 'Facial Recognition,F02.463.593.524.250.500',\n 'Facial Recognition,F02.463.593.524.500.500',\n 'Facial Recognition,F02.463.593.932.622.500',\n 'Facial Emotion Recognition,F02.463.593.524.250.500',\n 'Facial Emotion Recognition,F02.463.593.524.500.500',\n 'Facial Emotion Recognition,F02.463.593.932.622.500',\n 'Grandparents,F01.829.263.403',\n 'Grandparents,I01.880.853.150.452',\n 'Grandparents,M01.264',\n 'Grandmother,F01.829.263.403',\n 'Grandmother,I01.880.853.150.452',\n 'Grandmother,M01.264',\n 'Grandfather,F01.829.263.403',\n 'Grandfather,I01.880.853.150.452',\n 'Grandfather,M01.264',\n 'Help-Seeking Behavior,F01.145.813.217',\n 'Heuristics,F02.463.425.725.500',\n 'Heuristics,F02.463.785.810.500',\n 'Intimate Partner Violence,I01.198.240.856.575',\n 'Intimate Partner Violence,I01.880.735.900.688',\n 'Dating Violence,I01.198.240.856.575',\n 'Dating Violence,I01.880.735.900.688',\n 'Neurological Rehabilitation,E02.760.169.063.500.477',\n 'Neurological Rehabilitation,E02.831.477',\n 'Neurological Rehabilitation,H02.403.680.600.750',\n 'Neurological Rehabilitation,N02.421.784.511',\n 'Physical Abuse,I01.198.240.856.688',\n 'Physical Abuse,I01.880.735.900.744',\n 'Problem Behavior,F01.145.126.972',\n 'Problem Behavior,F01.145.179.750',\n '\"Dysfunctional Behavior, Psychology\",F01.145.126.972',\n '\"Dysfunctional Behavior, Psychology\",F01.145.179.750',\n 'Disruptive Behavior,F01.145.126.972',\n 'Disruptive Behavior,F01.145.179.750',\n 'Underage Drinking,F01.145.022.750',\n 'Underage Drinking,F01.145.317.269.875',\n 'Underage Drinking,I01.880.735.878',\n 'Legal Drinking Age,F01.145.022.750',\n 'Legal Drinking Age,F01.145.317.269.875',\n 'Legal Drinking Age,I01.880.735.878',\n 'Ectopic Gene Expression,G05.308.202',\n 'Cell Plasticity,G04.356.250',\n 'Cell Self Renewal,G04.144.220.235',\n 'Cell Self Renewal,G04.161.750.500.375',\n 'Cell Self Renewal,G05.113.415',\n 'Cell Self Renewal,G07.345.249.410.750.500.625',\n 'Stem Cell Self-Renewal,G04.144.220.235',\n 'Stem Cell Self-Renewal,G04.161.750.500.375',\n 'Stem Cell Self-Renewal,G05.113.415',\n 'Stem Cell Self-Renewal,G07.345.249.410.750.500.625',\n 'Rehabilitation Research,H01.770.644.145.472',\n 'Orthodontists,M01.526.485.330.655',\n 'Orthodontists,N02.360.330.655',\n 'Dentofacial Orthopedists,M01.526.485.330.655',\n 'Dentofacial Orthopedists,N02.360.330.655',\n 'Oral and Maxillofacial Surgeons,M01.526.485.330.483',\n 'Oral and Maxillofacial Surgeons,N02.360.330.483',\n 'Exodontists,M01.526.485.330.483',\n 'Exodontists,N02.360.330.483',\n 'Neuroprotection,G11.561.645',\n '\"Diet, Food, and Nutrition\",G07.203',\n 'Triticale,B01.650.940.800.575.912.250.822.906',\n 'Critical Care Outcomes,N04.761.559.590.399.250',\n 'Critical Care Outcomes,N05.715.360.575.575.399.250',\n 'Simulation Training,I02.903.847',\n 'Interactive Learning,I02.903.847',\n 'Millets,B01.650.940.800.575.912.250.822.587',\n 'Biobehavioral Sciences,H01.770.644.108.687',\n 'Protein Corona,D12.776.642',\n 'Vegetarians,M01.928',\n 'Lacto-Ovo Vegetarians,M01.928',\n 'Vegans,M01.928.500',\n 'Accounts Payable and Receivable,N03.219.463.030.080',\n 'Accounts Payable,N03.219.463.030.080',\n 'Youth Sports,I03.450.642.845.987',\n 'Organized Youth Sports,I03.450.642.845.987',\n 'Literacy,F01.145.209.429',\n 'Literacy,N01.824.196.500',\n 'Illiteracy,F01.145.209.429',\n 'Illiteracy,N01.824.196.500',\n 'Severe Acute Malnutrition,C18.654.521.719',\n '\"Banking, Personal\",N03.219.463.030.100',\n 'Savings Accounts,N03.219.463.030.100',\n 'Checking Accounts,N03.219.463.030.100',\n 'Evidence-Based Facility Design,N02.278.200.252',\n '\"Physical Appearance, Body\",E01.370.600.115.450',\n '\"Physical Appearance, Body\",G07.100.175',\n 'Fruit and Vegetable Juices,G07.203.100.606',\n 'Fruit and Vegetable Juices,J02.200.606',\n 'Vegetable Juices,G07.203.100.606',\n 'Vegetable Juices,J02.200.606',\n 'Fruit Juices,G07.203.100.606',\n 'Fruit Juices,J02.200.606',\n 'Ghee,D10.212.302.199.500',\n 'Ghee,G07.203.300.350.100.500',\n 'Ghee,G07.203.300.375.200.500',\n 'Ghee,J02.500.350.100.500',\n 'Ghee,J02.500.375.200.500',\n 'Hydraulic Fracking,J01.576.655.875.750.500',\n 'Psychological Trauma,F03.950.750.375',\n 'Peer Influence,F01.829.316.483.750',\n 'Peer Pressure,F01.829.316.483.750',\n 'Vegetable Products,G07.203.300.850.450',\n 'Vegetable Products,J02.500.850.800',\n 'Direct-to-Consumer Advertising,J01.219.687.274.500',\n 'Direct-To-Consumer Screening and Testing,E01.370.398',\n 'Direct-To-Consumer Screening and Testing,N02.421.726.233.166',\n 'Extracellular Vesicles,A11.284.295.588',\n 'Exovesicles,A11.284.295.588',\n 'Apoptotic Bodies,A11.284.295.588',\n 'Fungal Viruses,B04.352',\n 'Telocytes,A11.329.830.750',\n 'Exoskeleton Device,E07.341',\n 'Robotic Exoskeleton,E07.341',\n 'Shellfish Hypersensitivity,C20.543.480.370.763',\n '\"Failure to Rescue, Health Care\",E01.789.800.760.500',\n '\"Failure to Rescue, Health Care\",H01.770.644.145.431.500',\n '\"Failure to Rescue, Health Care\",N04.761.559.590.800.760.500',\n '\"Failure to Rescue, Health Care\",N05.715.360.575.575.800.760.500',\n 'Psychiatric Rehabilitation,H02.403.680.600.875',\n 'Psychiatric Rehabilitation,N02.421.784.578',\n 'Psychosocial Care,H02.403.680.600.875',\n 'Psychosocial Care,N02.421.784.578',\n 'Symptom Flare Up,C23.550.291.937.500',\n 'Symptom Exacerbation,C23.550.291.937.500',\n 'Isolated Heart Preparation,E05.519',\n 'Isolated Heart Preparation,E05.598.750',\n 'Langendorff Perfused Heart,E05.519',\n 'Langendorff Perfused Heart,E05.598.750',\n 'Working Heart Preparation Technique,E05.519',\n 'Working Heart Preparation Technique,E05.598.750',\n 'Working Heart Preparation,E05.519',\n 'Working Heart Preparation,E05.598.750',\n 'Isolated Heart Preparation Technique,E05.519',\n 'Isolated Heart Preparation Technique,E05.598.750',\n '\"Diet, Vegan\",E02.642.249.300.750',\n '\"Diet, Vegan\",G07.203.650.240.300.750',\n 'Veganism,E02.642.249.300.750',\n 'Veganism,G07.203.650.240.300.750',\n 'Behavior Observation Techniques,E05.796.112',\n 'Behavior Observation Techniques,F04.669.112',\n 'Behavior Rating Scale,F04.711.271',\n 'Behavior Test,F04.711.271',\n 'Alcohol Drinking in College,F01.145.317.269.625',\n '\"Obesity, Metabolically Benign\",C18.654.726.500.650',\n '\"Obesity, Metabolically Benign\",C23.888.144.699.500.250',\n '\"Obesity, Metabolically Benign\",E01.370.600.115.100.160.120.699.500.375',\n '\"Obesity, Metabolically Benign\",G07.100.100.160.120.699.500.375',\n 'Whole Grains,G07.203.300.300.550.500',\n 'Whole Grains,G07.203.300.775.500.500',\n 'Whole Grains,J02.500.300.550.500',\n 'Whole Grains,J02.500.775.500.500',\n 'Whole Grain Cereals,G07.203.300.300.550.500',\n 'Whole Grain Cereals,G07.203.300.775.500.500',\n 'Whole Grain Cereals,J02.500.300.550.500',\n 'Whole Grain Cereals,J02.500.775.500.500',\n 'Transanal Endoscopic Surgery,E01.370.388.250.630.500',\n 'Transanal Endoscopic Surgery,E04.210.240.250.680.500',\n 'Transanal Endoscopic Surgery,E04.502.250.250.250.680.500',\n 'Transanal Endoscopic Surgery,E04.502.250.630.500',\n 'Transanal Minimally Invasive Surgery,E01.370.388.250.630.500',\n 'Transanal Minimally Invasive Surgery,E04.210.240.250.680.500',\n 'Transanal Minimally Invasive Surgery,E04.502.250.250.250.680.500',\n 'Transanal Minimally Invasive Surgery,E04.502.250.630.500',\n 'Transanal Endoscopic Microsurgery,E01.370.388.250.630.500.500',\n 'Transanal Endoscopic Microsurgery,E04.210.240.250.680.500.500',\n 'Transanal Endoscopic Microsurgery,E04.494.787',\n 'Transanal Endoscopic Microsurgery,E04.502.250.250.250.680.500.500',\n 'Transanal Endoscopic Microsurgery,E04.502.250.630.500.500',\n 'Cold Injury,C26.212',\n 'Personal Protective Equipment,E07.700.560',\n 'Personal Protective Equipment,J01.637.708.560',\n 'Nerve Agents,D27.720.599',\n 'Nerve Agents,D27.720.777.300.500',\n 'Nerve Gas,D27.720.599',\n 'Nerve Gas,D27.720.777.300.500',\n 'War-Related Injuries,C26.946',\n 'War-Related Injuries,I01.880.735.950.500.951.500',\n 'War-Related Injuries,N06.850.460.350.600.903.500',\n 'War-Related Trauma,C26.946',\n 'War-Related Trauma,I01.880.735.950.500.951.500',\n 'War-Related Trauma,N06.850.460.350.600.903.500',\n 'Abnormal Involuntary Movement Scale,E01.370.600.550.162',\n 'Blood Alcohol Content,D02.033.375.135',\n 'Social Communication Disorder,F03.625.374.250',\n 'Legal Services,I01.880.604.583.482',\n 'Defamation,I01.198.240.240',\n 'Defamation,I01.880.735.191.051',\n 'Slander,I01.198.240.240',\n 'Slander,I01.880.735.191.051',\n 'Libel,I01.198.240.240',\n 'Libel,I01.880.735.191.051',\n 'Anger Management Therapy,F04.754.137.087',\n '\"Psychology, Sports\",F04.096.628.914',\n 'War Exposure,I01.880.735.950.500.951',\n 'War Exposure,N06.850.460.350.600.903',\n 'Childhood-Onset Fluency Disorder,F03.625.374.125',\n 'No-Show Patients,F01.100.150.750.500.600.750',\n 'No-Show Patients,F01.145.488.887.500.600.750',\n 'No-Show Patients,M01.643.550',\n 'No-Show Patients,N04.452.758.635.500',\n 'No-Show Patients,N05.300.150.800.500.600.750',\n 'Cellular Reprogramming Techniques,E05.200.500.380',\n 'Cellular Reprogramming Techniques,E05.242.378',\n 'Cellular Reprogramming Techniques,E05.393.085',\n 'Directed Differentiation Techniques,E05.200.500.380',\n 'Directed Differentiation Techniques,E05.242.378',\n 'Directed Differentiation Techniques,E05.393.085',\n 'Direct Cell Reprogramming Techniques,E05.200.500.380',\n 'Direct Cell Reprogramming Techniques,E05.242.378',\n 'Direct Cell Reprogramming Techniques,E05.393.085',\n 'Metacognition,F02.463.188.756',\n 'Metacognitive Awareness,F02.463.188.756',\n 'Metacognitive Monitoring,F02.463.188.756',\n 'Metacognitive Control,F02.463.188.756',\n 'Metaemotion,F02.463.188.756',\n 'Metamemory,F02.463.188.756',\n 'Prescription Drug Overuse,E02.319.306.500.750',\n '\"Near Miss, Healthcare\",E02.319.529.750',\n '\"Near Miss, Healthcare\",N02.421.450.500.750',\n '\"Near Miss, Healthcare\",N02.421.450.550',\n '\"Near Miss, Healthcare\",N04.761.700.594',\n '\"Near Miss, Healthcare\",N05.700.513',\n 'RNAi Therapeutics,E02.095.301.250',\n 'Dynamic Light Scattering,E05.196.822.325',\n 'Quasi-Elastic Light Scattering (QELS),E05.196.822.325',\n '\"Time Out, Healthcare\",N04.761.700.635',\n '\"Time Out, Healthcare\",N05.700.739',\n 'Surgical Time Out,N04.761.700.635',\n 'Surgical Time Out,N05.700.739',\n 'Healthcare Failure Mode and Effect Analysis,E05.318.740.600.800.715.500',\n 'Healthcare Failure Mode and Effect Analysis,N04.452.871.715.400',\n 'Healthcare Failure Mode and Effect Analysis,N05.715.360.750.625.700.690.400',\n 'Healthcare Failure Mode and Effect Analysis,N06.850.505.715.500',\n 'Healthcare Failure Mode and Effect Analysis,N06.850.520.830.600.800.715.500',\n 'Failure Mode and Effect Analysis,E05.318.740.600.800.715.500',\n 'Failure Mode and Effect Analysis,N04.452.871.715.400',\n 'Failure Mode and Effect Analysis,N05.715.360.750.625.700.690.400',\n 'Failure Mode and Effect Analysis,N06.850.505.715.500',\n 'Failure Mode and Effect Analysis,N06.850.520.830.600.800.715.500',\n 'Spirit Possession,K01.844.619.500',\n '\"Crew Resource Management, Healthcare\",N04.590.254',\n 'Computer Heuristics,L01.224.050.375.095',\n 'Ataxins,D12.776.631.069',\n 'Ataxins,D12.776.660.075',\n 'Alarmins,D23.035',\n 'Dermal Fillers,D27.720.102.461',\n 'Action Spectrum,E05.196.867.826.150',\n 'Diplomacy,F01.829.316.171',\n 'Diplomacy,F02.463.785.373.520.500',\n 'Diplomacy,I01.738.305',\n 'Mutation Accumulation,G05.365.590.594',\n 'Spontaneous Mutation Accumulation,G05.365.590.594',\n 'Internal Ribosome Entry Sites,D13.444.735.790.878.942.250',\n 'Internal Ribosome Entry Sites,G02.111.570.080.689.687.093',\n 'Internal Ribosome Entry Sites,G05.360.080.689.687.093',\n 'Biological Mimicry,G16.012.750',\n 'Biological Camouflage,G16.012.750',\n 'Specific Learning Disorder,F03.625.562.700',\n 'Potentially Inappropriate Medication List,N04.761.700.615',\n 'Potentially Inappropriate Medication List,N05.700.594',\n 'Beers Criteria,N04.761.700.615',\n 'Beers Criteria,N05.700.594',\n 'STOPP (Screening Tool of Older Persons Potentially Inappropriate Prescriptions),N04.761.700.615',\n 'STOPP (Screening Tool of Older Persons Potentially Inappropriate Prescriptions),N05.700.594',\n 'Medication Appropriateness Index,N04.761.700.615',\n 'Medication Appropriateness Index,N05.700.594',\n 'Late Onset Disorders,C23.550.291.883',\n 'Phakopsora pachyrhizi,B01.300.179.113',\n 'Farmers,M01.526.390',\n 'Ranchers,M01.526.390',\n 'Culturally Appropriate Technology,J01.897.052',\n 'Intermediate Technology,J01.897.052',\n 'Soft Technology,J01.897.052',\n 'Social Learning,F02.784.629.529.663',\n 'Financial Statements,N03.219.463.030.140',\n '\"Assets, Financial\",N03.219.463.030.140',\n 'Cash Flow Statement,N03.219.463.030.140',\n 'Balance Sheet,N03.219.463.030.140',\n 'Expense Statement,N03.219.463.030.140',\n 'Income Statement,N03.219.463.030.140',\n '\"Equity, Financial\",N03.219.463.030.140',\n '\"Liabilities, Financial\",N03.219.463.030.140',\n 'Miners,M01.526.693',\n 'Chronopharmacokinetics,G07.690.725.249',\n '\"Administrative Claims, Healthcare\",N04.452.859.564.137',\n 'Child Health,N01.400.225',\n 'Child Well Being,N01.400.225',\n 'Interleukin-33,D12.644.276.374.465.850',\n 'Interleukin-33,D12.776.467.374.465.850',\n 'Interleukin-33,D23.529.374.465.850',\n 'S100A12 Protein,D12.776.157.125.750.875',\n 'Telopodes,A11.284.180.900',\n 'Telopodes,A11.329.830.750.500',\n 'Podomers,A11.284.180.900',\n 'Podomers,A11.329.830.750.500',\n 'Podoms,A11.284.180.900',\n 'Podoms,A11.329.830.750.500',\n 'Drosophila simulans,B01.050.500.131.617.720.500.500.750.310.250.750',\n 'Optimism,F01.100.787',\n 'Positive Attitude,F01.100.787',\n 'Positive Thinking,F01.100.787',\n 'Pessimism,F01.100.893',\n 'Ataxin-1,D12.776.631.069.500',\n 'Ataxin-1,D12.776.660.075.500',\n 'Adolescent Health,N01.400.075',\n 'Adolescent Well Being,N01.400.075',\n 'Ataxin-2,D12.776.157.725.452.125',\n 'Ataxin-2,D12.776.631.069.750',\n 'Ataxin-2,D12.776.660.075.750',\n 'Ataxin-2,D12.776.664.962.452.125',\n 'Ataxin-3,D08.811.037.250',\n 'Ataxin-3,D12.776.631.069.875',\n 'Ataxin-3,D12.776.660.075.875',\n 'Point-of-Care Testing,N04.590.874.500',\n 'Bedside Testing,N04.590.874.500',\n 'Ataxin-7,D12.776.631.069.901',\n 'Ataxin-7,D12.776.660.075.900',\n 'Ataxin-10,D12.776.631.069.950',\n 'Glucagon-Like Peptide Receptors,D12.776.543.750.695.021',\n 'Glucagon-Like Peptide Receptors,D12.776.543.750.750.360.100',\n 'Glucagon-Like Peptide-1 Receptor,D12.776.543.750.695.021.500',\n 'Glucagon-Like Peptide-1 Receptor,D12.776.543.750.750.360.100.500',\n 'Glucagon-Like Peptide-2 Receptor,D12.776.543.750.695.021.600',\n 'Glucagon-Like Peptide-2 Receptor,D12.776.543.750.750.360.100.600',\n 'Receptor for Advanced Glycation End Products,D12.776.543.750.615',\n 'RNA Recognition Motif Proteins,D12.776.157.725.813',\n 'RNA Recognition Motif Proteins,D12.776.664.962.813',\n 'ELAV-Like Protein 2,D12.776.157.725.813.500.500',\n 'ELAV-Like Protein 2,D12.776.631.520.500',\n 'ELAV-Like Protein 2,D12.776.664.962.813.500.500',\n 'ELAV-Like Protein 3,D12.776.157.725.813.500.750',\n 'ELAV-Like Protein 3,D12.776.631.520.750',\n 'ELAV-Like Protein 3,D12.776.664.962.813.500.750',\n 'ELAV-Like Protein 4,D12.776.157.725.813.500.875',\n 'ELAV-Like Protein 4,D12.776.631.520.875',\n 'ELAV-Like Protein 4,D12.776.664.962.813.500.875',\n 'ELAV-Like Protein 1,D12.776.157.725.813.500.250',\n 'ELAV-Like Protein 1,D12.776.664.962.813.500.250',\n 'Whey,A12.790.760',\n 'Whey,G07.203.100.700.750',\n 'Whey,G07.203.300.350.525.760',\n 'Whey,J02.200.700.750',\n 'Whey,J02.500.350.525.760',\n 'Whey Proteins,A12.790.520.500',\n 'Whey Proteins,A12.790.760.500',\n 'Whey Proteins,D12.776.256.159.750.816',\n 'Whey Proteins,G07.203.300.350.525.760.500',\n 'Whey Proteins,G07.203.300.428.159.812.500',\n 'Whey Proteins,J02.500.350.525.520.500',\n 'Whey Proteins,J02.500.350.525.760.500',\n 'Whey Proteins,J02.500.428.159.750.500',\n 'Hoarding Disorder,F03.080.600.250',\n 'Obsessive Hoarding,F03.080.600.250',\n 'Poly(ADP-ribose) Polymerase Inhibitors,D27.505.519.389.739',\n 'Poly(ADP-ribose) Polymerase Inhibitors,D27.505.954.248.692',\n 'Autism Spectrum Disorder,F03.625.164.113',\n 'CELF Proteins,D12.776.157.725.813.250',\n 'CELF Proteins,D12.776.664.962.813.250',\n 'CELF1 Protein,D12.776.157.725.813.250.500',\n 'CELF1 Protein,D12.776.664.962.813.250.500',\n 'Industrial Development,I01.261.262.500',\n 'Industrial Development,J01.576.519',\n 'Technology Development,I01.261.262.500',\n 'Technology Development,J01.576.519',\n 'Industrialization,I01.261.262.500',\n 'Industrialization,J01.576.519',\n 'Cloud Computing,L01.224.097',\n 'Natural Resources,G16.500.275.553',\n 'Natural Resources,J01.728',\n 'Natural Resources,N06.230.350',\n 'Land Supply,G16.500.275.553',\n 'Land Supply,J01.728',\n 'Land Supply,N06.230.350',\n 'Glycemic Load,G07.203.650.660.750',\n 'Glycemic Load,J01.576.423.850.730.750.750',\n 'Glycemic Load,N06.850.601.750.750',\n 'Adenylyl Cyclase Inhibitors,D27.505.519.389.108',\n 'RAW 264.7 Cells,A11.251.210.172.875',\n 'RAW 264.7 Cells,A11.733.397.815',\n 'Accreditation,N03.706.110.070',\n 'Accreditation,N05.700.200.100',\n 'Clostridiales,B03.353.625',\n 'Graphic Novel,V02.700.415',\n 'Comic Book,V02.700.415',\n 'South Sudan,Z01.058.290.120.745',\n 'Motor Disorders,F03.608',\n 'Maternal Health,N01.400.900.500',\n 'Seed Bank,N02.278.065.650',\n 'Germplasm Bank,N02.278.065.650',\n 'Trauma and Stressor Related Disorders,F03.950',\n 'Maternal-Child Health Services,N02.421.143.130.660',\n 'Maternal-Child Health Services,N02.421.143.620.275',\n 'Serine-Arginine Splicing Factors,D12.776.157.725.829.500',\n 'Serine-Arginine Splicing Factors,D12.776.664.962.829.500',\n 'Infant Health,N01.400.388',\n 'Newborn Health,N01.400.388',\n 'Bipolar and Related Disorders,F03.084',\n 'Gender Dysphoria,F03.835.550',\n 'Formative Feedback,F02.784.629.529.223',\n 'Aripiprazole,D03.383.606.170',\n 'Aripiprazole,D03.633.100.810.835.122',\n 'Abilify,D03.383.606.170',\n 'Abilify,D03.633.100.810.835.122',\n 'OPC 14597,D03.383.606.170',\n 'OPC 14597,D03.633.100.810.835.122',\n 'Prunus dulcis,B01.650.940.800.575.912.250.859.937.500.625.500',\n 'Almonds,B01.650.940.800.575.912.250.859.937.500.625.500',\n 'Albumin-Bound Paclitaxel,D02.455.426.392.368.242.888.777.500',\n 'Albumin-Bound Paclitaxel,D02.455.849.291.850.777.500',\n 'Albumin-Bound Paclitaxel,D12.776.034.073',\n 'Abraxane,D02.455.426.392.368.242.888.777.500',\n 'Abraxane,D02.455.849.291.850.777.500',\n 'Abraxane,D12.776.034.073',\n 'ABI007,D02.455.426.392.368.242.888.777.500',\n 'ABI007,D02.455.849.291.850.777.500',\n 'ABI007,D12.776.034.073',\n 'Child Protective Services,I01.409.418.500',\n 'Child Protective Services,N03.540.400.500',\n 'Social Workers,M01.526.919',\n 'Prunus africana,B01.650.940.800.575.912.250.859.937.500.625.250',\n 'Prunus armeniaca,B01.650.940.800.575.912.250.859.937.500.625.375',\n 'Apricot,B01.650.940.800.575.912.250.859.937.500.625.375',\n 'Prunus avium,B01.650.940.800.575.912.250.859.937.500.625.400',\n 'Prunus serotina,B01.650.940.800.575.912.250.859.937.500.625.400',\n 'Sweet Cherries,B01.650.940.800.575.912.250.859.937.500.625.400',\n 'Prunus cerasus,B01.650.940.800.575.912.250.859.937.500.625.400',\n 'Refugium,G16.500.275.683',\n 'Refugium,G16.500.819',\n 'Distance Counseling,F02.784.176.350',\n 'Distance Counseling,F04.408.413.437',\n 'Distance Counseling,N02.421.143.303.175',\n 'Distance Counseling,N02.421.461.363.437',\n 'Distance Counseling,N04.452.758.849.550.500',\n 'Lubiprostone,D10.251.355.325.050.500',\n 'RU 0211,D10.251.355.325.050.500',\n 'Amitiza,D10.251.355.325.050.500',\n 'SPI 0211,D10.251.355.325.050.500',\n 'Prunus persica,B01.650.940.800.575.912.250.859.937.500.625.750',\n 'Peach,B01.650.940.800.575.912.250.859.937.500.625.750',\n 'Data Anonymization,H01.770.644.205',\n 'Data Anonymization,L01.224.134.500',\n 'Data Anonymization,N03.706.437.650.124.160',\n 'Data Anonymization,N04.452.910.200.500',\n 'De-Identification,H01.770.644.205',\n 'De-Identification,L01.224.134.500',\n 'De-Identification,N03.706.437.650.124.160',\n 'De-Identification,N04.452.910.200.500',\n 'Data Masking,H01.770.644.205',\n 'Data Masking,L01.224.134.500',\n 'Data Masking,N03.706.437.650.124.160',\n 'Data Masking,N04.452.910.200.500',\n 'Personally Identifiable Information,I01.880.604.583.080.660',\n 'Prunus domestica,B01.650.940.800.575.912.250.859.937.500.625.450',\n 'Plum,B01.650.940.800.575.912.250.859.937.500.625.450',\n 'Prunus cerasifera,B01.650.940.800.575.912.250.859.937.500.625.450',\n 'Prunus salicina,B01.650.940.800.575.912.250.859.937.500.625.450',\n 'Darbepoetin alfa,D12.776.395.240.150.500',\n 'Aranesp,D12.776.395.240.150.500',\n 'KRN 321,D12.776.395.240.150.500',\n '\"Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination\",D02.705.429.906.125',\n '\"Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination\",D03.383.533.375',\n '\"Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination\",D03.383.742.680.245.500.600.125',\n '\"Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination\",D03.633.100.759.138.881.125',\n '\"Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination\",D26.310.375',\n 'Atripla,D02.705.429.906.125',\n 'Atripla,D03.383.533.375',\n 'Atripla,D03.383.742.680.245.500.600.125',\n 'Atripla,D03.633.100.759.138.881.125',\n 'Atripla,D26.310.375',\n 'Bevacizumab,D12.776.124.486.485.114.224.060.375',\n 'Bevacizumab,D12.776.124.790.651.114.224.060.438',\n 'Bevacizumab,D12.776.377.715.548.114.224.200.438',\n 'Mvasi,D12.776.124.486.485.114.224.060.375',\n 'Mvasi,D12.776.124.790.651.114.224.060.438',\n 'Mvasi,D12.776.377.715.548.114.224.200.438',\n 'Bevacizumab-awwb,D12.776.124.486.485.114.224.060.375',\n 'Bevacizumab-awwb,D12.776.124.790.651.114.224.060.438',\n 'Bevacizumab-awwb,D12.776.377.715.548.114.224.200.438',\n 'Avastin,D12.776.124.486.485.114.224.060.375',\n 'Avastin,D12.776.124.790.651.114.224.060.438',\n 'Avastin,D12.776.377.715.548.114.224.200.438',\n 'Giraffes,B01.050.150.900.649.313.500.380.443',\n 'Okapis,B01.050.150.900.649.313.500.380.443',\n 'Risedronic Acid,D02.705.429.500.872',\n 'Risedronic Acid,D03.383.725.836',\n '1-Hydroxy-2-(3-pyridyl)ethylidene diphosphonate,D02.705.429.500.872',\n '1-Hydroxy-2-(3-pyridyl)ethylidene diphosphonate,D03.383.725.836',\n 'Atelvia,D02.705.429.500.872',\n 'Atelvia,D03.383.725.836',\n 'Risedronate Sodium,D02.705.429.500.872',\n 'Risedronate Sodium,D03.383.725.836',\n '2-(3-pyridinyl)-1-hydroxyethylidene-bisphosphonate,D02.705.429.500.872',\n '2-(3-pyridinyl)-1-hydroxyethylidene-bisphosphonate,D03.383.725.836',\n '\"Risedronic Acid, Monosodium Salt\",D02.705.429.500.872',\n '\"Risedronic Acid, Monosodium Salt\",D03.383.725.836',\n 'Actonel,D02.705.429.500.872',\n 'Actonel,D03.383.725.836',\n 'Risedronate,D02.705.429.500.872',\n 'Risedronate,D03.383.725.836',\n 'Bisphosphonate Risedronate Sodium,D02.705.429.500.872',\n 'Bisphosphonate Risedronate Sodium,D03.383.725.836',\n 'Fluticasone-Salmeterol Drug Combination,D02.033.100.291.057.750.500',\n 'Fluticasone-Salmeterol Drug Combination,D02.092.063.291.057.750.500',\n 'Fluticasone-Salmeterol Drug Combination,D02.092.471.683.061.750.500',\n 'Fluticasone-Salmeterol Drug Combination,D04.210.500.054.079.129.114.500',\n 'Fluticasone-Salmeterol Drug Combination,D26.310.438',\n '\"Fluticasone Propionate, Salmeterol Xinafoate Drug Combination\",D02.033.100.291.057.750.500',\n '\"Fluticasone Propionate, Salmeterol Xinafoate Drug Combination\",D02.092.063.291.057.750.500',\n '\"Fluticasone Propionate, Salmeterol Xinafoate Drug Combination\",D02.092.471.683.061.750.500',\n '\"Fluticasone Propionate, Salmeterol Xinafoate Drug Combination\",D04.210.500.054.079.129.114.500',\n '\"Fluticasone Propionate, Salmeterol Xinafoate Drug Combination\",D26.310.438',\n 'Advair Diskus,D02.033.100.291.057.750.500',\n 'Advair Diskus,D02.092.063.291.057.750.500',\n 'Advair Diskus,D02.092.471.683.061.750.500',\n 'Advair Diskus,D04.210.500.054.079.129.114.500',\n 'Advair Diskus,D26.310.438',\n 'Seretide,D02.033.100.291.057.750.500',\n 'Seretide,D02.092.063.291.057.750.500',\n 'Seretide,D02.092.471.683.061.750.500',\n 'Seretide,D04.210.500.054.079.129.114.500',\n 'Seretide,D26.310.438',\n 'Advair HFA,D02.033.100.291.057.750.500',\n 'Advair HFA,D02.092.063.291.057.750.500',\n 'Advair HFA,D02.092.471.683.061.750.500',\n 'Advair HFA,D04.210.500.054.079.129.114.500',\n 'Advair HFA,D26.310.438',\n 'Advair,D02.033.100.291.057.750.500',\n 'Advair,D02.092.063.291.057.750.500',\n 'Advair,D02.092.471.683.061.750.500',\n 'Advair,D04.210.500.054.079.129.114.500',\n 'Advair,D26.310.438',\n 'Fluticasone,D04.210.500.054.079.129.114',\n 'Flonase,D04.210.500.054.079.129.114',\n 'Flovent HFA,D04.210.500.054.079.129.114',\n 'Cutivate,D04.210.500.054.079.129.114',\n 'Fluticasone Propionate,D04.210.500.054.079.129.114',\n 'Flixonase,D04.210.500.054.079.129.114',\n 'Flixotide,D04.210.500.054.079.129.114',\n 'Flovent,D04.210.500.054.079.129.114',\n 'Salmeterol Xinafoate,D02.033.100.291.057.750',\n 'Salmeterol Xinafoate,D02.092.063.291.057.750',\n 'Salmeterol Xinafoate,D02.092.471.683.061.750',\n 'Salmeterol,D02.033.100.291.057.750',\n 'Salmeterol,D02.092.063.291.057.750',\n 'Salmeterol,D02.092.471.683.061.750',\n 'Serevent,D02.033.100.291.057.750',\n 'Serevent,D02.092.063.291.057.750',\n 'Serevent,D02.092.471.683.061.750',\n '\"Parks, Recreational\",J03.925.680',\n 'National Parks,J03.925.680',\n 'Community Parks,J03.925.680',\n 'Green Space,J03.925.680',\n 'Urban Parks,J03.925.680',\n 'Warfare and Armed Conflicts,I01.880.735.950',\n 'Armed Conflicts,I01.880.735.950.250',\n 'Wars,I01.880.735.950.250',\n 'Everolimus,D02.540.505.760.500',\n 'RAD 001,D02.540.505.760.500',\n 'Afinitor,D02.540.505.760.500',\n 'Certican,D02.540.505.760.500',\n '\"Aspirin, Dipyridamole Drug Combination\",D02.455.426.559.389.657.410.595.176.500',\n '\"Aspirin, Dipyridamole Drug Combination\",D03.383.742.175.500',\n '\"Aspirin, Dipyridamole Drug Combination\",D26.310.125',\n 'TX 3301,D02.455.426.559.389.657.410.595.176.500',\n 'TX 3301,D03.383.742.175.500',\n 'TX 3301,D26.310.125',\n 'Extended-Release Dipyridamole-Aspirin,D02.455.426.559.389.657.410.595.176.500',\n 'Extended-Release Dipyridamole-Aspirin,D03.383.742.175.500',\n 'Extended-Release Dipyridamole-Aspirin,D26.310.125',\n 'Asasantin,D02.455.426.559.389.657.410.595.176.500',\n 'Asasantin,D03.383.742.175.500',\n 'Asasantin,D26.310.125',\n 'Asasantin Retard,D02.455.426.559.389.657.410.595.176.500',\n 'Asasantin Retard,D03.383.742.175.500',\n 'Asasantin Retard,D26.310.125',\n 'Aggrenox,D02.455.426.559.389.657.410.595.176.500',\n 'Aggrenox,D03.383.742.175.500',\n 'Aggrenox,D26.310.125',\n 'Self-Control,F01.145.813.595',\n 'Saline Waters,G16.500.275.725',\n 'Brackish Water,G16.500.275.725',\n 'Compassion Fatigue,C23.888.369.500.500',\n 'Compassion Fatigue,F01.145.126.937.500',\n 'Compassion Fatigue,F01.145.126.990.734.500',\n 'Compassion Fatigue,F02.830.900.666.750',\n 'Plantaginaceae,B01.650.940.800.575.912.250.583.700',\n 'Stemodia,B01.650.940.800.575.912.250.583.700',\n 'Globularia,B01.650.940.800.575.912.250.583.700',\n 'Lamiales,B01.650.940.800.575.912.250.583',\n 'Proboscidea Plant,B01.650.940.800.575.912.250.583',\n 'Clinical Study,V03.175',\n 'Surgical Clearance,E01.370.505',\n 'Pemetrexed,D03.633.100.759.758.399.454.650',\n 'Pemetrexed,D12.125.067.625.525',\n 'Pemetrexed,D12.125.119.409.525',\n 'Pemetrexed Disodium,D03.633.100.759.758.399.454.650',\n 'Pemetrexed Disodium,D12.125.067.625.525',\n 'Pemetrexed Disodium,D12.125.119.409.525',\n 'LY 231514,D03.633.100.759.758.399.454.650',\n 'LY 231514,D12.125.067.625.525',\n 'LY 231514,D12.125.119.409.525',\n 'Alimta,D03.633.100.759.758.399.454.650',\n 'Alimta,D12.125.067.625.525',\n 'Alimta,D12.125.119.409.525',\n 'Brimonidine Tartrate,D03.633.100.857.070',\n '\"Brimonidine Tartrate (1:1), (S-(R*,R*))-Isomer\",D03.633.100.857.070',\n 'Brimonidine Purite,D03.633.100.857.070',\n 'AGN 190342,D03.633.100.857.070',\n 'Sanrosa,D03.633.100.857.070',\n 'Alphagan,D03.633.100.857.070',\n 'Brimonidine,D03.633.100.857.070',\n 'Alphagan P,D03.633.100.857.070',\n '\"UK 14,304\",D03.633.100.857.070',\n 'Ratio-Brimonidine,D03.633.100.857.070',\n '\"UK 14,304-18\",D03.633.100.857.070',\n 'UK 14308,D03.633.100.857.070',\n '\"Brimonidine Tartrate, (R-(R*,R*))-Isomer\",D03.633.100.857.070',\n 'Brimonidine Tartrate (1:1),D03.633.100.857.070',\n 'Mirvaso,D03.633.100.857.070',\n 'Clinical Studies as Topic,E05.318.372.250',\n 'Clinical Studies as Topic,N05.715.360.330.250',\n 'Clinical Studies as Topic,N06.850.520.450.250',\n 'Beijing,Z01.252.474.164.225',\n 'Beijing,Z01.433.114',\n 'African Union,I01.615.500.125',\n 'African Union,N03.540.089',\n 'Firmicutes,B03.353',\n 'Dutasteride,D04.210.500.925.100.125',\n 'Avodart,D04.210.500.925.100.125',\n 'GG 745,D04.210.500.925.100.125',\n 'GI198745,D04.210.500.925.100.125',\n 'Calceolariaceae,B01.650.940.800.575.912.250.583.190',\n 'Jovellana,B01.650.940.800.575.912.250.583.190',\n 'Calceolaria,B01.650.940.800.575.912.250.583.190',\n 'Porodittia,B01.650.940.800.575.912.250.583.190',\n 'Interferon beta-1a,D12.644.276.374.440.890.275.500',\n 'Interferon beta-1a,D12.776.467.374.440.890.275.500',\n 'Interferon beta-1a,D23.529.374.440.890.275.500',\n 'Avonex Pen,D12.644.276.374.440.890.275.500',\n 'Avonex Pen,D12.776.467.374.440.890.275.500',\n 'Avonex Pen,D23.529.374.440.890.275.500',\n 'Rebif,D12.644.276.374.440.890.275.500',\n 'Rebif,D12.776.467.374.440.890.275.500',\n 'Rebif,D23.529.374.440.890.275.500',\n 'Avonex,D12.644.276.374.440.890.275.500',\n 'Avonex,D12.776.467.374.440.890.275.500',\n 'Avonex,D23.529.374.440.890.275.500',\n 'Olmesartan Medoxomil,D03.383.129.308.674',\n 'Olmesartan Medoxomil,D03.383.129.617.584',\n 'Benicar,D03.383.129.308.674',\n 'Benicar,D03.383.129.617.584',\n 'Olmetec,D03.383.129.308.674',\n 'Olmetec,D03.383.129.617.584',\n 'CS 866,D03.383.129.308.674',\n 'CS 866,D03.383.129.617.584',\n 'Votum,D03.383.129.308.674',\n 'Votum,D03.383.129.617.584',\n '\"Amlodipine Besylate, Olmesartan Medoxomil Drug Combination\",D03.383.129.308.674.500',\n '\"Amlodipine Besylate, Olmesartan Medoxomil Drug Combination\",D03.383.129.617.584.500',\n '\"Amlodipine Besylate, Olmesartan Medoxomil Drug Combination\",D03.383.725.203.065.500',\n '\"Amlodipine Besylate, Olmesartan Medoxomil Drug Combination\",D26.310.063',\n 'Azor,D03.383.129.308.674.500',\n 'Azor,D03.383.129.617.584.500',\n 'Azor,D03.383.725.203.065.500',\n 'Azor,D26.310.063',\n 'Interferon beta-1b,D12.644.276.374.440.890.275.750',\n 'Interferon beta-1b,D12.776.467.374.440.890.275.750',\n 'Interferon beta-1b,D23.529.374.440.890.275.750',\n 'Betaseron,D12.644.276.374.440.890.275.750',\n 'Betaseron,D12.776.467.374.440.890.275.750',\n 'Betaseron,D23.529.374.440.890.275.750',\n 'Extavia,D12.644.276.374.440.890.275.750',\n 'Extavia,D12.776.467.374.440.890.275.750',\n 'Extavia,D23.529.374.440.890.275.750',\n 'Betaferon,D12.644.276.374.440.890.275.750',\n 'Betaferon,D12.776.467.374.440.890.275.750',\n 'Betaferon,D23.529.374.440.890.275.750',\n 'Nebivolol,D02.033.100.291.491',\n 'Nebivolol,D02.092.063.291.503',\n 'Nebivolol,D03.383.663.283.755',\n 'Nebivolol,D03.633.100.150.755',\n 'Bystolic,D02.033.100.291.491',\n 'Bystolic,D02.092.063.291.503',\n 'Bystolic,D03.383.663.283.755',\n 'Bystolic,D03.633.100.150.755',\n 'Nebilet,D02.033.100.291.491',\n 'Nebilet,D02.092.063.291.503',\n 'Nebilet,D03.383.663.283.755',\n 'Nebilet,D03.633.100.150.755',\n 'Silostar,D02.033.100.291.491',\n 'Silostar,D02.092.063.291.503',\n 'Silostar,D03.383.663.283.755',\n 'Silostar,D03.633.100.150.755',\n 'Nebivolol Hydrochloride,D02.033.100.291.491',\n 'Nebivolol Hydrochloride,D02.092.063.291.503',\n 'Nebivolol Hydrochloride,D03.383.663.283.755',\n 'Nebivolol Hydrochloride,D03.633.100.150.755',\n 'R 67555,D02.033.100.291.491',\n 'R 67555,D02.092.063.291.503',\n 'R 67555,D03.383.663.283.755',\n 'R 67555,D03.633.100.150.755',\n 'Lobivon,D02.033.100.291.491',\n 'Lobivon,D02.092.063.291.503',\n 'Lobivon,D03.383.663.283.755',\n 'Lobivon,D03.633.100.150.755',\n 'Celecoxib,D02.065.884.247',\n 'Celecoxib,D02.886.590.700.247',\n 'Celecoxib,D03.383.129.539.160',\n 'Celebrex,D02.065.884.247',\n 'Celebrex,D02.886.590.700.247',\n 'Celebrex,D03.383.129.539.160',\n 'SC 58635,D02.065.884.247',\n 'SC 58635,D02.886.590.700.247',\n 'SC 58635,D03.383.129.539.160',\n 'Varenicline,D03.633.100.079.900',\n 'Varenicline,D03.633.100.857.942',\n 'Chantix,D03.633.100.079.900',\n 'Chantix,D03.633.100.857.942',\n 'Varenicline Tartrate,D03.633.100.079.900',\n 'Varenicline Tartrate,D03.633.100.857.942',\n 'Champix,D03.633.100.079.900',\n 'Champix,D03.633.100.857.942',\n 'Tadalafil,D03.383.725.150.500',\n 'Tadalafil,D03.633.100.473.155.500',\n 'Tadalafil,D03.633.300.154.672',\n 'IC351,D03.383.725.150.500',\n 'IC351,D03.633.100.473.155.500',\n 'IC351,D03.633.300.154.672',\n 'Cialis,D03.383.725.150.500',\n 'Cialis,D03.633.100.473.155.500',\n 'Cialis,D03.633.300.154.672',\n 'Certolizumab Pegol,D05.750.741.125',\n 'Certolizumab Pegol,D12.644.541.500.650.250',\n 'Certolizumab Pegol,D12.776.124.486.485.114.224.060.500',\n 'Certolizumab Pegol,D12.776.124.486.485.680.650.250',\n 'Certolizumab Pegol,D12.776.124.790.651.114.224.060.500',\n 'Certolizumab Pegol,D12.776.124.790.651.680.650.250',\n 'Certolizumab Pegol,D12.776.377.715.548.114.224.200.500',\n 'Certolizumab Pegol,D12.776.377.715.548.680.650.250',\n 'Cimzia,D05.750.741.125',\n 'Cimzia,D12.644.541.500.650.250',\n 'Cimzia,D12.776.124.486.485.114.224.060.500',\n 'Cimzia,D12.776.124.486.485.680.650.250',\n 'Cimzia,D12.776.124.790.651.114.224.060.500',\n 'Cimzia,D12.776.124.790.651.680.650.250',\n 'Cimzia,D12.776.377.715.548.114.224.200.500',\n 'Cimzia,D12.776.377.715.548.680.650.250',\n 'CDP870,D05.750.741.125',\n 'CDP870,D12.644.541.500.650.250',\n 'CDP870,D12.776.124.486.485.114.224.060.500',\n 'CDP870,D12.776.124.486.485.680.650.250',\n 'CDP870,D12.776.124.790.651.114.224.060.500',\n 'CDP870,D12.776.124.790.651.680.650.250',\n 'CDP870,D12.776.377.715.548.114.224.200.500',\n 'CDP870,D12.776.377.715.548.680.650.250',\n '\"Censorship, Research\",I01.880.604.238',\n '\"Censorship, Research\",K01.752.566.479.173.200',\n '\"Censorship, Research\",N05.350.670.250',\n 'Data Accuracy,E05.318.308.028',\n 'Data Accuracy,E05.318.370.725.250',\n 'Data Accuracy,L01.399.250.202',\n 'Data Accuracy,N05.715.360.300.202',\n 'Data Accuracy,N05.715.360.325.685.250',\n 'Data Quality,E05.318.308.028',\n 'Data Quality,E05.318.370.725.250',\n 'Data Quality,L01.399.250.202',\n 'Data Quality,N05.715.360.300.202',\n 'Data Quality,N05.715.360.325.685.250',\n '\"Brimonidine Tartrate, Timolol Maleate Drug Combination\",D02.033.100.624.915.500',\n '\"Brimonidine Tartrate, Timolol Maleate Drug Combination\",D02.033.755.624.915.500',\n '\"Brimonidine Tartrate, Timolol Maleate Drug Combination\",D02.092.063.624.915.500',\n '\"Brimonidine Tartrate, Timolol Maleate Drug Combination\",D02.886.675.867.768.500',\n '\"Brimonidine Tartrate, Timolol Maleate Drug Combination\",D03.383.129.708.867.768.500',\n '\"Brimonidine Tartrate, Timolol Maleate Drug Combination\",D03.633.100.857.070.500',\n '\"Brimonidine Tartrate, Timolol Maleate Drug Combination\",D26.310.312',\n ...]"]}}],"execution_count":0},{"cell_type":"code","source":["meshheader = meshrdd.first()\nmeshrdd1=meshrdd.filter(lambda line: line != meshheader)\nmeshrdd1.collect()"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"28a05309-2bb8-4d38-b625-7a8e6cff6ba3"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[35]: ['Calcimycin,D03.633.100.221.173',\n 'A-23187,D03.633.100.221.173',\n 'Temefos,D02.705.400.625.800',\n 'Temefos,D02.705.539.345.800',\n 'Temefos,D02.886.300.692.800',\n 'Abate,D02.705.400.625.800',\n 'Abate,D02.705.539.345.800',\n 'Abate,D02.886.300.692.800',\n 'Difos,D02.705.400.625.800',\n 'Difos,D02.705.539.345.800',\n 'Difos,D02.886.300.692.800',\n 'Abattoirs,J01.576.423.200.700.100',\n 'Abattoirs,J03.540.020',\n 'Abbreviations as Topic,L01.559.598.400.556.131',\n 'Acronyms as Topic,L01.559.598.400.556.131',\n 'Abdomen,A01.923.047',\n '\"Abdomen, Acute\",C23.888.592.612.054.200',\n '\"Abdomen, Acute\",C23.888.821.030.249',\n 'Abdominal Injuries,C26.017',\n 'Abdominal Neoplasms,C04.588.033',\n 'Abdominal Muscles,A02.633.567.050',\n 'Cremaster Muscle,A02.633.567.050',\n 'Pyramidalis Muscle,A02.633.567.050',\n 'Quadratus Abdominis,A02.633.567.050',\n 'Transversus Abdominis,A02.633.567.050',\n 'Abducens Nerve,A08.800.800.120.030',\n 'Abelson murine leukemia virus,B04.613.807.375.525.020',\n 'Abelson murine leukemia virus,B04.820.650.375.525.020',\n 'Abetalipoproteinemia,C16.320.565.398.500.440.500',\n 'Abetalipoproteinemia,C18.452.584.500.875.440.500',\n 'Abetalipoproteinemia,C18.452.648.398.500.440.500',\n 'Congenital Abnormalities,C16.131',\n 'Fetal Malformations,C16.131',\n 'Fetal Anomalies,C16.131',\n '\"Abnormalities, Drug-Induced\",C16.131.042',\n '\"Abnormalities, Multiple\",C16.131.077',\n '\"Abnormalities, Radiation-Induced\",C16.131.080',\n '\"Abnormalities, Radiation-Induced\",C26.733.031',\n '\"Abnormalities, Radiation-Induced\",G01.750.748.500.031',\n '\"Abnormalities, Radiation-Induced\",N06.850.460.350.850.500.031',\n '\"Abnormalities, Radiation-Induced\",N06.850.810.300.360.031',\n 'ABO Blood-Group System,D23.050.301.290.031',\n 'ABO Blood-Group System,D23.050.705.230.031',\n 'Blood Group H Type 1 Antigen,D23.050.301.290.031',\n 'Blood Group H Type 1 Antigen,D23.050.705.230.031',\n 'ABO Factors,D23.050.301.290.031',\n 'ABO Factors,D23.050.705.230.031',\n 'Abomasum,A13.869.106',\n 'Abortifacient Agents,D27.505.696.875.131',\n 'Abortifacient Agents,D27.505.954.705.131',\n 'Abortifacient Effect,D27.505.696.875.131',\n 'Abortifacient Effect,D27.505.954.705.131',\n '\"Abortifacient Agents, Nonsteroidal\",D27.505.696.875.131.100',\n '\"Abortifacient Agents, Nonsteroidal\",D27.505.954.705.131.100',\n '\"Abortifacient Agents, Steroidal\",D27.505.696.875.131.200',\n '\"Abortifacient Agents, Steroidal\",D27.505.954.705.131.200',\n '\"Abortion, Spontaneous\",C13.703.039',\n '\"Abortion, Spontaneous\",G08.686.784.769.496.125',\n 'Early Pregnancy Loss,C13.703.039',\n 'Early Pregnancy Loss,G08.686.784.769.496.125',\n 'Miscarriage,C13.703.039',\n 'Miscarriage,G08.686.784.769.496.125',\n '\"Abortion, Tubal\",C13.703.039',\n '\"Abortion, Tubal\",G08.686.784.769.496.125',\n 'Abortion Applicants,M01.050',\n '\"Abortion Seekers, Repeated\",M01.050',\n '\"Abortion Seekers, Refused\",M01.050',\n '\"Abortion, Criminal\",I01.198.240.089',\n '\"Abortion, Eugenic\",E04.520.050.050',\n '\"Abortion, Selective\",E04.520.050.050',\n '\"Abortion, Habitual\",C13.703.039.089',\n '\"Abortion, Incomplete\",C13.703.039.093',\n '\"Abortion, Induced\",E04.520.050',\n 'Abortion Rate,E04.520.050',\n 'Abortion Techniques,E04.520.050',\n '\"Abortion, Drug-Induced\",E04.520.050',\n 'Previous Abortion,E04.520.050',\n '\"Abortion, Saline-Solution\",E04.520.050',\n '\"Abortion, Soap-Solution\",E04.520.050',\n 'Anti-Abortion Groups,E04.520.050',\n 'Embryotomy,E04.520.050',\n '\"Fertility Control, Postconception\",E04.520.050',\n 'Abortion Failure,E04.520.050',\n '\"Abortion, Rivanol\",E04.520.050',\n '\"Abortion, Legal\",E04.520.050.055',\n 'Abortion on Demand,E04.520.050.055',\n '\"Abortion, Missed\",C13.703.039.173',\n '\"Abortion, Septic\",C01.674.173',\n '\"Abortion, Septic\",C13.703.039.256',\n '\"Abortion, Septic\",C13.703.700.173',\n '\"Abortion, Therapeutic\",E04.520.050.060',\n '\"Abortion, Threatened\",C13.703.090',\n '\"Abortion, Veterinary\",C13.703.039.422',\n '\"Abortion, Veterinary\",C22.021',\n 'Abreaction,F04.754.720.107',\n 'Abrin,D08.811.277.450.430.700.750.111',\n 'Abrin,D12.776.503.499.249',\n 'Abrin,D12.776.765.678.906.111',\n 'Abrin C,D08.811.277.450.430.700.750.111',\n 'Abrin C,D12.776.503.499.249',\n 'Abrin C,D12.776.765.678.906.111',\n 'Abrin A,D08.811.277.450.430.700.750.111',\n 'Abrin A,D12.776.503.499.249',\n 'Abrin A,D12.776.765.678.906.111',\n 'Abruptio Placentae,C13.703.420.078',\n 'Abruptio Placentae,C13.703.590.132',\n 'Abscess,C01.830.025',\n 'Abscess,C23.550.470.756.100',\n 'Peritonsillar Abscess,C01.748.561.750.500',\n 'Peritonsillar Abscess,C01.830.025.675',\n 'Peritonsillar Abscess,C07.550.781.750.500',\n 'Peritonsillar Abscess,C08.730.561.750.500',\n 'Peritonsillar Abscess,C09.775.649.750.500',\n 'Abscisic Acid,D02.241.223.268.034',\n 'Abscisic Acid,D02.455.326.271.665.202.061',\n 'Abscisic Acid,D02.455.426.392.368.367.379.249.024',\n 'Abscisic Acid,D02.455.849.131.061',\n 'Abscisic Acid,D02.455.849.765.521.500',\n '\"Abscisic Acid, (+,-)-Isomer\",D02.241.223.268.034',\n '\"Abscisic Acid, (+,-)-Isomer\",D02.455.326.271.665.202.061',\n '\"Abscisic Acid, (+,-)-Isomer\",D02.455.426.392.368.367.379.249.024',\n '\"Abscisic Acid, (+,-)-Isomer\",D02.455.849.131.061',\n '\"Abscisic Acid, (+,-)-Isomer\",D02.455.849.765.521.500',\n '\"Abscisic Acid, (Z,E)-Isomer\",D02.241.223.268.034',\n '\"Abscisic Acid, (Z,E)-Isomer\",D02.455.326.271.665.202.061',\n '\"Abscisic Acid, (Z,E)-Isomer\",D02.455.426.392.368.367.379.249.024',\n '\"Abscisic Acid, (Z,E)-Isomer\",D02.455.849.131.061',\n '\"Abscisic Acid, (Z,E)-Isomer\",D02.455.849.765.521.500',\n '\"Abscisic Acid, (E,Z)-(+,-)-Isomer\",D02.241.223.268.034',\n '\"Abscisic Acid, (E,Z)-(+,-)-Isomer\",D02.455.326.271.665.202.061',\n '\"Abscisic Acid, (E,Z)-(+,-)-Isomer\",D02.455.426.392.368.367.379.249.024',\n '\"Abscisic Acid, (E,Z)-(+,-)-Isomer\",D02.455.849.131.061',\n '\"Abscisic Acid, (E,Z)-(+,-)-Isomer\",D02.455.849.765.521.500',\n '\"Abscisic Acid, (R)-Isomer\",D02.241.223.268.034',\n '\"Abscisic Acid, (R)-Isomer\",D02.455.326.271.665.202.061',\n '\"Abscisic Acid, (R)-Isomer\",D02.455.426.392.368.367.379.249.024',\n '\"Abscisic Acid, (R)-Isomer\",D02.455.849.131.061',\n '\"Abscisic Acid, (R)-Isomer\",D02.455.849.765.521.500',\n '\"Abscisic Acid Monoammonium Salt, (R)-Isomer\",D02.241.223.268.034',\n '\"Abscisic Acid Monoammonium Salt, (R)-Isomer\",D02.455.326.271.665.202.061',\n '\"Abscisic Acid Monoammonium Salt, (R)-Isomer\",D02.455.426.392.368.367.379.249.024',\n '\"Abscisic Acid Monoammonium Salt, (R)-Isomer\",D02.455.849.131.061',\n '\"Abscisic Acid Monoammonium Salt, (R)-Isomer\",D02.455.849.765.521.500',\n '\"Abscisic Acid, (E,E)-(+-)-Isomer\",D02.241.223.268.034',\n '\"Abscisic Acid, (E,E)-(+-)-Isomer\",D02.455.326.271.665.202.061',\n '\"Abscisic Acid, (E,E)-(+-)-Isomer\",D02.455.426.392.368.367.379.249.024',\n '\"Abscisic Acid, (E,E)-(+-)-Isomer\",D02.455.849.131.061',\n '\"Abscisic Acid, (E,E)-(+-)-Isomer\",D02.455.849.765.521.500',\n 'Absenteeism,F02.784.692.107',\n 'Absorption,G01.015',\n 'Absorption,G02.010',\n 'Absorption,G03.015',\n 'Absorption,G03.787.024',\n 'Absorption,G07.690.725.015',\n 'Abstracting and Indexing,L01.453.245.100',\n 'Indexing,L01.453.245.100',\n 'Indexes as Topic,L01.453.245.100',\n 'Abstracting,L01.453.245.100',\n 'Dental Abutments,E06.780.346.500',\n 'Dental Abutments,E07.695.190.175',\n 'Acacia,B01.650.940.800.575.912.250.401.025',\n 'Acacia catechu,B01.650.940.800.575.912.250.401.025',\n 'Academic Medical Centers,N02.278.020',\n 'Academies and Institutes,N03.540.052',\n 'Institutes,N03.540.052',\n 'Research Institutes,N03.540.052',\n 'Academies,N03.540.052',\n 'Acanthamoeba,B01.046.500.100.075.080',\n 'Acanthocephala,B01.050.500.500.132',\n 'Acanthocytes,A11.118.290.330.100',\n 'Acanthocytes,A11.443.240.330.100',\n 'Acanthocytes,A15.145.229.334.330.100',\n 'Acantholysis,C17.800.865.070',\n 'Acantholysis,C23.550.035',\n 'Acanthosis Nigricans,C17.800.621.430.530.100',\n 'Acari,B01.050.500.131.166.132',\n 'Acceleration,G01.482.107',\n 'Accessory Nerve,A08.800.800.120.060',\n 'Accident Prevention,N06.850.135.060',\n 'Accident Proneness,F01.145.015',\n 'Accidental Falls,N06.850.135.122',\n 'Slip and Fall,N06.850.135.122',\n 'Accidents,N06.850.135',\n '\"Accidents, Aviation\",N06.850.135.185',\n '\"Accidents, Home\",N06.850.135.217',\n '\"Accidents, Occupational\",N06.850.135.240',\n '\"Accidents, Industrial\",N06.850.135.240',\n '\"Accidents, Traffic\",N06.850.135.392',\n 'Traffic Collisions,N06.850.135.392',\n 'Traffic Crashes,N06.850.135.392',\n 'Acclimatization,G07.025.133',\n 'Acclimatization,G16.012.500.133',\n '\"Accommodation, Ocular\",G14.010',\n '\"Accommodation, Lens\",G14.010',\n 'Accounting,N03.219.463.030',\n 'Oil and Gas Industry,J01.576.655.875.750',\n 'Petroleum Industry,J01.576.655.875.750',\n 'Oil Refinery,J01.576.655.875.750',\n 'Natural Gas Industry,J01.576.655.875.750',\n 'Coal Industry,J01.576.655.875.200',\n 'Driving Under the Influence,F01.145.250.250',\n 'Driving Under the Influence,F01.145.263.500',\n 'Driving Under the Influence,I01.880.735.223.250',\n 'Driving Under the Influence,I03.125.649',\n 'Drinking and Driving,F01.145.250.250',\n 'Drinking and Driving,F01.145.263.500',\n 'Drinking and Driving,I01.880.735.223.250',\n 'Drinking and Driving,I03.125.649',\n 'Human Embryonic Stem Cells,A11.872.700.250.750',\n 'Mouse Embryonic Stem Cells,A11.872.700.250.875',\n 'Embryonic Germ Cells,A11.497.124',\n 'Embryonic Germ Cells,A11.872.700.250.625',\n 'Work Performance,I03.946.675',\n 'Job Performance,I03.946.675',\n 'Criminal Behavior,F01.145.250',\n 'Clinical Decision-Making,E01.055',\n 'Cognitive Aging,G07.345.124.260',\n 'Cognitive Neuroscience,F04.096.628.255.500',\n 'Cognitive Neuroscience,H01.158.610.030',\n 'Social Neuroscience,F04.096.628.255.500',\n 'Social Neuroscience,H01.158.610.030',\n 'Emotional Adjustment,F01.058.144',\n 'Emotional Adjustment,F01.752.543.500.250',\n 'Facial Recognition,F02.463.593.524.250.500',\n 'Facial Recognition,F02.463.593.524.500.500',\n 'Facial Recognition,F02.463.593.932.622.500',\n 'Facial Emotion Recognition,F02.463.593.524.250.500',\n 'Facial Emotion Recognition,F02.463.593.524.500.500',\n 'Facial Emotion Recognition,F02.463.593.932.622.500',\n 'Grandparents,F01.829.263.403',\n 'Grandparents,I01.880.853.150.452',\n 'Grandparents,M01.264',\n 'Grandmother,F01.829.263.403',\n 'Grandmother,I01.880.853.150.452',\n 'Grandmother,M01.264',\n 'Grandfather,F01.829.263.403',\n 'Grandfather,I01.880.853.150.452',\n 'Grandfather,M01.264',\n 'Help-Seeking Behavior,F01.145.813.217',\n 'Heuristics,F02.463.425.725.500',\n 'Heuristics,F02.463.785.810.500',\n 'Intimate Partner Violence,I01.198.240.856.575',\n 'Intimate Partner Violence,I01.880.735.900.688',\n 'Dating Violence,I01.198.240.856.575',\n 'Dating Violence,I01.880.735.900.688',\n 'Neurological Rehabilitation,E02.760.169.063.500.477',\n 'Neurological Rehabilitation,E02.831.477',\n 'Neurological Rehabilitation,H02.403.680.600.750',\n 'Neurological Rehabilitation,N02.421.784.511',\n 'Physical Abuse,I01.198.240.856.688',\n 'Physical Abuse,I01.880.735.900.744',\n 'Problem Behavior,F01.145.126.972',\n 'Problem Behavior,F01.145.179.750',\n '\"Dysfunctional Behavior, Psychology\",F01.145.126.972',\n '\"Dysfunctional Behavior, Psychology\",F01.145.179.750',\n 'Disruptive Behavior,F01.145.126.972',\n 'Disruptive Behavior,F01.145.179.750',\n 'Underage Drinking,F01.145.022.750',\n 'Underage Drinking,F01.145.317.269.875',\n 'Underage Drinking,I01.880.735.878',\n 'Legal Drinking Age,F01.145.022.750',\n 'Legal Drinking Age,F01.145.317.269.875',\n 'Legal Drinking Age,I01.880.735.878',\n 'Ectopic Gene Expression,G05.308.202',\n 'Cell Plasticity,G04.356.250',\n 'Cell Self Renewal,G04.144.220.235',\n 'Cell Self Renewal,G04.161.750.500.375',\n 'Cell Self Renewal,G05.113.415',\n 'Cell Self Renewal,G07.345.249.410.750.500.625',\n 'Stem Cell Self-Renewal,G04.144.220.235',\n 'Stem Cell Self-Renewal,G04.161.750.500.375',\n 'Stem Cell Self-Renewal,G05.113.415',\n 'Stem Cell Self-Renewal,G07.345.249.410.750.500.625',\n 'Rehabilitation Research,H01.770.644.145.472',\n 'Orthodontists,M01.526.485.330.655',\n 'Orthodontists,N02.360.330.655',\n 'Dentofacial Orthopedists,M01.526.485.330.655',\n 'Dentofacial Orthopedists,N02.360.330.655',\n 'Oral and Maxillofacial Surgeons,M01.526.485.330.483',\n 'Oral and Maxillofacial Surgeons,N02.360.330.483',\n 'Exodontists,M01.526.485.330.483',\n 'Exodontists,N02.360.330.483',\n 'Neuroprotection,G11.561.645',\n '\"Diet, Food, and Nutrition\",G07.203',\n 'Triticale,B01.650.940.800.575.912.250.822.906',\n 'Critical Care Outcomes,N04.761.559.590.399.250',\n 'Critical Care Outcomes,N05.715.360.575.575.399.250',\n 'Simulation Training,I02.903.847',\n 'Interactive Learning,I02.903.847',\n 'Millets,B01.650.940.800.575.912.250.822.587',\n 'Biobehavioral Sciences,H01.770.644.108.687',\n 'Protein Corona,D12.776.642',\n 'Vegetarians,M01.928',\n 'Lacto-Ovo Vegetarians,M01.928',\n 'Vegans,M01.928.500',\n 'Accounts Payable and Receivable,N03.219.463.030.080',\n 'Accounts Payable,N03.219.463.030.080',\n 'Youth Sports,I03.450.642.845.987',\n 'Organized Youth Sports,I03.450.642.845.987',\n 'Literacy,F01.145.209.429',\n 'Literacy,N01.824.196.500',\n 'Illiteracy,F01.145.209.429',\n 'Illiteracy,N01.824.196.500',\n 'Severe Acute Malnutrition,C18.654.521.719',\n '\"Banking, Personal\",N03.219.463.030.100',\n 'Savings Accounts,N03.219.463.030.100',\n 'Checking Accounts,N03.219.463.030.100',\n 'Evidence-Based Facility Design,N02.278.200.252',\n '\"Physical Appearance, Body\",E01.370.600.115.450',\n '\"Physical Appearance, Body\",G07.100.175',\n 'Fruit and Vegetable Juices,G07.203.100.606',\n 'Fruit and Vegetable Juices,J02.200.606',\n 'Vegetable Juices,G07.203.100.606',\n 'Vegetable Juices,J02.200.606',\n 'Fruit Juices,G07.203.100.606',\n 'Fruit Juices,J02.200.606',\n 'Ghee,D10.212.302.199.500',\n 'Ghee,G07.203.300.350.100.500',\n 'Ghee,G07.203.300.375.200.500',\n 'Ghee,J02.500.350.100.500',\n 'Ghee,J02.500.375.200.500',\n 'Hydraulic Fracking,J01.576.655.875.750.500',\n 'Psychological Trauma,F03.950.750.375',\n 'Peer Influence,F01.829.316.483.750',\n 'Peer Pressure,F01.829.316.483.750',\n 'Vegetable Products,G07.203.300.850.450',\n 'Vegetable Products,J02.500.850.800',\n 'Direct-to-Consumer Advertising,J01.219.687.274.500',\n 'Direct-To-Consumer Screening and Testing,E01.370.398',\n 'Direct-To-Consumer Screening and Testing,N02.421.726.233.166',\n 'Extracellular Vesicles,A11.284.295.588',\n 'Exovesicles,A11.284.295.588',\n 'Apoptotic Bodies,A11.284.295.588',\n 'Fungal Viruses,B04.352',\n 'Telocytes,A11.329.830.750',\n 'Exoskeleton Device,E07.341',\n 'Robotic Exoskeleton,E07.341',\n 'Shellfish Hypersensitivity,C20.543.480.370.763',\n '\"Failure to Rescue, Health Care\",E01.789.800.760.500',\n '\"Failure to Rescue, Health Care\",H01.770.644.145.431.500',\n '\"Failure to Rescue, Health Care\",N04.761.559.590.800.760.500',\n '\"Failure to Rescue, Health Care\",N05.715.360.575.575.800.760.500',\n 'Psychiatric Rehabilitation,H02.403.680.600.875',\n 'Psychiatric Rehabilitation,N02.421.784.578',\n 'Psychosocial Care,H02.403.680.600.875',\n 'Psychosocial Care,N02.421.784.578',\n 'Symptom Flare Up,C23.550.291.937.500',\n 'Symptom Exacerbation,C23.550.291.937.500',\n 'Isolated Heart Preparation,E05.519',\n 'Isolated Heart Preparation,E05.598.750',\n 'Langendorff Perfused Heart,E05.519',\n 'Langendorff Perfused Heart,E05.598.750',\n 'Working Heart Preparation Technique,E05.519',\n 'Working Heart Preparation Technique,E05.598.750',\n 'Working Heart Preparation,E05.519',\n 'Working Heart Preparation,E05.598.750',\n 'Isolated Heart Preparation Technique,E05.519',\n 'Isolated Heart Preparation Technique,E05.598.750',\n '\"Diet, Vegan\",E02.642.249.300.750',\n '\"Diet, Vegan\",G07.203.650.240.300.750',\n 'Veganism,E02.642.249.300.750',\n 'Veganism,G07.203.650.240.300.750',\n 'Behavior Observation Techniques,E05.796.112',\n 'Behavior Observation Techniques,F04.669.112',\n 'Behavior Rating Scale,F04.711.271',\n 'Behavior Test,F04.711.271',\n 'Alcohol Drinking in College,F01.145.317.269.625',\n '\"Obesity, Metabolically Benign\",C18.654.726.500.650',\n '\"Obesity, Metabolically Benign\",C23.888.144.699.500.250',\n '\"Obesity, Metabolically Benign\",E01.370.600.115.100.160.120.699.500.375',\n '\"Obesity, Metabolically Benign\",G07.100.100.160.120.699.500.375',\n 'Whole Grains,G07.203.300.300.550.500',\n 'Whole Grains,G07.203.300.775.500.500',\n 'Whole Grains,J02.500.300.550.500',\n 'Whole Grains,J02.500.775.500.500',\n 'Whole Grain Cereals,G07.203.300.300.550.500',\n 'Whole Grain Cereals,G07.203.300.775.500.500',\n 'Whole Grain Cereals,J02.500.300.550.500',\n 'Whole Grain Cereals,J02.500.775.500.500',\n 'Transanal Endoscopic Surgery,E01.370.388.250.630.500',\n 'Transanal Endoscopic Surgery,E04.210.240.250.680.500',\n 'Transanal Endoscopic Surgery,E04.502.250.250.250.680.500',\n 'Transanal Endoscopic Surgery,E04.502.250.630.500',\n 'Transanal Minimally Invasive Surgery,E01.370.388.250.630.500',\n 'Transanal Minimally Invasive Surgery,E04.210.240.250.680.500',\n 'Transanal Minimally Invasive Surgery,E04.502.250.250.250.680.500',\n 'Transanal Minimally Invasive Surgery,E04.502.250.630.500',\n 'Transanal Endoscopic Microsurgery,E01.370.388.250.630.500.500',\n 'Transanal Endoscopic Microsurgery,E04.210.240.250.680.500.500',\n 'Transanal Endoscopic Microsurgery,E04.494.787',\n 'Transanal Endoscopic Microsurgery,E04.502.250.250.250.680.500.500',\n 'Transanal Endoscopic Microsurgery,E04.502.250.630.500.500',\n 'Cold Injury,C26.212',\n 'Personal Protective Equipment,E07.700.560',\n 'Personal Protective Equipment,J01.637.708.560',\n 'Nerve Agents,D27.720.599',\n 'Nerve Agents,D27.720.777.300.500',\n 'Nerve Gas,D27.720.599',\n 'Nerve Gas,D27.720.777.300.500',\n 'War-Related Injuries,C26.946',\n 'War-Related Injuries,I01.880.735.950.500.951.500',\n 'War-Related Injuries,N06.850.460.350.600.903.500',\n 'War-Related Trauma,C26.946',\n 'War-Related Trauma,I01.880.735.950.500.951.500',\n 'War-Related Trauma,N06.850.460.350.600.903.500',\n 'Abnormal Involuntary Movement Scale,E01.370.600.550.162',\n 'Blood Alcohol Content,D02.033.375.135',\n 'Social Communication Disorder,F03.625.374.250',\n 'Legal Services,I01.880.604.583.482',\n 'Defamation,I01.198.240.240',\n 'Defamation,I01.880.735.191.051',\n 'Slander,I01.198.240.240',\n 'Slander,I01.880.735.191.051',\n 'Libel,I01.198.240.240',\n 'Libel,I01.880.735.191.051',\n 'Anger Management Therapy,F04.754.137.087',\n '\"Psychology, Sports\",F04.096.628.914',\n 'War Exposure,I01.880.735.950.500.951',\n 'War Exposure,N06.850.460.350.600.903',\n 'Childhood-Onset Fluency Disorder,F03.625.374.125',\n 'No-Show Patients,F01.100.150.750.500.600.750',\n 'No-Show Patients,F01.145.488.887.500.600.750',\n 'No-Show Patients,M01.643.550',\n 'No-Show Patients,N04.452.758.635.500',\n 'No-Show Patients,N05.300.150.800.500.600.750',\n 'Cellular Reprogramming Techniques,E05.200.500.380',\n 'Cellular Reprogramming Techniques,E05.242.378',\n 'Cellular Reprogramming Techniques,E05.393.085',\n 'Directed Differentiation Techniques,E05.200.500.380',\n 'Directed Differentiation Techniques,E05.242.378',\n 'Directed Differentiation Techniques,E05.393.085',\n 'Direct Cell Reprogramming Techniques,E05.200.500.380',\n 'Direct Cell Reprogramming Techniques,E05.242.378',\n 'Direct Cell Reprogramming Techniques,E05.393.085',\n 'Metacognition,F02.463.188.756',\n 'Metacognitive Awareness,F02.463.188.756',\n 'Metacognitive Monitoring,F02.463.188.756',\n 'Metacognitive Control,F02.463.188.756',\n 'Metaemotion,F02.463.188.756',\n 'Metamemory,F02.463.188.756',\n 'Prescription Drug Overuse,E02.319.306.500.750',\n '\"Near Miss, Healthcare\",E02.319.529.750',\n '\"Near Miss, Healthcare\",N02.421.450.500.750',\n '\"Near Miss, Healthcare\",N02.421.450.550',\n '\"Near Miss, Healthcare\",N04.761.700.594',\n '\"Near Miss, Healthcare\",N05.700.513',\n 'RNAi Therapeutics,E02.095.301.250',\n 'Dynamic Light Scattering,E05.196.822.325',\n 'Quasi-Elastic Light Scattering (QELS),E05.196.822.325',\n '\"Time Out, Healthcare\",N04.761.700.635',\n '\"Time Out, Healthcare\",N05.700.739',\n 'Surgical Time Out,N04.761.700.635',\n 'Surgical Time Out,N05.700.739',\n 'Healthcare Failure Mode and Effect Analysis,E05.318.740.600.800.715.500',\n 'Healthcare Failure Mode and Effect Analysis,N04.452.871.715.400',\n 'Healthcare Failure Mode and Effect Analysis,N05.715.360.750.625.700.690.400',\n 'Healthcare Failure Mode and Effect Analysis,N06.850.505.715.500',\n 'Healthcare Failure Mode and Effect Analysis,N06.850.520.830.600.800.715.500',\n 'Failure Mode and Effect Analysis,E05.318.740.600.800.715.500',\n 'Failure Mode and Effect Analysis,N04.452.871.715.400',\n 'Failure Mode and Effect Analysis,N05.715.360.750.625.700.690.400',\n 'Failure Mode and Effect Analysis,N06.850.505.715.500',\n 'Failure Mode and Effect Analysis,N06.850.520.830.600.800.715.500',\n 'Spirit Possession,K01.844.619.500',\n '\"Crew Resource Management, Healthcare\",N04.590.254',\n 'Computer Heuristics,L01.224.050.375.095',\n 'Ataxins,D12.776.631.069',\n 'Ataxins,D12.776.660.075',\n 'Alarmins,D23.035',\n 'Dermal Fillers,D27.720.102.461',\n 'Action Spectrum,E05.196.867.826.150',\n 'Diplomacy,F01.829.316.171',\n 'Diplomacy,F02.463.785.373.520.500',\n 'Diplomacy,I01.738.305',\n 'Mutation Accumulation,G05.365.590.594',\n 'Spontaneous Mutation Accumulation,G05.365.590.594',\n 'Internal Ribosome Entry Sites,D13.444.735.790.878.942.250',\n 'Internal Ribosome Entry Sites,G02.111.570.080.689.687.093',\n 'Internal Ribosome Entry Sites,G05.360.080.689.687.093',\n 'Biological Mimicry,G16.012.750',\n 'Biological Camouflage,G16.012.750',\n 'Specific Learning Disorder,F03.625.562.700',\n 'Potentially Inappropriate Medication List,N04.761.700.615',\n 'Potentially Inappropriate Medication List,N05.700.594',\n 'Beers Criteria,N04.761.700.615',\n 'Beers Criteria,N05.700.594',\n 'STOPP (Screening Tool of Older Persons Potentially Inappropriate Prescriptions),N04.761.700.615',\n 'STOPP (Screening Tool of Older Persons Potentially Inappropriate Prescriptions),N05.700.594',\n 'Medication Appropriateness Index,N04.761.700.615',\n 'Medication Appropriateness Index,N05.700.594',\n 'Late Onset Disorders,C23.550.291.883',\n 'Phakopsora pachyrhizi,B01.300.179.113',\n 'Farmers,M01.526.390',\n 'Ranchers,M01.526.390',\n 'Culturally Appropriate Technology,J01.897.052',\n 'Intermediate Technology,J01.897.052',\n 'Soft Technology,J01.897.052',\n 'Social Learning,F02.784.629.529.663',\n 'Financial Statements,N03.219.463.030.140',\n '\"Assets, Financial\",N03.219.463.030.140',\n 'Cash Flow Statement,N03.219.463.030.140',\n 'Balance Sheet,N03.219.463.030.140',\n 'Expense Statement,N03.219.463.030.140',\n 'Income Statement,N03.219.463.030.140',\n '\"Equity, Financial\",N03.219.463.030.140',\n '\"Liabilities, Financial\",N03.219.463.030.140',\n 'Miners,M01.526.693',\n 'Chronopharmacokinetics,G07.690.725.249',\n '\"Administrative Claims, Healthcare\",N04.452.859.564.137',\n 'Child Health,N01.400.225',\n 'Child Well Being,N01.400.225',\n 'Interleukin-33,D12.644.276.374.465.850',\n 'Interleukin-33,D12.776.467.374.465.850',\n 'Interleukin-33,D23.529.374.465.850',\n 'S100A12 Protein,D12.776.157.125.750.875',\n 'Telopodes,A11.284.180.900',\n 'Telopodes,A11.329.830.750.500',\n 'Podomers,A11.284.180.900',\n 'Podomers,A11.329.830.750.500',\n 'Podoms,A11.284.180.900',\n 'Podoms,A11.329.830.750.500',\n 'Drosophila simulans,B01.050.500.131.617.720.500.500.750.310.250.750',\n 'Optimism,F01.100.787',\n 'Positive Attitude,F01.100.787',\n 'Positive Thinking,F01.100.787',\n 'Pessimism,F01.100.893',\n 'Ataxin-1,D12.776.631.069.500',\n 'Ataxin-1,D12.776.660.075.500',\n 'Adolescent Health,N01.400.075',\n 'Adolescent Well Being,N01.400.075',\n 'Ataxin-2,D12.776.157.725.452.125',\n 'Ataxin-2,D12.776.631.069.750',\n 'Ataxin-2,D12.776.660.075.750',\n 'Ataxin-2,D12.776.664.962.452.125',\n 'Ataxin-3,D08.811.037.250',\n 'Ataxin-3,D12.776.631.069.875',\n 'Ataxin-3,D12.776.660.075.875',\n 'Point-of-Care Testing,N04.590.874.500',\n 'Bedside Testing,N04.590.874.500',\n 'Ataxin-7,D12.776.631.069.901',\n 'Ataxin-7,D12.776.660.075.900',\n 'Ataxin-10,D12.776.631.069.950',\n 'Glucagon-Like Peptide Receptors,D12.776.543.750.695.021',\n 'Glucagon-Like Peptide Receptors,D12.776.543.750.750.360.100',\n 'Glucagon-Like Peptide-1 Receptor,D12.776.543.750.695.021.500',\n 'Glucagon-Like Peptide-1 Receptor,D12.776.543.750.750.360.100.500',\n 'Glucagon-Like Peptide-2 Receptor,D12.776.543.750.695.021.600',\n 'Glucagon-Like Peptide-2 Receptor,D12.776.543.750.750.360.100.600',\n 'Receptor for Advanced Glycation End Products,D12.776.543.750.615',\n 'RNA Recognition Motif Proteins,D12.776.157.725.813',\n 'RNA Recognition Motif Proteins,D12.776.664.962.813',\n 'ELAV-Like Protein 2,D12.776.157.725.813.500.500',\n 'ELAV-Like Protein 2,D12.776.631.520.500',\n 'ELAV-Like Protein 2,D12.776.664.962.813.500.500',\n 'ELAV-Like Protein 3,D12.776.157.725.813.500.750',\n 'ELAV-Like Protein 3,D12.776.631.520.750',\n 'ELAV-Like Protein 3,D12.776.664.962.813.500.750',\n 'ELAV-Like Protein 4,D12.776.157.725.813.500.875',\n 'ELAV-Like Protein 4,D12.776.631.520.875',\n 'ELAV-Like Protein 4,D12.776.664.962.813.500.875',\n 'ELAV-Like Protein 1,D12.776.157.725.813.500.250',\n 'ELAV-Like Protein 1,D12.776.664.962.813.500.250',\n 'Whey,A12.790.760',\n 'Whey,G07.203.100.700.750',\n 'Whey,G07.203.300.350.525.760',\n 'Whey,J02.200.700.750',\n 'Whey,J02.500.350.525.760',\n 'Whey Proteins,A12.790.520.500',\n 'Whey Proteins,A12.790.760.500',\n 'Whey Proteins,D12.776.256.159.750.816',\n 'Whey Proteins,G07.203.300.350.525.760.500',\n 'Whey Proteins,G07.203.300.428.159.812.500',\n 'Whey Proteins,J02.500.350.525.520.500',\n 'Whey Proteins,J02.500.350.525.760.500',\n 'Whey Proteins,J02.500.428.159.750.500',\n 'Hoarding Disorder,F03.080.600.250',\n 'Obsessive Hoarding,F03.080.600.250',\n 'Poly(ADP-ribose) Polymerase Inhibitors,D27.505.519.389.739',\n 'Poly(ADP-ribose) Polymerase Inhibitors,D27.505.954.248.692',\n 'Autism Spectrum Disorder,F03.625.164.113',\n 'CELF Proteins,D12.776.157.725.813.250',\n 'CELF Proteins,D12.776.664.962.813.250',\n 'CELF1 Protein,D12.776.157.725.813.250.500',\n 'CELF1 Protein,D12.776.664.962.813.250.500',\n 'Industrial Development,I01.261.262.500',\n 'Industrial Development,J01.576.519',\n 'Technology Development,I01.261.262.500',\n 'Technology Development,J01.576.519',\n 'Industrialization,I01.261.262.500',\n 'Industrialization,J01.576.519',\n 'Cloud Computing,L01.224.097',\n 'Natural Resources,G16.500.275.553',\n 'Natural Resources,J01.728',\n 'Natural Resources,N06.230.350',\n 'Land Supply,G16.500.275.553',\n 'Land Supply,J01.728',\n 'Land Supply,N06.230.350',\n 'Glycemic Load,G07.203.650.660.750',\n 'Glycemic Load,J01.576.423.850.730.750.750',\n 'Glycemic Load,N06.850.601.750.750',\n 'Adenylyl Cyclase Inhibitors,D27.505.519.389.108',\n 'RAW 264.7 Cells,A11.251.210.172.875',\n 'RAW 264.7 Cells,A11.733.397.815',\n 'Accreditation,N03.706.110.070',\n 'Accreditation,N05.700.200.100',\n 'Clostridiales,B03.353.625',\n 'Graphic Novel,V02.700.415',\n 'Comic Book,V02.700.415',\n 'South Sudan,Z01.058.290.120.745',\n 'Motor Disorders,F03.608',\n 'Maternal Health,N01.400.900.500',\n 'Seed Bank,N02.278.065.650',\n 'Germplasm Bank,N02.278.065.650',\n 'Trauma and Stressor Related Disorders,F03.950',\n 'Maternal-Child Health Services,N02.421.143.130.660',\n 'Maternal-Child Health Services,N02.421.143.620.275',\n 'Serine-Arginine Splicing Factors,D12.776.157.725.829.500',\n 'Serine-Arginine Splicing Factors,D12.776.664.962.829.500',\n 'Infant Health,N01.400.388',\n 'Newborn Health,N01.400.388',\n 'Bipolar and Related Disorders,F03.084',\n 'Gender Dysphoria,F03.835.550',\n 'Formative Feedback,F02.784.629.529.223',\n 'Aripiprazole,D03.383.606.170',\n 'Aripiprazole,D03.633.100.810.835.122',\n 'Abilify,D03.383.606.170',\n 'Abilify,D03.633.100.810.835.122',\n 'OPC 14597,D03.383.606.170',\n 'OPC 14597,D03.633.100.810.835.122',\n 'Prunus dulcis,B01.650.940.800.575.912.250.859.937.500.625.500',\n 'Almonds,B01.650.940.800.575.912.250.859.937.500.625.500',\n 'Albumin-Bound Paclitaxel,D02.455.426.392.368.242.888.777.500',\n 'Albumin-Bound Paclitaxel,D02.455.849.291.850.777.500',\n 'Albumin-Bound Paclitaxel,D12.776.034.073',\n 'Abraxane,D02.455.426.392.368.242.888.777.500',\n 'Abraxane,D02.455.849.291.850.777.500',\n 'Abraxane,D12.776.034.073',\n 'ABI007,D02.455.426.392.368.242.888.777.500',\n 'ABI007,D02.455.849.291.850.777.500',\n 'ABI007,D12.776.034.073',\n 'Child Protective Services,I01.409.418.500',\n 'Child Protective Services,N03.540.400.500',\n 'Social Workers,M01.526.919',\n 'Prunus africana,B01.650.940.800.575.912.250.859.937.500.625.250',\n 'Prunus armeniaca,B01.650.940.800.575.912.250.859.937.500.625.375',\n 'Apricot,B01.650.940.800.575.912.250.859.937.500.625.375',\n 'Prunus avium,B01.650.940.800.575.912.250.859.937.500.625.400',\n 'Prunus serotina,B01.650.940.800.575.912.250.859.937.500.625.400',\n 'Sweet Cherries,B01.650.940.800.575.912.250.859.937.500.625.400',\n 'Prunus cerasus,B01.650.940.800.575.912.250.859.937.500.625.400',\n 'Refugium,G16.500.275.683',\n 'Refugium,G16.500.819',\n 'Distance Counseling,F02.784.176.350',\n 'Distance Counseling,F04.408.413.437',\n 'Distance Counseling,N02.421.143.303.175',\n 'Distance Counseling,N02.421.461.363.437',\n 'Distance Counseling,N04.452.758.849.550.500',\n 'Lubiprostone,D10.251.355.325.050.500',\n 'RU 0211,D10.251.355.325.050.500',\n 'Amitiza,D10.251.355.325.050.500',\n 'SPI 0211,D10.251.355.325.050.500',\n 'Prunus persica,B01.650.940.800.575.912.250.859.937.500.625.750',\n 'Peach,B01.650.940.800.575.912.250.859.937.500.625.750',\n 'Data Anonymization,H01.770.644.205',\n 'Data Anonymization,L01.224.134.500',\n 'Data Anonymization,N03.706.437.650.124.160',\n 'Data Anonymization,N04.452.910.200.500',\n 'De-Identification,H01.770.644.205',\n 'De-Identification,L01.224.134.500',\n 'De-Identification,N03.706.437.650.124.160',\n 'De-Identification,N04.452.910.200.500',\n 'Data Masking,H01.770.644.205',\n 'Data Masking,L01.224.134.500',\n 'Data Masking,N03.706.437.650.124.160',\n 'Data Masking,N04.452.910.200.500',\n 'Personally Identifiable Information,I01.880.604.583.080.660',\n 'Prunus domestica,B01.650.940.800.575.912.250.859.937.500.625.450',\n 'Plum,B01.650.940.800.575.912.250.859.937.500.625.450',\n 'Prunus cerasifera,B01.650.940.800.575.912.250.859.937.500.625.450',\n 'Prunus salicina,B01.650.940.800.575.912.250.859.937.500.625.450',\n 'Darbepoetin alfa,D12.776.395.240.150.500',\n 'Aranesp,D12.776.395.240.150.500',\n 'KRN 321,D12.776.395.240.150.500',\n '\"Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination\",D02.705.429.906.125',\n '\"Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination\",D03.383.533.375',\n '\"Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination\",D03.383.742.680.245.500.600.125',\n '\"Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination\",D03.633.100.759.138.881.125',\n '\"Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination\",D26.310.375',\n 'Atripla,D02.705.429.906.125',\n 'Atripla,D03.383.533.375',\n 'Atripla,D03.383.742.680.245.500.600.125',\n 'Atripla,D03.633.100.759.138.881.125',\n 'Atripla,D26.310.375',\n 'Bevacizumab,D12.776.124.486.485.114.224.060.375',\n 'Bevacizumab,D12.776.124.790.651.114.224.060.438',\n 'Bevacizumab,D12.776.377.715.548.114.224.200.438',\n 'Mvasi,D12.776.124.486.485.114.224.060.375',\n 'Mvasi,D12.776.124.790.651.114.224.060.438',\n 'Mvasi,D12.776.377.715.548.114.224.200.438',\n 'Bevacizumab-awwb,D12.776.124.486.485.114.224.060.375',\n 'Bevacizumab-awwb,D12.776.124.790.651.114.224.060.438',\n 'Bevacizumab-awwb,D12.776.377.715.548.114.224.200.438',\n 'Avastin,D12.776.124.486.485.114.224.060.375',\n 'Avastin,D12.776.124.790.651.114.224.060.438',\n 'Avastin,D12.776.377.715.548.114.224.200.438',\n 'Giraffes,B01.050.150.900.649.313.500.380.443',\n 'Okapis,B01.050.150.900.649.313.500.380.443',\n 'Risedronic Acid,D02.705.429.500.872',\n 'Risedronic Acid,D03.383.725.836',\n '1-Hydroxy-2-(3-pyridyl)ethylidene diphosphonate,D02.705.429.500.872',\n '1-Hydroxy-2-(3-pyridyl)ethylidene diphosphonate,D03.383.725.836',\n 'Atelvia,D02.705.429.500.872',\n 'Atelvia,D03.383.725.836',\n 'Risedronate Sodium,D02.705.429.500.872',\n 'Risedronate Sodium,D03.383.725.836',\n '2-(3-pyridinyl)-1-hydroxyethylidene-bisphosphonate,D02.705.429.500.872',\n '2-(3-pyridinyl)-1-hydroxyethylidene-bisphosphonate,D03.383.725.836',\n '\"Risedronic Acid, Monosodium Salt\",D02.705.429.500.872',\n '\"Risedronic Acid, Monosodium Salt\",D03.383.725.836',\n 'Actonel,D02.705.429.500.872',\n 'Actonel,D03.383.725.836',\n 'Risedronate,D02.705.429.500.872',\n 'Risedronate,D03.383.725.836',\n 'Bisphosphonate Risedronate Sodium,D02.705.429.500.872',\n 'Bisphosphonate Risedronate Sodium,D03.383.725.836',\n 'Fluticasone-Salmeterol Drug Combination,D02.033.100.291.057.750.500',\n 'Fluticasone-Salmeterol Drug Combination,D02.092.063.291.057.750.500',\n 'Fluticasone-Salmeterol Drug Combination,D02.092.471.683.061.750.500',\n 'Fluticasone-Salmeterol Drug Combination,D04.210.500.054.079.129.114.500',\n 'Fluticasone-Salmeterol Drug Combination,D26.310.438',\n '\"Fluticasone Propionate, Salmeterol Xinafoate Drug Combination\",D02.033.100.291.057.750.500',\n '\"Fluticasone Propionate, Salmeterol Xinafoate Drug Combination\",D02.092.063.291.057.750.500',\n '\"Fluticasone Propionate, Salmeterol Xinafoate Drug Combination\",D02.092.471.683.061.750.500',\n '\"Fluticasone Propionate, Salmeterol Xinafoate Drug Combination\",D04.210.500.054.079.129.114.500',\n '\"Fluticasone Propionate, Salmeterol Xinafoate Drug Combination\",D26.310.438',\n 'Advair Diskus,D02.033.100.291.057.750.500',\n 'Advair Diskus,D02.092.063.291.057.750.500',\n 'Advair Diskus,D02.092.471.683.061.750.500',\n 'Advair Diskus,D04.210.500.054.079.129.114.500',\n 'Advair Diskus,D26.310.438',\n 'Seretide,D02.033.100.291.057.750.500',\n 'Seretide,D02.092.063.291.057.750.500',\n 'Seretide,D02.092.471.683.061.750.500',\n 'Seretide,D04.210.500.054.079.129.114.500',\n 'Seretide,D26.310.438',\n 'Advair HFA,D02.033.100.291.057.750.500',\n 'Advair HFA,D02.092.063.291.057.750.500',\n 'Advair HFA,D02.092.471.683.061.750.500',\n 'Advair HFA,D04.210.500.054.079.129.114.500',\n 'Advair HFA,D26.310.438',\n 'Advair,D02.033.100.291.057.750.500',\n 'Advair,D02.092.063.291.057.750.500',\n 'Advair,D02.092.471.683.061.750.500',\n 'Advair,D04.210.500.054.079.129.114.500',\n 'Advair,D26.310.438',\n 'Fluticasone,D04.210.500.054.079.129.114',\n 'Flonase,D04.210.500.054.079.129.114',\n 'Flovent HFA,D04.210.500.054.079.129.114',\n 'Cutivate,D04.210.500.054.079.129.114',\n 'Fluticasone Propionate,D04.210.500.054.079.129.114',\n 'Flixonase,D04.210.500.054.079.129.114',\n 'Flixotide,D04.210.500.054.079.129.114',\n 'Flovent,D04.210.500.054.079.129.114',\n 'Salmeterol Xinafoate,D02.033.100.291.057.750',\n 'Salmeterol Xinafoate,D02.092.063.291.057.750',\n 'Salmeterol Xinafoate,D02.092.471.683.061.750',\n 'Salmeterol,D02.033.100.291.057.750',\n 'Salmeterol,D02.092.063.291.057.750',\n 'Salmeterol,D02.092.471.683.061.750',\n 'Serevent,D02.033.100.291.057.750',\n 'Serevent,D02.092.063.291.057.750',\n 'Serevent,D02.092.471.683.061.750',\n '\"Parks, Recreational\",J03.925.680',\n 'National Parks,J03.925.680',\n 'Community Parks,J03.925.680',\n 'Green Space,J03.925.680',\n 'Urban Parks,J03.925.680',\n 'Warfare and Armed Conflicts,I01.880.735.950',\n 'Armed Conflicts,I01.880.735.950.250',\n 'Wars,I01.880.735.950.250',\n 'Everolimus,D02.540.505.760.500',\n 'RAD 001,D02.540.505.760.500',\n 'Afinitor,D02.540.505.760.500',\n 'Certican,D02.540.505.760.500',\n '\"Aspirin, Dipyridamole Drug Combination\",D02.455.426.559.389.657.410.595.176.500',\n '\"Aspirin, Dipyridamole Drug Combination\",D03.383.742.175.500',\n '\"Aspirin, Dipyridamole Drug Combination\",D26.310.125',\n 'TX 3301,D02.455.426.559.389.657.410.595.176.500',\n 'TX 3301,D03.383.742.175.500',\n 'TX 3301,D26.310.125',\n 'Extended-Release Dipyridamole-Aspirin,D02.455.426.559.389.657.410.595.176.500',\n 'Extended-Release Dipyridamole-Aspirin,D03.383.742.175.500',\n 'Extended-Release Dipyridamole-Aspirin,D26.310.125',\n 'Asasantin,D02.455.426.559.389.657.410.595.176.500',\n 'Asasantin,D03.383.742.175.500',\n 'Asasantin,D26.310.125',\n 'Asasantin Retard,D02.455.426.559.389.657.410.595.176.500',\n 'Asasantin Retard,D03.383.742.175.500',\n 'Asasantin Retard,D26.310.125',\n 'Aggrenox,D02.455.426.559.389.657.410.595.176.500',\n 'Aggrenox,D03.383.742.175.500',\n 'Aggrenox,D26.310.125',\n 'Self-Control,F01.145.813.595',\n 'Saline Waters,G16.500.275.725',\n 'Brackish Water,G16.500.275.725',\n 'Compassion Fatigue,C23.888.369.500.500',\n 'Compassion Fatigue,F01.145.126.937.500',\n 'Compassion Fatigue,F01.145.126.990.734.500',\n 'Compassion Fatigue,F02.830.900.666.750',\n 'Plantaginaceae,B01.650.940.800.575.912.250.583.700',\n 'Stemodia,B01.650.940.800.575.912.250.583.700',\n 'Globularia,B01.650.940.800.575.912.250.583.700',\n 'Lamiales,B01.650.940.800.575.912.250.583',\n 'Proboscidea Plant,B01.650.940.800.575.912.250.583',\n 'Clinical Study,V03.175',\n 'Surgical Clearance,E01.370.505',\n 'Pemetrexed,D03.633.100.759.758.399.454.650',\n 'Pemetrexed,D12.125.067.625.525',\n 'Pemetrexed,D12.125.119.409.525',\n 'Pemetrexed Disodium,D03.633.100.759.758.399.454.650',\n 'Pemetrexed Disodium,D12.125.067.625.525',\n 'Pemetrexed Disodium,D12.125.119.409.525',\n 'LY 231514,D03.633.100.759.758.399.454.650',\n 'LY 231514,D12.125.067.625.525',\n 'LY 231514,D12.125.119.409.525',\n 'Alimta,D03.633.100.759.758.399.454.650',\n 'Alimta,D12.125.067.625.525',\n 'Alimta,D12.125.119.409.525',\n 'Brimonidine Tartrate,D03.633.100.857.070',\n '\"Brimonidine Tartrate (1:1), (S-(R*,R*))-Isomer\",D03.633.100.857.070',\n 'Brimonidine Purite,D03.633.100.857.070',\n 'AGN 190342,D03.633.100.857.070',\n 'Sanrosa,D03.633.100.857.070',\n 'Alphagan,D03.633.100.857.070',\n 'Brimonidine,D03.633.100.857.070',\n 'Alphagan P,D03.633.100.857.070',\n '\"UK 14,304\",D03.633.100.857.070',\n 'Ratio-Brimonidine,D03.633.100.857.070',\n '\"UK 14,304-18\",D03.633.100.857.070',\n 'UK 14308,D03.633.100.857.070',\n '\"Brimonidine Tartrate, (R-(R*,R*))-Isomer\",D03.633.100.857.070',\n 'Brimonidine Tartrate (1:1),D03.633.100.857.070',\n 'Mirvaso,D03.633.100.857.070',\n 'Clinical Studies as Topic,E05.318.372.250',\n 'Clinical Studies as Topic,N05.715.360.330.250',\n 'Clinical Studies as Topic,N06.850.520.450.250',\n 'Beijing,Z01.252.474.164.225',\n 'Beijing,Z01.433.114',\n 'African Union,I01.615.500.125',\n 'African Union,N03.540.089',\n 'Firmicutes,B03.353',\n 'Dutasteride,D04.210.500.925.100.125',\n 'Avodart,D04.210.500.925.100.125',\n 'GG 745,D04.210.500.925.100.125',\n 'GI198745,D04.210.500.925.100.125',\n 'Calceolariaceae,B01.650.940.800.575.912.250.583.190',\n 'Jovellana,B01.650.940.800.575.912.250.583.190',\n 'Calceolaria,B01.650.940.800.575.912.250.583.190',\n 'Porodittia,B01.650.940.800.575.912.250.583.190',\n 'Interferon beta-1a,D12.644.276.374.440.890.275.500',\n 'Interferon beta-1a,D12.776.467.374.440.890.275.500',\n 'Interferon beta-1a,D23.529.374.440.890.275.500',\n 'Avonex Pen,D12.644.276.374.440.890.275.500',\n 'Avonex Pen,D12.776.467.374.440.890.275.500',\n 'Avonex Pen,D23.529.374.440.890.275.500',\n 'Rebif,D12.644.276.374.440.890.275.500',\n 'Rebif,D12.776.467.374.440.890.275.500',\n 'Rebif,D23.529.374.440.890.275.500',\n 'Avonex,D12.644.276.374.440.890.275.500',\n 'Avonex,D12.776.467.374.440.890.275.500',\n 'Avonex,D23.529.374.440.890.275.500',\n 'Olmesartan Medoxomil,D03.383.129.308.674',\n 'Olmesartan Medoxomil,D03.383.129.617.584',\n 'Benicar,D03.383.129.308.674',\n 'Benicar,D03.383.129.617.584',\n 'Olmetec,D03.383.129.308.674',\n 'Olmetec,D03.383.129.617.584',\n 'CS 866,D03.383.129.308.674',\n 'CS 866,D03.383.129.617.584',\n 'Votum,D03.383.129.308.674',\n 'Votum,D03.383.129.617.584',\n '\"Amlodipine Besylate, Olmesartan Medoxomil Drug Combination\",D03.383.129.308.674.500',\n '\"Amlodipine Besylate, Olmesartan Medoxomil Drug Combination\",D03.383.129.617.584.500',\n '\"Amlodipine Besylate, Olmesartan Medoxomil Drug Combination\",D03.383.725.203.065.500',\n '\"Amlodipine Besylate, Olmesartan Medoxomil Drug Combination\",D26.310.063',\n 'Azor,D03.383.129.308.674.500',\n 'Azor,D03.383.129.617.584.500',\n 'Azor,D03.383.725.203.065.500',\n 'Azor,D26.310.063',\n 'Interferon beta-1b,D12.644.276.374.440.890.275.750',\n 'Interferon beta-1b,D12.776.467.374.440.890.275.750',\n 'Interferon beta-1b,D23.529.374.440.890.275.750',\n 'Betaseron,D12.644.276.374.440.890.275.750',\n 'Betaseron,D12.776.467.374.440.890.275.750',\n 'Betaseron,D23.529.374.440.890.275.750',\n 'Extavia,D12.644.276.374.440.890.275.750',\n 'Extavia,D12.776.467.374.440.890.275.750',\n 'Extavia,D23.529.374.440.890.275.750',\n 'Betaferon,D12.644.276.374.440.890.275.750',\n 'Betaferon,D12.776.467.374.440.890.275.750',\n 'Betaferon,D23.529.374.440.890.275.750',\n 'Nebivolol,D02.033.100.291.491',\n 'Nebivolol,D02.092.063.291.503',\n 'Nebivolol,D03.383.663.283.755',\n 'Nebivolol,D03.633.100.150.755',\n 'Bystolic,D02.033.100.291.491',\n 'Bystolic,D02.092.063.291.503',\n 'Bystolic,D03.383.663.283.755',\n 'Bystolic,D03.633.100.150.755',\n 'Nebilet,D02.033.100.291.491',\n 'Nebilet,D02.092.063.291.503',\n 'Nebilet,D03.383.663.283.755',\n 'Nebilet,D03.633.100.150.755',\n 'Silostar,D02.033.100.291.491',\n 'Silostar,D02.092.063.291.503',\n 'Silostar,D03.383.663.283.755',\n 'Silostar,D03.633.100.150.755',\n 'Nebivolol Hydrochloride,D02.033.100.291.491',\n 'Nebivolol Hydrochloride,D02.092.063.291.503',\n 'Nebivolol Hydrochloride,D03.383.663.283.755',\n 'Nebivolol Hydrochloride,D03.633.100.150.755',\n 'R 67555,D02.033.100.291.491',\n 'R 67555,D02.092.063.291.503',\n 'R 67555,D03.383.663.283.755',\n 'R 67555,D03.633.100.150.755',\n 'Lobivon,D02.033.100.291.491',\n 'Lobivon,D02.092.063.291.503',\n 'Lobivon,D03.383.663.283.755',\n 'Lobivon,D03.633.100.150.755',\n 'Celecoxib,D02.065.884.247',\n 'Celecoxib,D02.886.590.700.247',\n 'Celecoxib,D03.383.129.539.160',\n 'Celebrex,D02.065.884.247',\n 'Celebrex,D02.886.590.700.247',\n 'Celebrex,D03.383.129.539.160',\n 'SC 58635,D02.065.884.247',\n 'SC 58635,D02.886.590.700.247',\n 'SC 58635,D03.383.129.539.160',\n 'Varenicline,D03.633.100.079.900',\n 'Varenicline,D03.633.100.857.942',\n 'Chantix,D03.633.100.079.900',\n 'Chantix,D03.633.100.857.942',\n 'Varenicline Tartrate,D03.633.100.079.900',\n 'Varenicline Tartrate,D03.633.100.857.942',\n 'Champix,D03.633.100.079.900',\n 'Champix,D03.633.100.857.942',\n 'Tadalafil,D03.383.725.150.500',\n 'Tadalafil,D03.633.100.473.155.500',\n 'Tadalafil,D03.633.300.154.672',\n 'IC351,D03.383.725.150.500',\n 'IC351,D03.633.100.473.155.500',\n 'IC351,D03.633.300.154.672',\n 'Cialis,D03.383.725.150.500',\n 'Cialis,D03.633.100.473.155.500',\n 'Cialis,D03.633.300.154.672',\n 'Certolizumab Pegol,D05.750.741.125',\n 'Certolizumab Pegol,D12.644.541.500.650.250',\n 'Certolizumab Pegol,D12.776.124.486.485.114.224.060.500',\n 'Certolizumab Pegol,D12.776.124.486.485.680.650.250',\n 'Certolizumab Pegol,D12.776.124.790.651.114.224.060.500',\n 'Certolizumab Pegol,D12.776.124.790.651.680.650.250',\n 'Certolizumab Pegol,D12.776.377.715.548.114.224.200.500',\n 'Certolizumab Pegol,D12.776.377.715.548.680.650.250',\n 'Cimzia,D05.750.741.125',\n 'Cimzia,D12.644.541.500.650.250',\n 'Cimzia,D12.776.124.486.485.114.224.060.500',\n 'Cimzia,D12.776.124.486.485.680.650.250',\n 'Cimzia,D12.776.124.790.651.114.224.060.500',\n 'Cimzia,D12.776.124.790.651.680.650.250',\n 'Cimzia,D12.776.377.715.548.114.224.200.500',\n 'Cimzia,D12.776.377.715.548.680.650.250',\n 'CDP870,D05.750.741.125',\n 'CDP870,D12.644.541.500.650.250',\n 'CDP870,D12.776.124.486.485.114.224.060.500',\n 'CDP870,D12.776.124.486.485.680.650.250',\n 'CDP870,D12.776.124.790.651.114.224.060.500',\n 'CDP870,D12.776.124.790.651.680.650.250',\n 'CDP870,D12.776.377.715.548.114.224.200.500',\n 'CDP870,D12.776.377.715.548.680.650.250',\n '\"Censorship, Research\",I01.880.604.238',\n '\"Censorship, Research\",K01.752.566.479.173.200',\n '\"Censorship, Research\",N05.350.670.250',\n 'Data Accuracy,E05.318.308.028',\n 'Data Accuracy,E05.318.370.725.250',\n 'Data Accuracy,L01.399.250.202',\n 'Data Accuracy,N05.715.360.300.202',\n 'Data Accuracy,N05.715.360.325.685.250',\n 'Data Quality,E05.318.308.028',\n 'Data Quality,E05.318.370.725.250',\n 'Data Quality,L01.399.250.202',\n 'Data Quality,N05.715.360.300.202',\n 'Data Quality,N05.715.360.325.685.250',\n '\"Brimonidine Tartrate, Timolol Maleate Drug Combination\",D02.033.100.624.915.500',\n '\"Brimonidine Tartrate, Timolol Maleate Drug Combination\",D02.033.755.624.915.500',\n '\"Brimonidine Tartrate, Timolol Maleate Drug Combination\",D02.092.063.624.915.500',\n '\"Brimonidine Tartrate, Timolol Maleate Drug Combination\",D02.886.675.867.768.500',\n '\"Brimonidine Tartrate, Timolol Maleate Drug Combination\",D03.383.129.708.867.768.500',\n '\"Brimonidine Tartrate, Timolol Maleate Drug Combination\",D03.633.100.857.070.500',\n '\"Brimonidine Tartrate, Timolol Maleate Drug Combination\",D26.310.312',\n 'Combigan,D02.033.100.624.915.500',\n ...]","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[35]: ['Calcimycin,D03.633.100.221.173',\n 'A-23187,D03.633.100.221.173',\n 'Temefos,D02.705.400.625.800',\n 'Temefos,D02.705.539.345.800',\n 'Temefos,D02.886.300.692.800',\n 'Abate,D02.705.400.625.800',\n 'Abate,D02.705.539.345.800',\n 'Abate,D02.886.300.692.800',\n 'Difos,D02.705.400.625.800',\n 'Difos,D02.705.539.345.800',\n 'Difos,D02.886.300.692.800',\n 'Abattoirs,J01.576.423.200.700.100',\n 'Abattoirs,J03.540.020',\n 'Abbreviations as Topic,L01.559.598.400.556.131',\n 'Acronyms as Topic,L01.559.598.400.556.131',\n 'Abdomen,A01.923.047',\n '\"Abdomen, Acute\",C23.888.592.612.054.200',\n '\"Abdomen, Acute\",C23.888.821.030.249',\n 'Abdominal Injuries,C26.017',\n 'Abdominal Neoplasms,C04.588.033',\n 'Abdominal Muscles,A02.633.567.050',\n 'Cremaster Muscle,A02.633.567.050',\n 'Pyramidalis Muscle,A02.633.567.050',\n 'Quadratus Abdominis,A02.633.567.050',\n 'Transversus Abdominis,A02.633.567.050',\n 'Abducens Nerve,A08.800.800.120.030',\n 'Abelson murine leukemia virus,B04.613.807.375.525.020',\n 'Abelson murine leukemia virus,B04.820.650.375.525.020',\n 'Abetalipoproteinemia,C16.320.565.398.500.440.500',\n 'Abetalipoproteinemia,C18.452.584.500.875.440.500',\n 'Abetalipoproteinemia,C18.452.648.398.500.440.500',\n 'Congenital Abnormalities,C16.131',\n 'Fetal Malformations,C16.131',\n 'Fetal Anomalies,C16.131',\n '\"Abnormalities, Drug-Induced\",C16.131.042',\n '\"Abnormalities, Multiple\",C16.131.077',\n '\"Abnormalities, Radiation-Induced\",C16.131.080',\n '\"Abnormalities, Radiation-Induced\",C26.733.031',\n '\"Abnormalities, Radiation-Induced\",G01.750.748.500.031',\n '\"Abnormalities, Radiation-Induced\",N06.850.460.350.850.500.031',\n '\"Abnormalities, Radiation-Induced\",N06.850.810.300.360.031',\n 'ABO Blood-Group System,D23.050.301.290.031',\n 'ABO Blood-Group System,D23.050.705.230.031',\n 'Blood Group H Type 1 Antigen,D23.050.301.290.031',\n 'Blood Group H Type 1 Antigen,D23.050.705.230.031',\n 'ABO Factors,D23.050.301.290.031',\n 'ABO Factors,D23.050.705.230.031',\n 'Abomasum,A13.869.106',\n 'Abortifacient Agents,D27.505.696.875.131',\n 'Abortifacient Agents,D27.505.954.705.131',\n 'Abortifacient Effect,D27.505.696.875.131',\n 'Abortifacient Effect,D27.505.954.705.131',\n '\"Abortifacient Agents, Nonsteroidal\",D27.505.696.875.131.100',\n '\"Abortifacient Agents, Nonsteroidal\",D27.505.954.705.131.100',\n '\"Abortifacient Agents, Steroidal\",D27.505.696.875.131.200',\n '\"Abortifacient Agents, Steroidal\",D27.505.954.705.131.200',\n '\"Abortion, Spontaneous\",C13.703.039',\n '\"Abortion, Spontaneous\",G08.686.784.769.496.125',\n 'Early Pregnancy Loss,C13.703.039',\n 'Early Pregnancy Loss,G08.686.784.769.496.125',\n 'Miscarriage,C13.703.039',\n 'Miscarriage,G08.686.784.769.496.125',\n '\"Abortion, Tubal\",C13.703.039',\n '\"Abortion, Tubal\",G08.686.784.769.496.125',\n 'Abortion Applicants,M01.050',\n '\"Abortion Seekers, Repeated\",M01.050',\n '\"Abortion Seekers, Refused\",M01.050',\n '\"Abortion, Criminal\",I01.198.240.089',\n '\"Abortion, Eugenic\",E04.520.050.050',\n '\"Abortion, Selective\",E04.520.050.050',\n '\"Abortion, Habitual\",C13.703.039.089',\n '\"Abortion, Incomplete\",C13.703.039.093',\n '\"Abortion, Induced\",E04.520.050',\n 'Abortion Rate,E04.520.050',\n 'Abortion Techniques,E04.520.050',\n '\"Abortion, Drug-Induced\",E04.520.050',\n 'Previous Abortion,E04.520.050',\n '\"Abortion, Saline-Solution\",E04.520.050',\n '\"Abortion, Soap-Solution\",E04.520.050',\n 'Anti-Abortion Groups,E04.520.050',\n 'Embryotomy,E04.520.050',\n '\"Fertility Control, Postconception\",E04.520.050',\n 'Abortion Failure,E04.520.050',\n '\"Abortion, Rivanol\",E04.520.050',\n '\"Abortion, Legal\",E04.520.050.055',\n 'Abortion on Demand,E04.520.050.055',\n '\"Abortion, Missed\",C13.703.039.173',\n '\"Abortion, Septic\",C01.674.173',\n '\"Abortion, Septic\",C13.703.039.256',\n '\"Abortion, Septic\",C13.703.700.173',\n '\"Abortion, Therapeutic\",E04.520.050.060',\n '\"Abortion, Threatened\",C13.703.090',\n '\"Abortion, Veterinary\",C13.703.039.422',\n '\"Abortion, Veterinary\",C22.021',\n 'Abreaction,F04.754.720.107',\n 'Abrin,D08.811.277.450.430.700.750.111',\n 'Abrin,D12.776.503.499.249',\n 'Abrin,D12.776.765.678.906.111',\n 'Abrin C,D08.811.277.450.430.700.750.111',\n 'Abrin C,D12.776.503.499.249',\n 'Abrin C,D12.776.765.678.906.111',\n 'Abrin A,D08.811.277.450.430.700.750.111',\n 'Abrin A,D12.776.503.499.249',\n 'Abrin A,D12.776.765.678.906.111',\n 'Abruptio Placentae,C13.703.420.078',\n 'Abruptio Placentae,C13.703.590.132',\n 'Abscess,C01.830.025',\n 'Abscess,C23.550.470.756.100',\n 'Peritonsillar Abscess,C01.748.561.750.500',\n 'Peritonsillar Abscess,C01.830.025.675',\n 'Peritonsillar Abscess,C07.550.781.750.500',\n 'Peritonsillar Abscess,C08.730.561.750.500',\n 'Peritonsillar Abscess,C09.775.649.750.500',\n 'Abscisic Acid,D02.241.223.268.034',\n 'Abscisic Acid,D02.455.326.271.665.202.061',\n 'Abscisic Acid,D02.455.426.392.368.367.379.249.024',\n 'Abscisic Acid,D02.455.849.131.061',\n 'Abscisic Acid,D02.455.849.765.521.500',\n '\"Abscisic Acid, (+,-)-Isomer\",D02.241.223.268.034',\n '\"Abscisic Acid, (+,-)-Isomer\",D02.455.326.271.665.202.061',\n '\"Abscisic Acid, (+,-)-Isomer\",D02.455.426.392.368.367.379.249.024',\n '\"Abscisic Acid, (+,-)-Isomer\",D02.455.849.131.061',\n '\"Abscisic Acid, (+,-)-Isomer\",D02.455.849.765.521.500',\n '\"Abscisic Acid, (Z,E)-Isomer\",D02.241.223.268.034',\n '\"Abscisic Acid, (Z,E)-Isomer\",D02.455.326.271.665.202.061',\n '\"Abscisic Acid, (Z,E)-Isomer\",D02.455.426.392.368.367.379.249.024',\n '\"Abscisic Acid, (Z,E)-Isomer\",D02.455.849.131.061',\n '\"Abscisic Acid, (Z,E)-Isomer\",D02.455.849.765.521.500',\n '\"Abscisic Acid, (E,Z)-(+,-)-Isomer\",D02.241.223.268.034',\n '\"Abscisic Acid, (E,Z)-(+,-)-Isomer\",D02.455.326.271.665.202.061',\n '\"Abscisic Acid, (E,Z)-(+,-)-Isomer\",D02.455.426.392.368.367.379.249.024',\n '\"Abscisic Acid, (E,Z)-(+,-)-Isomer\",D02.455.849.131.061',\n '\"Abscisic Acid, (E,Z)-(+,-)-Isomer\",D02.455.849.765.521.500',\n '\"Abscisic Acid, (R)-Isomer\",D02.241.223.268.034',\n '\"Abscisic Acid, (R)-Isomer\",D02.455.326.271.665.202.061',\n '\"Abscisic Acid, (R)-Isomer\",D02.455.426.392.368.367.379.249.024',\n '\"Abscisic Acid, (R)-Isomer\",D02.455.849.131.061',\n '\"Abscisic Acid, (R)-Isomer\",D02.455.849.765.521.500',\n '\"Abscisic Acid Monoammonium Salt, (R)-Isomer\",D02.241.223.268.034',\n '\"Abscisic Acid Monoammonium Salt, (R)-Isomer\",D02.455.326.271.665.202.061',\n '\"Abscisic Acid Monoammonium Salt, (R)-Isomer\",D02.455.426.392.368.367.379.249.024',\n '\"Abscisic Acid Monoammonium Salt, (R)-Isomer\",D02.455.849.131.061',\n '\"Abscisic Acid Monoammonium Salt, (R)-Isomer\",D02.455.849.765.521.500',\n '\"Abscisic Acid, (E,E)-(+-)-Isomer\",D02.241.223.268.034',\n '\"Abscisic Acid, (E,E)-(+-)-Isomer\",D02.455.326.271.665.202.061',\n '\"Abscisic Acid, (E,E)-(+-)-Isomer\",D02.455.426.392.368.367.379.249.024',\n '\"Abscisic Acid, (E,E)-(+-)-Isomer\",D02.455.849.131.061',\n '\"Abscisic Acid, (E,E)-(+-)-Isomer\",D02.455.849.765.521.500',\n 'Absenteeism,F02.784.692.107',\n 'Absorption,G01.015',\n 'Absorption,G02.010',\n 'Absorption,G03.015',\n 'Absorption,G03.787.024',\n 'Absorption,G07.690.725.015',\n 'Abstracting and Indexing,L01.453.245.100',\n 'Indexing,L01.453.245.100',\n 'Indexes as Topic,L01.453.245.100',\n 'Abstracting,L01.453.245.100',\n 'Dental Abutments,E06.780.346.500',\n 'Dental Abutments,E07.695.190.175',\n 'Acacia,B01.650.940.800.575.912.250.401.025',\n 'Acacia catechu,B01.650.940.800.575.912.250.401.025',\n 'Academic Medical Centers,N02.278.020',\n 'Academies and Institutes,N03.540.052',\n 'Institutes,N03.540.052',\n 'Research Institutes,N03.540.052',\n 'Academies,N03.540.052',\n 'Acanthamoeba,B01.046.500.100.075.080',\n 'Acanthocephala,B01.050.500.500.132',\n 'Acanthocytes,A11.118.290.330.100',\n 'Acanthocytes,A11.443.240.330.100',\n 'Acanthocytes,A15.145.229.334.330.100',\n 'Acantholysis,C17.800.865.070',\n 'Acantholysis,C23.550.035',\n 'Acanthosis Nigricans,C17.800.621.430.530.100',\n 'Acari,B01.050.500.131.166.132',\n 'Acceleration,G01.482.107',\n 'Accessory Nerve,A08.800.800.120.060',\n 'Accident Prevention,N06.850.135.060',\n 'Accident Proneness,F01.145.015',\n 'Accidental Falls,N06.850.135.122',\n 'Slip and Fall,N06.850.135.122',\n 'Accidents,N06.850.135',\n '\"Accidents, Aviation\",N06.850.135.185',\n '\"Accidents, Home\",N06.850.135.217',\n '\"Accidents, Occupational\",N06.850.135.240',\n '\"Accidents, Industrial\",N06.850.135.240',\n '\"Accidents, Traffic\",N06.850.135.392',\n 'Traffic Collisions,N06.850.135.392',\n 'Traffic Crashes,N06.850.135.392',\n 'Acclimatization,G07.025.133',\n 'Acclimatization,G16.012.500.133',\n '\"Accommodation, Ocular\",G14.010',\n '\"Accommodation, Lens\",G14.010',\n 'Accounting,N03.219.463.030',\n 'Oil and Gas Industry,J01.576.655.875.750',\n 'Petroleum Industry,J01.576.655.875.750',\n 'Oil Refinery,J01.576.655.875.750',\n 'Natural Gas Industry,J01.576.655.875.750',\n 'Coal Industry,J01.576.655.875.200',\n 'Driving Under the Influence,F01.145.250.250',\n 'Driving Under the Influence,F01.145.263.500',\n 'Driving Under the Influence,I01.880.735.223.250',\n 'Driving Under the Influence,I03.125.649',\n 'Drinking and Driving,F01.145.250.250',\n 'Drinking and Driving,F01.145.263.500',\n 'Drinking and Driving,I01.880.735.223.250',\n 'Drinking and Driving,I03.125.649',\n 'Human Embryonic Stem Cells,A11.872.700.250.750',\n 'Mouse Embryonic Stem Cells,A11.872.700.250.875',\n 'Embryonic Germ Cells,A11.497.124',\n 'Embryonic Germ Cells,A11.872.700.250.625',\n 'Work Performance,I03.946.675',\n 'Job Performance,I03.946.675',\n 'Criminal Behavior,F01.145.250',\n 'Clinical Decision-Making,E01.055',\n 'Cognitive Aging,G07.345.124.260',\n 'Cognitive Neuroscience,F04.096.628.255.500',\n 'Cognitive Neuroscience,H01.158.610.030',\n 'Social Neuroscience,F04.096.628.255.500',\n 'Social Neuroscience,H01.158.610.030',\n 'Emotional Adjustment,F01.058.144',\n 'Emotional Adjustment,F01.752.543.500.250',\n 'Facial Recognition,F02.463.593.524.250.500',\n 'Facial Recognition,F02.463.593.524.500.500',\n 'Facial Recognition,F02.463.593.932.622.500',\n 'Facial Emotion Recognition,F02.463.593.524.250.500',\n 'Facial Emotion Recognition,F02.463.593.524.500.500',\n 'Facial Emotion Recognition,F02.463.593.932.622.500',\n 'Grandparents,F01.829.263.403',\n 'Grandparents,I01.880.853.150.452',\n 'Grandparents,M01.264',\n 'Grandmother,F01.829.263.403',\n 'Grandmother,I01.880.853.150.452',\n 'Grandmother,M01.264',\n 'Grandfather,F01.829.263.403',\n 'Grandfather,I01.880.853.150.452',\n 'Grandfather,M01.264',\n 'Help-Seeking Behavior,F01.145.813.217',\n 'Heuristics,F02.463.425.725.500',\n 'Heuristics,F02.463.785.810.500',\n 'Intimate Partner Violence,I01.198.240.856.575',\n 'Intimate Partner Violence,I01.880.735.900.688',\n 'Dating Violence,I01.198.240.856.575',\n 'Dating Violence,I01.880.735.900.688',\n 'Neurological Rehabilitation,E02.760.169.063.500.477',\n 'Neurological Rehabilitation,E02.831.477',\n 'Neurological Rehabilitation,H02.403.680.600.750',\n 'Neurological Rehabilitation,N02.421.784.511',\n 'Physical Abuse,I01.198.240.856.688',\n 'Physical Abuse,I01.880.735.900.744',\n 'Problem Behavior,F01.145.126.972',\n 'Problem Behavior,F01.145.179.750',\n '\"Dysfunctional Behavior, Psychology\",F01.145.126.972',\n '\"Dysfunctional Behavior, Psychology\",F01.145.179.750',\n 'Disruptive Behavior,F01.145.126.972',\n 'Disruptive Behavior,F01.145.179.750',\n 'Underage Drinking,F01.145.022.750',\n 'Underage Drinking,F01.145.317.269.875',\n 'Underage Drinking,I01.880.735.878',\n 'Legal Drinking Age,F01.145.022.750',\n 'Legal Drinking Age,F01.145.317.269.875',\n 'Legal Drinking Age,I01.880.735.878',\n 'Ectopic Gene Expression,G05.308.202',\n 'Cell Plasticity,G04.356.250',\n 'Cell Self Renewal,G04.144.220.235',\n 'Cell Self Renewal,G04.161.750.500.375',\n 'Cell Self Renewal,G05.113.415',\n 'Cell Self Renewal,G07.345.249.410.750.500.625',\n 'Stem Cell Self-Renewal,G04.144.220.235',\n 'Stem Cell Self-Renewal,G04.161.750.500.375',\n 'Stem Cell Self-Renewal,G05.113.415',\n 'Stem Cell Self-Renewal,G07.345.249.410.750.500.625',\n 'Rehabilitation Research,H01.770.644.145.472',\n 'Orthodontists,M01.526.485.330.655',\n 'Orthodontists,N02.360.330.655',\n 'Dentofacial Orthopedists,M01.526.485.330.655',\n 'Dentofacial Orthopedists,N02.360.330.655',\n 'Oral and Maxillofacial Surgeons,M01.526.485.330.483',\n 'Oral and Maxillofacial Surgeons,N02.360.330.483',\n 'Exodontists,M01.526.485.330.483',\n 'Exodontists,N02.360.330.483',\n 'Neuroprotection,G11.561.645',\n '\"Diet, Food, and Nutrition\",G07.203',\n 'Triticale,B01.650.940.800.575.912.250.822.906',\n 'Critical Care Outcomes,N04.761.559.590.399.250',\n 'Critical Care Outcomes,N05.715.360.575.575.399.250',\n 'Simulation Training,I02.903.847',\n 'Interactive Learning,I02.903.847',\n 'Millets,B01.650.940.800.575.912.250.822.587',\n 'Biobehavioral Sciences,H01.770.644.108.687',\n 'Protein Corona,D12.776.642',\n 'Vegetarians,M01.928',\n 'Lacto-Ovo Vegetarians,M01.928',\n 'Vegans,M01.928.500',\n 'Accounts Payable and Receivable,N03.219.463.030.080',\n 'Accounts Payable,N03.219.463.030.080',\n 'Youth Sports,I03.450.642.845.987',\n 'Organized Youth Sports,I03.450.642.845.987',\n 'Literacy,F01.145.209.429',\n 'Literacy,N01.824.196.500',\n 'Illiteracy,F01.145.209.429',\n 'Illiteracy,N01.824.196.500',\n 'Severe Acute Malnutrition,C18.654.521.719',\n '\"Banking, Personal\",N03.219.463.030.100',\n 'Savings Accounts,N03.219.463.030.100',\n 'Checking Accounts,N03.219.463.030.100',\n 'Evidence-Based Facility Design,N02.278.200.252',\n '\"Physical Appearance, Body\",E01.370.600.115.450',\n '\"Physical Appearance, Body\",G07.100.175',\n 'Fruit and Vegetable Juices,G07.203.100.606',\n 'Fruit and Vegetable Juices,J02.200.606',\n 'Vegetable Juices,G07.203.100.606',\n 'Vegetable Juices,J02.200.606',\n 'Fruit Juices,G07.203.100.606',\n 'Fruit Juices,J02.200.606',\n 'Ghee,D10.212.302.199.500',\n 'Ghee,G07.203.300.350.100.500',\n 'Ghee,G07.203.300.375.200.500',\n 'Ghee,J02.500.350.100.500',\n 'Ghee,J02.500.375.200.500',\n 'Hydraulic Fracking,J01.576.655.875.750.500',\n 'Psychological Trauma,F03.950.750.375',\n 'Peer Influence,F01.829.316.483.750',\n 'Peer Pressure,F01.829.316.483.750',\n 'Vegetable Products,G07.203.300.850.450',\n 'Vegetable Products,J02.500.850.800',\n 'Direct-to-Consumer Advertising,J01.219.687.274.500',\n 'Direct-To-Consumer Screening and Testing,E01.370.398',\n 'Direct-To-Consumer Screening and Testing,N02.421.726.233.166',\n 'Extracellular Vesicles,A11.284.295.588',\n 'Exovesicles,A11.284.295.588',\n 'Apoptotic Bodies,A11.284.295.588',\n 'Fungal Viruses,B04.352',\n 'Telocytes,A11.329.830.750',\n 'Exoskeleton Device,E07.341',\n 'Robotic Exoskeleton,E07.341',\n 'Shellfish Hypersensitivity,C20.543.480.370.763',\n '\"Failure to Rescue, Health Care\",E01.789.800.760.500',\n '\"Failure to Rescue, Health Care\",H01.770.644.145.431.500',\n '\"Failure to Rescue, Health Care\",N04.761.559.590.800.760.500',\n '\"Failure to Rescue, Health Care\",N05.715.360.575.575.800.760.500',\n 'Psychiatric Rehabilitation,H02.403.680.600.875',\n 'Psychiatric Rehabilitation,N02.421.784.578',\n 'Psychosocial Care,H02.403.680.600.875',\n 'Psychosocial Care,N02.421.784.578',\n 'Symptom Flare Up,C23.550.291.937.500',\n 'Symptom Exacerbation,C23.550.291.937.500',\n 'Isolated Heart Preparation,E05.519',\n 'Isolated Heart Preparation,E05.598.750',\n 'Langendorff Perfused Heart,E05.519',\n 'Langendorff Perfused Heart,E05.598.750',\n 'Working Heart Preparation Technique,E05.519',\n 'Working Heart Preparation Technique,E05.598.750',\n 'Working Heart Preparation,E05.519',\n 'Working Heart Preparation,E05.598.750',\n 'Isolated Heart Preparation Technique,E05.519',\n 'Isolated Heart Preparation Technique,E05.598.750',\n '\"Diet, Vegan\",E02.642.249.300.750',\n '\"Diet, Vegan\",G07.203.650.240.300.750',\n 'Veganism,E02.642.249.300.750',\n 'Veganism,G07.203.650.240.300.750',\n 'Behavior Observation Techniques,E05.796.112',\n 'Behavior Observation Techniques,F04.669.112',\n 'Behavior Rating Scale,F04.711.271',\n 'Behavior Test,F04.711.271',\n 'Alcohol Drinking in College,F01.145.317.269.625',\n '\"Obesity, Metabolically Benign\",C18.654.726.500.650',\n '\"Obesity, Metabolically Benign\",C23.888.144.699.500.250',\n '\"Obesity, Metabolically Benign\",E01.370.600.115.100.160.120.699.500.375',\n '\"Obesity, Metabolically Benign\",G07.100.100.160.120.699.500.375',\n 'Whole Grains,G07.203.300.300.550.500',\n 'Whole Grains,G07.203.300.775.500.500',\n 'Whole Grains,J02.500.300.550.500',\n 'Whole Grains,J02.500.775.500.500',\n 'Whole Grain Cereals,G07.203.300.300.550.500',\n 'Whole Grain Cereals,G07.203.300.775.500.500',\n 'Whole Grain Cereals,J02.500.300.550.500',\n 'Whole Grain Cereals,J02.500.775.500.500',\n 'Transanal Endoscopic Surgery,E01.370.388.250.630.500',\n 'Transanal Endoscopic Surgery,E04.210.240.250.680.500',\n 'Transanal Endoscopic Surgery,E04.502.250.250.250.680.500',\n 'Transanal Endoscopic Surgery,E04.502.250.630.500',\n 'Transanal Minimally Invasive Surgery,E01.370.388.250.630.500',\n 'Transanal Minimally Invasive Surgery,E04.210.240.250.680.500',\n 'Transanal Minimally Invasive Surgery,E04.502.250.250.250.680.500',\n 'Transanal Minimally Invasive Surgery,E04.502.250.630.500',\n 'Transanal Endoscopic Microsurgery,E01.370.388.250.630.500.500',\n 'Transanal Endoscopic Microsurgery,E04.210.240.250.680.500.500',\n 'Transanal Endoscopic Microsurgery,E04.494.787',\n 'Transanal Endoscopic Microsurgery,E04.502.250.250.250.680.500.500',\n 'Transanal Endoscopic Microsurgery,E04.502.250.630.500.500',\n 'Cold Injury,C26.212',\n 'Personal Protective Equipment,E07.700.560',\n 'Personal Protective Equipment,J01.637.708.560',\n 'Nerve Agents,D27.720.599',\n 'Nerve Agents,D27.720.777.300.500',\n 'Nerve Gas,D27.720.599',\n 'Nerve Gas,D27.720.777.300.500',\n 'War-Related Injuries,C26.946',\n 'War-Related Injuries,I01.880.735.950.500.951.500',\n 'War-Related Injuries,N06.850.460.350.600.903.500',\n 'War-Related Trauma,C26.946',\n 'War-Related Trauma,I01.880.735.950.500.951.500',\n 'War-Related Trauma,N06.850.460.350.600.903.500',\n 'Abnormal Involuntary Movement Scale,E01.370.600.550.162',\n 'Blood Alcohol Content,D02.033.375.135',\n 'Social Communication Disorder,F03.625.374.250',\n 'Legal Services,I01.880.604.583.482',\n 'Defamation,I01.198.240.240',\n 'Defamation,I01.880.735.191.051',\n 'Slander,I01.198.240.240',\n 'Slander,I01.880.735.191.051',\n 'Libel,I01.198.240.240',\n 'Libel,I01.880.735.191.051',\n 'Anger Management Therapy,F04.754.137.087',\n '\"Psychology, Sports\",F04.096.628.914',\n 'War Exposure,I01.880.735.950.500.951',\n 'War Exposure,N06.850.460.350.600.903',\n 'Childhood-Onset Fluency Disorder,F03.625.374.125',\n 'No-Show Patients,F01.100.150.750.500.600.750',\n 'No-Show Patients,F01.145.488.887.500.600.750',\n 'No-Show Patients,M01.643.550',\n 'No-Show Patients,N04.452.758.635.500',\n 'No-Show Patients,N05.300.150.800.500.600.750',\n 'Cellular Reprogramming Techniques,E05.200.500.380',\n 'Cellular Reprogramming Techniques,E05.242.378',\n 'Cellular Reprogramming Techniques,E05.393.085',\n 'Directed Differentiation Techniques,E05.200.500.380',\n 'Directed Differentiation Techniques,E05.242.378',\n 'Directed Differentiation Techniques,E05.393.085',\n 'Direct Cell Reprogramming Techniques,E05.200.500.380',\n 'Direct Cell Reprogramming Techniques,E05.242.378',\n 'Direct Cell Reprogramming Techniques,E05.393.085',\n 'Metacognition,F02.463.188.756',\n 'Metacognitive Awareness,F02.463.188.756',\n 'Metacognitive Monitoring,F02.463.188.756',\n 'Metacognitive Control,F02.463.188.756',\n 'Metaemotion,F02.463.188.756',\n 'Metamemory,F02.463.188.756',\n 'Prescription Drug Overuse,E02.319.306.500.750',\n '\"Near Miss, Healthcare\",E02.319.529.750',\n '\"Near Miss, Healthcare\",N02.421.450.500.750',\n '\"Near Miss, Healthcare\",N02.421.450.550',\n '\"Near Miss, Healthcare\",N04.761.700.594',\n '\"Near Miss, Healthcare\",N05.700.513',\n 'RNAi Therapeutics,E02.095.301.250',\n 'Dynamic Light Scattering,E05.196.822.325',\n 'Quasi-Elastic Light Scattering (QELS),E05.196.822.325',\n '\"Time Out, Healthcare\",N04.761.700.635',\n '\"Time Out, Healthcare\",N05.700.739',\n 'Surgical Time Out,N04.761.700.635',\n 'Surgical Time Out,N05.700.739',\n 'Healthcare Failure Mode and Effect Analysis,E05.318.740.600.800.715.500',\n 'Healthcare Failure Mode and Effect Analysis,N04.452.871.715.400',\n 'Healthcare Failure Mode and Effect Analysis,N05.715.360.750.625.700.690.400',\n 'Healthcare Failure Mode and Effect Analysis,N06.850.505.715.500',\n 'Healthcare Failure Mode and Effect Analysis,N06.850.520.830.600.800.715.500',\n 'Failure Mode and Effect Analysis,E05.318.740.600.800.715.500',\n 'Failure Mode and Effect Analysis,N04.452.871.715.400',\n 'Failure Mode and Effect Analysis,N05.715.360.750.625.700.690.400',\n 'Failure Mode and Effect Analysis,N06.850.505.715.500',\n 'Failure Mode and Effect Analysis,N06.850.520.830.600.800.715.500',\n 'Spirit Possession,K01.844.619.500',\n '\"Crew Resource Management, Healthcare\",N04.590.254',\n 'Computer Heuristics,L01.224.050.375.095',\n 'Ataxins,D12.776.631.069',\n 'Ataxins,D12.776.660.075',\n 'Alarmins,D23.035',\n 'Dermal Fillers,D27.720.102.461',\n 'Action Spectrum,E05.196.867.826.150',\n 'Diplomacy,F01.829.316.171',\n 'Diplomacy,F02.463.785.373.520.500',\n 'Diplomacy,I01.738.305',\n 'Mutation Accumulation,G05.365.590.594',\n 'Spontaneous Mutation Accumulation,G05.365.590.594',\n 'Internal Ribosome Entry Sites,D13.444.735.790.878.942.250',\n 'Internal Ribosome Entry Sites,G02.111.570.080.689.687.093',\n 'Internal Ribosome Entry Sites,G05.360.080.689.687.093',\n 'Biological Mimicry,G16.012.750',\n 'Biological Camouflage,G16.012.750',\n 'Specific Learning Disorder,F03.625.562.700',\n 'Potentially Inappropriate Medication List,N04.761.700.615',\n 'Potentially Inappropriate Medication List,N05.700.594',\n 'Beers Criteria,N04.761.700.615',\n 'Beers Criteria,N05.700.594',\n 'STOPP (Screening Tool of Older Persons Potentially Inappropriate Prescriptions),N04.761.700.615',\n 'STOPP (Screening Tool of Older Persons Potentially Inappropriate Prescriptions),N05.700.594',\n 'Medication Appropriateness Index,N04.761.700.615',\n 'Medication Appropriateness Index,N05.700.594',\n 'Late Onset Disorders,C23.550.291.883',\n 'Phakopsora pachyrhizi,B01.300.179.113',\n 'Farmers,M01.526.390',\n 'Ranchers,M01.526.390',\n 'Culturally Appropriate Technology,J01.897.052',\n 'Intermediate Technology,J01.897.052',\n 'Soft Technology,J01.897.052',\n 'Social Learning,F02.784.629.529.663',\n 'Financial Statements,N03.219.463.030.140',\n '\"Assets, Financial\",N03.219.463.030.140',\n 'Cash Flow Statement,N03.219.463.030.140',\n 'Balance Sheet,N03.219.463.030.140',\n 'Expense Statement,N03.219.463.030.140',\n 'Income Statement,N03.219.463.030.140',\n '\"Equity, Financial\",N03.219.463.030.140',\n '\"Liabilities, Financial\",N03.219.463.030.140',\n 'Miners,M01.526.693',\n 'Chronopharmacokinetics,G07.690.725.249',\n '\"Administrative Claims, Healthcare\",N04.452.859.564.137',\n 'Child Health,N01.400.225',\n 'Child Well Being,N01.400.225',\n 'Interleukin-33,D12.644.276.374.465.850',\n 'Interleukin-33,D12.776.467.374.465.850',\n 'Interleukin-33,D23.529.374.465.850',\n 'S100A12 Protein,D12.776.157.125.750.875',\n 'Telopodes,A11.284.180.900',\n 'Telopodes,A11.329.830.750.500',\n 'Podomers,A11.284.180.900',\n 'Podomers,A11.329.830.750.500',\n 'Podoms,A11.284.180.900',\n 'Podoms,A11.329.830.750.500',\n 'Drosophila simulans,B01.050.500.131.617.720.500.500.750.310.250.750',\n 'Optimism,F01.100.787',\n 'Positive Attitude,F01.100.787',\n 'Positive Thinking,F01.100.787',\n 'Pessimism,F01.100.893',\n 'Ataxin-1,D12.776.631.069.500',\n 'Ataxin-1,D12.776.660.075.500',\n 'Adolescent Health,N01.400.075',\n 'Adolescent Well Being,N01.400.075',\n 'Ataxin-2,D12.776.157.725.452.125',\n 'Ataxin-2,D12.776.631.069.750',\n 'Ataxin-2,D12.776.660.075.750',\n 'Ataxin-2,D12.776.664.962.452.125',\n 'Ataxin-3,D08.811.037.250',\n 'Ataxin-3,D12.776.631.069.875',\n 'Ataxin-3,D12.776.660.075.875',\n 'Point-of-Care Testing,N04.590.874.500',\n 'Bedside Testing,N04.590.874.500',\n 'Ataxin-7,D12.776.631.069.901',\n 'Ataxin-7,D12.776.660.075.900',\n 'Ataxin-10,D12.776.631.069.950',\n 'Glucagon-Like Peptide Receptors,D12.776.543.750.695.021',\n 'Glucagon-Like Peptide Receptors,D12.776.543.750.750.360.100',\n 'Glucagon-Like Peptide-1 Receptor,D12.776.543.750.695.021.500',\n 'Glucagon-Like Peptide-1 Receptor,D12.776.543.750.750.360.100.500',\n 'Glucagon-Like Peptide-2 Receptor,D12.776.543.750.695.021.600',\n 'Glucagon-Like Peptide-2 Receptor,D12.776.543.750.750.360.100.600',\n 'Receptor for Advanced Glycation End Products,D12.776.543.750.615',\n 'RNA Recognition Motif Proteins,D12.776.157.725.813',\n 'RNA Recognition Motif Proteins,D12.776.664.962.813',\n 'ELAV-Like Protein 2,D12.776.157.725.813.500.500',\n 'ELAV-Like Protein 2,D12.776.631.520.500',\n 'ELAV-Like Protein 2,D12.776.664.962.813.500.500',\n 'ELAV-Like Protein 3,D12.776.157.725.813.500.750',\n 'ELAV-Like Protein 3,D12.776.631.520.750',\n 'ELAV-Like Protein 3,D12.776.664.962.813.500.750',\n 'ELAV-Like Protein 4,D12.776.157.725.813.500.875',\n 'ELAV-Like Protein 4,D12.776.631.520.875',\n 'ELAV-Like Protein 4,D12.776.664.962.813.500.875',\n 'ELAV-Like Protein 1,D12.776.157.725.813.500.250',\n 'ELAV-Like Protein 1,D12.776.664.962.813.500.250',\n 'Whey,A12.790.760',\n 'Whey,G07.203.100.700.750',\n 'Whey,G07.203.300.350.525.760',\n 'Whey,J02.200.700.750',\n 'Whey,J02.500.350.525.760',\n 'Whey Proteins,A12.790.520.500',\n 'Whey Proteins,A12.790.760.500',\n 'Whey Proteins,D12.776.256.159.750.816',\n 'Whey Proteins,G07.203.300.350.525.760.500',\n 'Whey Proteins,G07.203.300.428.159.812.500',\n 'Whey Proteins,J02.500.350.525.520.500',\n 'Whey Proteins,J02.500.350.525.760.500',\n 'Whey Proteins,J02.500.428.159.750.500',\n 'Hoarding Disorder,F03.080.600.250',\n 'Obsessive Hoarding,F03.080.600.250',\n 'Poly(ADP-ribose) Polymerase Inhibitors,D27.505.519.389.739',\n 'Poly(ADP-ribose) Polymerase Inhibitors,D27.505.954.248.692',\n 'Autism Spectrum Disorder,F03.625.164.113',\n 'CELF Proteins,D12.776.157.725.813.250',\n 'CELF Proteins,D12.776.664.962.813.250',\n 'CELF1 Protein,D12.776.157.725.813.250.500',\n 'CELF1 Protein,D12.776.664.962.813.250.500',\n 'Industrial Development,I01.261.262.500',\n 'Industrial Development,J01.576.519',\n 'Technology Development,I01.261.262.500',\n 'Technology Development,J01.576.519',\n 'Industrialization,I01.261.262.500',\n 'Industrialization,J01.576.519',\n 'Cloud Computing,L01.224.097',\n 'Natural Resources,G16.500.275.553',\n 'Natural Resources,J01.728',\n 'Natural Resources,N06.230.350',\n 'Land Supply,G16.500.275.553',\n 'Land Supply,J01.728',\n 'Land Supply,N06.230.350',\n 'Glycemic Load,G07.203.650.660.750',\n 'Glycemic Load,J01.576.423.850.730.750.750',\n 'Glycemic Load,N06.850.601.750.750',\n 'Adenylyl Cyclase Inhibitors,D27.505.519.389.108',\n 'RAW 264.7 Cells,A11.251.210.172.875',\n 'RAW 264.7 Cells,A11.733.397.815',\n 'Accreditation,N03.706.110.070',\n 'Accreditation,N05.700.200.100',\n 'Clostridiales,B03.353.625',\n 'Graphic Novel,V02.700.415',\n 'Comic Book,V02.700.415',\n 'South Sudan,Z01.058.290.120.745',\n 'Motor Disorders,F03.608',\n 'Maternal Health,N01.400.900.500',\n 'Seed Bank,N02.278.065.650',\n 'Germplasm Bank,N02.278.065.650',\n 'Trauma and Stressor Related Disorders,F03.950',\n 'Maternal-Child Health Services,N02.421.143.130.660',\n 'Maternal-Child Health Services,N02.421.143.620.275',\n 'Serine-Arginine Splicing Factors,D12.776.157.725.829.500',\n 'Serine-Arginine Splicing Factors,D12.776.664.962.829.500',\n 'Infant Health,N01.400.388',\n 'Newborn Health,N01.400.388',\n 'Bipolar and Related Disorders,F03.084',\n 'Gender Dysphoria,F03.835.550',\n 'Formative Feedback,F02.784.629.529.223',\n 'Aripiprazole,D03.383.606.170',\n 'Aripiprazole,D03.633.100.810.835.122',\n 'Abilify,D03.383.606.170',\n 'Abilify,D03.633.100.810.835.122',\n 'OPC 14597,D03.383.606.170',\n 'OPC 14597,D03.633.100.810.835.122',\n 'Prunus dulcis,B01.650.940.800.575.912.250.859.937.500.625.500',\n 'Almonds,B01.650.940.800.575.912.250.859.937.500.625.500',\n 'Albumin-Bound Paclitaxel,D02.455.426.392.368.242.888.777.500',\n 'Albumin-Bound Paclitaxel,D02.455.849.291.850.777.500',\n 'Albumin-Bound Paclitaxel,D12.776.034.073',\n 'Abraxane,D02.455.426.392.368.242.888.777.500',\n 'Abraxane,D02.455.849.291.850.777.500',\n 'Abraxane,D12.776.034.073',\n 'ABI007,D02.455.426.392.368.242.888.777.500',\n 'ABI007,D02.455.849.291.850.777.500',\n 'ABI007,D12.776.034.073',\n 'Child Protective Services,I01.409.418.500',\n 'Child Protective Services,N03.540.400.500',\n 'Social Workers,M01.526.919',\n 'Prunus africana,B01.650.940.800.575.912.250.859.937.500.625.250',\n 'Prunus armeniaca,B01.650.940.800.575.912.250.859.937.500.625.375',\n 'Apricot,B01.650.940.800.575.912.250.859.937.500.625.375',\n 'Prunus avium,B01.650.940.800.575.912.250.859.937.500.625.400',\n 'Prunus serotina,B01.650.940.800.575.912.250.859.937.500.625.400',\n 'Sweet Cherries,B01.650.940.800.575.912.250.859.937.500.625.400',\n 'Prunus cerasus,B01.650.940.800.575.912.250.859.937.500.625.400',\n 'Refugium,G16.500.275.683',\n 'Refugium,G16.500.819',\n 'Distance Counseling,F02.784.176.350',\n 'Distance Counseling,F04.408.413.437',\n 'Distance Counseling,N02.421.143.303.175',\n 'Distance Counseling,N02.421.461.363.437',\n 'Distance Counseling,N04.452.758.849.550.500',\n 'Lubiprostone,D10.251.355.325.050.500',\n 'RU 0211,D10.251.355.325.050.500',\n 'Amitiza,D10.251.355.325.050.500',\n 'SPI 0211,D10.251.355.325.050.500',\n 'Prunus persica,B01.650.940.800.575.912.250.859.937.500.625.750',\n 'Peach,B01.650.940.800.575.912.250.859.937.500.625.750',\n 'Data Anonymization,H01.770.644.205',\n 'Data Anonymization,L01.224.134.500',\n 'Data Anonymization,N03.706.437.650.124.160',\n 'Data Anonymization,N04.452.910.200.500',\n 'De-Identification,H01.770.644.205',\n 'De-Identification,L01.224.134.500',\n 'De-Identification,N03.706.437.650.124.160',\n 'De-Identification,N04.452.910.200.500',\n 'Data Masking,H01.770.644.205',\n 'Data Masking,L01.224.134.500',\n 'Data Masking,N03.706.437.650.124.160',\n 'Data Masking,N04.452.910.200.500',\n 'Personally Identifiable Information,I01.880.604.583.080.660',\n 'Prunus domestica,B01.650.940.800.575.912.250.859.937.500.625.450',\n 'Plum,B01.650.940.800.575.912.250.859.937.500.625.450',\n 'Prunus cerasifera,B01.650.940.800.575.912.250.859.937.500.625.450',\n 'Prunus salicina,B01.650.940.800.575.912.250.859.937.500.625.450',\n 'Darbepoetin alfa,D12.776.395.240.150.500',\n 'Aranesp,D12.776.395.240.150.500',\n 'KRN 321,D12.776.395.240.150.500',\n '\"Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination\",D02.705.429.906.125',\n '\"Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination\",D03.383.533.375',\n '\"Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination\",D03.383.742.680.245.500.600.125',\n '\"Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination\",D03.633.100.759.138.881.125',\n '\"Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination\",D26.310.375',\n 'Atripla,D02.705.429.906.125',\n 'Atripla,D03.383.533.375',\n 'Atripla,D03.383.742.680.245.500.600.125',\n 'Atripla,D03.633.100.759.138.881.125',\n 'Atripla,D26.310.375',\n 'Bevacizumab,D12.776.124.486.485.114.224.060.375',\n 'Bevacizumab,D12.776.124.790.651.114.224.060.438',\n 'Bevacizumab,D12.776.377.715.548.114.224.200.438',\n 'Mvasi,D12.776.124.486.485.114.224.060.375',\n 'Mvasi,D12.776.124.790.651.114.224.060.438',\n 'Mvasi,D12.776.377.715.548.114.224.200.438',\n 'Bevacizumab-awwb,D12.776.124.486.485.114.224.060.375',\n 'Bevacizumab-awwb,D12.776.124.790.651.114.224.060.438',\n 'Bevacizumab-awwb,D12.776.377.715.548.114.224.200.438',\n 'Avastin,D12.776.124.486.485.114.224.060.375',\n 'Avastin,D12.776.124.790.651.114.224.060.438',\n 'Avastin,D12.776.377.715.548.114.224.200.438',\n 'Giraffes,B01.050.150.900.649.313.500.380.443',\n 'Okapis,B01.050.150.900.649.313.500.380.443',\n 'Risedronic Acid,D02.705.429.500.872',\n 'Risedronic Acid,D03.383.725.836',\n '1-Hydroxy-2-(3-pyridyl)ethylidene diphosphonate,D02.705.429.500.872',\n '1-Hydroxy-2-(3-pyridyl)ethylidene diphosphonate,D03.383.725.836',\n 'Atelvia,D02.705.429.500.872',\n 'Atelvia,D03.383.725.836',\n 'Risedronate Sodium,D02.705.429.500.872',\n 'Risedronate Sodium,D03.383.725.836',\n '2-(3-pyridinyl)-1-hydroxyethylidene-bisphosphonate,D02.705.429.500.872',\n '2-(3-pyridinyl)-1-hydroxyethylidene-bisphosphonate,D03.383.725.836',\n '\"Risedronic Acid, Monosodium Salt\",D02.705.429.500.872',\n '\"Risedronic Acid, Monosodium Salt\",D03.383.725.836',\n 'Actonel,D02.705.429.500.872',\n 'Actonel,D03.383.725.836',\n 'Risedronate,D02.705.429.500.872',\n 'Risedronate,D03.383.725.836',\n 'Bisphosphonate Risedronate Sodium,D02.705.429.500.872',\n 'Bisphosphonate Risedronate Sodium,D03.383.725.836',\n 'Fluticasone-Salmeterol Drug Combination,D02.033.100.291.057.750.500',\n 'Fluticasone-Salmeterol Drug Combination,D02.092.063.291.057.750.500',\n 'Fluticasone-Salmeterol Drug Combination,D02.092.471.683.061.750.500',\n 'Fluticasone-Salmeterol Drug Combination,D04.210.500.054.079.129.114.500',\n 'Fluticasone-Salmeterol Drug Combination,D26.310.438',\n '\"Fluticasone Propionate, Salmeterol Xinafoate Drug Combination\",D02.033.100.291.057.750.500',\n '\"Fluticasone Propionate, Salmeterol Xinafoate Drug Combination\",D02.092.063.291.057.750.500',\n '\"Fluticasone Propionate, Salmeterol Xinafoate Drug Combination\",D02.092.471.683.061.750.500',\n '\"Fluticasone Propionate, Salmeterol Xinafoate Drug Combination\",D04.210.500.054.079.129.114.500',\n '\"Fluticasone Propionate, Salmeterol Xinafoate Drug Combination\",D26.310.438',\n 'Advair Diskus,D02.033.100.291.057.750.500',\n 'Advair Diskus,D02.092.063.291.057.750.500',\n 'Advair Diskus,D02.092.471.683.061.750.500',\n 'Advair Diskus,D04.210.500.054.079.129.114.500',\n 'Advair Diskus,D26.310.438',\n 'Seretide,D02.033.100.291.057.750.500',\n 'Seretide,D02.092.063.291.057.750.500',\n 'Seretide,D02.092.471.683.061.750.500',\n 'Seretide,D04.210.500.054.079.129.114.500',\n 'Seretide,D26.310.438',\n 'Advair HFA,D02.033.100.291.057.750.500',\n 'Advair HFA,D02.092.063.291.057.750.500',\n 'Advair HFA,D02.092.471.683.061.750.500',\n 'Advair HFA,D04.210.500.054.079.129.114.500',\n 'Advair HFA,D26.310.438',\n 'Advair,D02.033.100.291.057.750.500',\n 'Advair,D02.092.063.291.057.750.500',\n 'Advair,D02.092.471.683.061.750.500',\n 'Advair,D04.210.500.054.079.129.114.500',\n 'Advair,D26.310.438',\n 'Fluticasone,D04.210.500.054.079.129.114',\n 'Flonase,D04.210.500.054.079.129.114',\n 'Flovent HFA,D04.210.500.054.079.129.114',\n 'Cutivate,D04.210.500.054.079.129.114',\n 'Fluticasone Propionate,D04.210.500.054.079.129.114',\n 'Flixonase,D04.210.500.054.079.129.114',\n 'Flixotide,D04.210.500.054.079.129.114',\n 'Flovent,D04.210.500.054.079.129.114',\n 'Salmeterol Xinafoate,D02.033.100.291.057.750',\n 'Salmeterol Xinafoate,D02.092.063.291.057.750',\n 'Salmeterol Xinafoate,D02.092.471.683.061.750',\n 'Salmeterol,D02.033.100.291.057.750',\n 'Salmeterol,D02.092.063.291.057.750',\n 'Salmeterol,D02.092.471.683.061.750',\n 'Serevent,D02.033.100.291.057.750',\n 'Serevent,D02.092.063.291.057.750',\n 'Serevent,D02.092.471.683.061.750',\n '\"Parks, Recreational\",J03.925.680',\n 'National Parks,J03.925.680',\n 'Community Parks,J03.925.680',\n 'Green Space,J03.925.680',\n 'Urban Parks,J03.925.680',\n 'Warfare and Armed Conflicts,I01.880.735.950',\n 'Armed Conflicts,I01.880.735.950.250',\n 'Wars,I01.880.735.950.250',\n 'Everolimus,D02.540.505.760.500',\n 'RAD 001,D02.540.505.760.500',\n 'Afinitor,D02.540.505.760.500',\n 'Certican,D02.540.505.760.500',\n '\"Aspirin, Dipyridamole Drug Combination\",D02.455.426.559.389.657.410.595.176.500',\n '\"Aspirin, Dipyridamole Drug Combination\",D03.383.742.175.500',\n '\"Aspirin, Dipyridamole Drug Combination\",D26.310.125',\n 'TX 3301,D02.455.426.559.389.657.410.595.176.500',\n 'TX 3301,D03.383.742.175.500',\n 'TX 3301,D26.310.125',\n 'Extended-Release Dipyridamole-Aspirin,D02.455.426.559.389.657.410.595.176.500',\n 'Extended-Release Dipyridamole-Aspirin,D03.383.742.175.500',\n 'Extended-Release Dipyridamole-Aspirin,D26.310.125',\n 'Asasantin,D02.455.426.559.389.657.410.595.176.500',\n 'Asasantin,D03.383.742.175.500',\n 'Asasantin,D26.310.125',\n 'Asasantin Retard,D02.455.426.559.389.657.410.595.176.500',\n 'Asasantin Retard,D03.383.742.175.500',\n 'Asasantin Retard,D26.310.125',\n 'Aggrenox,D02.455.426.559.389.657.410.595.176.500',\n 'Aggrenox,D03.383.742.175.500',\n 'Aggrenox,D26.310.125',\n 'Self-Control,F01.145.813.595',\n 'Saline Waters,G16.500.275.725',\n 'Brackish Water,G16.500.275.725',\n 'Compassion Fatigue,C23.888.369.500.500',\n 'Compassion Fatigue,F01.145.126.937.500',\n 'Compassion Fatigue,F01.145.126.990.734.500',\n 'Compassion Fatigue,F02.830.900.666.750',\n 'Plantaginaceae,B01.650.940.800.575.912.250.583.700',\n 'Stemodia,B01.650.940.800.575.912.250.583.700',\n 'Globularia,B01.650.940.800.575.912.250.583.700',\n 'Lamiales,B01.650.940.800.575.912.250.583',\n 'Proboscidea Plant,B01.650.940.800.575.912.250.583',\n 'Clinical Study,V03.175',\n 'Surgical Clearance,E01.370.505',\n 'Pemetrexed,D03.633.100.759.758.399.454.650',\n 'Pemetrexed,D12.125.067.625.525',\n 'Pemetrexed,D12.125.119.409.525',\n 'Pemetrexed Disodium,D03.633.100.759.758.399.454.650',\n 'Pemetrexed Disodium,D12.125.067.625.525',\n 'Pemetrexed Disodium,D12.125.119.409.525',\n 'LY 231514,D03.633.100.759.758.399.454.650',\n 'LY 231514,D12.125.067.625.525',\n 'LY 231514,D12.125.119.409.525',\n 'Alimta,D03.633.100.759.758.399.454.650',\n 'Alimta,D12.125.067.625.525',\n 'Alimta,D12.125.119.409.525',\n 'Brimonidine Tartrate,D03.633.100.857.070',\n '\"Brimonidine Tartrate (1:1), (S-(R*,R*))-Isomer\",D03.633.100.857.070',\n 'Brimonidine Purite,D03.633.100.857.070',\n 'AGN 190342,D03.633.100.857.070',\n 'Sanrosa,D03.633.100.857.070',\n 'Alphagan,D03.633.100.857.070',\n 'Brimonidine,D03.633.100.857.070',\n 'Alphagan P,D03.633.100.857.070',\n '\"UK 14,304\",D03.633.100.857.070',\n 'Ratio-Brimonidine,D03.633.100.857.070',\n '\"UK 14,304-18\",D03.633.100.857.070',\n 'UK 14308,D03.633.100.857.070',\n '\"Brimonidine Tartrate, (R-(R*,R*))-Isomer\",D03.633.100.857.070',\n 'Brimonidine Tartrate (1:1),D03.633.100.857.070',\n 'Mirvaso,D03.633.100.857.070',\n 'Clinical Studies as Topic,E05.318.372.250',\n 'Clinical Studies as Topic,N05.715.360.330.250',\n 'Clinical Studies as Topic,N06.850.520.450.250',\n 'Beijing,Z01.252.474.164.225',\n 'Beijing,Z01.433.114',\n 'African Union,I01.615.500.125',\n 'African Union,N03.540.089',\n 'Firmicutes,B03.353',\n 'Dutasteride,D04.210.500.925.100.125',\n 'Avodart,D04.210.500.925.100.125',\n 'GG 745,D04.210.500.925.100.125',\n 'GI198745,D04.210.500.925.100.125',\n 'Calceolariaceae,B01.650.940.800.575.912.250.583.190',\n 'Jovellana,B01.650.940.800.575.912.250.583.190',\n 'Calceolaria,B01.650.940.800.575.912.250.583.190',\n 'Porodittia,B01.650.940.800.575.912.250.583.190',\n 'Interferon beta-1a,D12.644.276.374.440.890.275.500',\n 'Interferon beta-1a,D12.776.467.374.440.890.275.500',\n 'Interferon beta-1a,D23.529.374.440.890.275.500',\n 'Avonex Pen,D12.644.276.374.440.890.275.500',\n 'Avonex Pen,D12.776.467.374.440.890.275.500',\n 'Avonex Pen,D23.529.374.440.890.275.500',\n 'Rebif,D12.644.276.374.440.890.275.500',\n 'Rebif,D12.776.467.374.440.890.275.500',\n 'Rebif,D23.529.374.440.890.275.500',\n 'Avonex,D12.644.276.374.440.890.275.500',\n 'Avonex,D12.776.467.374.440.890.275.500',\n 'Avonex,D23.529.374.440.890.275.500',\n 'Olmesartan Medoxomil,D03.383.129.308.674',\n 'Olmesartan Medoxomil,D03.383.129.617.584',\n 'Benicar,D03.383.129.308.674',\n 'Benicar,D03.383.129.617.584',\n 'Olmetec,D03.383.129.308.674',\n 'Olmetec,D03.383.129.617.584',\n 'CS 866,D03.383.129.308.674',\n 'CS 866,D03.383.129.617.584',\n 'Votum,D03.383.129.308.674',\n 'Votum,D03.383.129.617.584',\n '\"Amlodipine Besylate, Olmesartan Medoxomil Drug Combination\",D03.383.129.308.674.500',\n '\"Amlodipine Besylate, Olmesartan Medoxomil Drug Combination\",D03.383.129.617.584.500',\n '\"Amlodipine Besylate, Olmesartan Medoxomil Drug Combination\",D03.383.725.203.065.500',\n '\"Amlodipine Besylate, Olmesartan Medoxomil Drug Combination\",D26.310.063',\n 'Azor,D03.383.129.308.674.500',\n 'Azor,D03.383.129.617.584.500',\n 'Azor,D03.383.725.203.065.500',\n 'Azor,D26.310.063',\n 'Interferon beta-1b,D12.644.276.374.440.890.275.750',\n 'Interferon beta-1b,D12.776.467.374.440.890.275.750',\n 'Interferon beta-1b,D23.529.374.440.890.275.750',\n 'Betaseron,D12.644.276.374.440.890.275.750',\n 'Betaseron,D12.776.467.374.440.890.275.750',\n 'Betaseron,D23.529.374.440.890.275.750',\n 'Extavia,D12.644.276.374.440.890.275.750',\n 'Extavia,D12.776.467.374.440.890.275.750',\n 'Extavia,D23.529.374.440.890.275.750',\n 'Betaferon,D12.644.276.374.440.890.275.750',\n 'Betaferon,D12.776.467.374.440.890.275.750',\n 'Betaferon,D23.529.374.440.890.275.750',\n 'Nebivolol,D02.033.100.291.491',\n 'Nebivolol,D02.092.063.291.503',\n 'Nebivolol,D03.383.663.283.755',\n 'Nebivolol,D03.633.100.150.755',\n 'Bystolic,D02.033.100.291.491',\n 'Bystolic,D02.092.063.291.503',\n 'Bystolic,D03.383.663.283.755',\n 'Bystolic,D03.633.100.150.755',\n 'Nebilet,D02.033.100.291.491',\n 'Nebilet,D02.092.063.291.503',\n 'Nebilet,D03.383.663.283.755',\n 'Nebilet,D03.633.100.150.755',\n 'Silostar,D02.033.100.291.491',\n 'Silostar,D02.092.063.291.503',\n 'Silostar,D03.383.663.283.755',\n 'Silostar,D03.633.100.150.755',\n 'Nebivolol Hydrochloride,D02.033.100.291.491',\n 'Nebivolol Hydrochloride,D02.092.063.291.503',\n 'Nebivolol Hydrochloride,D03.383.663.283.755',\n 'Nebivolol Hydrochloride,D03.633.100.150.755',\n 'R 67555,D02.033.100.291.491',\n 'R 67555,D02.092.063.291.503',\n 'R 67555,D03.383.663.283.755',\n 'R 67555,D03.633.100.150.755',\n 'Lobivon,D02.033.100.291.491',\n 'Lobivon,D02.092.063.291.503',\n 'Lobivon,D03.383.663.283.755',\n 'Lobivon,D03.633.100.150.755',\n 'Celecoxib,D02.065.884.247',\n 'Celecoxib,D02.886.590.700.247',\n 'Celecoxib,D03.383.129.539.160',\n 'Celebrex,D02.065.884.247',\n 'Celebrex,D02.886.590.700.247',\n 'Celebrex,D03.383.129.539.160',\n 'SC 58635,D02.065.884.247',\n 'SC 58635,D02.886.590.700.247',\n 'SC 58635,D03.383.129.539.160',\n 'Varenicline,D03.633.100.079.900',\n 'Varenicline,D03.633.100.857.942',\n 'Chantix,D03.633.100.079.900',\n 'Chantix,D03.633.100.857.942',\n 'Varenicline Tartrate,D03.633.100.079.900',\n 'Varenicline Tartrate,D03.633.100.857.942',\n 'Champix,D03.633.100.079.900',\n 'Champix,D03.633.100.857.942',\n 'Tadalafil,D03.383.725.150.500',\n 'Tadalafil,D03.633.100.473.155.500',\n 'Tadalafil,D03.633.300.154.672',\n 'IC351,D03.383.725.150.500',\n 'IC351,D03.633.100.473.155.500',\n 'IC351,D03.633.300.154.672',\n 'Cialis,D03.383.725.150.500',\n 'Cialis,D03.633.100.473.155.500',\n 'Cialis,D03.633.300.154.672',\n 'Certolizumab Pegol,D05.750.741.125',\n 'Certolizumab Pegol,D12.644.541.500.650.250',\n 'Certolizumab Pegol,D12.776.124.486.485.114.224.060.500',\n 'Certolizumab Pegol,D12.776.124.486.485.680.650.250',\n 'Certolizumab Pegol,D12.776.124.790.651.114.224.060.500',\n 'Certolizumab Pegol,D12.776.124.790.651.680.650.250',\n 'Certolizumab Pegol,D12.776.377.715.548.114.224.200.500',\n 'Certolizumab Pegol,D12.776.377.715.548.680.650.250',\n 'Cimzia,D05.750.741.125',\n 'Cimzia,D12.644.541.500.650.250',\n 'Cimzia,D12.776.124.486.485.114.224.060.500',\n 'Cimzia,D12.776.124.486.485.680.650.250',\n 'Cimzia,D12.776.124.790.651.114.224.060.500',\n 'Cimzia,D12.776.124.790.651.680.650.250',\n 'Cimzia,D12.776.377.715.548.114.224.200.500',\n 'Cimzia,D12.776.377.715.548.680.650.250',\n 'CDP870,D05.750.741.125',\n 'CDP870,D12.644.541.500.650.250',\n 'CDP870,D12.776.124.486.485.114.224.060.500',\n 'CDP870,D12.776.124.486.485.680.650.250',\n 'CDP870,D12.776.124.790.651.114.224.060.500',\n 'CDP870,D12.776.124.790.651.680.650.250',\n 'CDP870,D12.776.377.715.548.114.224.200.500',\n 'CDP870,D12.776.377.715.548.680.650.250',\n '\"Censorship, Research\",I01.880.604.238',\n '\"Censorship, Research\",K01.752.566.479.173.200',\n '\"Censorship, Research\",N05.350.670.250',\n 'Data Accuracy,E05.318.308.028',\n 'Data Accuracy,E05.318.370.725.250',\n 'Data Accuracy,L01.399.250.202',\n 'Data Accuracy,N05.715.360.300.202',\n 'Data Accuracy,N05.715.360.325.685.250',\n 'Data Quality,E05.318.308.028',\n 'Data Quality,E05.318.370.725.250',\n 'Data Quality,L01.399.250.202',\n 'Data Quality,N05.715.360.300.202',\n 'Data Quality,N05.715.360.325.685.250',\n '\"Brimonidine Tartrate, Timolol Maleate Drug Combination\",D02.033.100.624.915.500',\n '\"Brimonidine Tartrate, Timolol Maleate Drug Combination\",D02.033.755.624.915.500',\n '\"Brimonidine Tartrate, Timolol Maleate Drug Combination\",D02.092.063.624.915.500',\n '\"Brimonidine Tartrate, Timolol Maleate Drug Combination\",D02.886.675.867.768.500',\n '\"Brimonidine Tartrate, Timolol Maleate Drug Combination\",D03.383.129.708.867.768.500',\n '\"Brimonidine Tartrate, Timolol Maleate Drug Combination\",D03.633.100.857.070.500',\n '\"Brimonidine Tartrate, Timolol Maleate Drug Combination\",D26.310.312',\n 'Combigan,D02.033.100.624.915.500',\n ...]"]}}],"execution_count":0},{"cell_type":"code","source":["splrdd= clinicrdd1.map(lambda x: x.split(\"|\")) #map() was used to apply lambda(transformation function) on every element of clinicrdd1 using by split () function used for splitting the string column on (\"|\") delimeter\nsplrdd.take(10)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"79f47c9b-9340-4e78-a7b6-281bd7b596f7"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[36]: [['NCT02758028',\n  'The University of Hong Kong',\n  'Recruiting',\n  'Aug 2005',\n  'Nov 2021',\n  'Interventional',\n  'Apr 2016',\n  '',\n  ''],\n ['NCT02751957',\n  'Duke University',\n  'Completed',\n  'Jul 2016',\n  'Jul 2020',\n  'Interventional',\n  'Apr 2016',\n  'Autistic Disorder,Autism Spectrum Disorder',\n  ''],\n ['NCT02758483',\n  'Universidade Federal do Rio de Janeiro',\n  'Completed',\n  'Mar 2017',\n  'Jan 2018',\n  'Interventional',\n  'Apr 2016',\n  'Diabetes Mellitus',\n  ''],\n ['NCT02759848',\n  'Istanbul Medeniyet University',\n  'Completed',\n  'Jan 2012',\n  'Dec 2014',\n  'Observational',\n  'May 2016',\n  'Tuberculosis,Lung Diseases,Pulmonary Disease',\n  ''],\n ['NCT02758860',\n  'University of Roma La Sapienza',\n  'Active, not recruiting',\n  'Jun 2016',\n  'Sep 2020',\n  'Observational [Patient Registry]',\n  'Apr 2016',\n  'Diverticular Diseases,Diverticulum,Diverticulosis',\n  ''],\n ['NCT02757209',\n  'Consorzio Futuro in Ricerca',\n  'Completed',\n  'Apr 2016',\n  'Jan 2018',\n  'Interventional',\n  'Apr 2016',\n  'Asthma',\n  'Fluticasone,Xhance,Budesonide,Formoterol Fumarate,Salmeterol Xinafoate'],\n ['NCT02752438',\n  'Ankara University',\n  'Unknown status',\n  'May 2016',\n  'Jul 2017',\n  'Observational [Patient Registry]',\n  'Apr 2016',\n  'Hypoventilation',\n  ''],\n ['NCT02753543',\n  'Ruijin Hospital',\n  'Unknown status',\n  'Nov 2015',\n  'Nov 2019',\n  'Interventional',\n  'Apr 2016',\n  'Lymphoma',\n  ''],\n ['NCT02757508',\n  'Washington University School of Medicine',\n  'Completed',\n  'Mar 2016',\n  'Jul 2017',\n  'Interventional',\n  'Apr 2016',\n  '',\n  'Vitamins'],\n ['NCT02753530',\n  'Orphazyme',\n  'Completed',\n  'Aug 2017',\n  'Jan 2021',\n  'Interventional',\n  'Apr 2016',\n  'Myositis',\n  '']]","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[36]: [['NCT02758028',\n  'The University of Hong Kong',\n  'Recruiting',\n  'Aug 2005',\n  'Nov 2021',\n  'Interventional',\n  'Apr 2016',\n  '',\n  ''],\n ['NCT02751957',\n  'Duke University',\n  'Completed',\n  'Jul 2016',\n  'Jul 2020',\n  'Interventional',\n  'Apr 2016',\n  'Autistic Disorder,Autism Spectrum Disorder',\n  ''],\n ['NCT02758483',\n  'Universidade Federal do Rio de Janeiro',\n  'Completed',\n  'Mar 2017',\n  'Jan 2018',\n  'Interventional',\n  'Apr 2016',\n  'Diabetes Mellitus',\n  ''],\n ['NCT02759848',\n  'Istanbul Medeniyet University',\n  'Completed',\n  'Jan 2012',\n  'Dec 2014',\n  'Observational',\n  'May 2016',\n  'Tuberculosis,Lung Diseases,Pulmonary Disease',\n  ''],\n ['NCT02758860',\n  'University of Roma La Sapienza',\n  'Active, not recruiting',\n  'Jun 2016',\n  'Sep 2020',\n  'Observational [Patient Registry]',\n  'Apr 2016',\n  'Diverticular Diseases,Diverticulum,Diverticulosis',\n  ''],\n ['NCT02757209',\n  'Consorzio Futuro in Ricerca',\n  'Completed',\n  'Apr 2016',\n  'Jan 2018',\n  'Interventional',\n  'Apr 2016',\n  'Asthma',\n  'Fluticasone,Xhance,Budesonide,Formoterol Fumarate,Salmeterol Xinafoate'],\n ['NCT02752438',\n  'Ankara University',\n  'Unknown status',\n  'May 2016',\n  'Jul 2017',\n  'Observational [Patient Registry]',\n  'Apr 2016',\n  'Hypoventilation',\n  ''],\n ['NCT02753543',\n  'Ruijin Hospital',\n  'Unknown status',\n  'Nov 2015',\n  'Nov 2019',\n  'Interventional',\n  'Apr 2016',\n  'Lymphoma',\n  ''],\n ['NCT02757508',\n  'Washington University School of Medicine',\n  'Completed',\n  'Mar 2016',\n  'Jul 2017',\n  'Interventional',\n  'Apr 2016',\n  '',\n  'Vitamins'],\n ['NCT02753530',\n  'Orphazyme',\n  'Completed',\n  'Aug 2017',\n  'Jan 2021',\n  'Interventional',\n  'Apr 2016',\n  'Myositis',\n  '']]"]}}],"execution_count":0},{"cell_type":"code","source":["import re\nsplitRDD=meshrdd1.map(lambda myrdd: re.split(',',myrdd)) #re.split() function used so that a list of string with matching occurrence of pattern in the string separated by \",\"\nsplitRDD.collect()"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"16bf4a8d-325a-449d-8d0e-1aebd5be1bf0"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[37]: [['Calcimycin', 'D03.633.100.221.173'],\n ['A-23187', 'D03.633.100.221.173'],\n ['Temefos', 'D02.705.400.625.800'],\n ['Temefos', 'D02.705.539.345.800'],\n ['Temefos', 'D02.886.300.692.800'],\n ['Abate', 'D02.705.400.625.800'],\n ['Abate', 'D02.705.539.345.800'],\n ['Abate', 'D02.886.300.692.800'],\n ['Difos', 'D02.705.400.625.800'],\n ['Difos', 'D02.705.539.345.800'],\n ['Difos', 'D02.886.300.692.800'],\n ['Abattoirs', 'J01.576.423.200.700.100'],\n ['Abattoirs', 'J03.540.020'],\n ['Abbreviations as Topic', 'L01.559.598.400.556.131'],\n ['Acronyms as Topic', 'L01.559.598.400.556.131'],\n ['Abdomen', 'A01.923.047'],\n ['\"Abdomen', ' Acute\"', 'C23.888.592.612.054.200'],\n ['\"Abdomen', ' Acute\"', 'C23.888.821.030.249'],\n ['Abdominal Injuries', 'C26.017'],\n ['Abdominal Neoplasms', 'C04.588.033'],\n ['Abdominal Muscles', 'A02.633.567.050'],\n ['Cremaster Muscle', 'A02.633.567.050'],\n ['Pyramidalis Muscle', 'A02.633.567.050'],\n ['Quadratus Abdominis', 'A02.633.567.050'],\n ['Transversus Abdominis', 'A02.633.567.050'],\n ['Abducens Nerve', 'A08.800.800.120.030'],\n ['Abelson murine leukemia virus', 'B04.613.807.375.525.020'],\n ['Abelson murine leukemia virus', 'B04.820.650.375.525.020'],\n ['Abetalipoproteinemia', 'C16.320.565.398.500.440.500'],\n ['Abetalipoproteinemia', 'C18.452.584.500.875.440.500'],\n ['Abetalipoproteinemia', 'C18.452.648.398.500.440.500'],\n ['Congenital Abnormalities', 'C16.131'],\n ['Fetal Malformations', 'C16.131'],\n ['Fetal Anomalies', 'C16.131'],\n ['\"Abnormalities', ' Drug-Induced\"', 'C16.131.042'],\n ['\"Abnormalities', ' Multiple\"', 'C16.131.077'],\n ['\"Abnormalities', ' Radiation-Induced\"', 'C16.131.080'],\n ['\"Abnormalities', ' Radiation-Induced\"', 'C26.733.031'],\n ['\"Abnormalities', ' Radiation-Induced\"', 'G01.750.748.500.031'],\n ['\"Abnormalities', ' Radiation-Induced\"', 'N06.850.460.350.850.500.031'],\n ['\"Abnormalities', ' Radiation-Induced\"', 'N06.850.810.300.360.031'],\n ['ABO Blood-Group System', 'D23.050.301.290.031'],\n ['ABO Blood-Group System', 'D23.050.705.230.031'],\n ['Blood Group H Type 1 Antigen', 'D23.050.301.290.031'],\n ['Blood Group H Type 1 Antigen', 'D23.050.705.230.031'],\n ['ABO Factors', 'D23.050.301.290.031'],\n ['ABO Factors', 'D23.050.705.230.031'],\n ['Abomasum', 'A13.869.106'],\n ['Abortifacient Agents', 'D27.505.696.875.131'],\n ['Abortifacient Agents', 'D27.505.954.705.131'],\n ['Abortifacient Effect', 'D27.505.696.875.131'],\n ['Abortifacient Effect', 'D27.505.954.705.131'],\n ['\"Abortifacient Agents', ' Nonsteroidal\"', 'D27.505.696.875.131.100'],\n ['\"Abortifacient Agents', ' Nonsteroidal\"', 'D27.505.954.705.131.100'],\n ['\"Abortifacient Agents', ' Steroidal\"', 'D27.505.696.875.131.200'],\n ['\"Abortifacient Agents', ' Steroidal\"', 'D27.505.954.705.131.200'],\n ['\"Abortion', ' Spontaneous\"', 'C13.703.039'],\n ['\"Abortion', ' Spontaneous\"', 'G08.686.784.769.496.125'],\n ['Early Pregnancy Loss', 'C13.703.039'],\n ['Early Pregnancy Loss', 'G08.686.784.769.496.125'],\n ['Miscarriage', 'C13.703.039'],\n ['Miscarriage', 'G08.686.784.769.496.125'],\n ['\"Abortion', ' Tubal\"', 'C13.703.039'],\n ['\"Abortion', ' Tubal\"', 'G08.686.784.769.496.125'],\n ['Abortion Applicants', 'M01.050'],\n ['\"Abortion Seekers', ' Repeated\"', 'M01.050'],\n ['\"Abortion Seekers', ' Refused\"', 'M01.050'],\n ['\"Abortion', ' Criminal\"', 'I01.198.240.089'],\n ['\"Abortion', ' Eugenic\"', 'E04.520.050.050'],\n ['\"Abortion', ' Selective\"', 'E04.520.050.050'],\n ['\"Abortion', ' Habitual\"', 'C13.703.039.089'],\n ['\"Abortion', ' Incomplete\"', 'C13.703.039.093'],\n ['\"Abortion', ' Induced\"', 'E04.520.050'],\n ['Abortion Rate', 'E04.520.050'],\n ['Abortion Techniques', 'E04.520.050'],\n ['\"Abortion', ' Drug-Induced\"', 'E04.520.050'],\n ['Previous Abortion', 'E04.520.050'],\n ['\"Abortion', ' Saline-Solution\"', 'E04.520.050'],\n ['\"Abortion', ' Soap-Solution\"', 'E04.520.050'],\n ['Anti-Abortion Groups', 'E04.520.050'],\n ['Embryotomy', 'E04.520.050'],\n ['\"Fertility Control', ' Postconception\"', 'E04.520.050'],\n ['Abortion Failure', 'E04.520.050'],\n ['\"Abortion', ' Rivanol\"', 'E04.520.050'],\n ['\"Abortion', ' Legal\"', 'E04.520.050.055'],\n ['Abortion on Demand', 'E04.520.050.055'],\n ['\"Abortion', ' Missed\"', 'C13.703.039.173'],\n ['\"Abortion', ' Septic\"', 'C01.674.173'],\n ['\"Abortion', ' Septic\"', 'C13.703.039.256'],\n ['\"Abortion', ' Septic\"', 'C13.703.700.173'],\n ['\"Abortion', ' Therapeutic\"', 'E04.520.050.060'],\n ['\"Abortion', ' Threatened\"', 'C13.703.090'],\n ['\"Abortion', ' Veterinary\"', 'C13.703.039.422'],\n ['\"Abortion', ' Veterinary\"', 'C22.021'],\n ['Abreaction', 'F04.754.720.107'],\n ['Abrin', 'D08.811.277.450.430.700.750.111'],\n ['Abrin', 'D12.776.503.499.249'],\n ['Abrin', 'D12.776.765.678.906.111'],\n ['Abrin C', 'D08.811.277.450.430.700.750.111'],\n ['Abrin C', 'D12.776.503.499.249'],\n ['Abrin C', 'D12.776.765.678.906.111'],\n ['Abrin A', 'D08.811.277.450.430.700.750.111'],\n ['Abrin A', 'D12.776.503.499.249'],\n ['Abrin A', 'D12.776.765.678.906.111'],\n ['Abruptio Placentae', 'C13.703.420.078'],\n ['Abruptio Placentae', 'C13.703.590.132'],\n ['Abscess', 'C01.830.025'],\n ['Abscess', 'C23.550.470.756.100'],\n ['Peritonsillar Abscess', 'C01.748.561.750.500'],\n ['Peritonsillar Abscess', 'C01.830.025.675'],\n ['Peritonsillar Abscess', 'C07.550.781.750.500'],\n ['Peritonsillar Abscess', 'C08.730.561.750.500'],\n ['Peritonsillar Abscess', 'C09.775.649.750.500'],\n ['Abscisic Acid', 'D02.241.223.268.034'],\n ['Abscisic Acid', 'D02.455.326.271.665.202.061'],\n ['Abscisic Acid', 'D02.455.426.392.368.367.379.249.024'],\n ['Abscisic Acid', 'D02.455.849.131.061'],\n ['Abscisic Acid', 'D02.455.849.765.521.500'],\n ['\"Abscisic Acid', ' (+', '-)-Isomer\"', 'D02.241.223.268.034'],\n ['\"Abscisic Acid', ' (+', '-)-Isomer\"', 'D02.455.326.271.665.202.061'],\n ['\"Abscisic Acid',\n  ' (+',\n  '-)-Isomer\"',\n  'D02.455.426.392.368.367.379.249.024'],\n ['\"Abscisic Acid', ' (+', '-)-Isomer\"', 'D02.455.849.131.061'],\n ['\"Abscisic Acid', ' (+', '-)-Isomer\"', 'D02.455.849.765.521.500'],\n ['\"Abscisic Acid', ' (Z', 'E)-Isomer\"', 'D02.241.223.268.034'],\n ['\"Abscisic Acid', ' (Z', 'E)-Isomer\"', 'D02.455.326.271.665.202.061'],\n ['\"Abscisic Acid',\n  ' (Z',\n  'E)-Isomer\"',\n  'D02.455.426.392.368.367.379.249.024'],\n ['\"Abscisic Acid', ' (Z', 'E)-Isomer\"', 'D02.455.849.131.061'],\n ['\"Abscisic Acid', ' (Z', 'E)-Isomer\"', 'D02.455.849.765.521.500'],\n ['\"Abscisic Acid', ' (E', 'Z)-(+', '-)-Isomer\"', 'D02.241.223.268.034'],\n ['\"Abscisic Acid',\n  ' (E',\n  'Z)-(+',\n  '-)-Isomer\"',\n  'D02.455.326.271.665.202.061'],\n ['\"Abscisic Acid',\n  ' (E',\n  'Z)-(+',\n  '-)-Isomer\"',\n  'D02.455.426.392.368.367.379.249.024'],\n ['\"Abscisic Acid', ' (E', 'Z)-(+', '-)-Isomer\"', 'D02.455.849.131.061'],\n ['\"Abscisic Acid', ' (E', 'Z)-(+', '-)-Isomer\"', 'D02.455.849.765.521.500'],\n ['\"Abscisic Acid', ' (R)-Isomer\"', 'D02.241.223.268.034'],\n ['\"Abscisic Acid', ' (R)-Isomer\"', 'D02.455.326.271.665.202.061'],\n ['\"Abscisic Acid', ' (R)-Isomer\"', 'D02.455.426.392.368.367.379.249.024'],\n ['\"Abscisic Acid', ' (R)-Isomer\"', 'D02.455.849.131.061'],\n ['\"Abscisic Acid', ' (R)-Isomer\"', 'D02.455.849.765.521.500'],\n ['\"Abscisic Acid Monoammonium Salt', ' (R)-Isomer\"', 'D02.241.223.268.034'],\n ['\"Abscisic Acid Monoammonium Salt',\n  ' (R)-Isomer\"',\n  'D02.455.326.271.665.202.061'],\n ['\"Abscisic Acid Monoammonium Salt',\n  ' (R)-Isomer\"',\n  'D02.455.426.392.368.367.379.249.024'],\n ['\"Abscisic Acid Monoammonium Salt', ' (R)-Isomer\"', 'D02.455.849.131.061'],\n ['\"Abscisic Acid Monoammonium Salt',\n  ' (R)-Isomer\"',\n  'D02.455.849.765.521.500'],\n ['\"Abscisic Acid', ' (E', 'E)-(+-)-Isomer\"', 'D02.241.223.268.034'],\n ['\"Abscisic Acid', ' (E', 'E)-(+-)-Isomer\"', 'D02.455.326.271.665.202.061'],\n ['\"Abscisic Acid',\n  ' (E',\n  'E)-(+-)-Isomer\"',\n  'D02.455.426.392.368.367.379.249.024'],\n ['\"Abscisic Acid', ' (E', 'E)-(+-)-Isomer\"', 'D02.455.849.131.061'],\n ['\"Abscisic Acid', ' (E', 'E)-(+-)-Isomer\"', 'D02.455.849.765.521.500'],\n ['Absenteeism', 'F02.784.692.107'],\n ['Absorption', 'G01.015'],\n ['Absorption', 'G02.010'],\n ['Absorption', 'G03.015'],\n ['Absorption', 'G03.787.024'],\n ['Absorption', 'G07.690.725.015'],\n ['Abstracting and Indexing', 'L01.453.245.100'],\n ['Indexing', 'L01.453.245.100'],\n ['Indexes as Topic', 'L01.453.245.100'],\n ['Abstracting', 'L01.453.245.100'],\n ['Dental Abutments', 'E06.780.346.500'],\n ['Dental Abutments', 'E07.695.190.175'],\n ['Acacia', 'B01.650.940.800.575.912.250.401.025'],\n ['Acacia catechu', 'B01.650.940.800.575.912.250.401.025'],\n ['Academic Medical Centers', 'N02.278.020'],\n ['Academies and Institutes', 'N03.540.052'],\n ['Institutes', 'N03.540.052'],\n ['Research Institutes', 'N03.540.052'],\n ['Academies', 'N03.540.052'],\n ['Acanthamoeba', 'B01.046.500.100.075.080'],\n ['Acanthocephala', 'B01.050.500.500.132'],\n ['Acanthocytes', 'A11.118.290.330.100'],\n ['Acanthocytes', 'A11.443.240.330.100'],\n ['Acanthocytes', 'A15.145.229.334.330.100'],\n ['Acantholysis', 'C17.800.865.070'],\n ['Acantholysis', 'C23.550.035'],\n ['Acanthosis Nigricans', 'C17.800.621.430.530.100'],\n ['Acari', 'B01.050.500.131.166.132'],\n ['Acceleration', 'G01.482.107'],\n ['Accessory Nerve', 'A08.800.800.120.060'],\n ['Accident Prevention', 'N06.850.135.060'],\n ['Accident Proneness', 'F01.145.015'],\n ['Accidental Falls', 'N06.850.135.122'],\n ['Slip and Fall', 'N06.850.135.122'],\n ['Accidents', 'N06.850.135'],\n ['\"Accidents', ' Aviation\"', 'N06.850.135.185'],\n ['\"Accidents', ' Home\"', 'N06.850.135.217'],\n ['\"Accidents', ' Occupational\"', 'N06.850.135.240'],\n ['\"Accidents', ' Industrial\"', 'N06.850.135.240'],\n ['\"Accidents', ' Traffic\"', 'N06.850.135.392'],\n ['Traffic Collisions', 'N06.850.135.392'],\n ['Traffic Crashes', 'N06.850.135.392'],\n ['Acclimatization', 'G07.025.133'],\n ['Acclimatization', 'G16.012.500.133'],\n ['\"Accommodation', ' Ocular\"', 'G14.010'],\n ['\"Accommodation', ' Lens\"', 'G14.010'],\n ['Accounting', 'N03.219.463.030'],\n ['Oil and Gas Industry', 'J01.576.655.875.750'],\n ['Petroleum Industry', 'J01.576.655.875.750'],\n ['Oil Refinery', 'J01.576.655.875.750'],\n ['Natural Gas Industry', 'J01.576.655.875.750'],\n ['Coal Industry', 'J01.576.655.875.200'],\n ['Driving Under the Influence', 'F01.145.250.250'],\n ['Driving Under the Influence', 'F01.145.263.500'],\n ['Driving Under the Influence', 'I01.880.735.223.250'],\n ['Driving Under the Influence', 'I03.125.649'],\n ['Drinking and Driving', 'F01.145.250.250'],\n ['Drinking and Driving', 'F01.145.263.500'],\n ['Drinking and Driving', 'I01.880.735.223.250'],\n ['Drinking and Driving', 'I03.125.649'],\n ['Human Embryonic Stem Cells', 'A11.872.700.250.750'],\n ['Mouse Embryonic Stem Cells', 'A11.872.700.250.875'],\n ['Embryonic Germ Cells', 'A11.497.124'],\n ['Embryonic Germ Cells', 'A11.872.700.250.625'],\n ['Work Performance', 'I03.946.675'],\n ['Job Performance', 'I03.946.675'],\n ['Criminal Behavior', 'F01.145.250'],\n ['Clinical Decision-Making', 'E01.055'],\n ['Cognitive Aging', 'G07.345.124.260'],\n ['Cognitive Neuroscience', 'F04.096.628.255.500'],\n ['Cognitive Neuroscience', 'H01.158.610.030'],\n ['Social Neuroscience', 'F04.096.628.255.500'],\n ['Social Neuroscience', 'H01.158.610.030'],\n ['Emotional Adjustment', 'F01.058.144'],\n ['Emotional Adjustment', 'F01.752.543.500.250'],\n ['Facial Recognition', 'F02.463.593.524.250.500'],\n ['Facial Recognition', 'F02.463.593.524.500.500'],\n ['Facial Recognition', 'F02.463.593.932.622.500'],\n ['Facial Emotion Recognition', 'F02.463.593.524.250.500'],\n ['Facial Emotion Recognition', 'F02.463.593.524.500.500'],\n ['Facial Emotion Recognition', 'F02.463.593.932.622.500'],\n ['Grandparents', 'F01.829.263.403'],\n ['Grandparents', 'I01.880.853.150.452'],\n ['Grandparents', 'M01.264'],\n ['Grandmother', 'F01.829.263.403'],\n ['Grandmother', 'I01.880.853.150.452'],\n ['Grandmother', 'M01.264'],\n ['Grandfather', 'F01.829.263.403'],\n ['Grandfather', 'I01.880.853.150.452'],\n ['Grandfather', 'M01.264'],\n ['Help-Seeking Behavior', 'F01.145.813.217'],\n ['Heuristics', 'F02.463.425.725.500'],\n ['Heuristics', 'F02.463.785.810.500'],\n ['Intimate Partner Violence', 'I01.198.240.856.575'],\n ['Intimate Partner Violence', 'I01.880.735.900.688'],\n ['Dating Violence', 'I01.198.240.856.575'],\n ['Dating Violence', 'I01.880.735.900.688'],\n ['Neurological Rehabilitation', 'E02.760.169.063.500.477'],\n ['Neurological Rehabilitation', 'E02.831.477'],\n ['Neurological Rehabilitation', 'H02.403.680.600.750'],\n ['Neurological Rehabilitation', 'N02.421.784.511'],\n ['Physical Abuse', 'I01.198.240.856.688'],\n ['Physical Abuse', 'I01.880.735.900.744'],\n ['Problem Behavior', 'F01.145.126.972'],\n ['Problem Behavior', 'F01.145.179.750'],\n ['\"Dysfunctional Behavior', ' Psychology\"', 'F01.145.126.972'],\n ['\"Dysfunctional Behavior', ' Psychology\"', 'F01.145.179.750'],\n ['Disruptive Behavior', 'F01.145.126.972'],\n ['Disruptive Behavior', 'F01.145.179.750'],\n ['Underage Drinking', 'F01.145.022.750'],\n ['Underage Drinking', 'F01.145.317.269.875'],\n ['Underage Drinking', 'I01.880.735.878'],\n ['Legal Drinking Age', 'F01.145.022.750'],\n ['Legal Drinking Age', 'F01.145.317.269.875'],\n ['Legal Drinking Age', 'I01.880.735.878'],\n ['Ectopic Gene Expression', 'G05.308.202'],\n ['Cell Plasticity', 'G04.356.250'],\n ['Cell Self Renewal', 'G04.144.220.235'],\n ['Cell Self Renewal', 'G04.161.750.500.375'],\n ['Cell Self Renewal', 'G05.113.415'],\n ['Cell Self Renewal', 'G07.345.249.410.750.500.625'],\n ['Stem Cell Self-Renewal', 'G04.144.220.235'],\n ['Stem Cell Self-Renewal', 'G04.161.750.500.375'],\n ['Stem Cell Self-Renewal', 'G05.113.415'],\n ['Stem Cell Self-Renewal', 'G07.345.249.410.750.500.625'],\n ['Rehabilitation Research', 'H01.770.644.145.472'],\n ['Orthodontists', 'M01.526.485.330.655'],\n ['Orthodontists', 'N02.360.330.655'],\n ['Dentofacial Orthopedists', 'M01.526.485.330.655'],\n ['Dentofacial Orthopedists', 'N02.360.330.655'],\n ['Oral and Maxillofacial Surgeons', 'M01.526.485.330.483'],\n ['Oral and Maxillofacial Surgeons', 'N02.360.330.483'],\n ['Exodontists', 'M01.526.485.330.483'],\n ['Exodontists', 'N02.360.330.483'],\n ['Neuroprotection', 'G11.561.645'],\n ['\"Diet', ' Food', ' and Nutrition\"', 'G07.203'],\n ['Triticale', 'B01.650.940.800.575.912.250.822.906'],\n ['Critical Care Outcomes', 'N04.761.559.590.399.250'],\n ['Critical Care Outcomes', 'N05.715.360.575.575.399.250'],\n ['Simulation Training', 'I02.903.847'],\n ['Interactive Learning', 'I02.903.847'],\n ['Millets', 'B01.650.940.800.575.912.250.822.587'],\n ['Biobehavioral Sciences', 'H01.770.644.108.687'],\n ['Protein Corona', 'D12.776.642'],\n ['Vegetarians', 'M01.928'],\n ['Lacto-Ovo Vegetarians', 'M01.928'],\n ['Vegans', 'M01.928.500'],\n ['Accounts Payable and Receivable', 'N03.219.463.030.080'],\n ['Accounts Payable', 'N03.219.463.030.080'],\n ['Youth Sports', 'I03.450.642.845.987'],\n ['Organized Youth Sports', 'I03.450.642.845.987'],\n ['Literacy', 'F01.145.209.429'],\n ['Literacy', 'N01.824.196.500'],\n ['Illiteracy', 'F01.145.209.429'],\n ['Illiteracy', 'N01.824.196.500'],\n ['Severe Acute Malnutrition', 'C18.654.521.719'],\n ['\"Banking', ' Personal\"', 'N03.219.463.030.100'],\n ['Savings Accounts', 'N03.219.463.030.100'],\n ['Checking Accounts', 'N03.219.463.030.100'],\n ['Evidence-Based Facility Design', 'N02.278.200.252'],\n ['\"Physical Appearance', ' Body\"', 'E01.370.600.115.450'],\n ['\"Physical Appearance', ' Body\"', 'G07.100.175'],\n ['Fruit and Vegetable Juices', 'G07.203.100.606'],\n ['Fruit and Vegetable Juices', 'J02.200.606'],\n ['Vegetable Juices', 'G07.203.100.606'],\n ['Vegetable Juices', 'J02.200.606'],\n ['Fruit Juices', 'G07.203.100.606'],\n ['Fruit Juices', 'J02.200.606'],\n ['Ghee', 'D10.212.302.199.500'],\n ['Ghee', 'G07.203.300.350.100.500'],\n ['Ghee', 'G07.203.300.375.200.500'],\n ['Ghee', 'J02.500.350.100.500'],\n ['Ghee', 'J02.500.375.200.500'],\n ['Hydraulic Fracking', 'J01.576.655.875.750.500'],\n ['Psychological Trauma', 'F03.950.750.375'],\n ['Peer Influence', 'F01.829.316.483.750'],\n ['Peer Pressure', 'F01.829.316.483.750'],\n ['Vegetable Products', 'G07.203.300.850.450'],\n ['Vegetable Products', 'J02.500.850.800'],\n ['Direct-to-Consumer Advertising', 'J01.219.687.274.500'],\n ['Direct-To-Consumer Screening and Testing', 'E01.370.398'],\n ['Direct-To-Consumer Screening and Testing', 'N02.421.726.233.166'],\n ['Extracellular Vesicles', 'A11.284.295.588'],\n ['Exovesicles', 'A11.284.295.588'],\n ['Apoptotic Bodies', 'A11.284.295.588'],\n ['Fungal Viruses', 'B04.352'],\n ['Telocytes', 'A11.329.830.750'],\n ['Exoskeleton Device', 'E07.341'],\n ['Robotic Exoskeleton', 'E07.341'],\n ['Shellfish Hypersensitivity', 'C20.543.480.370.763'],\n ['\"Failure to Rescue', ' Health Care\"', 'E01.789.800.760.500'],\n ['\"Failure to Rescue', ' Health Care\"', 'H01.770.644.145.431.500'],\n ['\"Failure to Rescue', ' Health Care\"', 'N04.761.559.590.800.760.500'],\n ['\"Failure to Rescue', ' Health Care\"', 'N05.715.360.575.575.800.760.500'],\n ['Psychiatric Rehabilitation', 'H02.403.680.600.875'],\n ['Psychiatric Rehabilitation', 'N02.421.784.578'],\n ['Psychosocial Care', 'H02.403.680.600.875'],\n ['Psychosocial Care', 'N02.421.784.578'],\n ['Symptom Flare Up', 'C23.550.291.937.500'],\n ['Symptom Exacerbation', 'C23.550.291.937.500'],\n ['Isolated Heart Preparation', 'E05.519'],\n ['Isolated Heart Preparation', 'E05.598.750'],\n ['Langendorff Perfused Heart', 'E05.519'],\n ['Langendorff Perfused Heart', 'E05.598.750'],\n ['Working Heart Preparation Technique', 'E05.519'],\n ['Working Heart Preparation Technique', 'E05.598.750'],\n ['Working Heart Preparation', 'E05.519'],\n ['Working Heart Preparation', 'E05.598.750'],\n ['Isolated Heart Preparation Technique', 'E05.519'],\n ['Isolated Heart Preparation Technique', 'E05.598.750'],\n ['\"Diet', ' Vegan\"', 'E02.642.249.300.750'],\n ['\"Diet', ' Vegan\"', 'G07.203.650.240.300.750'],\n ['Veganism', 'E02.642.249.300.750'],\n ['Veganism', 'G07.203.650.240.300.750'],\n ['Behavior Observation Techniques', 'E05.796.112'],\n ['Behavior Observation Techniques', 'F04.669.112'],\n ['Behavior Rating Scale', 'F04.711.271'],\n ['Behavior Test', 'F04.711.271'],\n ['Alcohol Drinking in College', 'F01.145.317.269.625'],\n ['\"Obesity', ' Metabolically Benign\"', 'C18.654.726.500.650'],\n ['\"Obesity', ' Metabolically Benign\"', 'C23.888.144.699.500.250'],\n ['\"Obesity',\n  ' Metabolically Benign\"',\n  'E01.370.600.115.100.160.120.699.500.375'],\n ['\"Obesity', ' Metabolically Benign\"', 'G07.100.100.160.120.699.500.375'],\n ['Whole Grains', 'G07.203.300.300.550.500'],\n ['Whole Grains', 'G07.203.300.775.500.500'],\n ['Whole Grains', 'J02.500.300.550.500'],\n ['Whole Grains', 'J02.500.775.500.500'],\n ['Whole Grain Cereals', 'G07.203.300.300.550.500'],\n ['Whole Grain Cereals', 'G07.203.300.775.500.500'],\n ['Whole Grain Cereals', 'J02.500.300.550.500'],\n ['Whole Grain Cereals', 'J02.500.775.500.500'],\n ['Transanal Endoscopic Surgery', 'E01.370.388.250.630.500'],\n ['Transanal Endoscopic Surgery', 'E04.210.240.250.680.500'],\n ['Transanal Endoscopic Surgery', 'E04.502.250.250.250.680.500'],\n ['Transanal Endoscopic Surgery', 'E04.502.250.630.500'],\n ['Transanal Minimally Invasive Surgery', 'E01.370.388.250.630.500'],\n ['Transanal Minimally Invasive Surgery', 'E04.210.240.250.680.500'],\n ['Transanal Minimally Invasive Surgery', 'E04.502.250.250.250.680.500'],\n ['Transanal Minimally Invasive Surgery', 'E04.502.250.630.500'],\n ['Transanal Endoscopic Microsurgery', 'E01.370.388.250.630.500.500'],\n ['Transanal Endoscopic Microsurgery', 'E04.210.240.250.680.500.500'],\n ['Transanal Endoscopic Microsurgery', 'E04.494.787'],\n ['Transanal Endoscopic Microsurgery', 'E04.502.250.250.250.680.500.500'],\n ['Transanal Endoscopic Microsurgery', 'E04.502.250.630.500.500'],\n ['Cold Injury', 'C26.212'],\n ['Personal Protective Equipment', 'E07.700.560'],\n ['Personal Protective Equipment', 'J01.637.708.560'],\n ['Nerve Agents', 'D27.720.599'],\n ['Nerve Agents', 'D27.720.777.300.500'],\n ['Nerve Gas', 'D27.720.599'],\n ['Nerve Gas', 'D27.720.777.300.500'],\n ['War-Related Injuries', 'C26.946'],\n ['War-Related Injuries', 'I01.880.735.950.500.951.500'],\n ['War-Related Injuries', 'N06.850.460.350.600.903.500'],\n ['War-Related Trauma', 'C26.946'],\n ['War-Related Trauma', 'I01.880.735.950.500.951.500'],\n ['War-Related Trauma', 'N06.850.460.350.600.903.500'],\n ['Abnormal Involuntary Movement Scale', 'E01.370.600.550.162'],\n ['Blood Alcohol Content', 'D02.033.375.135'],\n ['Social Communication Disorder', 'F03.625.374.250'],\n ['Legal Services', 'I01.880.604.583.482'],\n ['Defamation', 'I01.198.240.240'],\n ['Defamation', 'I01.880.735.191.051'],\n ['Slander', 'I01.198.240.240'],\n ['Slander', 'I01.880.735.191.051'],\n ['Libel', 'I01.198.240.240'],\n ['Libel', 'I01.880.735.191.051'],\n ['Anger Management Therapy', 'F04.754.137.087'],\n ['\"Psychology', ' Sports\"', 'F04.096.628.914'],\n ['War Exposure', 'I01.880.735.950.500.951'],\n ['War Exposure', 'N06.850.460.350.600.903'],\n ['Childhood-Onset Fluency Disorder', 'F03.625.374.125'],\n ['No-Show Patients', 'F01.100.150.750.500.600.750'],\n ['No-Show Patients', 'F01.145.488.887.500.600.750'],\n ['No-Show Patients', 'M01.643.550'],\n ['No-Show Patients', 'N04.452.758.635.500'],\n ['No-Show Patients', 'N05.300.150.800.500.600.750'],\n ['Cellular Reprogramming Techniques', 'E05.200.500.380'],\n ['Cellular Reprogramming Techniques', 'E05.242.378'],\n ['Cellular Reprogramming Techniques', 'E05.393.085'],\n ['Directed Differentiation Techniques', 'E05.200.500.380'],\n ['Directed Differentiation Techniques', 'E05.242.378'],\n ['Directed Differentiation Techniques', 'E05.393.085'],\n ['Direct Cell Reprogramming Techniques', 'E05.200.500.380'],\n ['Direct Cell Reprogramming Techniques', 'E05.242.378'],\n ['Direct Cell Reprogramming Techniques', 'E05.393.085'],\n ['Metacognition', 'F02.463.188.756'],\n ['Metacognitive Awareness', 'F02.463.188.756'],\n ['Metacognitive Monitoring', 'F02.463.188.756'],\n ['Metacognitive Control', 'F02.463.188.756'],\n ['Metaemotion', 'F02.463.188.756'],\n ['Metamemory', 'F02.463.188.756'],\n ['Prescription Drug Overuse', 'E02.319.306.500.750'],\n ['\"Near Miss', ' Healthcare\"', 'E02.319.529.750'],\n ['\"Near Miss', ' Healthcare\"', 'N02.421.450.500.750'],\n ['\"Near Miss', ' Healthcare\"', 'N02.421.450.550'],\n ['\"Near Miss', ' Healthcare\"', 'N04.761.700.594'],\n ['\"Near Miss', ' Healthcare\"', 'N05.700.513'],\n ['RNAi Therapeutics', 'E02.095.301.250'],\n ['Dynamic Light Scattering', 'E05.196.822.325'],\n ['Quasi-Elastic Light Scattering (QELS)', 'E05.196.822.325'],\n ['\"Time Out', ' Healthcare\"', 'N04.761.700.635'],\n ['\"Time Out', ' Healthcare\"', 'N05.700.739'],\n ['Surgical Time Out', 'N04.761.700.635'],\n ['Surgical Time Out', 'N05.700.739'],\n ['Healthcare Failure Mode and Effect Analysis',\n  'E05.318.740.600.800.715.500'],\n ['Healthcare Failure Mode and Effect Analysis', 'N04.452.871.715.400'],\n ['Healthcare Failure Mode and Effect Analysis',\n  'N05.715.360.750.625.700.690.400'],\n ['Healthcare Failure Mode and Effect Analysis', 'N06.850.505.715.500'],\n ['Healthcare Failure Mode and Effect Analysis',\n  'N06.850.520.830.600.800.715.500'],\n ['Failure Mode and Effect Analysis', 'E05.318.740.600.800.715.500'],\n ['Failure Mode and Effect Analysis', 'N04.452.871.715.400'],\n ['Failure Mode and Effect Analysis', 'N05.715.360.750.625.700.690.400'],\n ['Failure Mode and Effect Analysis', 'N06.850.505.715.500'],\n ['Failure Mode and Effect Analysis', 'N06.850.520.830.600.800.715.500'],\n ['Spirit Possession', 'K01.844.619.500'],\n ['\"Crew Resource Management', ' Healthcare\"', 'N04.590.254'],\n ['Computer Heuristics', 'L01.224.050.375.095'],\n ['Ataxins', 'D12.776.631.069'],\n ['Ataxins', 'D12.776.660.075'],\n ['Alarmins', 'D23.035'],\n ['Dermal Fillers', 'D27.720.102.461'],\n ['Action Spectrum', 'E05.196.867.826.150'],\n ['Diplomacy', 'F01.829.316.171'],\n ['Diplomacy', 'F02.463.785.373.520.500'],\n ['Diplomacy', 'I01.738.305'],\n ['Mutation Accumulation', 'G05.365.590.594'],\n ['Spontaneous Mutation Accumulation', 'G05.365.590.594'],\n ['Internal Ribosome Entry Sites', 'D13.444.735.790.878.942.250'],\n ['Internal Ribosome Entry Sites', 'G02.111.570.080.689.687.093'],\n ['Internal Ribosome Entry Sites', 'G05.360.080.689.687.093'],\n ['Biological Mimicry', 'G16.012.750'],\n ['Biological Camouflage', 'G16.012.750'],\n ['Specific Learning Disorder', 'F03.625.562.700'],\n ['Potentially Inappropriate Medication List', 'N04.761.700.615'],\n ['Potentially Inappropriate Medication List', 'N05.700.594'],\n ['Beers Criteria', 'N04.761.700.615'],\n ['Beers Criteria', 'N05.700.594'],\n ['STOPP (Screening Tool of Older Persons Potentially Inappropriate Prescriptions)',\n  'N04.761.700.615'],\n ['STOPP (Screening Tool of Older Persons Potentially Inappropriate Prescriptions)',\n  'N05.700.594'],\n ['Medication Appropriateness Index', 'N04.761.700.615'],\n ['Medication Appropriateness Index', 'N05.700.594'],\n ['Late Onset Disorders', 'C23.550.291.883'],\n ['Phakopsora pachyrhizi', 'B01.300.179.113'],\n ['Farmers', 'M01.526.390'],\n ['Ranchers', 'M01.526.390'],\n ['Culturally Appropriate Technology', 'J01.897.052'],\n ['Intermediate Technology', 'J01.897.052'],\n ['Soft Technology', 'J01.897.052'],\n ['Social Learning', 'F02.784.629.529.663'],\n ['Financial Statements', 'N03.219.463.030.140'],\n ['\"Assets', ' Financial\"', 'N03.219.463.030.140'],\n ['Cash Flow Statement', 'N03.219.463.030.140'],\n ['Balance Sheet', 'N03.219.463.030.140'],\n ['Expense Statement', 'N03.219.463.030.140'],\n ['Income Statement', 'N03.219.463.030.140'],\n ['\"Equity', ' Financial\"', 'N03.219.463.030.140'],\n ['\"Liabilities', ' Financial\"', 'N03.219.463.030.140'],\n ['Miners', 'M01.526.693'],\n ['Chronopharmacokinetics', 'G07.690.725.249'],\n ['\"Administrative Claims', ' Healthcare\"', 'N04.452.859.564.137'],\n ['Child Health', 'N01.400.225'],\n ['Child Well Being', 'N01.400.225'],\n ['Interleukin-33', 'D12.644.276.374.465.850'],\n ['Interleukin-33', 'D12.776.467.374.465.850'],\n ['Interleukin-33', 'D23.529.374.465.850'],\n ['S100A12 Protein', 'D12.776.157.125.750.875'],\n ['Telopodes', 'A11.284.180.900'],\n ['Telopodes', 'A11.329.830.750.500'],\n ['Podomers', 'A11.284.180.900'],\n ['Podomers', 'A11.329.830.750.500'],\n ['Podoms', 'A11.284.180.900'],\n ['Podoms', 'A11.329.830.750.500'],\n ['Drosophila simulans', 'B01.050.500.131.617.720.500.500.750.310.250.750'],\n ['Optimism', 'F01.100.787'],\n ['Positive Attitude', 'F01.100.787'],\n ['Positive Thinking', 'F01.100.787'],\n ['Pessimism', 'F01.100.893'],\n ['Ataxin-1', 'D12.776.631.069.500'],\n ['Ataxin-1', 'D12.776.660.075.500'],\n ['Adolescent Health', 'N01.400.075'],\n ['Adolescent Well Being', 'N01.400.075'],\n ['Ataxin-2', 'D12.776.157.725.452.125'],\n ['Ataxin-2', 'D12.776.631.069.750'],\n ['Ataxin-2', 'D12.776.660.075.750'],\n ['Ataxin-2', 'D12.776.664.962.452.125'],\n ['Ataxin-3', 'D08.811.037.250'],\n ['Ataxin-3', 'D12.776.631.069.875'],\n ['Ataxin-3', 'D12.776.660.075.875'],\n ['Point-of-Care Testing', 'N04.590.874.500'],\n ['Bedside Testing', 'N04.590.874.500'],\n ['Ataxin-7', 'D12.776.631.069.901'],\n ['Ataxin-7', 'D12.776.660.075.900'],\n ['Ataxin-10', 'D12.776.631.069.950'],\n ['Glucagon-Like Peptide Receptors', 'D12.776.543.750.695.021'],\n ['Glucagon-Like Peptide Receptors', 'D12.776.543.750.750.360.100'],\n ['Glucagon-Like Peptide-1 Receptor', 'D12.776.543.750.695.021.500'],\n ['Glucagon-Like Peptide-1 Receptor', 'D12.776.543.750.750.360.100.500'],\n ['Glucagon-Like Peptide-2 Receptor', 'D12.776.543.750.695.021.600'],\n ['Glucagon-Like Peptide-2 Receptor', 'D12.776.543.750.750.360.100.600'],\n ['Receptor for Advanced Glycation End Products', 'D12.776.543.750.615'],\n ['RNA Recognition Motif Proteins', 'D12.776.157.725.813'],\n ['RNA Recognition Motif Proteins', 'D12.776.664.962.813'],\n ['ELAV-Like Protein 2', 'D12.776.157.725.813.500.500'],\n ['ELAV-Like Protein 2', 'D12.776.631.520.500'],\n ['ELAV-Like Protein 2', 'D12.776.664.962.813.500.500'],\n ['ELAV-Like Protein 3', 'D12.776.157.725.813.500.750'],\n ['ELAV-Like Protein 3', 'D12.776.631.520.750'],\n ['ELAV-Like Protein 3', 'D12.776.664.962.813.500.750'],\n ['ELAV-Like Protein 4', 'D12.776.157.725.813.500.875'],\n ['ELAV-Like Protein 4', 'D12.776.631.520.875'],\n ['ELAV-Like Protein 4', 'D12.776.664.962.813.500.875'],\n ['ELAV-Like Protein 1', 'D12.776.157.725.813.500.250'],\n ['ELAV-Like Protein 1', 'D12.776.664.962.813.500.250'],\n ['Whey', 'A12.790.760'],\n ['Whey', 'G07.203.100.700.750'],\n ['Whey', 'G07.203.300.350.525.760'],\n ['Whey', 'J02.200.700.750'],\n ['Whey', 'J02.500.350.525.760'],\n ['Whey Proteins', 'A12.790.520.500'],\n ['Whey Proteins', 'A12.790.760.500'],\n ['Whey Proteins', 'D12.776.256.159.750.816'],\n ['Whey Proteins', 'G07.203.300.350.525.760.500'],\n ['Whey Proteins', 'G07.203.300.428.159.812.500'],\n ['Whey Proteins', 'J02.500.350.525.520.500'],\n ['Whey Proteins', 'J02.500.350.525.760.500'],\n ['Whey Proteins', 'J02.500.428.159.750.500'],\n ['Hoarding Disorder', 'F03.080.600.250'],\n ['Obsessive Hoarding', 'F03.080.600.250'],\n ['Poly(ADP-ribose) Polymerase Inhibitors', 'D27.505.519.389.739'],\n ['Poly(ADP-ribose) Polymerase Inhibitors', 'D27.505.954.248.692'],\n ['Autism Spectrum Disorder', 'F03.625.164.113'],\n ['CELF Proteins', 'D12.776.157.725.813.250'],\n ['CELF Proteins', 'D12.776.664.962.813.250'],\n ['CELF1 Protein', 'D12.776.157.725.813.250.500'],\n ['CELF1 Protein', 'D12.776.664.962.813.250.500'],\n ['Industrial Development', 'I01.261.262.500'],\n ['Industrial Development', 'J01.576.519'],\n ['Technology Development', 'I01.261.262.500'],\n ['Technology Development', 'J01.576.519'],\n ['Industrialization', 'I01.261.262.500'],\n ['Industrialization', 'J01.576.519'],\n ['Cloud Computing', 'L01.224.097'],\n ['Natural Resources', 'G16.500.275.553'],\n ['Natural Resources', 'J01.728'],\n ['Natural Resources', 'N06.230.350'],\n ['Land Supply', 'G16.500.275.553'],\n ['Land Supply', 'J01.728'],\n ['Land Supply', 'N06.230.350'],\n ['Glycemic Load', 'G07.203.650.660.750'],\n ['Glycemic Load', 'J01.576.423.850.730.750.750'],\n ['Glycemic Load', 'N06.850.601.750.750'],\n ['Adenylyl Cyclase Inhibitors', 'D27.505.519.389.108'],\n ['RAW 264.7 Cells', 'A11.251.210.172.875'],\n ['RAW 264.7 Cells', 'A11.733.397.815'],\n ['Accreditation', 'N03.706.110.070'],\n ['Accreditation', 'N05.700.200.100'],\n ['Clostridiales', 'B03.353.625'],\n ['Graphic Novel', 'V02.700.415'],\n ['Comic Book', 'V02.700.415'],\n ['South Sudan', 'Z01.058.290.120.745'],\n ['Motor Disorders', 'F03.608'],\n ['Maternal Health', 'N01.400.900.500'],\n ['Seed Bank', 'N02.278.065.650'],\n ['Germplasm Bank', 'N02.278.065.650'],\n ['Trauma and Stressor Related Disorders', 'F03.950'],\n ['Maternal-Child Health Services', 'N02.421.143.130.660'],\n ['Maternal-Child Health Services', 'N02.421.143.620.275'],\n ['Serine-Arginine Splicing Factors', 'D12.776.157.725.829.500'],\n ['Serine-Arginine Splicing Factors', 'D12.776.664.962.829.500'],\n ['Infant Health', 'N01.400.388'],\n ['Newborn Health', 'N01.400.388'],\n ['Bipolar and Related Disorders', 'F03.084'],\n ['Gender Dysphoria', 'F03.835.550'],\n ['Formative Feedback', 'F02.784.629.529.223'],\n ['Aripiprazole', 'D03.383.606.170'],\n ['Aripiprazole', 'D03.633.100.810.835.122'],\n ['Abilify', 'D03.383.606.170'],\n ['Abilify', 'D03.633.100.810.835.122'],\n ['OPC 14597', 'D03.383.606.170'],\n ['OPC 14597', 'D03.633.100.810.835.122'],\n ['Prunus dulcis', 'B01.650.940.800.575.912.250.859.937.500.625.500'],\n ['Almonds', 'B01.650.940.800.575.912.250.859.937.500.625.500'],\n ['Albumin-Bound Paclitaxel', 'D02.455.426.392.368.242.888.777.500'],\n ['Albumin-Bound Paclitaxel', 'D02.455.849.291.850.777.500'],\n ['Albumin-Bound Paclitaxel', 'D12.776.034.073'],\n ['Abraxane', 'D02.455.426.392.368.242.888.777.500'],\n ['Abraxane', 'D02.455.849.291.850.777.500'],\n ['Abraxane', 'D12.776.034.073'],\n ['ABI007', 'D02.455.426.392.368.242.888.777.500'],\n ['ABI007', 'D02.455.849.291.850.777.500'],\n ['ABI007', 'D12.776.034.073'],\n ['Child Protective Services', 'I01.409.418.500'],\n ['Child Protective Services', 'N03.540.400.500'],\n ['Social Workers', 'M01.526.919'],\n ['Prunus africana', 'B01.650.940.800.575.912.250.859.937.500.625.250'],\n ['Prunus armeniaca', 'B01.650.940.800.575.912.250.859.937.500.625.375'],\n ['Apricot', 'B01.650.940.800.575.912.250.859.937.500.625.375'],\n ['Prunus avium', 'B01.650.940.800.575.912.250.859.937.500.625.400'],\n ['Prunus serotina', 'B01.650.940.800.575.912.250.859.937.500.625.400'],\n ['Sweet Cherries', 'B01.650.940.800.575.912.250.859.937.500.625.400'],\n ['Prunus cerasus', 'B01.650.940.800.575.912.250.859.937.500.625.400'],\n ['Refugium', 'G16.500.275.683'],\n ['Refugium', 'G16.500.819'],\n ['Distance Counseling', 'F02.784.176.350'],\n ['Distance Counseling', 'F04.408.413.437'],\n ['Distance Counseling', 'N02.421.143.303.175'],\n ['Distance Counseling', 'N02.421.461.363.437'],\n ['Distance Counseling', 'N04.452.758.849.550.500'],\n ['Lubiprostone', 'D10.251.355.325.050.500'],\n ['RU 0211', 'D10.251.355.325.050.500'],\n ['Amitiza', 'D10.251.355.325.050.500'],\n ['SPI 0211', 'D10.251.355.325.050.500'],\n ['Prunus persica', 'B01.650.940.800.575.912.250.859.937.500.625.750'],\n ['Peach', 'B01.650.940.800.575.912.250.859.937.500.625.750'],\n ['Data Anonymization', 'H01.770.644.205'],\n ['Data Anonymization', 'L01.224.134.500'],\n ['Data Anonymization', 'N03.706.437.650.124.160'],\n ['Data Anonymization', 'N04.452.910.200.500'],\n ['De-Identification', 'H01.770.644.205'],\n ['De-Identification', 'L01.224.134.500'],\n ['De-Identification', 'N03.706.437.650.124.160'],\n ['De-Identification', 'N04.452.910.200.500'],\n ['Data Masking', 'H01.770.644.205'],\n ['Data Masking', 'L01.224.134.500'],\n ['Data Masking', 'N03.706.437.650.124.160'],\n ['Data Masking', 'N04.452.910.200.500'],\n ['Personally Identifiable Information', 'I01.880.604.583.080.660'],\n ['Prunus domestica', 'B01.650.940.800.575.912.250.859.937.500.625.450'],\n ['Plum', 'B01.650.940.800.575.912.250.859.937.500.625.450'],\n ['Prunus cerasifera', 'B01.650.940.800.575.912.250.859.937.500.625.450'],\n ['Prunus salicina', 'B01.650.940.800.575.912.250.859.937.500.625.450'],\n ['Darbepoetin alfa', 'D12.776.395.240.150.500'],\n ['Aranesp', 'D12.776.395.240.150.500'],\n ['KRN 321', 'D12.776.395.240.150.500'],\n ['\"Efavirenz',\n  ' Emtricitabine',\n  ' Tenofovir Disoproxil Fumarate Drug Combination\"',\n  'D02.705.429.906.125'],\n ['\"Efavirenz',\n  ' Emtricitabine',\n  ' Tenofovir Disoproxil Fumarate Drug Combination\"',\n  'D03.383.533.375'],\n ['\"Efavirenz',\n  ' Emtricitabine',\n  ' Tenofovir Disoproxil Fumarate Drug Combination\"',\n  'D03.383.742.680.245.500.600.125'],\n ['\"Efavirenz',\n  ' Emtricitabine',\n  ' Tenofovir Disoproxil Fumarate Drug Combination\"',\n  'D03.633.100.759.138.881.125'],\n ['\"Efavirenz',\n  ' Emtricitabine',\n  ' Tenofovir Disoproxil Fumarate Drug Combination\"',\n  'D26.310.375'],\n ['Atripla', 'D02.705.429.906.125'],\n ['Atripla', 'D03.383.533.375'],\n ['Atripla', 'D03.383.742.680.245.500.600.125'],\n ['Atripla', 'D03.633.100.759.138.881.125'],\n ['Atripla', 'D26.310.375'],\n ['Bevacizumab', 'D12.776.124.486.485.114.224.060.375'],\n ['Bevacizumab', 'D12.776.124.790.651.114.224.060.438'],\n ['Bevacizumab', 'D12.776.377.715.548.114.224.200.438'],\n ['Mvasi', 'D12.776.124.486.485.114.224.060.375'],\n ['Mvasi', 'D12.776.124.790.651.114.224.060.438'],\n ['Mvasi', 'D12.776.377.715.548.114.224.200.438'],\n ['Bevacizumab-awwb', 'D12.776.124.486.485.114.224.060.375'],\n ['Bevacizumab-awwb', 'D12.776.124.790.651.114.224.060.438'],\n ['Bevacizumab-awwb', 'D12.776.377.715.548.114.224.200.438'],\n ['Avastin', 'D12.776.124.486.485.114.224.060.375'],\n ['Avastin', 'D12.776.124.790.651.114.224.060.438'],\n ['Avastin', 'D12.776.377.715.548.114.224.200.438'],\n ['Giraffes', 'B01.050.150.900.649.313.500.380.443'],\n ['Okapis', 'B01.050.150.900.649.313.500.380.443'],\n ['Risedronic Acid', 'D02.705.429.500.872'],\n ['Risedronic Acid', 'D03.383.725.836'],\n ['1-Hydroxy-2-(3-pyridyl)ethylidene diphosphonate', 'D02.705.429.500.872'],\n ['1-Hydroxy-2-(3-pyridyl)ethylidene diphosphonate', 'D03.383.725.836'],\n ['Atelvia', 'D02.705.429.500.872'],\n ['Atelvia', 'D03.383.725.836'],\n ['Risedronate Sodium', 'D02.705.429.500.872'],\n ['Risedronate Sodium', 'D03.383.725.836'],\n ['2-(3-pyridinyl)-1-hydroxyethylidene-bisphosphonate', 'D02.705.429.500.872'],\n ['2-(3-pyridinyl)-1-hydroxyethylidene-bisphosphonate', 'D03.383.725.836'],\n ['\"Risedronic Acid', ' Monosodium Salt\"', 'D02.705.429.500.872'],\n ['\"Risedronic Acid', ' Monosodium Salt\"', 'D03.383.725.836'],\n ['Actonel', 'D02.705.429.500.872'],\n ['Actonel', 'D03.383.725.836'],\n ['Risedronate', 'D02.705.429.500.872'],\n ['Risedronate', 'D03.383.725.836'],\n ['Bisphosphonate Risedronate Sodium', 'D02.705.429.500.872'],\n ['Bisphosphonate Risedronate Sodium', 'D03.383.725.836'],\n ['Fluticasone-Salmeterol Drug Combination', 'D02.033.100.291.057.750.500'],\n ['Fluticasone-Salmeterol Drug Combination', 'D02.092.063.291.057.750.500'],\n ['Fluticasone-Salmeterol Drug Combination', 'D02.092.471.683.061.750.500'],\n ['Fluticasone-Salmeterol Drug Combination',\n  'D04.210.500.054.079.129.114.500'],\n ['Fluticasone-Salmeterol Drug Combination', 'D26.310.438'],\n ['\"Fluticasone Propionate',\n  ' Salmeterol Xinafoate Drug Combination\"',\n  'D02.033.100.291.057.750.500'],\n ['\"Fluticasone Propionate',\n  ' Salmeterol Xinafoate Drug Combination\"',\n  'D02.092.063.291.057.750.500'],\n ['\"Fluticasone Propionate',\n  ' Salmeterol Xinafoate Drug Combination\"',\n  'D02.092.471.683.061.750.500'],\n ['\"Fluticasone Propionate',\n  ' Salmeterol Xinafoate Drug Combination\"',\n  'D04.210.500.054.079.129.114.500'],\n ['\"Fluticasone Propionate',\n  ' Salmeterol Xinafoate Drug Combination\"',\n  'D26.310.438'],\n ['Advair Diskus', 'D02.033.100.291.057.750.500'],\n ['Advair Diskus', 'D02.092.063.291.057.750.500'],\n ['Advair Diskus', 'D02.092.471.683.061.750.500'],\n ['Advair Diskus', 'D04.210.500.054.079.129.114.500'],\n ['Advair Diskus', 'D26.310.438'],\n ['Seretide', 'D02.033.100.291.057.750.500'],\n ['Seretide', 'D02.092.063.291.057.750.500'],\n ['Seretide', 'D02.092.471.683.061.750.500'],\n ['Seretide', 'D04.210.500.054.079.129.114.500'],\n ['Seretide', 'D26.310.438'],\n ['Advair HFA', 'D02.033.100.291.057.750.500'],\n ['Advair HFA', 'D02.092.063.291.057.750.500'],\n ['Advair HFA', 'D02.092.471.683.061.750.500'],\n ['Advair HFA', 'D04.210.500.054.079.129.114.500'],\n ['Advair HFA', 'D26.310.438'],\n ['Advair', 'D02.033.100.291.057.750.500'],\n ['Advair', 'D02.092.063.291.057.750.500'],\n ['Advair', 'D02.092.471.683.061.750.500'],\n ['Advair', 'D04.210.500.054.079.129.114.500'],\n ['Advair', 'D26.310.438'],\n ['Fluticasone', 'D04.210.500.054.079.129.114'],\n ['Flonase', 'D04.210.500.054.079.129.114'],\n ['Flovent HFA', 'D04.210.500.054.079.129.114'],\n ['Cutivate', 'D04.210.500.054.079.129.114'],\n ['Fluticasone Propionate', 'D04.210.500.054.079.129.114'],\n ['Flixonase', 'D04.210.500.054.079.129.114'],\n ['Flixotide', 'D04.210.500.054.079.129.114'],\n ['Flovent', 'D04.210.500.054.079.129.114'],\n ['Salmeterol Xinafoate', 'D02.033.100.291.057.750'],\n ['Salmeterol Xinafoate', 'D02.092.063.291.057.750'],\n ['Salmeterol Xinafoate', 'D02.092.471.683.061.750'],\n ['Salmeterol', 'D02.033.100.291.057.750'],\n ['Salmeterol', 'D02.092.063.291.057.750'],\n ['Salmeterol', 'D02.092.471.683.061.750'],\n ['Serevent', 'D02.033.100.291.057.750'],\n ['Serevent', 'D02.092.063.291.057.750'],\n ['Serevent', 'D02.092.471.683.061.750'],\n ['\"Parks', ' Recreational\"', 'J03.925.680'],\n ['National Parks', 'J03.925.680'],\n ['Community Parks', 'J03.925.680'],\n ['Green Space', 'J03.925.680'],\n ['Urban Parks', 'J03.925.680'],\n ['Warfare and Armed Conflicts', 'I01.880.735.950'],\n ['Armed Conflicts', 'I01.880.735.950.250'],\n ['Wars', 'I01.880.735.950.250'],\n ['Everolimus', 'D02.540.505.760.500'],\n ['RAD 001', 'D02.540.505.760.500'],\n ['Afinitor', 'D02.540.505.760.500'],\n ['Certican', 'D02.540.505.760.500'],\n ['\"Aspirin',\n  ' Dipyridamole Drug Combination\"',\n  'D02.455.426.559.389.657.410.595.176.500'],\n ['\"Aspirin', ' Dipyridamole Drug Combination\"', 'D03.383.742.175.500'],\n ['\"Aspirin', ' Dipyridamole Drug Combination\"', 'D26.310.125'],\n ['TX 3301', 'D02.455.426.559.389.657.410.595.176.500'],\n ['TX 3301', 'D03.383.742.175.500'],\n ['TX 3301', 'D26.310.125'],\n ['Extended-Release Dipyridamole-Aspirin',\n  'D02.455.426.559.389.657.410.595.176.500'],\n ['Extended-Release Dipyridamole-Aspirin', 'D03.383.742.175.500'],\n ['Extended-Release Dipyridamole-Aspirin', 'D26.310.125'],\n ['Asasantin', 'D02.455.426.559.389.657.410.595.176.500'],\n ['Asasantin', 'D03.383.742.175.500'],\n ['Asasantin', 'D26.310.125'],\n ['Asasantin Retard', 'D02.455.426.559.389.657.410.595.176.500'],\n ['Asasantin Retard', 'D03.383.742.175.500'],\n ['Asasantin Retard', 'D26.310.125'],\n ['Aggrenox', 'D02.455.426.559.389.657.410.595.176.500'],\n ['Aggrenox', 'D03.383.742.175.500'],\n ['Aggrenox', 'D26.310.125'],\n ['Self-Control', 'F01.145.813.595'],\n ['Saline Waters', 'G16.500.275.725'],\n ['Brackish Water', 'G16.500.275.725'],\n ['Compassion Fatigue', 'C23.888.369.500.500'],\n ['Compassion Fatigue', 'F01.145.126.937.500'],\n ['Compassion Fatigue', 'F01.145.126.990.734.500'],\n ['Compassion Fatigue', 'F02.830.900.666.750'],\n ['Plantaginaceae', 'B01.650.940.800.575.912.250.583.700'],\n ['Stemodia', 'B01.650.940.800.575.912.250.583.700'],\n ['Globularia', 'B01.650.940.800.575.912.250.583.700'],\n ['Lamiales', 'B01.650.940.800.575.912.250.583'],\n ['Proboscidea Plant', 'B01.650.940.800.575.912.250.583'],\n ['Clinical Study', 'V03.175'],\n ['Surgical Clearance', 'E01.370.505'],\n ['Pemetrexed', 'D03.633.100.759.758.399.454.650'],\n ['Pemetrexed', 'D12.125.067.625.525'],\n ['Pemetrexed', 'D12.125.119.409.525'],\n ['Pemetrexed Disodium', 'D03.633.100.759.758.399.454.650'],\n ['Pemetrexed Disodium', 'D12.125.067.625.525'],\n ['Pemetrexed Disodium', 'D12.125.119.409.525'],\n ['LY 231514', 'D03.633.100.759.758.399.454.650'],\n ['LY 231514', 'D12.125.067.625.525'],\n ['LY 231514', 'D12.125.119.409.525'],\n ['Alimta', 'D03.633.100.759.758.399.454.650'],\n ['Alimta', 'D12.125.067.625.525'],\n ['Alimta', 'D12.125.119.409.525'],\n ['Brimonidine Tartrate', 'D03.633.100.857.070'],\n ['\"Brimonidine Tartrate (1:1)',\n  ' (S-(R*',\n  'R*))-Isomer\"',\n  'D03.633.100.857.070'],\n ['Brimonidine Purite', 'D03.633.100.857.070'],\n ['AGN 190342', 'D03.633.100.857.070'],\n ['Sanrosa', 'D03.633.100.857.070'],\n ['Alphagan', 'D03.633.100.857.070'],\n ['Brimonidine', 'D03.633.100.857.070'],\n ['Alphagan P', 'D03.633.100.857.070'],\n ['\"UK 14', '304\"', 'D03.633.100.857.070'],\n ['Ratio-Brimonidine', 'D03.633.100.857.070'],\n ['\"UK 14', '304-18\"', 'D03.633.100.857.070'],\n ['UK 14308', 'D03.633.100.857.070'],\n ['\"Brimonidine Tartrate', ' (R-(R*', 'R*))-Isomer\"', 'D03.633.100.857.070'],\n ['Brimonidine Tartrate (1:1)', 'D03.633.100.857.070'],\n ['Mirvaso', 'D03.633.100.857.070'],\n ['Clinical Studies as Topic', 'E05.318.372.250'],\n ['Clinical Studies as Topic', 'N05.715.360.330.250'],\n ['Clinical Studies as Topic', 'N06.850.520.450.250'],\n ['Beijing', 'Z01.252.474.164.225'],\n ['Beijing', 'Z01.433.114'],\n ['African Union', 'I01.615.500.125'],\n ['African Union', 'N03.540.089'],\n ['Firmicutes', 'B03.353'],\n ['Dutasteride', 'D04.210.500.925.100.125'],\n ['Avodart', 'D04.210.500.925.100.125'],\n ['GG 745', 'D04.210.500.925.100.125'],\n ['GI198745', 'D04.210.500.925.100.125'],\n ['Calceolariaceae', 'B01.650.940.800.575.912.250.583.190'],\n ['Jovellana', 'B01.650.940.800.575.912.250.583.190'],\n ['Calceolaria', 'B01.650.940.800.575.912.250.583.190'],\n ['Porodittia', 'B01.650.940.800.575.912.250.583.190'],\n ['Interferon beta-1a', 'D12.644.276.374.440.890.275.500'],\n ['Interferon beta-1a', 'D12.776.467.374.440.890.275.500'],\n ['Interferon beta-1a', 'D23.529.374.440.890.275.500'],\n ['Avonex Pen', 'D12.644.276.374.440.890.275.500'],\n ['Avonex Pen', 'D12.776.467.374.440.890.275.500'],\n ['Avonex Pen', 'D23.529.374.440.890.275.500'],\n ['Rebif', 'D12.644.276.374.440.890.275.500'],\n ['Rebif', 'D12.776.467.374.440.890.275.500'],\n ['Rebif', 'D23.529.374.440.890.275.500'],\n ['Avonex', 'D12.644.276.374.440.890.275.500'],\n ['Avonex', 'D12.776.467.374.440.890.275.500'],\n ['Avonex', 'D23.529.374.440.890.275.500'],\n ['Olmesartan Medoxomil', 'D03.383.129.308.674'],\n ['Olmesartan Medoxomil', 'D03.383.129.617.584'],\n ['Benicar', 'D03.383.129.308.674'],\n ['Benicar', 'D03.383.129.617.584'],\n ['Olmetec', 'D03.383.129.308.674'],\n ['Olmetec', 'D03.383.129.617.584'],\n ['CS 866', 'D03.383.129.308.674'],\n ['CS 866', 'D03.383.129.617.584'],\n ['Votum', 'D03.383.129.308.674'],\n ['Votum', 'D03.383.129.617.584'],\n ['\"Amlodipine Besylate',\n  ' Olmesartan Medoxomil Drug Combination\"',\n  'D03.383.129.308.674.500'],\n ['\"Amlodipine Besylate',\n  ' Olmesartan Medoxomil Drug Combination\"',\n  'D03.383.129.617.584.500'],\n ['\"Amlodipine Besylate',\n  ' Olmesartan Medoxomil Drug Combination\"',\n  'D03.383.725.203.065.500'],\n ['\"Amlodipine Besylate',\n  ' Olmesartan Medoxomil Drug Combination\"',\n  'D26.310.063'],\n ['Azor', 'D03.383.129.308.674.500'],\n ['Azor', 'D03.383.129.617.584.500'],\n ['Azor', 'D03.383.725.203.065.500'],\n ['Azor', 'D26.310.063'],\n ['Interferon beta-1b', 'D12.644.276.374.440.890.275.750'],\n ['Interferon beta-1b', 'D12.776.467.374.440.890.275.750'],\n ['Interferon beta-1b', 'D23.529.374.440.890.275.750'],\n ['Betaseron', 'D12.644.276.374.440.890.275.750'],\n ['Betaseron', 'D12.776.467.374.440.890.275.750'],\n ['Betaseron', 'D23.529.374.440.890.275.750'],\n ['Extavia', 'D12.644.276.374.440.890.275.750'],\n ['Extavia', 'D12.776.467.374.440.890.275.750'],\n ['Extavia', 'D23.529.374.440.890.275.750'],\n ['Betaferon', 'D12.644.276.374.440.890.275.750'],\n ['Betaferon', 'D12.776.467.374.440.890.275.750'],\n ['Betaferon', 'D23.529.374.440.890.275.750'],\n ['Nebivolol', 'D02.033.100.291.491'],\n ['Nebivolol', 'D02.092.063.291.503'],\n ['Nebivolol', 'D03.383.663.283.755'],\n ['Nebivolol', 'D03.633.100.150.755'],\n ['Bystolic', 'D02.033.100.291.491'],\n ['Bystolic', 'D02.092.063.291.503'],\n ['Bystolic', 'D03.383.663.283.755'],\n ['Bystolic', 'D03.633.100.150.755'],\n ['Nebilet', 'D02.033.100.291.491'],\n ['Nebilet', 'D02.092.063.291.503'],\n ['Nebilet', 'D03.383.663.283.755'],\n ['Nebilet', 'D03.633.100.150.755'],\n ['Silostar', 'D02.033.100.291.491'],\n ['Silostar', 'D02.092.063.291.503'],\n ['Silostar', 'D03.383.663.283.755'],\n ['Silostar', 'D03.633.100.150.755'],\n ['Nebivolol Hydrochloride', 'D02.033.100.291.491'],\n ['Nebivolol Hydrochloride', 'D02.092.063.291.503'],\n ['Nebivolol Hydrochloride', 'D03.383.663.283.755'],\n ['Nebivolol Hydrochloride', 'D03.633.100.150.755'],\n ['R 67555', 'D02.033.100.291.491'],\n ['R 67555', 'D02.092.063.291.503'],\n ['R 67555', 'D03.383.663.283.755'],\n ['R 67555', 'D03.633.100.150.755'],\n ['Lobivon', 'D02.033.100.291.491'],\n ['Lobivon', 'D02.092.063.291.503'],\n ['Lobivon', 'D03.383.663.283.755'],\n ['Lobivon', 'D03.633.100.150.755'],\n ['Celecoxib', 'D02.065.884.247'],\n ['Celecoxib', 'D02.886.590.700.247'],\n ['Celecoxib', 'D03.383.129.539.160'],\n ['Celebrex', 'D02.065.884.247'],\n ['Celebrex', 'D02.886.590.700.247'],\n ['Celebrex', 'D03.383.129.539.160'],\n ['SC 58635', 'D02.065.884.247'],\n ['SC 58635', 'D02.886.590.700.247'],\n ['SC 58635', 'D03.383.129.539.160'],\n ['Varenicline', 'D03.633.100.079.900'],\n ['Varenicline', 'D03.633.100.857.942'],\n ['Chantix', 'D03.633.100.079.900'],\n ['Chantix', 'D03.633.100.857.942'],\n ['Varenicline Tartrate', 'D03.633.100.079.900'],\n ['Varenicline Tartrate', 'D03.633.100.857.942'],\n ['Champix', 'D03.633.100.079.900'],\n ['Champix', 'D03.633.100.857.942'],\n ['Tadalafil', 'D03.383.725.150.500'],\n ['Tadalafil', 'D03.633.100.473.155.500'],\n ['Tadalafil', 'D03.633.300.154.672'],\n ['IC351', 'D03.383.725.150.500'],\n ['IC351', 'D03.633.100.473.155.500'],\n ['IC351', 'D03.633.300.154.672'],\n ['Cialis', 'D03.383.725.150.500'],\n ['Cialis', 'D03.633.100.473.155.500'],\n ['Cialis', 'D03.633.300.154.672'],\n ['Certolizumab Pegol', 'D05.750.741.125'],\n ['Certolizumab Pegol', 'D12.644.541.500.650.250'],\n ['Certolizumab Pegol', 'D12.776.124.486.485.114.224.060.500'],\n ['Certolizumab Pegol', 'D12.776.124.486.485.680.650.250'],\n ['Certolizumab Pegol', 'D12.776.124.790.651.114.224.060.500'],\n ['Certolizumab Pegol', 'D12.776.124.790.651.680.650.250'],\n ['Certolizumab Pegol', 'D12.776.377.715.548.114.224.200.500'],\n ['Certolizumab Pegol', 'D12.776.377.715.548.680.650.250'],\n ['Cimzia', 'D05.750.741.125'],\n ['Cimzia', 'D12.644.541.500.650.250'],\n ['Cimzia', 'D12.776.124.486.485.114.224.060.500'],\n ['Cimzia', 'D12.776.124.486.485.680.650.250'],\n ['Cimzia', 'D12.776.124.790.651.114.224.060.500'],\n ['Cimzia', 'D12.776.124.790.651.680.650.250'],\n ['Cimzia', 'D12.776.377.715.548.114.224.200.500'],\n ['Cimzia', 'D12.776.377.715.548.680.650.250'],\n ['CDP870', 'D05.750.741.125'],\n ['CDP870', 'D12.644.541.500.650.250'],\n ['CDP870', 'D12.776.124.486.485.114.224.060.500'],\n ['CDP870', 'D12.776.124.486.485.680.650.250'],\n ['CDP870', 'D12.776.124.790.651.114.224.060.500'],\n ['CDP870', 'D12.776.124.790.651.680.650.250'],\n ['CDP870', 'D12.776.377.715.548.114.224.200.500'],\n ['CDP870', 'D12.776.377.715.548.680.650.250'],\n ['\"Censorship', ' Research\"', 'I01.880.604.238'],\n ['\"Censorship', ' Research\"', 'K01.752.566.479.173.200'],\n ['\"Censorship', ' Research\"', 'N05.350.670.250'],\n ['Data Accuracy', 'E05.318.308.028'],\n ['Data Accuracy', 'E05.318.370.725.250'],\n ['Data Accuracy', 'L01.399.250.202'],\n ['Data Accuracy', 'N05.715.360.300.202'],\n ['Data Accuracy', 'N05.715.360.325.685.250'],\n ['Data Quality', 'E05.318.308.028'],\n ['Data Quality', 'E05.318.370.725.250'],\n ['Data Quality', 'L01.399.250.202'],\n ['Data Quality', 'N05.715.360.300.202'],\n ['Data Quality', 'N05.715.360.325.685.250'],\n ['\"Brimonidine Tartrate',\n  ' Timolol Maleate Drug Combination\"',\n  'D02.033.100.624.915.500'],\n ['\"Brimonidine Tartrate',\n  ' Timolol Maleate Drug Combination\"',\n  'D02.033.755.624.915.500'],\n ['\"Brimonidine Tartrate',\n  ' Timolol Maleate Drug Combination\"',\n  'D02.092.063.624.915.500'],\n ['\"Brimonidine Tartrate',\n  ' Timolol Maleate Drug Combination\"',\n  'D02.886.675.867.768.500'],\n ['\"Brimonidine Tartrate',\n  ' Timolol Maleate Drug Combination\"',\n  'D03.383.129.708.867.768.500'],\n ['\"Brimonidine Tartrate',\n  ' Timolol Maleate Drug Combination\"',\n  'D03.633.100.857.070.500'],\n ['\"Brimonidine Tartrate',\n  ' Timolol Maleate Drug Combination\"',\n  'D26.310.312'],\n ['Combigan', 'D02.033.100.624.915.500'],\n ...]","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[37]: [['Calcimycin', 'D03.633.100.221.173'],\n ['A-23187', 'D03.633.100.221.173'],\n ['Temefos', 'D02.705.400.625.800'],\n ['Temefos', 'D02.705.539.345.800'],\n ['Temefos', 'D02.886.300.692.800'],\n ['Abate', 'D02.705.400.625.800'],\n ['Abate', 'D02.705.539.345.800'],\n ['Abate', 'D02.886.300.692.800'],\n ['Difos', 'D02.705.400.625.800'],\n ['Difos', 'D02.705.539.345.800'],\n ['Difos', 'D02.886.300.692.800'],\n ['Abattoirs', 'J01.576.423.200.700.100'],\n ['Abattoirs', 'J03.540.020'],\n ['Abbreviations as Topic', 'L01.559.598.400.556.131'],\n ['Acronyms as Topic', 'L01.559.598.400.556.131'],\n ['Abdomen', 'A01.923.047'],\n ['\"Abdomen', ' Acute\"', 'C23.888.592.612.054.200'],\n ['\"Abdomen', ' Acute\"', 'C23.888.821.030.249'],\n ['Abdominal Injuries', 'C26.017'],\n ['Abdominal Neoplasms', 'C04.588.033'],\n ['Abdominal Muscles', 'A02.633.567.050'],\n ['Cremaster Muscle', 'A02.633.567.050'],\n ['Pyramidalis Muscle', 'A02.633.567.050'],\n ['Quadratus Abdominis', 'A02.633.567.050'],\n ['Transversus Abdominis', 'A02.633.567.050'],\n ['Abducens Nerve', 'A08.800.800.120.030'],\n ['Abelson murine leukemia virus', 'B04.613.807.375.525.020'],\n ['Abelson murine leukemia virus', 'B04.820.650.375.525.020'],\n ['Abetalipoproteinemia', 'C16.320.565.398.500.440.500'],\n ['Abetalipoproteinemia', 'C18.452.584.500.875.440.500'],\n ['Abetalipoproteinemia', 'C18.452.648.398.500.440.500'],\n ['Congenital Abnormalities', 'C16.131'],\n ['Fetal Malformations', 'C16.131'],\n ['Fetal Anomalies', 'C16.131'],\n ['\"Abnormalities', ' Drug-Induced\"', 'C16.131.042'],\n ['\"Abnormalities', ' Multiple\"', 'C16.131.077'],\n ['\"Abnormalities', ' Radiation-Induced\"', 'C16.131.080'],\n ['\"Abnormalities', ' Radiation-Induced\"', 'C26.733.031'],\n ['\"Abnormalities', ' Radiation-Induced\"', 'G01.750.748.500.031'],\n ['\"Abnormalities', ' Radiation-Induced\"', 'N06.850.460.350.850.500.031'],\n ['\"Abnormalities', ' Radiation-Induced\"', 'N06.850.810.300.360.031'],\n ['ABO Blood-Group System', 'D23.050.301.290.031'],\n ['ABO Blood-Group System', 'D23.050.705.230.031'],\n ['Blood Group H Type 1 Antigen', 'D23.050.301.290.031'],\n ['Blood Group H Type 1 Antigen', 'D23.050.705.230.031'],\n ['ABO Factors', 'D23.050.301.290.031'],\n ['ABO Factors', 'D23.050.705.230.031'],\n ['Abomasum', 'A13.869.106'],\n ['Abortifacient Agents', 'D27.505.696.875.131'],\n ['Abortifacient Agents', 'D27.505.954.705.131'],\n ['Abortifacient Effect', 'D27.505.696.875.131'],\n ['Abortifacient Effect', 'D27.505.954.705.131'],\n ['\"Abortifacient Agents', ' Nonsteroidal\"', 'D27.505.696.875.131.100'],\n ['\"Abortifacient Agents', ' Nonsteroidal\"', 'D27.505.954.705.131.100'],\n ['\"Abortifacient Agents', ' Steroidal\"', 'D27.505.696.875.131.200'],\n ['\"Abortifacient Agents', ' Steroidal\"', 'D27.505.954.705.131.200'],\n ['\"Abortion', ' Spontaneous\"', 'C13.703.039'],\n ['\"Abortion', ' Spontaneous\"', 'G08.686.784.769.496.125'],\n ['Early Pregnancy Loss', 'C13.703.039'],\n ['Early Pregnancy Loss', 'G08.686.784.769.496.125'],\n ['Miscarriage', 'C13.703.039'],\n ['Miscarriage', 'G08.686.784.769.496.125'],\n ['\"Abortion', ' Tubal\"', 'C13.703.039'],\n ['\"Abortion', ' Tubal\"', 'G08.686.784.769.496.125'],\n ['Abortion Applicants', 'M01.050'],\n ['\"Abortion Seekers', ' Repeated\"', 'M01.050'],\n ['\"Abortion Seekers', ' Refused\"', 'M01.050'],\n ['\"Abortion', ' Criminal\"', 'I01.198.240.089'],\n ['\"Abortion', ' Eugenic\"', 'E04.520.050.050'],\n ['\"Abortion', ' Selective\"', 'E04.520.050.050'],\n ['\"Abortion', ' Habitual\"', 'C13.703.039.089'],\n ['\"Abortion', ' Incomplete\"', 'C13.703.039.093'],\n ['\"Abortion', ' Induced\"', 'E04.520.050'],\n ['Abortion Rate', 'E04.520.050'],\n ['Abortion Techniques', 'E04.520.050'],\n ['\"Abortion', ' Drug-Induced\"', 'E04.520.050'],\n ['Previous Abortion', 'E04.520.050'],\n ['\"Abortion', ' Saline-Solution\"', 'E04.520.050'],\n ['\"Abortion', ' Soap-Solution\"', 'E04.520.050'],\n ['Anti-Abortion Groups', 'E04.520.050'],\n ['Embryotomy', 'E04.520.050'],\n ['\"Fertility Control', ' Postconception\"', 'E04.520.050'],\n ['Abortion Failure', 'E04.520.050'],\n ['\"Abortion', ' Rivanol\"', 'E04.520.050'],\n ['\"Abortion', ' Legal\"', 'E04.520.050.055'],\n ['Abortion on Demand', 'E04.520.050.055'],\n ['\"Abortion', ' Missed\"', 'C13.703.039.173'],\n ['\"Abortion', ' Septic\"', 'C01.674.173'],\n ['\"Abortion', ' Septic\"', 'C13.703.039.256'],\n ['\"Abortion', ' Septic\"', 'C13.703.700.173'],\n ['\"Abortion', ' Therapeutic\"', 'E04.520.050.060'],\n ['\"Abortion', ' Threatened\"', 'C13.703.090'],\n ['\"Abortion', ' Veterinary\"', 'C13.703.039.422'],\n ['\"Abortion', ' Veterinary\"', 'C22.021'],\n ['Abreaction', 'F04.754.720.107'],\n ['Abrin', 'D08.811.277.450.430.700.750.111'],\n ['Abrin', 'D12.776.503.499.249'],\n ['Abrin', 'D12.776.765.678.906.111'],\n ['Abrin C', 'D08.811.277.450.430.700.750.111'],\n ['Abrin C', 'D12.776.503.499.249'],\n ['Abrin C', 'D12.776.765.678.906.111'],\n ['Abrin A', 'D08.811.277.450.430.700.750.111'],\n ['Abrin A', 'D12.776.503.499.249'],\n ['Abrin A', 'D12.776.765.678.906.111'],\n ['Abruptio Placentae', 'C13.703.420.078'],\n ['Abruptio Placentae', 'C13.703.590.132'],\n ['Abscess', 'C01.830.025'],\n ['Abscess', 'C23.550.470.756.100'],\n ['Peritonsillar Abscess', 'C01.748.561.750.500'],\n ['Peritonsillar Abscess', 'C01.830.025.675'],\n ['Peritonsillar Abscess', 'C07.550.781.750.500'],\n ['Peritonsillar Abscess', 'C08.730.561.750.500'],\n ['Peritonsillar Abscess', 'C09.775.649.750.500'],\n ['Abscisic Acid', 'D02.241.223.268.034'],\n ['Abscisic Acid', 'D02.455.326.271.665.202.061'],\n ['Abscisic Acid', 'D02.455.426.392.368.367.379.249.024'],\n ['Abscisic Acid', 'D02.455.849.131.061'],\n ['Abscisic Acid', 'D02.455.849.765.521.500'],\n ['\"Abscisic Acid', ' (+', '-)-Isomer\"', 'D02.241.223.268.034'],\n ['\"Abscisic Acid', ' (+', '-)-Isomer\"', 'D02.455.326.271.665.202.061'],\n ['\"Abscisic Acid',\n  ' (+',\n  '-)-Isomer\"',\n  'D02.455.426.392.368.367.379.249.024'],\n ['\"Abscisic Acid', ' (+', '-)-Isomer\"', 'D02.455.849.131.061'],\n ['\"Abscisic Acid', ' (+', '-)-Isomer\"', 'D02.455.849.765.521.500'],\n ['\"Abscisic Acid', ' (Z', 'E)-Isomer\"', 'D02.241.223.268.034'],\n ['\"Abscisic Acid', ' (Z', 'E)-Isomer\"', 'D02.455.326.271.665.202.061'],\n ['\"Abscisic Acid',\n  ' (Z',\n  'E)-Isomer\"',\n  'D02.455.426.392.368.367.379.249.024'],\n ['\"Abscisic Acid', ' (Z', 'E)-Isomer\"', 'D02.455.849.131.061'],\n ['\"Abscisic Acid', ' (Z', 'E)-Isomer\"', 'D02.455.849.765.521.500'],\n ['\"Abscisic Acid', ' (E', 'Z)-(+', '-)-Isomer\"', 'D02.241.223.268.034'],\n ['\"Abscisic Acid',\n  ' (E',\n  'Z)-(+',\n  '-)-Isomer\"',\n  'D02.455.326.271.665.202.061'],\n ['\"Abscisic Acid',\n  ' (E',\n  'Z)-(+',\n  '-)-Isomer\"',\n  'D02.455.426.392.368.367.379.249.024'],\n ['\"Abscisic Acid', ' (E', 'Z)-(+', '-)-Isomer\"', 'D02.455.849.131.061'],\n ['\"Abscisic Acid', ' (E', 'Z)-(+', '-)-Isomer\"', 'D02.455.849.765.521.500'],\n ['\"Abscisic Acid', ' (R)-Isomer\"', 'D02.241.223.268.034'],\n ['\"Abscisic Acid', ' (R)-Isomer\"', 'D02.455.326.271.665.202.061'],\n ['\"Abscisic Acid', ' (R)-Isomer\"', 'D02.455.426.392.368.367.379.249.024'],\n ['\"Abscisic Acid', ' (R)-Isomer\"', 'D02.455.849.131.061'],\n ['\"Abscisic Acid', ' (R)-Isomer\"', 'D02.455.849.765.521.500'],\n ['\"Abscisic Acid Monoammonium Salt', ' (R)-Isomer\"', 'D02.241.223.268.034'],\n ['\"Abscisic Acid Monoammonium Salt',\n  ' (R)-Isomer\"',\n  'D02.455.326.271.665.202.061'],\n ['\"Abscisic Acid Monoammonium Salt',\n  ' (R)-Isomer\"',\n  'D02.455.426.392.368.367.379.249.024'],\n ['\"Abscisic Acid Monoammonium Salt', ' (R)-Isomer\"', 'D02.455.849.131.061'],\n ['\"Abscisic Acid Monoammonium Salt',\n  ' (R)-Isomer\"',\n  'D02.455.849.765.521.500'],\n ['\"Abscisic Acid', ' (E', 'E)-(+-)-Isomer\"', 'D02.241.223.268.034'],\n ['\"Abscisic Acid', ' (E', 'E)-(+-)-Isomer\"', 'D02.455.326.271.665.202.061'],\n ['\"Abscisic Acid',\n  ' (E',\n  'E)-(+-)-Isomer\"',\n  'D02.455.426.392.368.367.379.249.024'],\n ['\"Abscisic Acid', ' (E', 'E)-(+-)-Isomer\"', 'D02.455.849.131.061'],\n ['\"Abscisic Acid', ' (E', 'E)-(+-)-Isomer\"', 'D02.455.849.765.521.500'],\n ['Absenteeism', 'F02.784.692.107'],\n ['Absorption', 'G01.015'],\n ['Absorption', 'G02.010'],\n ['Absorption', 'G03.015'],\n ['Absorption', 'G03.787.024'],\n ['Absorption', 'G07.690.725.015'],\n ['Abstracting and Indexing', 'L01.453.245.100'],\n ['Indexing', 'L01.453.245.100'],\n ['Indexes as Topic', 'L01.453.245.100'],\n ['Abstracting', 'L01.453.245.100'],\n ['Dental Abutments', 'E06.780.346.500'],\n ['Dental Abutments', 'E07.695.190.175'],\n ['Acacia', 'B01.650.940.800.575.912.250.401.025'],\n ['Acacia catechu', 'B01.650.940.800.575.912.250.401.025'],\n ['Academic Medical Centers', 'N02.278.020'],\n ['Academies and Institutes', 'N03.540.052'],\n ['Institutes', 'N03.540.052'],\n ['Research Institutes', 'N03.540.052'],\n ['Academies', 'N03.540.052'],\n ['Acanthamoeba', 'B01.046.500.100.075.080'],\n ['Acanthocephala', 'B01.050.500.500.132'],\n ['Acanthocytes', 'A11.118.290.330.100'],\n ['Acanthocytes', 'A11.443.240.330.100'],\n ['Acanthocytes', 'A15.145.229.334.330.100'],\n ['Acantholysis', 'C17.800.865.070'],\n ['Acantholysis', 'C23.550.035'],\n ['Acanthosis Nigricans', 'C17.800.621.430.530.100'],\n ['Acari', 'B01.050.500.131.166.132'],\n ['Acceleration', 'G01.482.107'],\n ['Accessory Nerve', 'A08.800.800.120.060'],\n ['Accident Prevention', 'N06.850.135.060'],\n ['Accident Proneness', 'F01.145.015'],\n ['Accidental Falls', 'N06.850.135.122'],\n ['Slip and Fall', 'N06.850.135.122'],\n ['Accidents', 'N06.850.135'],\n ['\"Accidents', ' Aviation\"', 'N06.850.135.185'],\n ['\"Accidents', ' Home\"', 'N06.850.135.217'],\n ['\"Accidents', ' Occupational\"', 'N06.850.135.240'],\n ['\"Accidents', ' Industrial\"', 'N06.850.135.240'],\n ['\"Accidents', ' Traffic\"', 'N06.850.135.392'],\n ['Traffic Collisions', 'N06.850.135.392'],\n ['Traffic Crashes', 'N06.850.135.392'],\n ['Acclimatization', 'G07.025.133'],\n ['Acclimatization', 'G16.012.500.133'],\n ['\"Accommodation', ' Ocular\"', 'G14.010'],\n ['\"Accommodation', ' Lens\"', 'G14.010'],\n ['Accounting', 'N03.219.463.030'],\n ['Oil and Gas Industry', 'J01.576.655.875.750'],\n ['Petroleum Industry', 'J01.576.655.875.750'],\n ['Oil Refinery', 'J01.576.655.875.750'],\n ['Natural Gas Industry', 'J01.576.655.875.750'],\n ['Coal Industry', 'J01.576.655.875.200'],\n ['Driving Under the Influence', 'F01.145.250.250'],\n ['Driving Under the Influence', 'F01.145.263.500'],\n ['Driving Under the Influence', 'I01.880.735.223.250'],\n ['Driving Under the Influence', 'I03.125.649'],\n ['Drinking and Driving', 'F01.145.250.250'],\n ['Drinking and Driving', 'F01.145.263.500'],\n ['Drinking and Driving', 'I01.880.735.223.250'],\n ['Drinking and Driving', 'I03.125.649'],\n ['Human Embryonic Stem Cells', 'A11.872.700.250.750'],\n ['Mouse Embryonic Stem Cells', 'A11.872.700.250.875'],\n ['Embryonic Germ Cells', 'A11.497.124'],\n ['Embryonic Germ Cells', 'A11.872.700.250.625'],\n ['Work Performance', 'I03.946.675'],\n ['Job Performance', 'I03.946.675'],\n ['Criminal Behavior', 'F01.145.250'],\n ['Clinical Decision-Making', 'E01.055'],\n ['Cognitive Aging', 'G07.345.124.260'],\n ['Cognitive Neuroscience', 'F04.096.628.255.500'],\n ['Cognitive Neuroscience', 'H01.158.610.030'],\n ['Social Neuroscience', 'F04.096.628.255.500'],\n ['Social Neuroscience', 'H01.158.610.030'],\n ['Emotional Adjustment', 'F01.058.144'],\n ['Emotional Adjustment', 'F01.752.543.500.250'],\n ['Facial Recognition', 'F02.463.593.524.250.500'],\n ['Facial Recognition', 'F02.463.593.524.500.500'],\n ['Facial Recognition', 'F02.463.593.932.622.500'],\n ['Facial Emotion Recognition', 'F02.463.593.524.250.500'],\n ['Facial Emotion Recognition', 'F02.463.593.524.500.500'],\n ['Facial Emotion Recognition', 'F02.463.593.932.622.500'],\n ['Grandparents', 'F01.829.263.403'],\n ['Grandparents', 'I01.880.853.150.452'],\n ['Grandparents', 'M01.264'],\n ['Grandmother', 'F01.829.263.403'],\n ['Grandmother', 'I01.880.853.150.452'],\n ['Grandmother', 'M01.264'],\n ['Grandfather', 'F01.829.263.403'],\n ['Grandfather', 'I01.880.853.150.452'],\n ['Grandfather', 'M01.264'],\n ['Help-Seeking Behavior', 'F01.145.813.217'],\n ['Heuristics', 'F02.463.425.725.500'],\n ['Heuristics', 'F02.463.785.810.500'],\n ['Intimate Partner Violence', 'I01.198.240.856.575'],\n ['Intimate Partner Violence', 'I01.880.735.900.688'],\n ['Dating Violence', 'I01.198.240.856.575'],\n ['Dating Violence', 'I01.880.735.900.688'],\n ['Neurological Rehabilitation', 'E02.760.169.063.500.477'],\n ['Neurological Rehabilitation', 'E02.831.477'],\n ['Neurological Rehabilitation', 'H02.403.680.600.750'],\n ['Neurological Rehabilitation', 'N02.421.784.511'],\n ['Physical Abuse', 'I01.198.240.856.688'],\n ['Physical Abuse', 'I01.880.735.900.744'],\n ['Problem Behavior', 'F01.145.126.972'],\n ['Problem Behavior', 'F01.145.179.750'],\n ['\"Dysfunctional Behavior', ' Psychology\"', 'F01.145.126.972'],\n ['\"Dysfunctional Behavior', ' Psychology\"', 'F01.145.179.750'],\n ['Disruptive Behavior', 'F01.145.126.972'],\n ['Disruptive Behavior', 'F01.145.179.750'],\n ['Underage Drinking', 'F01.145.022.750'],\n ['Underage Drinking', 'F01.145.317.269.875'],\n ['Underage Drinking', 'I01.880.735.878'],\n ['Legal Drinking Age', 'F01.145.022.750'],\n ['Legal Drinking Age', 'F01.145.317.269.875'],\n ['Legal Drinking Age', 'I01.880.735.878'],\n ['Ectopic Gene Expression', 'G05.308.202'],\n ['Cell Plasticity', 'G04.356.250'],\n ['Cell Self Renewal', 'G04.144.220.235'],\n ['Cell Self Renewal', 'G04.161.750.500.375'],\n ['Cell Self Renewal', 'G05.113.415'],\n ['Cell Self Renewal', 'G07.345.249.410.750.500.625'],\n ['Stem Cell Self-Renewal', 'G04.144.220.235'],\n ['Stem Cell Self-Renewal', 'G04.161.750.500.375'],\n ['Stem Cell Self-Renewal', 'G05.113.415'],\n ['Stem Cell Self-Renewal', 'G07.345.249.410.750.500.625'],\n ['Rehabilitation Research', 'H01.770.644.145.472'],\n ['Orthodontists', 'M01.526.485.330.655'],\n ['Orthodontists', 'N02.360.330.655'],\n ['Dentofacial Orthopedists', 'M01.526.485.330.655'],\n ['Dentofacial Orthopedists', 'N02.360.330.655'],\n ['Oral and Maxillofacial Surgeons', 'M01.526.485.330.483'],\n ['Oral and Maxillofacial Surgeons', 'N02.360.330.483'],\n ['Exodontists', 'M01.526.485.330.483'],\n ['Exodontists', 'N02.360.330.483'],\n ['Neuroprotection', 'G11.561.645'],\n ['\"Diet', ' Food', ' and Nutrition\"', 'G07.203'],\n ['Triticale', 'B01.650.940.800.575.912.250.822.906'],\n ['Critical Care Outcomes', 'N04.761.559.590.399.250'],\n ['Critical Care Outcomes', 'N05.715.360.575.575.399.250'],\n ['Simulation Training', 'I02.903.847'],\n ['Interactive Learning', 'I02.903.847'],\n ['Millets', 'B01.650.940.800.575.912.250.822.587'],\n ['Biobehavioral Sciences', 'H01.770.644.108.687'],\n ['Protein Corona', 'D12.776.642'],\n ['Vegetarians', 'M01.928'],\n ['Lacto-Ovo Vegetarians', 'M01.928'],\n ['Vegans', 'M01.928.500'],\n ['Accounts Payable and Receivable', 'N03.219.463.030.080'],\n ['Accounts Payable', 'N03.219.463.030.080'],\n ['Youth Sports', 'I03.450.642.845.987'],\n ['Organized Youth Sports', 'I03.450.642.845.987'],\n ['Literacy', 'F01.145.209.429'],\n ['Literacy', 'N01.824.196.500'],\n ['Illiteracy', 'F01.145.209.429'],\n ['Illiteracy', 'N01.824.196.500'],\n ['Severe Acute Malnutrition', 'C18.654.521.719'],\n ['\"Banking', ' Personal\"', 'N03.219.463.030.100'],\n ['Savings Accounts', 'N03.219.463.030.100'],\n ['Checking Accounts', 'N03.219.463.030.100'],\n ['Evidence-Based Facility Design', 'N02.278.200.252'],\n ['\"Physical Appearance', ' Body\"', 'E01.370.600.115.450'],\n ['\"Physical Appearance', ' Body\"', 'G07.100.175'],\n ['Fruit and Vegetable Juices', 'G07.203.100.606'],\n ['Fruit and Vegetable Juices', 'J02.200.606'],\n ['Vegetable Juices', 'G07.203.100.606'],\n ['Vegetable Juices', 'J02.200.606'],\n ['Fruit Juices', 'G07.203.100.606'],\n ['Fruit Juices', 'J02.200.606'],\n ['Ghee', 'D10.212.302.199.500'],\n ['Ghee', 'G07.203.300.350.100.500'],\n ['Ghee', 'G07.203.300.375.200.500'],\n ['Ghee', 'J02.500.350.100.500'],\n ['Ghee', 'J02.500.375.200.500'],\n ['Hydraulic Fracking', 'J01.576.655.875.750.500'],\n ['Psychological Trauma', 'F03.950.750.375'],\n ['Peer Influence', 'F01.829.316.483.750'],\n ['Peer Pressure', 'F01.829.316.483.750'],\n ['Vegetable Products', 'G07.203.300.850.450'],\n ['Vegetable Products', 'J02.500.850.800'],\n ['Direct-to-Consumer Advertising', 'J01.219.687.274.500'],\n ['Direct-To-Consumer Screening and Testing', 'E01.370.398'],\n ['Direct-To-Consumer Screening and Testing', 'N02.421.726.233.166'],\n ['Extracellular Vesicles', 'A11.284.295.588'],\n ['Exovesicles', 'A11.284.295.588'],\n ['Apoptotic Bodies', 'A11.284.295.588'],\n ['Fungal Viruses', 'B04.352'],\n ['Telocytes', 'A11.329.830.750'],\n ['Exoskeleton Device', 'E07.341'],\n ['Robotic Exoskeleton', 'E07.341'],\n ['Shellfish Hypersensitivity', 'C20.543.480.370.763'],\n ['\"Failure to Rescue', ' Health Care\"', 'E01.789.800.760.500'],\n ['\"Failure to Rescue', ' Health Care\"', 'H01.770.644.145.431.500'],\n ['\"Failure to Rescue', ' Health Care\"', 'N04.761.559.590.800.760.500'],\n ['\"Failure to Rescue', ' Health Care\"', 'N05.715.360.575.575.800.760.500'],\n ['Psychiatric Rehabilitation', 'H02.403.680.600.875'],\n ['Psychiatric Rehabilitation', 'N02.421.784.578'],\n ['Psychosocial Care', 'H02.403.680.600.875'],\n ['Psychosocial Care', 'N02.421.784.578'],\n ['Symptom Flare Up', 'C23.550.291.937.500'],\n ['Symptom Exacerbation', 'C23.550.291.937.500'],\n ['Isolated Heart Preparation', 'E05.519'],\n ['Isolated Heart Preparation', 'E05.598.750'],\n ['Langendorff Perfused Heart', 'E05.519'],\n ['Langendorff Perfused Heart', 'E05.598.750'],\n ['Working Heart Preparation Technique', 'E05.519'],\n ['Working Heart Preparation Technique', 'E05.598.750'],\n ['Working Heart Preparation', 'E05.519'],\n ['Working Heart Preparation', 'E05.598.750'],\n ['Isolated Heart Preparation Technique', 'E05.519'],\n ['Isolated Heart Preparation Technique', 'E05.598.750'],\n ['\"Diet', ' Vegan\"', 'E02.642.249.300.750'],\n ['\"Diet', ' Vegan\"', 'G07.203.650.240.300.750'],\n ['Veganism', 'E02.642.249.300.750'],\n ['Veganism', 'G07.203.650.240.300.750'],\n ['Behavior Observation Techniques', 'E05.796.112'],\n ['Behavior Observation Techniques', 'F04.669.112'],\n ['Behavior Rating Scale', 'F04.711.271'],\n ['Behavior Test', 'F04.711.271'],\n ['Alcohol Drinking in College', 'F01.145.317.269.625'],\n ['\"Obesity', ' Metabolically Benign\"', 'C18.654.726.500.650'],\n ['\"Obesity', ' Metabolically Benign\"', 'C23.888.144.699.500.250'],\n ['\"Obesity',\n  ' Metabolically Benign\"',\n  'E01.370.600.115.100.160.120.699.500.375'],\n ['\"Obesity', ' Metabolically Benign\"', 'G07.100.100.160.120.699.500.375'],\n ['Whole Grains', 'G07.203.300.300.550.500'],\n ['Whole Grains', 'G07.203.300.775.500.500'],\n ['Whole Grains', 'J02.500.300.550.500'],\n ['Whole Grains', 'J02.500.775.500.500'],\n ['Whole Grain Cereals', 'G07.203.300.300.550.500'],\n ['Whole Grain Cereals', 'G07.203.300.775.500.500'],\n ['Whole Grain Cereals', 'J02.500.300.550.500'],\n ['Whole Grain Cereals', 'J02.500.775.500.500'],\n ['Transanal Endoscopic Surgery', 'E01.370.388.250.630.500'],\n ['Transanal Endoscopic Surgery', 'E04.210.240.250.680.500'],\n ['Transanal Endoscopic Surgery', 'E04.502.250.250.250.680.500'],\n ['Transanal Endoscopic Surgery', 'E04.502.250.630.500'],\n ['Transanal Minimally Invasive Surgery', 'E01.370.388.250.630.500'],\n ['Transanal Minimally Invasive Surgery', 'E04.210.240.250.680.500'],\n ['Transanal Minimally Invasive Surgery', 'E04.502.250.250.250.680.500'],\n ['Transanal Minimally Invasive Surgery', 'E04.502.250.630.500'],\n ['Transanal Endoscopic Microsurgery', 'E01.370.388.250.630.500.500'],\n ['Transanal Endoscopic Microsurgery', 'E04.210.240.250.680.500.500'],\n ['Transanal Endoscopic Microsurgery', 'E04.494.787'],\n ['Transanal Endoscopic Microsurgery', 'E04.502.250.250.250.680.500.500'],\n ['Transanal Endoscopic Microsurgery', 'E04.502.250.630.500.500'],\n ['Cold Injury', 'C26.212'],\n ['Personal Protective Equipment', 'E07.700.560'],\n ['Personal Protective Equipment', 'J01.637.708.560'],\n ['Nerve Agents', 'D27.720.599'],\n ['Nerve Agents', 'D27.720.777.300.500'],\n ['Nerve Gas', 'D27.720.599'],\n ['Nerve Gas', 'D27.720.777.300.500'],\n ['War-Related Injuries', 'C26.946'],\n ['War-Related Injuries', 'I01.880.735.950.500.951.500'],\n ['War-Related Injuries', 'N06.850.460.350.600.903.500'],\n ['War-Related Trauma', 'C26.946'],\n ['War-Related Trauma', 'I01.880.735.950.500.951.500'],\n ['War-Related Trauma', 'N06.850.460.350.600.903.500'],\n ['Abnormal Involuntary Movement Scale', 'E01.370.600.550.162'],\n ['Blood Alcohol Content', 'D02.033.375.135'],\n ['Social Communication Disorder', 'F03.625.374.250'],\n ['Legal Services', 'I01.880.604.583.482'],\n ['Defamation', 'I01.198.240.240'],\n ['Defamation', 'I01.880.735.191.051'],\n ['Slander', 'I01.198.240.240'],\n ['Slander', 'I01.880.735.191.051'],\n ['Libel', 'I01.198.240.240'],\n ['Libel', 'I01.880.735.191.051'],\n ['Anger Management Therapy', 'F04.754.137.087'],\n ['\"Psychology', ' Sports\"', 'F04.096.628.914'],\n ['War Exposure', 'I01.880.735.950.500.951'],\n ['War Exposure', 'N06.850.460.350.600.903'],\n ['Childhood-Onset Fluency Disorder', 'F03.625.374.125'],\n ['No-Show Patients', 'F01.100.150.750.500.600.750'],\n ['No-Show Patients', 'F01.145.488.887.500.600.750'],\n ['No-Show Patients', 'M01.643.550'],\n ['No-Show Patients', 'N04.452.758.635.500'],\n ['No-Show Patients', 'N05.300.150.800.500.600.750'],\n ['Cellular Reprogramming Techniques', 'E05.200.500.380'],\n ['Cellular Reprogramming Techniques', 'E05.242.378'],\n ['Cellular Reprogramming Techniques', 'E05.393.085'],\n ['Directed Differentiation Techniques', 'E05.200.500.380'],\n ['Directed Differentiation Techniques', 'E05.242.378'],\n ['Directed Differentiation Techniques', 'E05.393.085'],\n ['Direct Cell Reprogramming Techniques', 'E05.200.500.380'],\n ['Direct Cell Reprogramming Techniques', 'E05.242.378'],\n ['Direct Cell Reprogramming Techniques', 'E05.393.085'],\n ['Metacognition', 'F02.463.188.756'],\n ['Metacognitive Awareness', 'F02.463.188.756'],\n ['Metacognitive Monitoring', 'F02.463.188.756'],\n ['Metacognitive Control', 'F02.463.188.756'],\n ['Metaemotion', 'F02.463.188.756'],\n ['Metamemory', 'F02.463.188.756'],\n ['Prescription Drug Overuse', 'E02.319.306.500.750'],\n ['\"Near Miss', ' Healthcare\"', 'E02.319.529.750'],\n ['\"Near Miss', ' Healthcare\"', 'N02.421.450.500.750'],\n ['\"Near Miss', ' Healthcare\"', 'N02.421.450.550'],\n ['\"Near Miss', ' Healthcare\"', 'N04.761.700.594'],\n ['\"Near Miss', ' Healthcare\"', 'N05.700.513'],\n ['RNAi Therapeutics', 'E02.095.301.250'],\n ['Dynamic Light Scattering', 'E05.196.822.325'],\n ['Quasi-Elastic Light Scattering (QELS)', 'E05.196.822.325'],\n ['\"Time Out', ' Healthcare\"', 'N04.761.700.635'],\n ['\"Time Out', ' Healthcare\"', 'N05.700.739'],\n ['Surgical Time Out', 'N04.761.700.635'],\n ['Surgical Time Out', 'N05.700.739'],\n ['Healthcare Failure Mode and Effect Analysis',\n  'E05.318.740.600.800.715.500'],\n ['Healthcare Failure Mode and Effect Analysis', 'N04.452.871.715.400'],\n ['Healthcare Failure Mode and Effect Analysis',\n  'N05.715.360.750.625.700.690.400'],\n ['Healthcare Failure Mode and Effect Analysis', 'N06.850.505.715.500'],\n ['Healthcare Failure Mode and Effect Analysis',\n  'N06.850.520.830.600.800.715.500'],\n ['Failure Mode and Effect Analysis', 'E05.318.740.600.800.715.500'],\n ['Failure Mode and Effect Analysis', 'N04.452.871.715.400'],\n ['Failure Mode and Effect Analysis', 'N05.715.360.750.625.700.690.400'],\n ['Failure Mode and Effect Analysis', 'N06.850.505.715.500'],\n ['Failure Mode and Effect Analysis', 'N06.850.520.830.600.800.715.500'],\n ['Spirit Possession', 'K01.844.619.500'],\n ['\"Crew Resource Management', ' Healthcare\"', 'N04.590.254'],\n ['Computer Heuristics', 'L01.224.050.375.095'],\n ['Ataxins', 'D12.776.631.069'],\n ['Ataxins', 'D12.776.660.075'],\n ['Alarmins', 'D23.035'],\n ['Dermal Fillers', 'D27.720.102.461'],\n ['Action Spectrum', 'E05.196.867.826.150'],\n ['Diplomacy', 'F01.829.316.171'],\n ['Diplomacy', 'F02.463.785.373.520.500'],\n ['Diplomacy', 'I01.738.305'],\n ['Mutation Accumulation', 'G05.365.590.594'],\n ['Spontaneous Mutation Accumulation', 'G05.365.590.594'],\n ['Internal Ribosome Entry Sites', 'D13.444.735.790.878.942.250'],\n ['Internal Ribosome Entry Sites', 'G02.111.570.080.689.687.093'],\n ['Internal Ribosome Entry Sites', 'G05.360.080.689.687.093'],\n ['Biological Mimicry', 'G16.012.750'],\n ['Biological Camouflage', 'G16.012.750'],\n ['Specific Learning Disorder', 'F03.625.562.700'],\n ['Potentially Inappropriate Medication List', 'N04.761.700.615'],\n ['Potentially Inappropriate Medication List', 'N05.700.594'],\n ['Beers Criteria', 'N04.761.700.615'],\n ['Beers Criteria', 'N05.700.594'],\n ['STOPP (Screening Tool of Older Persons Potentially Inappropriate Prescriptions)',\n  'N04.761.700.615'],\n ['STOPP (Screening Tool of Older Persons Potentially Inappropriate Prescriptions)',\n  'N05.700.594'],\n ['Medication Appropriateness Index', 'N04.761.700.615'],\n ['Medication Appropriateness Index', 'N05.700.594'],\n ['Late Onset Disorders', 'C23.550.291.883'],\n ['Phakopsora pachyrhizi', 'B01.300.179.113'],\n ['Farmers', 'M01.526.390'],\n ['Ranchers', 'M01.526.390'],\n ['Culturally Appropriate Technology', 'J01.897.052'],\n ['Intermediate Technology', 'J01.897.052'],\n ['Soft Technology', 'J01.897.052'],\n ['Social Learning', 'F02.784.629.529.663'],\n ['Financial Statements', 'N03.219.463.030.140'],\n ['\"Assets', ' Financial\"', 'N03.219.463.030.140'],\n ['Cash Flow Statement', 'N03.219.463.030.140'],\n ['Balance Sheet', 'N03.219.463.030.140'],\n ['Expense Statement', 'N03.219.463.030.140'],\n ['Income Statement', 'N03.219.463.030.140'],\n ['\"Equity', ' Financial\"', 'N03.219.463.030.140'],\n ['\"Liabilities', ' Financial\"', 'N03.219.463.030.140'],\n ['Miners', 'M01.526.693'],\n ['Chronopharmacokinetics', 'G07.690.725.249'],\n ['\"Administrative Claims', ' Healthcare\"', 'N04.452.859.564.137'],\n ['Child Health', 'N01.400.225'],\n ['Child Well Being', 'N01.400.225'],\n ['Interleukin-33', 'D12.644.276.374.465.850'],\n ['Interleukin-33', 'D12.776.467.374.465.850'],\n ['Interleukin-33', 'D23.529.374.465.850'],\n ['S100A12 Protein', 'D12.776.157.125.750.875'],\n ['Telopodes', 'A11.284.180.900'],\n ['Telopodes', 'A11.329.830.750.500'],\n ['Podomers', 'A11.284.180.900'],\n ['Podomers', 'A11.329.830.750.500'],\n ['Podoms', 'A11.284.180.900'],\n ['Podoms', 'A11.329.830.750.500'],\n ['Drosophila simulans', 'B01.050.500.131.617.720.500.500.750.310.250.750'],\n ['Optimism', 'F01.100.787'],\n ['Positive Attitude', 'F01.100.787'],\n ['Positive Thinking', 'F01.100.787'],\n ['Pessimism', 'F01.100.893'],\n ['Ataxin-1', 'D12.776.631.069.500'],\n ['Ataxin-1', 'D12.776.660.075.500'],\n ['Adolescent Health', 'N01.400.075'],\n ['Adolescent Well Being', 'N01.400.075'],\n ['Ataxin-2', 'D12.776.157.725.452.125'],\n ['Ataxin-2', 'D12.776.631.069.750'],\n ['Ataxin-2', 'D12.776.660.075.750'],\n ['Ataxin-2', 'D12.776.664.962.452.125'],\n ['Ataxin-3', 'D08.811.037.250'],\n ['Ataxin-3', 'D12.776.631.069.875'],\n ['Ataxin-3', 'D12.776.660.075.875'],\n ['Point-of-Care Testing', 'N04.590.874.500'],\n ['Bedside Testing', 'N04.590.874.500'],\n ['Ataxin-7', 'D12.776.631.069.901'],\n ['Ataxin-7', 'D12.776.660.075.900'],\n ['Ataxin-10', 'D12.776.631.069.950'],\n ['Glucagon-Like Peptide Receptors', 'D12.776.543.750.695.021'],\n ['Glucagon-Like Peptide Receptors', 'D12.776.543.750.750.360.100'],\n ['Glucagon-Like Peptide-1 Receptor', 'D12.776.543.750.695.021.500'],\n ['Glucagon-Like Peptide-1 Receptor', 'D12.776.543.750.750.360.100.500'],\n ['Glucagon-Like Peptide-2 Receptor', 'D12.776.543.750.695.021.600'],\n ['Glucagon-Like Peptide-2 Receptor', 'D12.776.543.750.750.360.100.600'],\n ['Receptor for Advanced Glycation End Products', 'D12.776.543.750.615'],\n ['RNA Recognition Motif Proteins', 'D12.776.157.725.813'],\n ['RNA Recognition Motif Proteins', 'D12.776.664.962.813'],\n ['ELAV-Like Protein 2', 'D12.776.157.725.813.500.500'],\n ['ELAV-Like Protein 2', 'D12.776.631.520.500'],\n ['ELAV-Like Protein 2', 'D12.776.664.962.813.500.500'],\n ['ELAV-Like Protein 3', 'D12.776.157.725.813.500.750'],\n ['ELAV-Like Protein 3', 'D12.776.631.520.750'],\n ['ELAV-Like Protein 3', 'D12.776.664.962.813.500.750'],\n ['ELAV-Like Protein 4', 'D12.776.157.725.813.500.875'],\n ['ELAV-Like Protein 4', 'D12.776.631.520.875'],\n ['ELAV-Like Protein 4', 'D12.776.664.962.813.500.875'],\n ['ELAV-Like Protein 1', 'D12.776.157.725.813.500.250'],\n ['ELAV-Like Protein 1', 'D12.776.664.962.813.500.250'],\n ['Whey', 'A12.790.760'],\n ['Whey', 'G07.203.100.700.750'],\n ['Whey', 'G07.203.300.350.525.760'],\n ['Whey', 'J02.200.700.750'],\n ['Whey', 'J02.500.350.525.760'],\n ['Whey Proteins', 'A12.790.520.500'],\n ['Whey Proteins', 'A12.790.760.500'],\n ['Whey Proteins', 'D12.776.256.159.750.816'],\n ['Whey Proteins', 'G07.203.300.350.525.760.500'],\n ['Whey Proteins', 'G07.203.300.428.159.812.500'],\n ['Whey Proteins', 'J02.500.350.525.520.500'],\n ['Whey Proteins', 'J02.500.350.525.760.500'],\n ['Whey Proteins', 'J02.500.428.159.750.500'],\n ['Hoarding Disorder', 'F03.080.600.250'],\n ['Obsessive Hoarding', 'F03.080.600.250'],\n ['Poly(ADP-ribose) Polymerase Inhibitors', 'D27.505.519.389.739'],\n ['Poly(ADP-ribose) Polymerase Inhibitors', 'D27.505.954.248.692'],\n ['Autism Spectrum Disorder', 'F03.625.164.113'],\n ['CELF Proteins', 'D12.776.157.725.813.250'],\n ['CELF Proteins', 'D12.776.664.962.813.250'],\n ['CELF1 Protein', 'D12.776.157.725.813.250.500'],\n ['CELF1 Protein', 'D12.776.664.962.813.250.500'],\n ['Industrial Development', 'I01.261.262.500'],\n ['Industrial Development', 'J01.576.519'],\n ['Technology Development', 'I01.261.262.500'],\n ['Technology Development', 'J01.576.519'],\n ['Industrialization', 'I01.261.262.500'],\n ['Industrialization', 'J01.576.519'],\n ['Cloud Computing', 'L01.224.097'],\n ['Natural Resources', 'G16.500.275.553'],\n ['Natural Resources', 'J01.728'],\n ['Natural Resources', 'N06.230.350'],\n ['Land Supply', 'G16.500.275.553'],\n ['Land Supply', 'J01.728'],\n ['Land Supply', 'N06.230.350'],\n ['Glycemic Load', 'G07.203.650.660.750'],\n ['Glycemic Load', 'J01.576.423.850.730.750.750'],\n ['Glycemic Load', 'N06.850.601.750.750'],\n ['Adenylyl Cyclase Inhibitors', 'D27.505.519.389.108'],\n ['RAW 264.7 Cells', 'A11.251.210.172.875'],\n ['RAW 264.7 Cells', 'A11.733.397.815'],\n ['Accreditation', 'N03.706.110.070'],\n ['Accreditation', 'N05.700.200.100'],\n ['Clostridiales', 'B03.353.625'],\n ['Graphic Novel', 'V02.700.415'],\n ['Comic Book', 'V02.700.415'],\n ['South Sudan', 'Z01.058.290.120.745'],\n ['Motor Disorders', 'F03.608'],\n ['Maternal Health', 'N01.400.900.500'],\n ['Seed Bank', 'N02.278.065.650'],\n ['Germplasm Bank', 'N02.278.065.650'],\n ['Trauma and Stressor Related Disorders', 'F03.950'],\n ['Maternal-Child Health Services', 'N02.421.143.130.660'],\n ['Maternal-Child Health Services', 'N02.421.143.620.275'],\n ['Serine-Arginine Splicing Factors', 'D12.776.157.725.829.500'],\n ['Serine-Arginine Splicing Factors', 'D12.776.664.962.829.500'],\n ['Infant Health', 'N01.400.388'],\n ['Newborn Health', 'N01.400.388'],\n ['Bipolar and Related Disorders', 'F03.084'],\n ['Gender Dysphoria', 'F03.835.550'],\n ['Formative Feedback', 'F02.784.629.529.223'],\n ['Aripiprazole', 'D03.383.606.170'],\n ['Aripiprazole', 'D03.633.100.810.835.122'],\n ['Abilify', 'D03.383.606.170'],\n ['Abilify', 'D03.633.100.810.835.122'],\n ['OPC 14597', 'D03.383.606.170'],\n ['OPC 14597', 'D03.633.100.810.835.122'],\n ['Prunus dulcis', 'B01.650.940.800.575.912.250.859.937.500.625.500'],\n ['Almonds', 'B01.650.940.800.575.912.250.859.937.500.625.500'],\n ['Albumin-Bound Paclitaxel', 'D02.455.426.392.368.242.888.777.500'],\n ['Albumin-Bound Paclitaxel', 'D02.455.849.291.850.777.500'],\n ['Albumin-Bound Paclitaxel', 'D12.776.034.073'],\n ['Abraxane', 'D02.455.426.392.368.242.888.777.500'],\n ['Abraxane', 'D02.455.849.291.850.777.500'],\n ['Abraxane', 'D12.776.034.073'],\n ['ABI007', 'D02.455.426.392.368.242.888.777.500'],\n ['ABI007', 'D02.455.849.291.850.777.500'],\n ['ABI007', 'D12.776.034.073'],\n ['Child Protective Services', 'I01.409.418.500'],\n ['Child Protective Services', 'N03.540.400.500'],\n ['Social Workers', 'M01.526.919'],\n ['Prunus africana', 'B01.650.940.800.575.912.250.859.937.500.625.250'],\n ['Prunus armeniaca', 'B01.650.940.800.575.912.250.859.937.500.625.375'],\n ['Apricot', 'B01.650.940.800.575.912.250.859.937.500.625.375'],\n ['Prunus avium', 'B01.650.940.800.575.912.250.859.937.500.625.400'],\n ['Prunus serotina', 'B01.650.940.800.575.912.250.859.937.500.625.400'],\n ['Sweet Cherries', 'B01.650.940.800.575.912.250.859.937.500.625.400'],\n ['Prunus cerasus', 'B01.650.940.800.575.912.250.859.937.500.625.400'],\n ['Refugium', 'G16.500.275.683'],\n ['Refugium', 'G16.500.819'],\n ['Distance Counseling', 'F02.784.176.350'],\n ['Distance Counseling', 'F04.408.413.437'],\n ['Distance Counseling', 'N02.421.143.303.175'],\n ['Distance Counseling', 'N02.421.461.363.437'],\n ['Distance Counseling', 'N04.452.758.849.550.500'],\n ['Lubiprostone', 'D10.251.355.325.050.500'],\n ['RU 0211', 'D10.251.355.325.050.500'],\n ['Amitiza', 'D10.251.355.325.050.500'],\n ['SPI 0211', 'D10.251.355.325.050.500'],\n ['Prunus persica', 'B01.650.940.800.575.912.250.859.937.500.625.750'],\n ['Peach', 'B01.650.940.800.575.912.250.859.937.500.625.750'],\n ['Data Anonymization', 'H01.770.644.205'],\n ['Data Anonymization', 'L01.224.134.500'],\n ['Data Anonymization', 'N03.706.437.650.124.160'],\n ['Data Anonymization', 'N04.452.910.200.500'],\n ['De-Identification', 'H01.770.644.205'],\n ['De-Identification', 'L01.224.134.500'],\n ['De-Identification', 'N03.706.437.650.124.160'],\n ['De-Identification', 'N04.452.910.200.500'],\n ['Data Masking', 'H01.770.644.205'],\n ['Data Masking', 'L01.224.134.500'],\n ['Data Masking', 'N03.706.437.650.124.160'],\n ['Data Masking', 'N04.452.910.200.500'],\n ['Personally Identifiable Information', 'I01.880.604.583.080.660'],\n ['Prunus domestica', 'B01.650.940.800.575.912.250.859.937.500.625.450'],\n ['Plum', 'B01.650.940.800.575.912.250.859.937.500.625.450'],\n ['Prunus cerasifera', 'B01.650.940.800.575.912.250.859.937.500.625.450'],\n ['Prunus salicina', 'B01.650.940.800.575.912.250.859.937.500.625.450'],\n ['Darbepoetin alfa', 'D12.776.395.240.150.500'],\n ['Aranesp', 'D12.776.395.240.150.500'],\n ['KRN 321', 'D12.776.395.240.150.500'],\n ['\"Efavirenz',\n  ' Emtricitabine',\n  ' Tenofovir Disoproxil Fumarate Drug Combination\"',\n  'D02.705.429.906.125'],\n ['\"Efavirenz',\n  ' Emtricitabine',\n  ' Tenofovir Disoproxil Fumarate Drug Combination\"',\n  'D03.383.533.375'],\n ['\"Efavirenz',\n  ' Emtricitabine',\n  ' Tenofovir Disoproxil Fumarate Drug Combination\"',\n  'D03.383.742.680.245.500.600.125'],\n ['\"Efavirenz',\n  ' Emtricitabine',\n  ' Tenofovir Disoproxil Fumarate Drug Combination\"',\n  'D03.633.100.759.138.881.125'],\n ['\"Efavirenz',\n  ' Emtricitabine',\n  ' Tenofovir Disoproxil Fumarate Drug Combination\"',\n  'D26.310.375'],\n ['Atripla', 'D02.705.429.906.125'],\n ['Atripla', 'D03.383.533.375'],\n ['Atripla', 'D03.383.742.680.245.500.600.125'],\n ['Atripla', 'D03.633.100.759.138.881.125'],\n ['Atripla', 'D26.310.375'],\n ['Bevacizumab', 'D12.776.124.486.485.114.224.060.375'],\n ['Bevacizumab', 'D12.776.124.790.651.114.224.060.438'],\n ['Bevacizumab', 'D12.776.377.715.548.114.224.200.438'],\n ['Mvasi', 'D12.776.124.486.485.114.224.060.375'],\n ['Mvasi', 'D12.776.124.790.651.114.224.060.438'],\n ['Mvasi', 'D12.776.377.715.548.114.224.200.438'],\n ['Bevacizumab-awwb', 'D12.776.124.486.485.114.224.060.375'],\n ['Bevacizumab-awwb', 'D12.776.124.790.651.114.224.060.438'],\n ['Bevacizumab-awwb', 'D12.776.377.715.548.114.224.200.438'],\n ['Avastin', 'D12.776.124.486.485.114.224.060.375'],\n ['Avastin', 'D12.776.124.790.651.114.224.060.438'],\n ['Avastin', 'D12.776.377.715.548.114.224.200.438'],\n ['Giraffes', 'B01.050.150.900.649.313.500.380.443'],\n ['Okapis', 'B01.050.150.900.649.313.500.380.443'],\n ['Risedronic Acid', 'D02.705.429.500.872'],\n ['Risedronic Acid', 'D03.383.725.836'],\n ['1-Hydroxy-2-(3-pyridyl)ethylidene diphosphonate', 'D02.705.429.500.872'],\n ['1-Hydroxy-2-(3-pyridyl)ethylidene diphosphonate', 'D03.383.725.836'],\n ['Atelvia', 'D02.705.429.500.872'],\n ['Atelvia', 'D03.383.725.836'],\n ['Risedronate Sodium', 'D02.705.429.500.872'],\n ['Risedronate Sodium', 'D03.383.725.836'],\n ['2-(3-pyridinyl)-1-hydroxyethylidene-bisphosphonate', 'D02.705.429.500.872'],\n ['2-(3-pyridinyl)-1-hydroxyethylidene-bisphosphonate', 'D03.383.725.836'],\n ['\"Risedronic Acid', ' Monosodium Salt\"', 'D02.705.429.500.872'],\n ['\"Risedronic Acid', ' Monosodium Salt\"', 'D03.383.725.836'],\n ['Actonel', 'D02.705.429.500.872'],\n ['Actonel', 'D03.383.725.836'],\n ['Risedronate', 'D02.705.429.500.872'],\n ['Risedronate', 'D03.383.725.836'],\n ['Bisphosphonate Risedronate Sodium', 'D02.705.429.500.872'],\n ['Bisphosphonate Risedronate Sodium', 'D03.383.725.836'],\n ['Fluticasone-Salmeterol Drug Combination', 'D02.033.100.291.057.750.500'],\n ['Fluticasone-Salmeterol Drug Combination', 'D02.092.063.291.057.750.500'],\n ['Fluticasone-Salmeterol Drug Combination', 'D02.092.471.683.061.750.500'],\n ['Fluticasone-Salmeterol Drug Combination',\n  'D04.210.500.054.079.129.114.500'],\n ['Fluticasone-Salmeterol Drug Combination', 'D26.310.438'],\n ['\"Fluticasone Propionate',\n  ' Salmeterol Xinafoate Drug Combination\"',\n  'D02.033.100.291.057.750.500'],\n ['\"Fluticasone Propionate',\n  ' Salmeterol Xinafoate Drug Combination\"',\n  'D02.092.063.291.057.750.500'],\n ['\"Fluticasone Propionate',\n  ' Salmeterol Xinafoate Drug Combination\"',\n  'D02.092.471.683.061.750.500'],\n ['\"Fluticasone Propionate',\n  ' Salmeterol Xinafoate Drug Combination\"',\n  'D04.210.500.054.079.129.114.500'],\n ['\"Fluticasone Propionate',\n  ' Salmeterol Xinafoate Drug Combination\"',\n  'D26.310.438'],\n ['Advair Diskus', 'D02.033.100.291.057.750.500'],\n ['Advair Diskus', 'D02.092.063.291.057.750.500'],\n ['Advair Diskus', 'D02.092.471.683.061.750.500'],\n ['Advair Diskus', 'D04.210.500.054.079.129.114.500'],\n ['Advair Diskus', 'D26.310.438'],\n ['Seretide', 'D02.033.100.291.057.750.500'],\n ['Seretide', 'D02.092.063.291.057.750.500'],\n ['Seretide', 'D02.092.471.683.061.750.500'],\n ['Seretide', 'D04.210.500.054.079.129.114.500'],\n ['Seretide', 'D26.310.438'],\n ['Advair HFA', 'D02.033.100.291.057.750.500'],\n ['Advair HFA', 'D02.092.063.291.057.750.500'],\n ['Advair HFA', 'D02.092.471.683.061.750.500'],\n ['Advair HFA', 'D04.210.500.054.079.129.114.500'],\n ['Advair HFA', 'D26.310.438'],\n ['Advair', 'D02.033.100.291.057.750.500'],\n ['Advair', 'D02.092.063.291.057.750.500'],\n ['Advair', 'D02.092.471.683.061.750.500'],\n ['Advair', 'D04.210.500.054.079.129.114.500'],\n ['Advair', 'D26.310.438'],\n ['Fluticasone', 'D04.210.500.054.079.129.114'],\n ['Flonase', 'D04.210.500.054.079.129.114'],\n ['Flovent HFA', 'D04.210.500.054.079.129.114'],\n ['Cutivate', 'D04.210.500.054.079.129.114'],\n ['Fluticasone Propionate', 'D04.210.500.054.079.129.114'],\n ['Flixonase', 'D04.210.500.054.079.129.114'],\n ['Flixotide', 'D04.210.500.054.079.129.114'],\n ['Flovent', 'D04.210.500.054.079.129.114'],\n ['Salmeterol Xinafoate', 'D02.033.100.291.057.750'],\n ['Salmeterol Xinafoate', 'D02.092.063.291.057.750'],\n ['Salmeterol Xinafoate', 'D02.092.471.683.061.750'],\n ['Salmeterol', 'D02.033.100.291.057.750'],\n ['Salmeterol', 'D02.092.063.291.057.750'],\n ['Salmeterol', 'D02.092.471.683.061.750'],\n ['Serevent', 'D02.033.100.291.057.750'],\n ['Serevent', 'D02.092.063.291.057.750'],\n ['Serevent', 'D02.092.471.683.061.750'],\n ['\"Parks', ' Recreational\"', 'J03.925.680'],\n ['National Parks', 'J03.925.680'],\n ['Community Parks', 'J03.925.680'],\n ['Green Space', 'J03.925.680'],\n ['Urban Parks', 'J03.925.680'],\n ['Warfare and Armed Conflicts', 'I01.880.735.950'],\n ['Armed Conflicts', 'I01.880.735.950.250'],\n ['Wars', 'I01.880.735.950.250'],\n ['Everolimus', 'D02.540.505.760.500'],\n ['RAD 001', 'D02.540.505.760.500'],\n ['Afinitor', 'D02.540.505.760.500'],\n ['Certican', 'D02.540.505.760.500'],\n ['\"Aspirin',\n  ' Dipyridamole Drug Combination\"',\n  'D02.455.426.559.389.657.410.595.176.500'],\n ['\"Aspirin', ' Dipyridamole Drug Combination\"', 'D03.383.742.175.500'],\n ['\"Aspirin', ' Dipyridamole Drug Combination\"', 'D26.310.125'],\n ['TX 3301', 'D02.455.426.559.389.657.410.595.176.500'],\n ['TX 3301', 'D03.383.742.175.500'],\n ['TX 3301', 'D26.310.125'],\n ['Extended-Release Dipyridamole-Aspirin',\n  'D02.455.426.559.389.657.410.595.176.500'],\n ['Extended-Release Dipyridamole-Aspirin', 'D03.383.742.175.500'],\n ['Extended-Release Dipyridamole-Aspirin', 'D26.310.125'],\n ['Asasantin', 'D02.455.426.559.389.657.410.595.176.500'],\n ['Asasantin', 'D03.383.742.175.500'],\n ['Asasantin', 'D26.310.125'],\n ['Asasantin Retard', 'D02.455.426.559.389.657.410.595.176.500'],\n ['Asasantin Retard', 'D03.383.742.175.500'],\n ['Asasantin Retard', 'D26.310.125'],\n ['Aggrenox', 'D02.455.426.559.389.657.410.595.176.500'],\n ['Aggrenox', 'D03.383.742.175.500'],\n ['Aggrenox', 'D26.310.125'],\n ['Self-Control', 'F01.145.813.595'],\n ['Saline Waters', 'G16.500.275.725'],\n ['Brackish Water', 'G16.500.275.725'],\n ['Compassion Fatigue', 'C23.888.369.500.500'],\n ['Compassion Fatigue', 'F01.145.126.937.500'],\n ['Compassion Fatigue', 'F01.145.126.990.734.500'],\n ['Compassion Fatigue', 'F02.830.900.666.750'],\n ['Plantaginaceae', 'B01.650.940.800.575.912.250.583.700'],\n ['Stemodia', 'B01.650.940.800.575.912.250.583.700'],\n ['Globularia', 'B01.650.940.800.575.912.250.583.700'],\n ['Lamiales', 'B01.650.940.800.575.912.250.583'],\n ['Proboscidea Plant', 'B01.650.940.800.575.912.250.583'],\n ['Clinical Study', 'V03.175'],\n ['Surgical Clearance', 'E01.370.505'],\n ['Pemetrexed', 'D03.633.100.759.758.399.454.650'],\n ['Pemetrexed', 'D12.125.067.625.525'],\n ['Pemetrexed', 'D12.125.119.409.525'],\n ['Pemetrexed Disodium', 'D03.633.100.759.758.399.454.650'],\n ['Pemetrexed Disodium', 'D12.125.067.625.525'],\n ['Pemetrexed Disodium', 'D12.125.119.409.525'],\n ['LY 231514', 'D03.633.100.759.758.399.454.650'],\n ['LY 231514', 'D12.125.067.625.525'],\n ['LY 231514', 'D12.125.119.409.525'],\n ['Alimta', 'D03.633.100.759.758.399.454.650'],\n ['Alimta', 'D12.125.067.625.525'],\n ['Alimta', 'D12.125.119.409.525'],\n ['Brimonidine Tartrate', 'D03.633.100.857.070'],\n ['\"Brimonidine Tartrate (1:1)',\n  ' (S-(R*',\n  'R*))-Isomer\"',\n  'D03.633.100.857.070'],\n ['Brimonidine Purite', 'D03.633.100.857.070'],\n ['AGN 190342', 'D03.633.100.857.070'],\n ['Sanrosa', 'D03.633.100.857.070'],\n ['Alphagan', 'D03.633.100.857.070'],\n ['Brimonidine', 'D03.633.100.857.070'],\n ['Alphagan P', 'D03.633.100.857.070'],\n ['\"UK 14', '304\"', 'D03.633.100.857.070'],\n ['Ratio-Brimonidine', 'D03.633.100.857.070'],\n ['\"UK 14', '304-18\"', 'D03.633.100.857.070'],\n ['UK 14308', 'D03.633.100.857.070'],\n ['\"Brimonidine Tartrate', ' (R-(R*', 'R*))-Isomer\"', 'D03.633.100.857.070'],\n ['Brimonidine Tartrate (1:1)', 'D03.633.100.857.070'],\n ['Mirvaso', 'D03.633.100.857.070'],\n ['Clinical Studies as Topic', 'E05.318.372.250'],\n ['Clinical Studies as Topic', 'N05.715.360.330.250'],\n ['Clinical Studies as Topic', 'N06.850.520.450.250'],\n ['Beijing', 'Z01.252.474.164.225'],\n ['Beijing', 'Z01.433.114'],\n ['African Union', 'I01.615.500.125'],\n ['African Union', 'N03.540.089'],\n ['Firmicutes', 'B03.353'],\n ['Dutasteride', 'D04.210.500.925.100.125'],\n ['Avodart', 'D04.210.500.925.100.125'],\n ['GG 745', 'D04.210.500.925.100.125'],\n ['GI198745', 'D04.210.500.925.100.125'],\n ['Calceolariaceae', 'B01.650.940.800.575.912.250.583.190'],\n ['Jovellana', 'B01.650.940.800.575.912.250.583.190'],\n ['Calceolaria', 'B01.650.940.800.575.912.250.583.190'],\n ['Porodittia', 'B01.650.940.800.575.912.250.583.190'],\n ['Interferon beta-1a', 'D12.644.276.374.440.890.275.500'],\n ['Interferon beta-1a', 'D12.776.467.374.440.890.275.500'],\n ['Interferon beta-1a', 'D23.529.374.440.890.275.500'],\n ['Avonex Pen', 'D12.644.276.374.440.890.275.500'],\n ['Avonex Pen', 'D12.776.467.374.440.890.275.500'],\n ['Avonex Pen', 'D23.529.374.440.890.275.500'],\n ['Rebif', 'D12.644.276.374.440.890.275.500'],\n ['Rebif', 'D12.776.467.374.440.890.275.500'],\n ['Rebif', 'D23.529.374.440.890.275.500'],\n ['Avonex', 'D12.644.276.374.440.890.275.500'],\n ['Avonex', 'D12.776.467.374.440.890.275.500'],\n ['Avonex', 'D23.529.374.440.890.275.500'],\n ['Olmesartan Medoxomil', 'D03.383.129.308.674'],\n ['Olmesartan Medoxomil', 'D03.383.129.617.584'],\n ['Benicar', 'D03.383.129.308.674'],\n ['Benicar', 'D03.383.129.617.584'],\n ['Olmetec', 'D03.383.129.308.674'],\n ['Olmetec', 'D03.383.129.617.584'],\n ['CS 866', 'D03.383.129.308.674'],\n ['CS 866', 'D03.383.129.617.584'],\n ['Votum', 'D03.383.129.308.674'],\n ['Votum', 'D03.383.129.617.584'],\n ['\"Amlodipine Besylate',\n  ' Olmesartan Medoxomil Drug Combination\"',\n  'D03.383.129.308.674.500'],\n ['\"Amlodipine Besylate',\n  ' Olmesartan Medoxomil Drug Combination\"',\n  'D03.383.129.617.584.500'],\n ['\"Amlodipine Besylate',\n  ' Olmesartan Medoxomil Drug Combination\"',\n  'D03.383.725.203.065.500'],\n ['\"Amlodipine Besylate',\n  ' Olmesartan Medoxomil Drug Combination\"',\n  'D26.310.063'],\n ['Azor', 'D03.383.129.308.674.500'],\n ['Azor', 'D03.383.129.617.584.500'],\n ['Azor', 'D03.383.725.203.065.500'],\n ['Azor', 'D26.310.063'],\n ['Interferon beta-1b', 'D12.644.276.374.440.890.275.750'],\n ['Interferon beta-1b', 'D12.776.467.374.440.890.275.750'],\n ['Interferon beta-1b', 'D23.529.374.440.890.275.750'],\n ['Betaseron', 'D12.644.276.374.440.890.275.750'],\n ['Betaseron', 'D12.776.467.374.440.890.275.750'],\n ['Betaseron', 'D23.529.374.440.890.275.750'],\n ['Extavia', 'D12.644.276.374.440.890.275.750'],\n ['Extavia', 'D12.776.467.374.440.890.275.750'],\n ['Extavia', 'D23.529.374.440.890.275.750'],\n ['Betaferon', 'D12.644.276.374.440.890.275.750'],\n ['Betaferon', 'D12.776.467.374.440.890.275.750'],\n ['Betaferon', 'D23.529.374.440.890.275.750'],\n ['Nebivolol', 'D02.033.100.291.491'],\n ['Nebivolol', 'D02.092.063.291.503'],\n ['Nebivolol', 'D03.383.663.283.755'],\n ['Nebivolol', 'D03.633.100.150.755'],\n ['Bystolic', 'D02.033.100.291.491'],\n ['Bystolic', 'D02.092.063.291.503'],\n ['Bystolic', 'D03.383.663.283.755'],\n ['Bystolic', 'D03.633.100.150.755'],\n ['Nebilet', 'D02.033.100.291.491'],\n ['Nebilet', 'D02.092.063.291.503'],\n ['Nebilet', 'D03.383.663.283.755'],\n ['Nebilet', 'D03.633.100.150.755'],\n ['Silostar', 'D02.033.100.291.491'],\n ['Silostar', 'D02.092.063.291.503'],\n ['Silostar', 'D03.383.663.283.755'],\n ['Silostar', 'D03.633.100.150.755'],\n ['Nebivolol Hydrochloride', 'D02.033.100.291.491'],\n ['Nebivolol Hydrochloride', 'D02.092.063.291.503'],\n ['Nebivolol Hydrochloride', 'D03.383.663.283.755'],\n ['Nebivolol Hydrochloride', 'D03.633.100.150.755'],\n ['R 67555', 'D02.033.100.291.491'],\n ['R 67555', 'D02.092.063.291.503'],\n ['R 67555', 'D03.383.663.283.755'],\n ['R 67555', 'D03.633.100.150.755'],\n ['Lobivon', 'D02.033.100.291.491'],\n ['Lobivon', 'D02.092.063.291.503'],\n ['Lobivon', 'D03.383.663.283.755'],\n ['Lobivon', 'D03.633.100.150.755'],\n ['Celecoxib', 'D02.065.884.247'],\n ['Celecoxib', 'D02.886.590.700.247'],\n ['Celecoxib', 'D03.383.129.539.160'],\n ['Celebrex', 'D02.065.884.247'],\n ['Celebrex', 'D02.886.590.700.247'],\n ['Celebrex', 'D03.383.129.539.160'],\n ['SC 58635', 'D02.065.884.247'],\n ['SC 58635', 'D02.886.590.700.247'],\n ['SC 58635', 'D03.383.129.539.160'],\n ['Varenicline', 'D03.633.100.079.900'],\n ['Varenicline', 'D03.633.100.857.942'],\n ['Chantix', 'D03.633.100.079.900'],\n ['Chantix', 'D03.633.100.857.942'],\n ['Varenicline Tartrate', 'D03.633.100.079.900'],\n ['Varenicline Tartrate', 'D03.633.100.857.942'],\n ['Champix', 'D03.633.100.079.900'],\n ['Champix', 'D03.633.100.857.942'],\n ['Tadalafil', 'D03.383.725.150.500'],\n ['Tadalafil', 'D03.633.100.473.155.500'],\n ['Tadalafil', 'D03.633.300.154.672'],\n ['IC351', 'D03.383.725.150.500'],\n ['IC351', 'D03.633.100.473.155.500'],\n ['IC351', 'D03.633.300.154.672'],\n ['Cialis', 'D03.383.725.150.500'],\n ['Cialis', 'D03.633.100.473.155.500'],\n ['Cialis', 'D03.633.300.154.672'],\n ['Certolizumab Pegol', 'D05.750.741.125'],\n ['Certolizumab Pegol', 'D12.644.541.500.650.250'],\n ['Certolizumab Pegol', 'D12.776.124.486.485.114.224.060.500'],\n ['Certolizumab Pegol', 'D12.776.124.486.485.680.650.250'],\n ['Certolizumab Pegol', 'D12.776.124.790.651.114.224.060.500'],\n ['Certolizumab Pegol', 'D12.776.124.790.651.680.650.250'],\n ['Certolizumab Pegol', 'D12.776.377.715.548.114.224.200.500'],\n ['Certolizumab Pegol', 'D12.776.377.715.548.680.650.250'],\n ['Cimzia', 'D05.750.741.125'],\n ['Cimzia', 'D12.644.541.500.650.250'],\n ['Cimzia', 'D12.776.124.486.485.114.224.060.500'],\n ['Cimzia', 'D12.776.124.486.485.680.650.250'],\n ['Cimzia', 'D12.776.124.790.651.114.224.060.500'],\n ['Cimzia', 'D12.776.124.790.651.680.650.250'],\n ['Cimzia', 'D12.776.377.715.548.114.224.200.500'],\n ['Cimzia', 'D12.776.377.715.548.680.650.250'],\n ['CDP870', 'D05.750.741.125'],\n ['CDP870', 'D12.644.541.500.650.250'],\n ['CDP870', 'D12.776.124.486.485.114.224.060.500'],\n ['CDP870', 'D12.776.124.486.485.680.650.250'],\n ['CDP870', 'D12.776.124.790.651.114.224.060.500'],\n ['CDP870', 'D12.776.124.790.651.680.650.250'],\n ['CDP870', 'D12.776.377.715.548.114.224.200.500'],\n ['CDP870', 'D12.776.377.715.548.680.650.250'],\n ['\"Censorship', ' Research\"', 'I01.880.604.238'],\n ['\"Censorship', ' Research\"', 'K01.752.566.479.173.200'],\n ['\"Censorship', ' Research\"', 'N05.350.670.250'],\n ['Data Accuracy', 'E05.318.308.028'],\n ['Data Accuracy', 'E05.318.370.725.250'],\n ['Data Accuracy', 'L01.399.250.202'],\n ['Data Accuracy', 'N05.715.360.300.202'],\n ['Data Accuracy', 'N05.715.360.325.685.250'],\n ['Data Quality', 'E05.318.308.028'],\n ['Data Quality', 'E05.318.370.725.250'],\n ['Data Quality', 'L01.399.250.202'],\n ['Data Quality', 'N05.715.360.300.202'],\n ['Data Quality', 'N05.715.360.325.685.250'],\n ['\"Brimonidine Tartrate',\n  ' Timolol Maleate Drug Combination\"',\n  'D02.033.100.624.915.500'],\n ['\"Brimonidine Tartrate',\n  ' Timolol Maleate Drug Combination\"',\n  'D02.033.755.624.915.500'],\n ['\"Brimonidine Tartrate',\n  ' Timolol Maleate Drug Combination\"',\n  'D02.092.063.624.915.500'],\n ['\"Brimonidine Tartrate',\n  ' Timolol Maleate Drug Combination\"',\n  'D02.886.675.867.768.500'],\n ['\"Brimonidine Tartrate',\n  ' Timolol Maleate Drug Combination\"',\n  'D03.383.129.708.867.768.500'],\n ['\"Brimonidine Tartrate',\n  ' Timolol Maleate Drug Combination\"',\n  'D03.633.100.857.070.500'],\n ['\"Brimonidine Tartrate',\n  ' Timolol Maleate Drug Combination\"',\n  'D26.310.312'],\n ['Combigan', 'D02.033.100.624.915.500'],\n ...]"]}}],"execution_count":0},{"cell_type":"code","source":["pharmardd= sc.textFile(pharma)  # read from text file words.txt on DBFS\npharmardd.collect()"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"c29105df-e27e-4cb4-9ab2-02971cf8ca09"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[38]: ['\"Company\",\"Parent_Company\",\"Penalty_Amount\",\"Subtraction_From_Penalty\",\"Penalty_Amount_Adjusted_For_Eliminating_Multiple_Counting\",\"Penalty_Year\",\"Penalty_Date\",\"Offense_Group\",\"Primary_Offense\",\"Secondary_Offense\",\"Description\",\"Level_of_Government\",\"Action_Type\",\"Agency\",\"Civil/Criminal\",\"Prosecution_Agreement\",\"Court\",\"Case_ID\",\"Private_Litigation_Case_Title\",\"Lawsuit_Resolution\",\"Facility_State\",\"City\",\"Address\",\"Zip\",\"NAICS_Code\",\"NAICS_Translation\",\"HQ_Country_of_Parent\",\"HQ_State_of_Parent\",\"Ownership_Structure\",\"Parent_Company_Stock_Ticker\",\"Major_Industry_of_Parent\",\"Specific_Industry_of_Parent\",\"Info_Source\",\"Notes\"',\n '\"Abbott Laboratories\",\"Abbott Laboratories\",\"$5,475,000\",\"$0\",\"$5,475,000\",\"2013\",\"20131227\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"Abbott Laboratories agreed to $5.475 million to resolve allegations that it violated the False Claims Act by paying kickbacks to induce doctors to implant the company\\'s carotid, biliary and peripheral vascular products.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/abbott-laboratories-pays-us-5475-million-settle-claims-company-paid-kickbacks-physicians\",\"\"',\n '\"Abbott Laboratories Inc.\",\"AbbVie\",\"$1,500,000,000\",\"$0\",\"$1,500,000,000\",\"2012\",\"20120507\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Global Health Care Company Abbott Laboratories Inc. has pleaded guilty and agreed to pay $1.5 billion to resolve its criminal and civil liability arising from the company\\'s unlawful promotion of the prescription drug Depakote for uses not approved as safe and effective by the Food and Drug Administration. The resolution - the second largest payment by a drug company - includes a criminal fine and forfeiture totaling $700 million and civil settlements with the federal government and the states totaling $800 million. Abbott also will be subject to court-supervised probation and reporting obligations for Abbotts CEO and Board of Directors.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABBV\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/abbott-labs-pay-15-billion-resolve-criminal-civil-investigations-label-promotion-depakote\",\"\"',\n '\"Abbott Laboratories Inc.\",\"AbbVie\",\"$126,500,000\",\"$0\",\"$126,500,000\",\"2010\",\"20101207\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Abbott Laboratories Inc., B. Braun Medical Inc. and Roxane Laboratories Inc. n/k/a Boehringer Ingelheim Roxane Inc. and affiliated entities agreed to pay $421 million to settle False Claims Act allegations, that they engaged in a scheme to report false and inflated prices for numerous pharmaceutical products knowing that federal healthcare programs relied on those reported prices to set payment rates.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABBV\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/pharmaceutical-manufacturers-pay-4212-million-settle-false-claims-act-cases\",\"\"',\n '\"Abbott Laboratories Puerto Rico, Inc.\",\"Abbott Laboratories\",\"$49,045\",\"$0\",\"$49,045\",\"2009\",\"20090305\",\"employment-related offenses\",\"wage and hour violation\",\"Fair Labor Standards Act\",\"\",\"federal\",\"agency action\",\"Labor Department Wage and Hour Division\",\"civil\",\"\",\"\",\"1527129\",\"\",\"\",\"Puerto Rico\",\"San Juan\",\"\",\"\",\"423450\",\"423450: Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"March 7, 2017 download of a dataset posted by the Wage and Hour Division at https://enforcedata.dol.gov/views/data_summary.php\",\"Date and year are the Findings End Date in the dataset posted by the Wage and Hour Division, which does not provide case opening or closing dates. The company name is the Legal Name provided by the dataset unless that field is blank, in which case the Trade Name is used. The dataset provides only one address and does not indicate whether it is the company headquarters address or the establishment address. The penalty amount is the total of civil monetary penalties and mandated back wages. The original dataset provides a breakdown.\"',\n '\"Acclarent Inc.\",\"Johnson & Johnson\",\"$18,000,000\",\"$0\",\"$18,000,000\",\"2016\",\"20160722\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"California-based medical device manufacturer Acclarent Inc., a subsidiary of Johnson & Johnson, agreed to pay $18 million to resolve allegations that the company caused health care providers to submit false claims to Medicare and other federal health care programs by marketing and distributing its sinus spacer product for use as a drug delivery device without Food and Drug Administration approval.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"JNJ\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/johnson-johnson-subsidiary-acclarent-inc-pays-government-18-million-settle-false-claims-act\",\"\"',\n '\"Advanced Medical Optics\",\"Abbott Laboratories\",\"$16,800\",\"$0\",\"$16,800\",\"2004\",\"20040412\",\"employment-related offenses\",\"labor relations violation\",\"\",\"back pay award in unfair labor practices case\",\"federal\",\"agency action\",\"National Labor Relations Board\",\"civil\",\"\",\"\",\"21-CA-36104-001\",\"\",\"\",\"California\",\"Irvine\",\"\",\"92606\",\"333314\",\"333314: Optical Instrument and Lens Manufacturing\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from an NLRB dataset covering 1999-2011 downloaded at https://catalog.data.gov/dataset/nlrb-cats-final-c-case-data-bulk-19990101-20110930-in-xml\",\"\"',\n '\"Advanced Neuromodulation Systems, Inc.\",\"Abbott Laboratories\",\"$2,950,000\",\"$0\",\"$2,950,000\",\"2007\",\"20070702\",\"healthcare-related offenses\",\"HHS civil monetary penalties\",\"kickbacks and bribery\",\"The HHS Inspector General announced that Advanced Neuromodulation Systems, Inc.,  a medical device manufacturer specializing in spinal cord stimulation used for pain management, agreed to pay $2.95 million to settle allegations that it paid kickbacks to physicians in violation of the Civil Monetary Penalties Law (CMPL). The company also entered into a 3-year Corporate Integrity Agreement.\",\"federal\",\"agency action\",\"Health & Human Services Department Office of Inspector General\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://oig.hhs.gov/publications/docs/press/2007/ANS%20Press%20Release.pdf\",\"\"',\n '\"Advanced Sterilization Products\",\"Johnson & Johnson\",\"$136,800\",\"$0\",\"$136,800\",\"2014\",\"20140520\",\"environment-related offenses\",\"environmental violation\",\"\",\"The U.S. Environmental Protection Agency announced that an Irvine, Calif. company, Advanced Sterilization Products, has agreed to pay a $136,800 penalty for the sale and distribution of unregistered and misbranded pesticides to veterinary clinics and laboratories nationwide.\",\"federal\",\"agency action\",\"Environmental Protection Agency\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"Irvine\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"JNJ\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://archive.epa.gov/epapages/newsroom_archive/newsreleases/8e820317c86e4c5685257cde00717855.html\",\"\"',\n '\"Advanced Sterilization Products, a division of Ethicon Inc.\",\"Johnson & Johnson\",\"$1,200,000\",\"$0\",\"$1,200,000\",\"2013\",\"20131204\",\"safety-related offenses\",\"drug or medical equipment safety violation\",\"\",\"Settlement of a civil money penalty action against Advanced Sterilization Products, a division of Ethicon Inc., a Johnson & Johnson company, and two of ASP\\'s executives alleging that ASP manufactured and distributed adulterated and misbranded sterilization monitoring products.\",\"federal\",\"agency action\",\"Food and Drug Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"Irvine\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"JNJ\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm377588.htm\",\"\"',\n '\"Alere San Diego Inc.\",\"Abbott Laboratories\",\"$10,572\",\"$0\",\"$10,572\",\"2017\",\"20170309\",\"employment-related offenses\",\"wage and hour violation\",\"Fair Labor Standards Act\",\"\",\"federal\",\"agency action\",\"Labor Department Wage and Hour Division\",\"civil\",\"\",\"\",\"1813371\",\"\",\"\",\"California\",\"Pomona\",\"828 Towne Center Dr.\",\"91767\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"July 23, 2017 download of a dataset posted by the Wage and Hour Division at https://enforcedata.dol.gov/views/data_summary.php\",\"Date and year are the Findings End Date in the dataset posted by the Wage and Hour Division, which does not provide case opening or closing dates. The company name is the Legal Name provided by the dataset unless that field is blank, in which case the Trade Name is used. The dataset provides only one address and does not indicate whether it is the company headquarters address or the establishment address. The penalty amount is the total of civil monetary penalties and mandated back wages. The original dataset provides a breakdown.\"',\n '\"Allergan Inc.\",\"AbbVie\",\"$600,000,000\",\"$0\",\"$600,000,000\",\"2010\",\"20100901\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"American pharmaceutical manufacturer Allergan Inc. has agreed to plead guilty and pay $600 million to resolve its criminal and civil liability arising from the company\\'s unlawful promotion of its biological product, Botox Therapeutic, for uses not approved as safe and effective by the Food and Drug Administration. The resolution included a criminal fine and forfeiture totaling $375 million and a civil settlement with the federal government and the states of $225 million.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABBV\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/allergan-agrees-plead-guilty-and-pay-600-million-resolve-allegations-label-promotion-botox\",\"\"',\n '\"Allergan Inc.\",\"AbbVie\",\"$15,000,000\",\"$0\",\"$15,000,000\",\"2017\",\"20170117\",\"financial offenses\",\"investor protection violation\",\"\",\"Allergan Inc. admitted securities law violations and agreed to pay a $15 million penalty for disclosure failures in the wake of a hostile takeover bid.\",\"federal\",\"agency action\",\"Securities and Exchange Commission\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABBV\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.sec.gov/news/pressrelease/2017-16.html\",\"\"',\n '\"Alpharma Inc.\",\"Pfizer\",\"$42,500,000\",\"$0\",\"$42,500,000\",\"2010\",\"20100316\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"Alpharma Inc. agreed to pay $42.5 million to resolve False Claims Act allegations in connection with the marketing of the morphine-based drug Kadian. The settlement resolved allegations that between January 1, 2000 and December 29, 2008 Alpharma paid health care providers to induce them to promote or prescribe Kadian, and made misrepresentations about the safety and efficacy of the drug. \",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New York\",\"publicly traded\",\"PFE\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/alpharma-pay-425-million-resolve-false-claims-act-allegations-connection-promotion-drug\",\"\"',\n '\"Alpharma, Inc.\",\"Pfizer\",\"$2,500,000\",\"$0\",\"$2,500,000\",\"2004\",\"20040812\",\"competition-related offenses\",\"price-fixing or anti-competitive practices\",\"consumer protection violation\",\"Generic drug manufacturers Alpharma Inc. and Perrigo Company agreed to give up a total of $6.25 million in illegal profits to settle Federal Trade Commission allegations that their agreement to limit competition for over-the-counter store-brand children\\'s liquid ibuprofen drove up prices and violated federal law.\",\"federal\",\"agency action\",\"Federal Trade Commission\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New York\",\"publicly traded\",\"PFE\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.ftc.gov/news-events/press-releases/2004/08/generic-drug-marketers-settle-ftc-charges\",\"\"',\n '\"American Pharmaceutical Partners, Inc.\",\"Bristol-Myers Squibb\",\"$160,203\",\"$0\",\"$160,203\",\"2004\",\"20041226\",\"employment-related offenses\",\"wage and hour violation\",\"Fair Labor Standards Act\",\"\",\"federal\",\"agency action\",\"Labor Department Wage and Hour Division\",\"civil\",\"\",\"\",\"1379241\",\"\",\"\",\"New York\",\"Grand Island\",\"\",\"14072\",\"32541\",\"32541: Pharmaceutical and Medicine Manufacturing\",\"USA\",\"New York\",\"publicly traded\",\"BMY\",\"pharmaceuticals\",\"pharmaceuticals\",\"March 7, 2017 download of a dataset posted by the Wage and Hour Division at https://enforcedata.dol.gov/views/data_summary.php\",\"Date and year are the Findings End Date in the dataset posted by the Wage and Hour Division, which does not provide case opening or closing dates. The company name is the Legal Name provided by the dataset unless that field is blank, in which case the Trade Name is used. The dataset provides only one address and does not indicate whether it is the company headquarters address or the establishment address. The penalty amount is the total of civil monetary penalties and mandated back wages. The original dataset provides a breakdown.\"',\n '\"Amgen Inc.\",\"Amgen\",\"$762,000,000\",\"$0\",\"$762,000,000\",\"2012\",\"20121219\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"U.S. District Judge Sterling Johnson, Jr. accepted a guilty plea by American biotechnology giant Amgen Inc. for illegally introducing a misbranded drug into interstate commerce. The plea is part of a global settlement with the United States in which Amgen agreed to pay $762 million to resolve criminal and civil liability arising from its sale and promotion of certain drugs.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"California\",\"publicly traded\",\"AMGN\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/amgen-inc-pleads-guilty-federal-charge-brooklyn-ny-pays-762-million-resolve-criminal\",\"\"',\n '\"Amgen Inc.\",\"Amgen\",\"$24,900,000\",\"$0\",\"$24,900,000\",\"2013\",\"20130416\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"Amgen Inc. agreed to pay the United States $24.9 million to settle allegations that it violated the False Claims Act. The company was accused of paying kickbacks  to long-term care pharmacy providers Omnicare Inc., PharMerica Corporation and Kindred Healthcare Inc. in return for implementing \"\"therapeutic interchange\"\" programs that were designed to switch Medicare and Medicaid beneficiaries from a competitor drug to Amgen\\'s Aranesp.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"California\",\"publicly traded\",\"AMGN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/amgen-pay-us-249-million-resolve-false-claims-act-allegations\",\"\"',\n '\"Amgen, Inc.\",\"Amgen\",\"$40,000\",\"$0\",\"$40,000\",\"2011\",\"20110302\",\"employment-related offenses\",\"labor relations violation\",\"\",\"back pay award in unfair labor practices case\",\"federal\",\"agency action\",\"National Labor Relations Board\",\"civil\",\"\",\"\",\"14-CA-30273-001\",\"\",\"\",\"Missouri\",\"St. Louis\",\"\",\"63130\",\"541720\",\"541720: Research and Development in the Social Sciences and Humanities\",\"USA\",\"California\",\"publicly traded\",\"AMGN\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from an NLRB dataset covering 1999-2011 downloaded at https://catalog.data.gov/dataset/nlrb-cats-final-c-case-data-bulk-19990101-20110930-in-xml\",\"\"',\n '\"Amneal Pharmaceuticals of NY, LLC\",\"Amneal Pharmaceuticals\",\"$99,000\",\"$0\",\"$99,000\",\"2015\",\"20150930\",\"employment-related offenses\",\"employment discrimination\",\"\",\"\",\"federal\",\"agency action\",\"Office of Federal Contract Compliance Programs\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"AMRX\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.dol.gov/ofccp/foia/files/AmnealPharmaceuticalsCA_Redacted.pdf\",\"\"',\n '\"Astellas Pharma US Inc.\",\"Astellas Pharma\",\"$7,300,000\",\"$0\",\"$7,300,000\",\"2014\",\"20140416\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"off-label or unapproved promotion of medical products\",\"Astellas Pharma US Inc. agreed to pay $7.3 million to resolve allegations that it violated the False Claims Act in connection with its marketing and promotion of the drug Mycamine for pediatric use, which had not received FDA approval.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Japan\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/astellas-pharma-us-inc-pay-73-million-resolve-false-claims-act-allegations-relating-marketing\",\"\"',\n '\"AstraZeneca\",\"AstraZeneca\",\"$250,000\",\"$0\",\"$250,000\",\"2011\",\"20110606\",\"employment-related offenses\",\"employment discrimination\",\"\",\"AstraZeneca agreed to pay $250,000 to 124 women who allegedly were subjected to pay discrimination while working at the corporation\\'s Philadelphia Business Center in Wayne, Pa. The action resolved a lawsuit filed by the U.S. Department of Labor in May 2010 alleging that the company discriminated against female sales specialists by paying them salaries that were, on average, $1,700 less than their male counterparts. \",\"federal\",\"agency action\",\"Office of Federal Contract Compliance Programs\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Pennsylvania\",\"Wayne\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.dol.gov/opa/media/press/ofccp/OFCCP20110829.htm\",\"\"',\n '\"AstraZeneca LP\",\"AstraZeneca\",\"$520,000,000\",\"$0\",\"$520,000,000\",\"2010\",\"20100427\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"AstraZeneca LP and AstraZeneca Pharmaceuticals LP will pay $520 million to resolve allegations that AstraZeneca illegally marketed the anti-psychotic drug Seroquel for uses not approved as safe and effective by the Food and Drug Administration, the Departments of Justice and Health and Human Services\\' Health Care Fraud Enforcement Action Team.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/pharmaceutical-giant-astrazeneca-pay-520-million-label-drug-marketing\",\"\"',\n '\"AstraZeneca LP\",\"AstraZeneca\",\"$46,500,000\",\"$0\",\"$46,500,000\",\"2015\",\"20150706\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"AstraZeneca LP agreed to pay the United States and participating states a total of $46.5 million, plus interest, to resolve allegations that it knowingly underpaid rebates owed under the Medicaid Drug Rebate Program.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/astrazeneca-and-cephalon-pay-465-million-and-75-million-respectively-allegedly-underpaying\",\"\"',\n '\"AstraZeneca LP\",\"AstraZeneca\",\"$7,900,000\",\"$0\",\"$7,900,000\",\"2015\",\"20150211\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"AstraZeneca LP, a pharmaceutical manufacturer based in Delaware, agreed to pay the government $7.9 million to settle allegations that it engaged in a kickback scheme in violation of the False Claims Act.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/astrazeneca-pay-79-million-resolve-kickback-allegations\",\"\"',\n '\"AstraZeneca Pharmaceuticals\",\"AstraZeneca\",\"$2,600,000\",\"$0\",\"$2,600,000\",\"2009\",\"20091019\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Mylan Pharmaceuticals, UDL Laboratories, AstraZeneca Pharmaceuticals and Ortho McNeil Pharmaceutical entered into settlement agreements for a total of $124 million to resolve claims that they violated the False Claims Act by failing to pay appropriate rebates to state Medicaid programs for drugs paid for by those programs.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/four-pharmaceutical-companies-pay-124-million-submission-false-claims-medicaid\",\"\"',\n '\"AstraZeneca Pharmaceuticals LP\",\"AstraZeneca\",\"$354,900,000\",\"$0\",\"$354,900,000\",\"2003\",\"20030620\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"AstraZeneca Pharmaceuticals LP pleaded guilty in federal district court in Wilmington, Delaware and agreed to pay $354.9 million to resolve criminal charges and civil liabilities in connection with its drug pricing and marketing practices with regard to Zoladex, a drug used primarily for the treatment of prostate cancer. AstraZeneca agreed to pay a criminal fine of $63.9 million as part of pleaded guilty to conspiring to violate the Prescription Drug Marketing Act by causing to be submitted claims for payment for the prescription of Zoladex which had been provided as free samples to urologists. AstraZeneca agreed to settle its federal civil False Claim Act liabilities and to pay the U.S. government $266.1 million to resolve allegations it caused false and fraudulent claims to be filed with the Medicare; another $24.9 million was to be paid to states to resolve similar claims concerning Medicaid.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/archive/opa/pr/2003/June/03_civ_371.htm\",\"\"',\n '\"AstraZeneca PLC\",\"AstraZeneca\",\"$5,522,000\",\"$0\",\"$5,522,000\",\"2016\",\"20160830\",\"competition-related offenses\",\"kickbacks and bribery\",\"\",\"\",\"federal\",\"agency action\",\"Securities and Exchange Commission\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.sec.gov/litigation/admin/2016/34-78730.pdf\",\"\"',\n '\"Aventis Pharmaceutical Inc.\",\"Sanofi\",\"$95,500,000\",\"$0\",\"$95,500,000\",\"2009\",\"20090528\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Aventis Pharmaceutical Inc. agreed to pay the United States $95.5 million to settle allegations that it violated the False Claims Act by misreporting drug prices in order to reduce its Medicaid Drug Rebate obligations.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"France\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/aventis-pharmaceutical-pay-us-955-million-settle-false-claims-act-allegations\",\"\"',\n '\"Aventis Pharmaceuticals Inc.\",\"Sanofi\",\"$190,000,000\",\"$0\",\"$190,000,000\",\"2007\",\"20070910\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"fraud\",\"Aventis Pharmaceuticals Inc. paid the United States and a number of states, as well as the District of Columbia, over $190 million to resolve allegations that the company caused false claims to be filed with Medicare and other federal health programs as a result of the company\\'s alleged fraudulent pricing and marketing of drugs. Aventis, which changed its name to Sanofi-Aventis,  agreed to settle False Claims Act allegations concerning its pricing and marketing of Anzemet, an antiemetic drug used primarily in conjunction with oncology and radiation treatment to prevent nausea and vomiting. \",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"France\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/archive/opa/pr/2007/September/07_civ_694.html\",\"\"',\n '\"AVEO Pharmaceuticals Inc.\",\"AVEO Pharmaceuticals\",\"$4,000,000\",\"$0\",\"$4,000,000\",\"2016\",\"20160329\",\"financial offenses\",\"investor protection violation\",\"\",\"The SEC ann\n\n*** WARNING: max output size exceeded, skipping output. ***\n\nodt\",\"$7,499\",\"$0\",\"$7,499\",\"2014\",\"20140502\",\"environment-related offenses\",\"environmental violation\",\"\",\"\",\"state\",\"agency action\",\"New York Department of Environmental Conservation\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"New York\",\"Hobart\",\"\",\"\",\"\",\"\",\"Ireland\",\"\",\"publicly traded\",\"MNK\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://web.archive.org/web/20201128041726/https://www.dec.ny.gov/docs/regions_pdf/mallinckrodt.pdf\",\"\"',\n '\"EMD Chemicals Inc.\",\"Merck KGaA (EMD)\",\"$30,700\",\"$0\",\"$30,700\",\"2008\",\"20080717\",\"environment-related offenses\",\"environmental violation\",\"\",\"\",\"state\",\"agency action\",\"Ohio Environmental Protection Agency\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Ohio\",\"Cincinnati\",\"\",\"\",\"\",\"\",\"Germany\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://edocpub.epa.ohio.gov/publicportal/ViewDocument.aspx?docid=52149\",\"Penalty listed includes a $6,140 Supplemental Environmental Project.\"',\n '\"EMD Chemicals Inc.\",\"Merck KGaA (EMD)\",\"$32,000\",\"$0\",\"$32,000\",\"2005\",\"20050721\",\"environment-related offenses\",\"environmental violation\",\"\",\"\",\"state\",\"agency action\",\"Ohio Environmental Protection Agency\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Ohio\",\"Cincinnati\",\"\",\"\",\"\",\"\",\"Germany\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://edocpub.epa.ohio.gov/publicportal/ViewDocument.aspx?docid=295488\",\"\"',\n '\"PHIBRO-TECH, INC\",\"Phibro Animal Health\",\"$15,000\",\"$0\",\"$15,000\",\"2011\",\"20110216\",\"environment-related offenses\",\"environmental violation\",\"\",\"hazardous waste violation\",\"state\",\"agency action\",\"South Carolina Department of Health and Environmental Control\",\"civil\",\"\",\"\",\"11-04-HW\",\"\",\"\",\"South Carolina\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"PAHC\",\"pharmaceuticals\",\"animal health products\",\"Contained in data received from the agency on October 22, 2020 in response to an open records request.\",\"\"',\n '\"PHIBRO-TECH\",\"Phibro Animal Health\",\"$7,500\",\"$0\",\"$7,500\",\"2004\",\"20040730\",\"environment-related offenses\",\"environmental violation\",\"\",\"air quality violation\",\"state\",\"agency action\",\"South Carolina Department of Health and Environmental Control\",\"civil\",\"\",\"\",\"04-046-A\",\"\",\"\",\"South Carolina\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"PAHC\",\"pharmaceuticals\",\"animal health products\",\"Contained in data received from the agency on October 22, 2020 in response to an open records request.\",\"\"',\n '\"Merck Sharp & Dohme Corp.\",\"Merck\",\"$20,925\",\"$0\",\"$20,925\",\"2020\",\"20200325\",\"environment-related offenses\",\"environmental violation\",\"\",\"\",\"state\",\"agency action\",\"Virginia Department of Environmental Quality\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Virginia\",\"Elkton\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"MRK\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.deq.virginia.gov/permits-regulations/enforcement/final-orders\",\"\"',\n '\"Merck Sharp & Dohme Corp.\",\"Merck\",\"$17,290\",\"$0\",\"$17,290\",\"2019\",\"20190822\",\"environment-related offenses\",\"environmental violation\",\"\",\"\",\"state\",\"agency action\",\"Virginia Department of Environmental Quality\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Virginia\",\"Elkton\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"MRK\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.deq.virginia.gov/permits-regulations/enforcement/final-orders\",\"\"',\n '\"Indivior plc\",\"Indivior Inc.\",\"$300,000,000\",\"$0\",\"$300,000,000\",\"2021\",\"20210427\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Indivior agreed to pay over $300 million to state governments to resolve allegations that it falsely and aggressively marketed Suboxone, resulting in improper use of state Medicaid funds. Suboxone is a drug product approved for use by recovering opioid addicts to avoid or reduce withdrawal symptoms while they undergo treatment. \",\"state\",\"agency action\",\"Multistate Attorneys General Case\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Virginia\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.oag.ca.gov/news/press-releases/attorney-general-bonta-announces-300-million-settlement-against-indivior\",\"\"',\n '\"CSL Behring, LLC\",\"CSL Limited\",\"$527,144\",\"$0\",\"$527,144\",\"2021\",\"20210504\",\"environment-related offenses\",\"environmental violation\",\"\",\"Clean Air Act\",\"federal\",\"agency action\",\"Environmental Protection Agency referral to the Justice Department\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Illinois\",\"\",\"\",\"\",\"\",\"\",\"Australia\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.epa.gov/newsreleases/epa-reaches-settlement-csl-behring-illinois-improve-risk-management-program\",\"\"',\n '\"Incyte Corporation\",\"Incyte Corp.\",\"$12,600,000\",\"$0\",\"$12,600,000\",\"2021\",\"20210504\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"The settlement resolved allegations that, from November 2011 through December 2014, Incyte Corporation purportedly used an independent foundation as a conduit to pay the copays of certain federal beneficiaries taking Incyte\\' drug Jakafi, which was approved to treat myleofibrosis in 2011. Specifically, Incyte was the sole donor to a fund that was opened in November 2011 to assist only myleofibrosis patients. After the fund opened, the government alleges that Incyte used the fund to pay the copays of federal beneficiaries taking Jakafi who were ineligible for assistance from the fund because they did not have myleofibrosis. Incyte managers pressured the foundation, through phone calls and emails, to provide economic assistance to these ineligible patients, and Incyte\\'s contractor helped ineligible patients to complete applications submitted to the fund for assistance. The government alleges that through this conduct, Incyte caused false claims for Jakafi to be submitted to Medicare and TRICARE.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Delaware\",\"publicly traded\",\"INCY\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/incyte-corporation-pay-126-million-resolve-false-claims-act-allegations-paying-kickbacks\",\"\"',\n '\"Bristol-Myers Squibb\",\"Bristol-Myers Squibb\",\"$75,000,000\",\"$0\",\"$75,000,000\",\"2021\",\"20210401\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Bristol-Myers Squibb agreed to pay the United States and participating states a total of $75 million, plus interest, to resolve allegations that it knowingly underpaid rebates owed under the Medicaid Drug Rebate Program. Of that amount, BMS will pay approximately $41 million, plus interest, to the United States, and the remainder to states participating in the settlement.\",\"federal\",\"agency action\",\"U.S. Attorney-Eastern District of Pennsylvania\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New York\",\"publicly traded\",\"BMY\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/usao-edpa/pr/bristol-myers-squibb-pay-75-million-resolve-false-claims-act-allegations-underpayment\",\"\"',\n '\"Morton Grove Pharmaceuticals, Inc.\",\"Wockhardt Limited\",\"$9,000\",\"$0\",\"$9,000\",\"2007\",\"20070829\",\"miscellaneous offenses\",\"campaign finance violation\",\"\",\"\",\"federal\",\"agency action\",\"Federal Election Commission\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"India\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.fec.gov/data/legal/matter-under-review/5784/\",\"\"',\n '\"BAUSCH AND LOMB PHARMACEUTICALS, INC.\",\"Bausch Health\",\"$7,000\",\"$0\",\"$7,000\",\"2000\",\"20000321\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Florida\",\"TAMPA\",\"8500 HIDDEN RIVER PARKWAY\",\"33637\",\"000000\",\"\",\"Canada\",\"\",\"publicly traded\",\"BHC\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"MALLINCKRODT INC.\",\"Mallinckrodt\",\"$7,000\",\"$0\",\"$7,000\",\"2000\",\"20000607\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Missouri\",\"ST. LOUIS\",\"MALLINCKRODT & SECOND STREETS Z-4\",\"63147\",\"000000\",\"\",\"Ireland\",\"\",\"publicly traded\",\"MNK\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"DURAMED PHARMACEUTICALS, INC.\",\"Teva Pharmaceutical Industries\",\"$7,000\",\"$0\",\"$7,000\",\"2001\",\"20010823\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Ohio\",\"CINCINNATI\",\"5040 DURAMED ROAD\",\"45213\",\"000000\",\"\",\"Israel\",\"\",\"publicly traded\",\"TEVA\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"TEVA PHARMACEUTICALS INC.\",\"Teva Pharmaceutical Industries\",\"$15,300\",\"$0\",\"$15,300\",\"2002\",\"20020828\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Missouri\",\"MEXICO\",\"5000 SNYDER DRIVE\",\"65265\",\"325412\",\"325412: Pharmaceutical Preparation Manufacturing\",\"Israel\",\"\",\"publicly traded\",\"TEVA\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"K V PHARMACEUTICAL\",\"KV Pharmaceutical\",\"$9,000\",\"$0\",\"$9,000\",\"2000\",\"20000120\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Missouri\",\"ST. LOUIS\",\"2303 SCHUETZ\",\"63146\",\"000000\",\"\",\"USA\",\"Missouri\",\"out of business\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"IMPAX LABORATORIES, INC\",\"Amneal Pharmaceuticals\",\"$18,000\",\"$0\",\"$18,000\",\"2004\",\"20040617\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"HAYWARD\",\"30831 HUNTWOOD AVE\",\"94544\",\"325412\",\"325412: Pharmaceutical Preparation Manufacturing\",\"USA\",\"New Jersey\",\"publicly traded\",\"AMRX\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"ALPHARMA ANIMAL HEALTH COMPANY\",\"Zoetis\",\"$18,300\",\"$0\",\"$18,300\",\"2001\",\"20010925\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Arkansas\",\"LOWELL\",\"415 BLOOMINGTON\",\"72745\",\"000000\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"ZTS\",\"pharmaceuticals\",\"animal health products\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"GILEAD SCIENCES\",\"Gilead Sciences\",\"$5,700\",\"$0\",\"$5,700\",\"2000\",\"20000128\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"FOSTER CITY\",\"333 LAKESIDE DRIVE\",\"94404\",\"000000\",\"\",\"USA\",\"California\",\"publicly traded\",\"GILD\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"CHIRON CORPORATION\",\"Novartis\",\"$90,140\",\"$0\",\"$90,140\",\"2000\",\"20000607\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"EMERYVILLE\",\"6455 CHRISTIE AVE\",\"94608\",\"000000\",\"\",\"Switzerland\",\"\",\"publicly traded\",\"NYSE: NVS\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"PHIBRO-TECH INC.\",\"Phibro Animal Health\",\"$31,600\",\"$0\",\"$31,600\",\"2000\",\"20000711\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"UNION CITY\",\"34400 ZWISSIG WAY\",\"94587\",\"000000\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"PAHC\",\"pharmaceuticals\",\"animal health products\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"TEVA SICOR\",\"Teva Pharmaceutical Industries\",\"$5,000\",\"$0\",\"$5,000\",\"2005\",\"20051212\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"IRVINE\",\"19 HUGHES\",\"92618\",\"325412\",\"325412: Pharmaceutical Preparation Manufacturing\",\"Israel\",\"\",\"publicly traded\",\"TEVA\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"PHARMAVITE CORP\",\"Otsuka Pharmaceutical\",\"$18,300\",\"$0\",\"$18,300\",\"2001\",\"20011115\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"SAN FERNANDO\",\"1150 AVIATION PLACE\",\"91340\",\"000000\",\"\",\"Japan\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"PHARMAVITE\",\"Otsuka Pharmaceutical\",\"$20,055\",\"$0\",\"$20,055\",\"2005\",\"20050503\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"SAN FERNANADO\",\"1150 AVIATION PLACE\",\"91342\",\"325412\",\"325412: Pharmaceutical Preparation Manufacturing\",\"Japan\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"GENENTECH\",\"Roche\",\"$11,240\",\"$0\",\"$11,240\",\"2003\",\"20030116\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"SOUTH SAN FRANCISCO\",\"1 DNA WAY, BLDG. #5 STABILITY LABS\",\"94080\",\"325412\",\"325412: Pharmaceutical Preparation Manufacturing\",\"Switzerland\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"ELAN PHARMACEUTICALS INC.\",\"Perrigo\",\"$7,125\",\"$0\",\"$7,125\",\"2003\",\"20030910\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"SOUTH SAN FRANCISCO\",\"800 GATEWAY BLVD.\",\"94080\",\"325412\",\"325412: Pharmaceutical Preparation Manufacturing\",\"Ireland\",\"\",\"publicly traded\",\"PRGO\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"ELAN PHARMACEUTICALS INC.\",\"Perrigo\",\"$18,225\",\"$0\",\"$18,225\",\"2004\",\"20040809\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"SOUTH SAN FRANCISCO\",\"800 GATEWAY BLVD.\",\"94080\",\"325412\",\"325412: Pharmaceutical Preparation Manufacturing\",\"Ireland\",\"\",\"publicly traded\",\"PRGO\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"AMPHASTAR PHARMACEUTICALS INC\",\"Amphastar Pharmaceuticals\",\"$18,500\",\"$0\",\"$18,500\",\"2002\",\"20021011\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"RANCHO CUCAMONGA\",\"11570 6TH ST\",\"91730\",\"325412\",\"325412: Pharmaceutical Preparation Manufacturing\",\"USA\",\"California\",\"publicly traded\",\"AMPH\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"BAXTER HEALTHCARE CORP DBA BAXTER BIOSCIENCE\",\"Takeda Pharmaceutical\",\"$195,000\",\"$0\",\"$195,000\",\"2011\",\"20110121\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"LOS ANGELES\",\"4501 COLORADO BLVD.\",\"90039\",\"325412\",\"325412: Pharmaceutical Preparation Manufacturing\",\"Japan\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"ROCHE MOLECULAR SYSTEMS INC\",\"Roche\",\"$9,225\",\"$0\",\"$9,225\",\"2002\",\"20021105\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"ALAMEDA\",\"1145 ATLANTIC AVE\",\"94501\",\"000000\",\"\",\"Switzerland\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"PHIBRO-TECH, INC.\",\"Phibro Animal Health\",\"$10,950\",\"$0\",\"$10,950\",\"2000\",\"20000912\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"South Carolina\",\"SUMTER\",\"2395 CAINS MILL RD.\",\"29151\",\"000000\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"PAHC\",\"pharmaceuticals\",\"animal health products\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"TEVA PHARMACEUTICAL\",\"Teva Pharmaceutical Industries\",\"$5,000\",\"$0\",\"$5,000\",\"2000\",\"20000809\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"New Jersey\",\"ELMWOOD PARK\",\"92 ROUTE 46 EAST\",\"07407\",\"000000\",\"\",\"Israel\",\"\",\"publicly traded\",\"TEVA\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"St. Jude Medical Inc.\",\"Abbott Laboratories\",\"$27,000,000\",\"$0\",\"$27,000,000\",\"2021\",\"20210708\",\"safety-related offenses\",\"drug or medical equipment safety violation\",\"False Claims Act and related\",\"St. Jude Medical Inc. agreed to pay $27 million to settle allegations under the False Claims Act that, between November 2014 and October 2016, it knowingly sold defective heart devices to health care facilities that, in turn, implanted the devices into patients insured by federal health care programs.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/st-jude-agrees-pay-27-million-allegedly-selling-defective-heart-devices\",\"\"',\n '\"Alere Inc.\",\"Abbott Laboratories\",\"$38,750,000\",\"$0\",\"$38,750,000\",\"2021\",\"20210708\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"drug or medical equipment safety violation\",\"Medical device manufacturers Alere Inc. and Alere San Diego Inc. agreed to pay $38.75 million to resolve allegations that the companies violated the False Claims Act by billing, and causing others to bill, the Medicare program for defective rapid point-of-care testing devices.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/medical-device-companies-alere-inc-and-alere-san-diego-inc-agree-pay-3875-million-settle\",\"\"',\n '\"GlaxoSmithKline, LLC\",\"GlaxoSmithKline\",\"$15,000,000\",\"$0\",\"$15,000,000\",\"2013\",\"20131217\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"False Claims Act and related\",\"The Maryland Attorney announced the state had recovered $15 million from GlaxoSmithKline, LLC, resolving allegations that the company engaged in improper marketing of the prescription drugs Avandia, Avandamet and Avandaryl, all of which are used to treat diabetes.\",\"state\",\"agency action\",\"Maryland Attorney General\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Maryland\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: GSK\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.marylandattorneygeneral.gov/press/2013/121713a.pdf\",\"\"',\n '\"Purdue Pharma\",\"Purdue Pharma\",\"$10,000,000,000\",\"$0\",\"$10,000,000,000\",\"2021\",\"20210901\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"A federal bankruptcy judge approved a deal worth an estimated $10 billion between Purdue Pharma and state governments (and others) that had sued the company over its role in causing and perpetuating the opioid crisis. The settlement included a plan under which Purdue Pharma would be converted into a trust with responsibility for distributing funds for treatment programs. The settlement included payment of $4.3 billion by the Sackler family, which has controlled the company and which grew enormously wealthy from its operations. In exchange, the family was granted immunity from opioid lawsuits. \",\"state\",\"agency action\",\"Multistate Attorneys General Case\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Connecticut\",\"out of business\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.washingtonpost.com/business/2021/09/01/purdue-pharma-bankruptcy-judge-ruling/\",\"\"',\n '\"Bristol Myers Squibb Co.\",\"Bristol-Myers Squibb\",\"$75,000,000\",\"$0\",\"$75,000,000\",\"2021\",\"20210817\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Bristol Myers Squibb agreed to pay a total of $75 million in settlement of allegations it overcharged state Medicaid programs for drugs.\",\"state\",\"agency action\",\"Multistate Attorneys General Case\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New York\",\"publicly traded\",\"BMY\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://portal.ct.gov/AG/Press-Releases/2021-Press-Releases/AG-Tong-Announces-75-Million-Settlement-with-Bristol-Myers-Squibb-over-Medicaid-Charges\",\"\"',\n '\"Johnson & Johnson\",\"Johnson & Johnson\",\"$5,000,000,000\",\"$0\",\"$5,000,000,000\",\"2021\",\"20210721\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Johnson & Johnson, the parent company of Janssen Pharmaceuticals, reached an agreement with a group of states under which it would pay $5 billion to resolve Janssen\\'s involvement in litigation alleging improper sale of pain medications, contributing to the national opioid epidemic.\",\"state\",\"agency action\",\"Multistate Attorneys General Case\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"JNJ\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://ncdoj.gov/attorney-general-josh-stein-announces-26-billion-agreement-with-opioid-distributors-manufacturer/\",\"\"',\n '\"Endo Health Solutions\",\"Endo International\",\"$50,000,000\",\"$0\",\"$50,000,000\",\"2021\",\"20210910\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"settlement with drug manufacturer in multi-company opioid litigation\",\"state\",\"agency action\",\"New York Attorney General\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"New York\",\"\",\"\",\"\",\"\",\"\",\"Ireland\",\"\",\"publicly traded\",\"ENDP\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://ag.ny.gov/press-release/2021/attorney-general-james-secures-50-million-opioid-abatement-drug-manufacturer-endo\",\"\"',\n '\"Perrigo Company\",\"Perrigo\",\"$20,000\",\"$0\",\"$20,000\",\"2021\",\"20210501\",\"employment-related offenses\",\"employment discrimination\",\"\",\"\",\"local\",\"agency action\",\"New York City Commission on Human Rights\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"New York\",\"\",\"\",\"\",\"\",\"\",\"Ireland\",\"\",\"publicly traded\",\"PRGO\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www1.nyc.gov/site/cchr/enforcement/2021-settlements.page\",\"\"']","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[38]: ['\"Company\",\"Parent_Company\",\"Penalty_Amount\",\"Subtraction_From_Penalty\",\"Penalty_Amount_Adjusted_For_Eliminating_Multiple_Counting\",\"Penalty_Year\",\"Penalty_Date\",\"Offense_Group\",\"Primary_Offense\",\"Secondary_Offense\",\"Description\",\"Level_of_Government\",\"Action_Type\",\"Agency\",\"Civil/Criminal\",\"Prosecution_Agreement\",\"Court\",\"Case_ID\",\"Private_Litigation_Case_Title\",\"Lawsuit_Resolution\",\"Facility_State\",\"City\",\"Address\",\"Zip\",\"NAICS_Code\",\"NAICS_Translation\",\"HQ_Country_of_Parent\",\"HQ_State_of_Parent\",\"Ownership_Structure\",\"Parent_Company_Stock_Ticker\",\"Major_Industry_of_Parent\",\"Specific_Industry_of_Parent\",\"Info_Source\",\"Notes\"',\n '\"Abbott Laboratories\",\"Abbott Laboratories\",\"$5,475,000\",\"$0\",\"$5,475,000\",\"2013\",\"20131227\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"Abbott Laboratories agreed to $5.475 million to resolve allegations that it violated the False Claims Act by paying kickbacks to induce doctors to implant the company\\'s carotid, biliary and peripheral vascular products.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/abbott-laboratories-pays-us-5475-million-settle-claims-company-paid-kickbacks-physicians\",\"\"',\n '\"Abbott Laboratories Inc.\",\"AbbVie\",\"$1,500,000,000\",\"$0\",\"$1,500,000,000\",\"2012\",\"20120507\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Global Health Care Company Abbott Laboratories Inc. has pleaded guilty and agreed to pay $1.5 billion to resolve its criminal and civil liability arising from the company\\'s unlawful promotion of the prescription drug Depakote for uses not approved as safe and effective by the Food and Drug Administration. The resolution - the second largest payment by a drug company - includes a criminal fine and forfeiture totaling $700 million and civil settlements with the federal government and the states totaling $800 million. Abbott also will be subject to court-supervised probation and reporting obligations for Abbotts CEO and Board of Directors.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABBV\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/abbott-labs-pay-15-billion-resolve-criminal-civil-investigations-label-promotion-depakote\",\"\"',\n '\"Abbott Laboratories Inc.\",\"AbbVie\",\"$126,500,000\",\"$0\",\"$126,500,000\",\"2010\",\"20101207\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Abbott Laboratories Inc., B. Braun Medical Inc. and Roxane Laboratories Inc. n/k/a Boehringer Ingelheim Roxane Inc. and affiliated entities agreed to pay $421 million to settle False Claims Act allegations, that they engaged in a scheme to report false and inflated prices for numerous pharmaceutical products knowing that federal healthcare programs relied on those reported prices to set payment rates.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABBV\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/pharmaceutical-manufacturers-pay-4212-million-settle-false-claims-act-cases\",\"\"',\n '\"Abbott Laboratories Puerto Rico, Inc.\",\"Abbott Laboratories\",\"$49,045\",\"$0\",\"$49,045\",\"2009\",\"20090305\",\"employment-related offenses\",\"wage and hour violation\",\"Fair Labor Standards Act\",\"\",\"federal\",\"agency action\",\"Labor Department Wage and Hour Division\",\"civil\",\"\",\"\",\"1527129\",\"\",\"\",\"Puerto Rico\",\"San Juan\",\"\",\"\",\"423450\",\"423450: Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"March 7, 2017 download of a dataset posted by the Wage and Hour Division at https://enforcedata.dol.gov/views/data_summary.php\",\"Date and year are the Findings End Date in the dataset posted by the Wage and Hour Division, which does not provide case opening or closing dates. The company name is the Legal Name provided by the dataset unless that field is blank, in which case the Trade Name is used. The dataset provides only one address and does not indicate whether it is the company headquarters address or the establishment address. The penalty amount is the total of civil monetary penalties and mandated back wages. The original dataset provides a breakdown.\"',\n '\"Acclarent Inc.\",\"Johnson & Johnson\",\"$18,000,000\",\"$0\",\"$18,000,000\",\"2016\",\"20160722\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"California-based medical device manufacturer Acclarent Inc., a subsidiary of Johnson & Johnson, agreed to pay $18 million to resolve allegations that the company caused health care providers to submit false claims to Medicare and other federal health care programs by marketing and distributing its sinus spacer product for use as a drug delivery device without Food and Drug Administration approval.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"JNJ\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/johnson-johnson-subsidiary-acclarent-inc-pays-government-18-million-settle-false-claims-act\",\"\"',\n '\"Advanced Medical Optics\",\"Abbott Laboratories\",\"$16,800\",\"$0\",\"$16,800\",\"2004\",\"20040412\",\"employment-related offenses\",\"labor relations violation\",\"\",\"back pay award in unfair labor practices case\",\"federal\",\"agency action\",\"National Labor Relations Board\",\"civil\",\"\",\"\",\"21-CA-36104-001\",\"\",\"\",\"California\",\"Irvine\",\"\",\"92606\",\"333314\",\"333314: Optical Instrument and Lens Manufacturing\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from an NLRB dataset covering 1999-2011 downloaded at https://catalog.data.gov/dataset/nlrb-cats-final-c-case-data-bulk-19990101-20110930-in-xml\",\"\"',\n '\"Advanced Neuromodulation Systems, Inc.\",\"Abbott Laboratories\",\"$2,950,000\",\"$0\",\"$2,950,000\",\"2007\",\"20070702\",\"healthcare-related offenses\",\"HHS civil monetary penalties\",\"kickbacks and bribery\",\"The HHS Inspector General announced that Advanced Neuromodulation Systems, Inc.,  a medical device manufacturer specializing in spinal cord stimulation used for pain management, agreed to pay $2.95 million to settle allegations that it paid kickbacks to physicians in violation of the Civil Monetary Penalties Law (CMPL). The company also entered into a 3-year Corporate Integrity Agreement.\",\"federal\",\"agency action\",\"Health & Human Services Department Office of Inspector General\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://oig.hhs.gov/publications/docs/press/2007/ANS%20Press%20Release.pdf\",\"\"',\n '\"Advanced Sterilization Products\",\"Johnson & Johnson\",\"$136,800\",\"$0\",\"$136,800\",\"2014\",\"20140520\",\"environment-related offenses\",\"environmental violation\",\"\",\"The U.S. Environmental Protection Agency announced that an Irvine, Calif. company, Advanced Sterilization Products, has agreed to pay a $136,800 penalty for the sale and distribution of unregistered and misbranded pesticides to veterinary clinics and laboratories nationwide.\",\"federal\",\"agency action\",\"Environmental Protection Agency\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"Irvine\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"JNJ\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://archive.epa.gov/epapages/newsroom_archive/newsreleases/8e820317c86e4c5685257cde00717855.html\",\"\"',\n '\"Advanced Sterilization Products, a division of Ethicon Inc.\",\"Johnson & Johnson\",\"$1,200,000\",\"$0\",\"$1,200,000\",\"2013\",\"20131204\",\"safety-related offenses\",\"drug or medical equipment safety violation\",\"\",\"Settlement of a civil money penalty action against Advanced Sterilization Products, a division of Ethicon Inc., a Johnson & Johnson company, and two of ASP\\'s executives alleging that ASP manufactured and distributed adulterated and misbranded sterilization monitoring products.\",\"federal\",\"agency action\",\"Food and Drug Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"Irvine\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"JNJ\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm377588.htm\",\"\"',\n '\"Alere San Diego Inc.\",\"Abbott Laboratories\",\"$10,572\",\"$0\",\"$10,572\",\"2017\",\"20170309\",\"employment-related offenses\",\"wage and hour violation\",\"Fair Labor Standards Act\",\"\",\"federal\",\"agency action\",\"Labor Department Wage and Hour Division\",\"civil\",\"\",\"\",\"1813371\",\"\",\"\",\"California\",\"Pomona\",\"828 Towne Center Dr.\",\"91767\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"July 23, 2017 download of a dataset posted by the Wage and Hour Division at https://enforcedata.dol.gov/views/data_summary.php\",\"Date and year are the Findings End Date in the dataset posted by the Wage and Hour Division, which does not provide case opening or closing dates. The company name is the Legal Name provided by the dataset unless that field is blank, in which case the Trade Name is used. The dataset provides only one address and does not indicate whether it is the company headquarters address or the establishment address. The penalty amount is the total of civil monetary penalties and mandated back wages. The original dataset provides a breakdown.\"',\n '\"Allergan Inc.\",\"AbbVie\",\"$600,000,000\",\"$0\",\"$600,000,000\",\"2010\",\"20100901\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"American pharmaceutical manufacturer Allergan Inc. has agreed to plead guilty and pay $600 million to resolve its criminal and civil liability arising from the company\\'s unlawful promotion of its biological product, Botox Therapeutic, for uses not approved as safe and effective by the Food and Drug Administration. The resolution included a criminal fine and forfeiture totaling $375 million and a civil settlement with the federal government and the states of $225 million.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABBV\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/allergan-agrees-plead-guilty-and-pay-600-million-resolve-allegations-label-promotion-botox\",\"\"',\n '\"Allergan Inc.\",\"AbbVie\",\"$15,000,000\",\"$0\",\"$15,000,000\",\"2017\",\"20170117\",\"financial offenses\",\"investor protection violation\",\"\",\"Allergan Inc. admitted securities law violations and agreed to pay a $15 million penalty for disclosure failures in the wake of a hostile takeover bid.\",\"federal\",\"agency action\",\"Securities and Exchange Commission\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABBV\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.sec.gov/news/pressrelease/2017-16.html\",\"\"',\n '\"Alpharma Inc.\",\"Pfizer\",\"$42,500,000\",\"$0\",\"$42,500,000\",\"2010\",\"20100316\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"Alpharma Inc. agreed to pay $42.5 million to resolve False Claims Act allegations in connection with the marketing of the morphine-based drug Kadian. The settlement resolved allegations that between January 1, 2000 and December 29, 2008 Alpharma paid health care providers to induce them to promote or prescribe Kadian, and made misrepresentations about the safety and efficacy of the drug. \",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New York\",\"publicly traded\",\"PFE\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/alpharma-pay-425-million-resolve-false-claims-act-allegations-connection-promotion-drug\",\"\"',\n '\"Alpharma, Inc.\",\"Pfizer\",\"$2,500,000\",\"$0\",\"$2,500,000\",\"2004\",\"20040812\",\"competition-related offenses\",\"price-fixing or anti-competitive practices\",\"consumer protection violation\",\"Generic drug manufacturers Alpharma Inc. and Perrigo Company agreed to give up a total of $6.25 million in illegal profits to settle Federal Trade Commission allegations that their agreement to limit competition for over-the-counter store-brand children\\'s liquid ibuprofen drove up prices and violated federal law.\",\"federal\",\"agency action\",\"Federal Trade Commission\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New York\",\"publicly traded\",\"PFE\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.ftc.gov/news-events/press-releases/2004/08/generic-drug-marketers-settle-ftc-charges\",\"\"',\n '\"American Pharmaceutical Partners, Inc.\",\"Bristol-Myers Squibb\",\"$160,203\",\"$0\",\"$160,203\",\"2004\",\"20041226\",\"employment-related offenses\",\"wage and hour violation\",\"Fair Labor Standards Act\",\"\",\"federal\",\"agency action\",\"Labor Department Wage and Hour Division\",\"civil\",\"\",\"\",\"1379241\",\"\",\"\",\"New York\",\"Grand Island\",\"\",\"14072\",\"32541\",\"32541: Pharmaceutical and Medicine Manufacturing\",\"USA\",\"New York\",\"publicly traded\",\"BMY\",\"pharmaceuticals\",\"pharmaceuticals\",\"March 7, 2017 download of a dataset posted by the Wage and Hour Division at https://enforcedata.dol.gov/views/data_summary.php\",\"Date and year are the Findings End Date in the dataset posted by the Wage and Hour Division, which does not provide case opening or closing dates. The company name is the Legal Name provided by the dataset unless that field is blank, in which case the Trade Name is used. The dataset provides only one address and does not indicate whether it is the company headquarters address or the establishment address. The penalty amount is the total of civil monetary penalties and mandated back wages. The original dataset provides a breakdown.\"',\n '\"Amgen Inc.\",\"Amgen\",\"$762,000,000\",\"$0\",\"$762,000,000\",\"2012\",\"20121219\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"U.S. District Judge Sterling Johnson, Jr. accepted a guilty plea by American biotechnology giant Amgen Inc. for illegally introducing a misbranded drug into interstate commerce. The plea is part of a global settlement with the United States in which Amgen agreed to pay $762 million to resolve criminal and civil liability arising from its sale and promotion of certain drugs.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"California\",\"publicly traded\",\"AMGN\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/amgen-inc-pleads-guilty-federal-charge-brooklyn-ny-pays-762-million-resolve-criminal\",\"\"',\n '\"Amgen Inc.\",\"Amgen\",\"$24,900,000\",\"$0\",\"$24,900,000\",\"2013\",\"20130416\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"Amgen Inc. agreed to pay the United States $24.9 million to settle allegations that it violated the False Claims Act. The company was accused of paying kickbacks  to long-term care pharmacy providers Omnicare Inc., PharMerica Corporation and Kindred Healthcare Inc. in return for implementing \"\"therapeutic interchange\"\" programs that were designed to switch Medicare and Medicaid beneficiaries from a competitor drug to Amgen\\'s Aranesp.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"California\",\"publicly traded\",\"AMGN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/amgen-pay-us-249-million-resolve-false-claims-act-allegations\",\"\"',\n '\"Amgen, Inc.\",\"Amgen\",\"$40,000\",\"$0\",\"$40,000\",\"2011\",\"20110302\",\"employment-related offenses\",\"labor relations violation\",\"\",\"back pay award in unfair labor practices case\",\"federal\",\"agency action\",\"National Labor Relations Board\",\"civil\",\"\",\"\",\"14-CA-30273-001\",\"\",\"\",\"Missouri\",\"St. Louis\",\"\",\"63130\",\"541720\",\"541720: Research and Development in the Social Sciences and Humanities\",\"USA\",\"California\",\"publicly traded\",\"AMGN\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from an NLRB dataset covering 1999-2011 downloaded at https://catalog.data.gov/dataset/nlrb-cats-final-c-case-data-bulk-19990101-20110930-in-xml\",\"\"',\n '\"Amneal Pharmaceuticals of NY, LLC\",\"Amneal Pharmaceuticals\",\"$99,000\",\"$0\",\"$99,000\",\"2015\",\"20150930\",\"employment-related offenses\",\"employment discrimination\",\"\",\"\",\"federal\",\"agency action\",\"Office of Federal Contract Compliance Programs\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"AMRX\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.dol.gov/ofccp/foia/files/AmnealPharmaceuticalsCA_Redacted.pdf\",\"\"',\n '\"Astellas Pharma US Inc.\",\"Astellas Pharma\",\"$7,300,000\",\"$0\",\"$7,300,000\",\"2014\",\"20140416\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"off-label or unapproved promotion of medical products\",\"Astellas Pharma US Inc. agreed to pay $7.3 million to resolve allegations that it violated the False Claims Act in connection with its marketing and promotion of the drug Mycamine for pediatric use, which had not received FDA approval.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Japan\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/astellas-pharma-us-inc-pay-73-million-resolve-false-claims-act-allegations-relating-marketing\",\"\"',\n '\"AstraZeneca\",\"AstraZeneca\",\"$250,000\",\"$0\",\"$250,000\",\"2011\",\"20110606\",\"employment-related offenses\",\"employment discrimination\",\"\",\"AstraZeneca agreed to pay $250,000 to 124 women who allegedly were subjected to pay discrimination while working at the corporation\\'s Philadelphia Business Center in Wayne, Pa. The action resolved a lawsuit filed by the U.S. Department of Labor in May 2010 alleging that the company discriminated against female sales specialists by paying them salaries that were, on average, $1,700 less than their male counterparts. \",\"federal\",\"agency action\",\"Office of Federal Contract Compliance Programs\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Pennsylvania\",\"Wayne\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.dol.gov/opa/media/press/ofccp/OFCCP20110829.htm\",\"\"',\n '\"AstraZeneca LP\",\"AstraZeneca\",\"$520,000,000\",\"$0\",\"$520,000,000\",\"2010\",\"20100427\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"AstraZeneca LP and AstraZeneca Pharmaceuticals LP will pay $520 million to resolve allegations that AstraZeneca illegally marketed the anti-psychotic drug Seroquel for uses not approved as safe and effective by the Food and Drug Administration, the Departments of Justice and Health and Human Services\\' Health Care Fraud Enforcement Action Team.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/pharmaceutical-giant-astrazeneca-pay-520-million-label-drug-marketing\",\"\"',\n '\"AstraZeneca LP\",\"AstraZeneca\",\"$46,500,000\",\"$0\",\"$46,500,000\",\"2015\",\"20150706\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"AstraZeneca LP agreed to pay the United States and participating states a total of $46.5 million, plus interest, to resolve allegations that it knowingly underpaid rebates owed under the Medicaid Drug Rebate Program.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/astrazeneca-and-cephalon-pay-465-million-and-75-million-respectively-allegedly-underpaying\",\"\"',\n '\"AstraZeneca LP\",\"AstraZeneca\",\"$7,900,000\",\"$0\",\"$7,900,000\",\"2015\",\"20150211\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"AstraZeneca LP, a pharmaceutical manufacturer based in Delaware, agreed to pay the government $7.9 million to settle allegations that it engaged in a kickback scheme in violation of the False Claims Act.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/astrazeneca-pay-79-million-resolve-kickback-allegations\",\"\"',\n '\"AstraZeneca Pharmaceuticals\",\"AstraZeneca\",\"$2,600,000\",\"$0\",\"$2,600,000\",\"2009\",\"20091019\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Mylan Pharmaceuticals, UDL Laboratories, AstraZeneca Pharmaceuticals and Ortho McNeil Pharmaceutical entered into settlement agreements for a total of $124 million to resolve claims that they violated the False Claims Act by failing to pay appropriate rebates to state Medicaid programs for drugs paid for by those programs.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/four-pharmaceutical-companies-pay-124-million-submission-false-claims-medicaid\",\"\"',\n '\"AstraZeneca Pharmaceuticals LP\",\"AstraZeneca\",\"$354,900,000\",\"$0\",\"$354,900,000\",\"2003\",\"20030620\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"AstraZeneca Pharmaceuticals LP pleaded guilty in federal district court in Wilmington, Delaware and agreed to pay $354.9 million to resolve criminal charges and civil liabilities in connection with its drug pricing and marketing practices with regard to Zoladex, a drug used primarily for the treatment of prostate cancer. AstraZeneca agreed to pay a criminal fine of $63.9 million as part of pleaded guilty to conspiring to violate the Prescription Drug Marketing Act by causing to be submitted claims for payment for the prescription of Zoladex which had been provided as free samples to urologists. AstraZeneca agreed to settle its federal civil False Claim Act liabilities and to pay the U.S. government $266.1 million to resolve allegations it caused false and fraudulent claims to be filed with the Medicare; another $24.9 million was to be paid to states to resolve similar claims concerning Medicaid.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/archive/opa/pr/2003/June/03_civ_371.htm\",\"\"',\n '\"AstraZeneca PLC\",\"AstraZeneca\",\"$5,522,000\",\"$0\",\"$5,522,000\",\"2016\",\"20160830\",\"competition-related offenses\",\"kickbacks and bribery\",\"\",\"\",\"federal\",\"agency action\",\"Securities and Exchange Commission\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.sec.gov/litigation/admin/2016/34-78730.pdf\",\"\"',\n '\"Aventis Pharmaceutical Inc.\",\"Sanofi\",\"$95,500,000\",\"$0\",\"$95,500,000\",\"2009\",\"20090528\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Aventis Pharmaceutical Inc. agreed to pay the United States $95.5 million to settle allegations that it violated the False Claims Act by misreporting drug prices in order to reduce its Medicaid Drug Rebate obligations.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"France\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/aventis-pharmaceutical-pay-us-955-million-settle-false-claims-act-allegations\",\"\"',\n '\"Aventis Pharmaceuticals Inc.\",\"Sanofi\",\"$190,000,000\",\"$0\",\"$190,000,000\",\"2007\",\"20070910\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"fraud\",\"Aventis Pharmaceuticals Inc. paid the United States and a number of states, as well as the District of Columbia, over $190 million to resolve allegations that the company caused false claims to be filed with Medicare and other federal health programs as a result of the company\\'s alleged fraudulent pricing and marketing of drugs. Aventis, which changed its name to Sanofi-Aventis,  agreed to settle False Claims Act allegations concerning its pricing and marketing of Anzemet, an antiemetic drug used primarily in conjunction with oncology and radiation treatment to prevent nausea and vomiting. \",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"France\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/archive/opa/pr/2007/September/07_civ_694.html\",\"\"',\n '\"AVEO Pharmaceuticals Inc.\",\"AVEO Pharmaceuticals\",\"$4,000,000\",\"$0\",\"$4,000,000\",\"2016\",\"20160329\",\"financial offenses\",\"investor protection violation\",\"\",\"The SEC ann\n\n*** WARNING: max output size exceeded, skipping output. ***\n\nodt\",\"$7,499\",\"$0\",\"$7,499\",\"2014\",\"20140502\",\"environment-related offenses\",\"environmental violation\",\"\",\"\",\"state\",\"agency action\",\"New York Department of Environmental Conservation\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"New York\",\"Hobart\",\"\",\"\",\"\",\"\",\"Ireland\",\"\",\"publicly traded\",\"MNK\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://web.archive.org/web/20201128041726/https://www.dec.ny.gov/docs/regions_pdf/mallinckrodt.pdf\",\"\"',\n '\"EMD Chemicals Inc.\",\"Merck KGaA (EMD)\",\"$30,700\",\"$0\",\"$30,700\",\"2008\",\"20080717\",\"environment-related offenses\",\"environmental violation\",\"\",\"\",\"state\",\"agency action\",\"Ohio Environmental Protection Agency\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Ohio\",\"Cincinnati\",\"\",\"\",\"\",\"\",\"Germany\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://edocpub.epa.ohio.gov/publicportal/ViewDocument.aspx?docid=52149\",\"Penalty listed includes a $6,140 Supplemental Environmental Project.\"',\n '\"EMD Chemicals Inc.\",\"Merck KGaA (EMD)\",\"$32,000\",\"$0\",\"$32,000\",\"2005\",\"20050721\",\"environment-related offenses\",\"environmental violation\",\"\",\"\",\"state\",\"agency action\",\"Ohio Environmental Protection Agency\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Ohio\",\"Cincinnati\",\"\",\"\",\"\",\"\",\"Germany\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://edocpub.epa.ohio.gov/publicportal/ViewDocument.aspx?docid=295488\",\"\"',\n '\"PHIBRO-TECH, INC\",\"Phibro Animal Health\",\"$15,000\",\"$0\",\"$15,000\",\"2011\",\"20110216\",\"environment-related offenses\",\"environmental violation\",\"\",\"hazardous waste violation\",\"state\",\"agency action\",\"South Carolina Department of Health and Environmental Control\",\"civil\",\"\",\"\",\"11-04-HW\",\"\",\"\",\"South Carolina\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"PAHC\",\"pharmaceuticals\",\"animal health products\",\"Contained in data received from the agency on October 22, 2020 in response to an open records request.\",\"\"',\n '\"PHIBRO-TECH\",\"Phibro Animal Health\",\"$7,500\",\"$0\",\"$7,500\",\"2004\",\"20040730\",\"environment-related offenses\",\"environmental violation\",\"\",\"air quality violation\",\"state\",\"agency action\",\"South Carolina Department of Health and Environmental Control\",\"civil\",\"\",\"\",\"04-046-A\",\"\",\"\",\"South Carolina\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"PAHC\",\"pharmaceuticals\",\"animal health products\",\"Contained in data received from the agency on October 22, 2020 in response to an open records request.\",\"\"',\n '\"Merck Sharp & Dohme Corp.\",\"Merck\",\"$20,925\",\"$0\",\"$20,925\",\"2020\",\"20200325\",\"environment-related offenses\",\"environmental violation\",\"\",\"\",\"state\",\"agency action\",\"Virginia Department of Environmental Quality\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Virginia\",\"Elkton\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"MRK\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.deq.virginia.gov/permits-regulations/enforcement/final-orders\",\"\"',\n '\"Merck Sharp & Dohme Corp.\",\"Merck\",\"$17,290\",\"$0\",\"$17,290\",\"2019\",\"20190822\",\"environment-related offenses\",\"environmental violation\",\"\",\"\",\"state\",\"agency action\",\"Virginia Department of Environmental Quality\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Virginia\",\"Elkton\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"MRK\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.deq.virginia.gov/permits-regulations/enforcement/final-orders\",\"\"',\n '\"Indivior plc\",\"Indivior Inc.\",\"$300,000,000\",\"$0\",\"$300,000,000\",\"2021\",\"20210427\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Indivior agreed to pay over $300 million to state governments to resolve allegations that it falsely and aggressively marketed Suboxone, resulting in improper use of state Medicaid funds. Suboxone is a drug product approved for use by recovering opioid addicts to avoid or reduce withdrawal symptoms while they undergo treatment. \",\"state\",\"agency action\",\"Multistate Attorneys General Case\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Virginia\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.oag.ca.gov/news/press-releases/attorney-general-bonta-announces-300-million-settlement-against-indivior\",\"\"',\n '\"CSL Behring, LLC\",\"CSL Limited\",\"$527,144\",\"$0\",\"$527,144\",\"2021\",\"20210504\",\"environment-related offenses\",\"environmental violation\",\"\",\"Clean Air Act\",\"federal\",\"agency action\",\"Environmental Protection Agency referral to the Justice Department\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Illinois\",\"\",\"\",\"\",\"\",\"\",\"Australia\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.epa.gov/newsreleases/epa-reaches-settlement-csl-behring-illinois-improve-risk-management-program\",\"\"',\n '\"Incyte Corporation\",\"Incyte Corp.\",\"$12,600,000\",\"$0\",\"$12,600,000\",\"2021\",\"20210504\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"The settlement resolved allegations that, from November 2011 through December 2014, Incyte Corporation purportedly used an independent foundation as a conduit to pay the copays of certain federal beneficiaries taking Incyte\\' drug Jakafi, which was approved to treat myleofibrosis in 2011. Specifically, Incyte was the sole donor to a fund that was opened in November 2011 to assist only myleofibrosis patients. After the fund opened, the government alleges that Incyte used the fund to pay the copays of federal beneficiaries taking Jakafi who were ineligible for assistance from the fund because they did not have myleofibrosis. Incyte managers pressured the foundation, through phone calls and emails, to provide economic assistance to these ineligible patients, and Incyte\\'s contractor helped ineligible patients to complete applications submitted to the fund for assistance. The government alleges that through this conduct, Incyte caused false claims for Jakafi to be submitted to Medicare and TRICARE.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Delaware\",\"publicly traded\",\"INCY\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/incyte-corporation-pay-126-million-resolve-false-claims-act-allegations-paying-kickbacks\",\"\"',\n '\"Bristol-Myers Squibb\",\"Bristol-Myers Squibb\",\"$75,000,000\",\"$0\",\"$75,000,000\",\"2021\",\"20210401\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Bristol-Myers Squibb agreed to pay the United States and participating states a total of $75 million, plus interest, to resolve allegations that it knowingly underpaid rebates owed under the Medicaid Drug Rebate Program. Of that amount, BMS will pay approximately $41 million, plus interest, to the United States, and the remainder to states participating in the settlement.\",\"federal\",\"agency action\",\"U.S. Attorney-Eastern District of Pennsylvania\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New York\",\"publicly traded\",\"BMY\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/usao-edpa/pr/bristol-myers-squibb-pay-75-million-resolve-false-claims-act-allegations-underpayment\",\"\"',\n '\"Morton Grove Pharmaceuticals, Inc.\",\"Wockhardt Limited\",\"$9,000\",\"$0\",\"$9,000\",\"2007\",\"20070829\",\"miscellaneous offenses\",\"campaign finance violation\",\"\",\"\",\"federal\",\"agency action\",\"Federal Election Commission\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"India\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.fec.gov/data/legal/matter-under-review/5784/\",\"\"',\n '\"BAUSCH AND LOMB PHARMACEUTICALS, INC.\",\"Bausch Health\",\"$7,000\",\"$0\",\"$7,000\",\"2000\",\"20000321\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Florida\",\"TAMPA\",\"8500 HIDDEN RIVER PARKWAY\",\"33637\",\"000000\",\"\",\"Canada\",\"\",\"publicly traded\",\"BHC\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"MALLINCKRODT INC.\",\"Mallinckrodt\",\"$7,000\",\"$0\",\"$7,000\",\"2000\",\"20000607\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Missouri\",\"ST. LOUIS\",\"MALLINCKRODT & SECOND STREETS Z-4\",\"63147\",\"000000\",\"\",\"Ireland\",\"\",\"publicly traded\",\"MNK\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"DURAMED PHARMACEUTICALS, INC.\",\"Teva Pharmaceutical Industries\",\"$7,000\",\"$0\",\"$7,000\",\"2001\",\"20010823\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Ohio\",\"CINCINNATI\",\"5040 DURAMED ROAD\",\"45213\",\"000000\",\"\",\"Israel\",\"\",\"publicly traded\",\"TEVA\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"TEVA PHARMACEUTICALS INC.\",\"Teva Pharmaceutical Industries\",\"$15,300\",\"$0\",\"$15,300\",\"2002\",\"20020828\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Missouri\",\"MEXICO\",\"5000 SNYDER DRIVE\",\"65265\",\"325412\",\"325412: Pharmaceutical Preparation Manufacturing\",\"Israel\",\"\",\"publicly traded\",\"TEVA\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"K V PHARMACEUTICAL\",\"KV Pharmaceutical\",\"$9,000\",\"$0\",\"$9,000\",\"2000\",\"20000120\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Missouri\",\"ST. LOUIS\",\"2303 SCHUETZ\",\"63146\",\"000000\",\"\",\"USA\",\"Missouri\",\"out of business\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"IMPAX LABORATORIES, INC\",\"Amneal Pharmaceuticals\",\"$18,000\",\"$0\",\"$18,000\",\"2004\",\"20040617\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"HAYWARD\",\"30831 HUNTWOOD AVE\",\"94544\",\"325412\",\"325412: Pharmaceutical Preparation Manufacturing\",\"USA\",\"New Jersey\",\"publicly traded\",\"AMRX\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"ALPHARMA ANIMAL HEALTH COMPANY\",\"Zoetis\",\"$18,300\",\"$0\",\"$18,300\",\"2001\",\"20010925\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Arkansas\",\"LOWELL\",\"415 BLOOMINGTON\",\"72745\",\"000000\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"ZTS\",\"pharmaceuticals\",\"animal health products\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"GILEAD SCIENCES\",\"Gilead Sciences\",\"$5,700\",\"$0\",\"$5,700\",\"2000\",\"20000128\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"FOSTER CITY\",\"333 LAKESIDE DRIVE\",\"94404\",\"000000\",\"\",\"USA\",\"California\",\"publicly traded\",\"GILD\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"CHIRON CORPORATION\",\"Novartis\",\"$90,140\",\"$0\",\"$90,140\",\"2000\",\"20000607\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"EMERYVILLE\",\"6455 CHRISTIE AVE\",\"94608\",\"000000\",\"\",\"Switzerland\",\"\",\"publicly traded\",\"NYSE: NVS\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"PHIBRO-TECH INC.\",\"Phibro Animal Health\",\"$31,600\",\"$0\",\"$31,600\",\"2000\",\"20000711\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"UNION CITY\",\"34400 ZWISSIG WAY\",\"94587\",\"000000\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"PAHC\",\"pharmaceuticals\",\"animal health products\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"TEVA SICOR\",\"Teva Pharmaceutical Industries\",\"$5,000\",\"$0\",\"$5,000\",\"2005\",\"20051212\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"IRVINE\",\"19 HUGHES\",\"92618\",\"325412\",\"325412: Pharmaceutical Preparation Manufacturing\",\"Israel\",\"\",\"publicly traded\",\"TEVA\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"PHARMAVITE CORP\",\"Otsuka Pharmaceutical\",\"$18,300\",\"$0\",\"$18,300\",\"2001\",\"20011115\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"SAN FERNANDO\",\"1150 AVIATION PLACE\",\"91340\",\"000000\",\"\",\"Japan\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"PHARMAVITE\",\"Otsuka Pharmaceutical\",\"$20,055\",\"$0\",\"$20,055\",\"2005\",\"20050503\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"SAN FERNANADO\",\"1150 AVIATION PLACE\",\"91342\",\"325412\",\"325412: Pharmaceutical Preparation Manufacturing\",\"Japan\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"GENENTECH\",\"Roche\",\"$11,240\",\"$0\",\"$11,240\",\"2003\",\"20030116\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"SOUTH SAN FRANCISCO\",\"1 DNA WAY, BLDG. #5 STABILITY LABS\",\"94080\",\"325412\",\"325412: Pharmaceutical Preparation Manufacturing\",\"Switzerland\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"ELAN PHARMACEUTICALS INC.\",\"Perrigo\",\"$7,125\",\"$0\",\"$7,125\",\"2003\",\"20030910\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"SOUTH SAN FRANCISCO\",\"800 GATEWAY BLVD.\",\"94080\",\"325412\",\"325412: Pharmaceutical Preparation Manufacturing\",\"Ireland\",\"\",\"publicly traded\",\"PRGO\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"ELAN PHARMACEUTICALS INC.\",\"Perrigo\",\"$18,225\",\"$0\",\"$18,225\",\"2004\",\"20040809\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"SOUTH SAN FRANCISCO\",\"800 GATEWAY BLVD.\",\"94080\",\"325412\",\"325412: Pharmaceutical Preparation Manufacturing\",\"Ireland\",\"\",\"publicly traded\",\"PRGO\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"AMPHASTAR PHARMACEUTICALS INC\",\"Amphastar Pharmaceuticals\",\"$18,500\",\"$0\",\"$18,500\",\"2002\",\"20021011\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"RANCHO CUCAMONGA\",\"11570 6TH ST\",\"91730\",\"325412\",\"325412: Pharmaceutical Preparation Manufacturing\",\"USA\",\"California\",\"publicly traded\",\"AMPH\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"BAXTER HEALTHCARE CORP DBA BAXTER BIOSCIENCE\",\"Takeda Pharmaceutical\",\"$195,000\",\"$0\",\"$195,000\",\"2011\",\"20110121\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"LOS ANGELES\",\"4501 COLORADO BLVD.\",\"90039\",\"325412\",\"325412: Pharmaceutical Preparation Manufacturing\",\"Japan\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"ROCHE MOLECULAR SYSTEMS INC\",\"Roche\",\"$9,225\",\"$0\",\"$9,225\",\"2002\",\"20021105\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"ALAMEDA\",\"1145 ATLANTIC AVE\",\"94501\",\"000000\",\"\",\"Switzerland\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"PHIBRO-TECH, INC.\",\"Phibro Animal Health\",\"$10,950\",\"$0\",\"$10,950\",\"2000\",\"20000912\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"South Carolina\",\"SUMTER\",\"2395 CAINS MILL RD.\",\"29151\",\"000000\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"PAHC\",\"pharmaceuticals\",\"animal health products\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"TEVA PHARMACEUTICAL\",\"Teva Pharmaceutical Industries\",\"$5,000\",\"$0\",\"$5,000\",\"2000\",\"20000809\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"New Jersey\",\"ELMWOOD PARK\",\"92 ROUTE 46 EAST\",\"07407\",\"000000\",\"\",\"Israel\",\"\",\"publicly traded\",\"TEVA\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"St. Jude Medical Inc.\",\"Abbott Laboratories\",\"$27,000,000\",\"$0\",\"$27,000,000\",\"2021\",\"20210708\",\"safety-related offenses\",\"drug or medical equipment safety violation\",\"False Claims Act and related\",\"St. Jude Medical Inc. agreed to pay $27 million to settle allegations under the False Claims Act that, between November 2014 and October 2016, it knowingly sold defective heart devices to health care facilities that, in turn, implanted the devices into patients insured by federal health care programs.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/st-jude-agrees-pay-27-million-allegedly-selling-defective-heart-devices\",\"\"',\n '\"Alere Inc.\",\"Abbott Laboratories\",\"$38,750,000\",\"$0\",\"$38,750,000\",\"2021\",\"20210708\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"drug or medical equipment safety violation\",\"Medical device manufacturers Alere Inc. and Alere San Diego Inc. agreed to pay $38.75 million to resolve allegations that the companies violated the False Claims Act by billing, and causing others to bill, the Medicare program for defective rapid point-of-care testing devices.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/medical-device-companies-alere-inc-and-alere-san-diego-inc-agree-pay-3875-million-settle\",\"\"',\n '\"GlaxoSmithKline, LLC\",\"GlaxoSmithKline\",\"$15,000,000\",\"$0\",\"$15,000,000\",\"2013\",\"20131217\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"False Claims Act and related\",\"The Maryland Attorney announced the state had recovered $15 million from GlaxoSmithKline, LLC, resolving allegations that the company engaged in improper marketing of the prescription drugs Avandia, Avandamet and Avandaryl, all of which are used to treat diabetes.\",\"state\",\"agency action\",\"Maryland Attorney General\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Maryland\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: GSK\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.marylandattorneygeneral.gov/press/2013/121713a.pdf\",\"\"',\n '\"Purdue Pharma\",\"Purdue Pharma\",\"$10,000,000,000\",\"$0\",\"$10,000,000,000\",\"2021\",\"20210901\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"A federal bankruptcy judge approved a deal worth an estimated $10 billion between Purdue Pharma and state governments (and others) that had sued the company over its role in causing and perpetuating the opioid crisis. The settlement included a plan under which Purdue Pharma would be converted into a trust with responsibility for distributing funds for treatment programs. The settlement included payment of $4.3 billion by the Sackler family, which has controlled the company and which grew enormously wealthy from its operations. In exchange, the family was granted immunity from opioid lawsuits. \",\"state\",\"agency action\",\"Multistate Attorneys General Case\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Connecticut\",\"out of business\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.washingtonpost.com/business/2021/09/01/purdue-pharma-bankruptcy-judge-ruling/\",\"\"',\n '\"Bristol Myers Squibb Co.\",\"Bristol-Myers Squibb\",\"$75,000,000\",\"$0\",\"$75,000,000\",\"2021\",\"20210817\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Bristol Myers Squibb agreed to pay a total of $75 million in settlement of allegations it overcharged state Medicaid programs for drugs.\",\"state\",\"agency action\",\"Multistate Attorneys General Case\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New York\",\"publicly traded\",\"BMY\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://portal.ct.gov/AG/Press-Releases/2021-Press-Releases/AG-Tong-Announces-75-Million-Settlement-with-Bristol-Myers-Squibb-over-Medicaid-Charges\",\"\"',\n '\"Johnson & Johnson\",\"Johnson & Johnson\",\"$5,000,000,000\",\"$0\",\"$5,000,000,000\",\"2021\",\"20210721\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Johnson & Johnson, the parent company of Janssen Pharmaceuticals, reached an agreement with a group of states under which it would pay $5 billion to resolve Janssen\\'s involvement in litigation alleging improper sale of pain medications, contributing to the national opioid epidemic.\",\"state\",\"agency action\",\"Multistate Attorneys General Case\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"JNJ\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://ncdoj.gov/attorney-general-josh-stein-announces-26-billion-agreement-with-opioid-distributors-manufacturer/\",\"\"',\n '\"Endo Health Solutions\",\"Endo International\",\"$50,000,000\",\"$0\",\"$50,000,000\",\"2021\",\"20210910\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"settlement with drug manufacturer in multi-company opioid litigation\",\"state\",\"agency action\",\"New York Attorney General\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"New York\",\"\",\"\",\"\",\"\",\"\",\"Ireland\",\"\",\"publicly traded\",\"ENDP\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://ag.ny.gov/press-release/2021/attorney-general-james-secures-50-million-opioid-abatement-drug-manufacturer-endo\",\"\"',\n '\"Perrigo Company\",\"Perrigo\",\"$20,000\",\"$0\",\"$20,000\",\"2021\",\"20210501\",\"employment-related offenses\",\"employment discrimination\",\"\",\"\",\"local\",\"agency action\",\"New York City Commission on Human Rights\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"New York\",\"\",\"\",\"\",\"\",\"\",\"Ireland\",\"\",\"publicly traded\",\"PRGO\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www1.nyc.gov/site/cchr/enforcement/2021-settlements.page\",\"\"']"]}}],"execution_count":0},{"cell_type":"code","source":["pharmaheader = pharmardd.first()\npharmardd1=pharmardd.filter(lambda line: line != pharmaheader)\npharmardd1.collect()"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"743e3eb1-927a-49a7-81c1-e74897d2fccd"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[39]: ['\"Abbott Laboratories\",\"Abbott Laboratories\",\"$5,475,000\",\"$0\",\"$5,475,000\",\"2013\",\"20131227\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"Abbott Laboratories agreed to $5.475 million to resolve allegations that it violated the False Claims Act by paying kickbacks to induce doctors to implant the company\\'s carotid, biliary and peripheral vascular products.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/abbott-laboratories-pays-us-5475-million-settle-claims-company-paid-kickbacks-physicians\",\"\"',\n '\"Abbott Laboratories Inc.\",\"AbbVie\",\"$1,500,000,000\",\"$0\",\"$1,500,000,000\",\"2012\",\"20120507\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Global Health Care Company Abbott Laboratories Inc. has pleaded guilty and agreed to pay $1.5 billion to resolve its criminal and civil liability arising from the company\\'s unlawful promotion of the prescription drug Depakote for uses not approved as safe and effective by the Food and Drug Administration. The resolution - the second largest payment by a drug company - includes a criminal fine and forfeiture totaling $700 million and civil settlements with the federal government and the states totaling $800 million. Abbott also will be subject to court-supervised probation and reporting obligations for Abbotts CEO and Board of Directors.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABBV\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/abbott-labs-pay-15-billion-resolve-criminal-civil-investigations-label-promotion-depakote\",\"\"',\n '\"Abbott Laboratories Inc.\",\"AbbVie\",\"$126,500,000\",\"$0\",\"$126,500,000\",\"2010\",\"20101207\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Abbott Laboratories Inc., B. Braun Medical Inc. and Roxane Laboratories Inc. n/k/a Boehringer Ingelheim Roxane Inc. and affiliated entities agreed to pay $421 million to settle False Claims Act allegations, that they engaged in a scheme to report false and inflated prices for numerous pharmaceutical products knowing that federal healthcare programs relied on those reported prices to set payment rates.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABBV\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/pharmaceutical-manufacturers-pay-4212-million-settle-false-claims-act-cases\",\"\"',\n '\"Abbott Laboratories Puerto Rico, Inc.\",\"Abbott Laboratories\",\"$49,045\",\"$0\",\"$49,045\",\"2009\",\"20090305\",\"employment-related offenses\",\"wage and hour violation\",\"Fair Labor Standards Act\",\"\",\"federal\",\"agency action\",\"Labor Department Wage and Hour Division\",\"civil\",\"\",\"\",\"1527129\",\"\",\"\",\"Puerto Rico\",\"San Juan\",\"\",\"\",\"423450\",\"423450: Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"March 7, 2017 download of a dataset posted by the Wage and Hour Division at https://enforcedata.dol.gov/views/data_summary.php\",\"Date and year are the Findings End Date in the dataset posted by the Wage and Hour Division, which does not provide case opening or closing dates. The company name is the Legal Name provided by the dataset unless that field is blank, in which case the Trade Name is used. The dataset provides only one address and does not indicate whether it is the company headquarters address or the establishment address. The penalty amount is the total of civil monetary penalties and mandated back wages. The original dataset provides a breakdown.\"',\n '\"Acclarent Inc.\",\"Johnson & Johnson\",\"$18,000,000\",\"$0\",\"$18,000,000\",\"2016\",\"20160722\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"California-based medical device manufacturer Acclarent Inc., a subsidiary of Johnson & Johnson, agreed to pay $18 million to resolve allegations that the company caused health care providers to submit false claims to Medicare and other federal health care programs by marketing and distributing its sinus spacer product for use as a drug delivery device without Food and Drug Administration approval.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"JNJ\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/johnson-johnson-subsidiary-acclarent-inc-pays-government-18-million-settle-false-claims-act\",\"\"',\n '\"Advanced Medical Optics\",\"Abbott Laboratories\",\"$16,800\",\"$0\",\"$16,800\",\"2004\",\"20040412\",\"employment-related offenses\",\"labor relations violation\",\"\",\"back pay award in unfair labor practices case\",\"federal\",\"agency action\",\"National Labor Relations Board\",\"civil\",\"\",\"\",\"21-CA-36104-001\",\"\",\"\",\"California\",\"Irvine\",\"\",\"92606\",\"333314\",\"333314: Optical Instrument and Lens Manufacturing\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from an NLRB dataset covering 1999-2011 downloaded at https://catalog.data.gov/dataset/nlrb-cats-final-c-case-data-bulk-19990101-20110930-in-xml\",\"\"',\n '\"Advanced Neuromodulation Systems, Inc.\",\"Abbott Laboratories\",\"$2,950,000\",\"$0\",\"$2,950,000\",\"2007\",\"20070702\",\"healthcare-related offenses\",\"HHS civil monetary penalties\",\"kickbacks and bribery\",\"The HHS Inspector General announced that Advanced Neuromodulation Systems, Inc.,  a medical device manufacturer specializing in spinal cord stimulation used for pain management, agreed to pay $2.95 million to settle allegations that it paid kickbacks to physicians in violation of the Civil Monetary Penalties Law (CMPL). The company also entered into a 3-year Corporate Integrity Agreement.\",\"federal\",\"agency action\",\"Health & Human Services Department Office of Inspector General\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://oig.hhs.gov/publications/docs/press/2007/ANS%20Press%20Release.pdf\",\"\"',\n '\"Advanced Sterilization Products\",\"Johnson & Johnson\",\"$136,800\",\"$0\",\"$136,800\",\"2014\",\"20140520\",\"environment-related offenses\",\"environmental violation\",\"\",\"The U.S. Environmental Protection Agency announced that an Irvine, Calif. company, Advanced Sterilization Products, has agreed to pay a $136,800 penalty for the sale and distribution of unregistered and misbranded pesticides to veterinary clinics and laboratories nationwide.\",\"federal\",\"agency action\",\"Environmental Protection Agency\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"Irvine\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"JNJ\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://archive.epa.gov/epapages/newsroom_archive/newsreleases/8e820317c86e4c5685257cde00717855.html\",\"\"',\n '\"Advanced Sterilization Products, a division of Ethicon Inc.\",\"Johnson & Johnson\",\"$1,200,000\",\"$0\",\"$1,200,000\",\"2013\",\"20131204\",\"safety-related offenses\",\"drug or medical equipment safety violation\",\"\",\"Settlement of a civil money penalty action against Advanced Sterilization Products, a division of Ethicon Inc., a Johnson & Johnson company, and two of ASP\\'s executives alleging that ASP manufactured and distributed adulterated and misbranded sterilization monitoring products.\",\"federal\",\"agency action\",\"Food and Drug Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"Irvine\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"JNJ\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm377588.htm\",\"\"',\n '\"Alere San Diego Inc.\",\"Abbott Laboratories\",\"$10,572\",\"$0\",\"$10,572\",\"2017\",\"20170309\",\"employment-related offenses\",\"wage and hour violation\",\"Fair Labor Standards Act\",\"\",\"federal\",\"agency action\",\"Labor Department Wage and Hour Division\",\"civil\",\"\",\"\",\"1813371\",\"\",\"\",\"California\",\"Pomona\",\"828 Towne Center Dr.\",\"91767\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"July 23, 2017 download of a dataset posted by the Wage and Hour Division at https://enforcedata.dol.gov/views/data_summary.php\",\"Date and year are the Findings End Date in the dataset posted by the Wage and Hour Division, which does not provide case opening or closing dates. The company name is the Legal Name provided by the dataset unless that field is blank, in which case the Trade Name is used. The dataset provides only one address and does not indicate whether it is the company headquarters address or the establishment address. The penalty amount is the total of civil monetary penalties and mandated back wages. The original dataset provides a breakdown.\"',\n '\"Allergan Inc.\",\"AbbVie\",\"$600,000,000\",\"$0\",\"$600,000,000\",\"2010\",\"20100901\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"American pharmaceutical manufacturer Allergan Inc. has agreed to plead guilty and pay $600 million to resolve its criminal and civil liability arising from the company\\'s unlawful promotion of its biological product, Botox Therapeutic, for uses not approved as safe and effective by the Food and Drug Administration. The resolution included a criminal fine and forfeiture totaling $375 million and a civil settlement with the federal government and the states of $225 million.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABBV\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/allergan-agrees-plead-guilty-and-pay-600-million-resolve-allegations-label-promotion-botox\",\"\"',\n '\"Allergan Inc.\",\"AbbVie\",\"$15,000,000\",\"$0\",\"$15,000,000\",\"2017\",\"20170117\",\"financial offenses\",\"investor protection violation\",\"\",\"Allergan Inc. admitted securities law violations and agreed to pay a $15 million penalty for disclosure failures in the wake of a hostile takeover bid.\",\"federal\",\"agency action\",\"Securities and Exchange Commission\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABBV\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.sec.gov/news/pressrelease/2017-16.html\",\"\"',\n '\"Alpharma Inc.\",\"Pfizer\",\"$42,500,000\",\"$0\",\"$42,500,000\",\"2010\",\"20100316\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"Alpharma Inc. agreed to pay $42.5 million to resolve False Claims Act allegations in connection with the marketing of the morphine-based drug Kadian. The settlement resolved allegations that between January 1, 2000 and December 29, 2008 Alpharma paid health care providers to induce them to promote or prescribe Kadian, and made misrepresentations about the safety and efficacy of the drug. \",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New York\",\"publicly traded\",\"PFE\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/alpharma-pay-425-million-resolve-false-claims-act-allegations-connection-promotion-drug\",\"\"',\n '\"Alpharma, Inc.\",\"Pfizer\",\"$2,500,000\",\"$0\",\"$2,500,000\",\"2004\",\"20040812\",\"competition-related offenses\",\"price-fixing or anti-competitive practices\",\"consumer protection violation\",\"Generic drug manufacturers Alpharma Inc. and Perrigo Company agreed to give up a total of $6.25 million in illegal profits to settle Federal Trade Commission allegations that their agreement to limit competition for over-the-counter store-brand children\\'s liquid ibuprofen drove up prices and violated federal law.\",\"federal\",\"agency action\",\"Federal Trade Commission\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New York\",\"publicly traded\",\"PFE\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.ftc.gov/news-events/press-releases/2004/08/generic-drug-marketers-settle-ftc-charges\",\"\"',\n '\"American Pharmaceutical Partners, Inc.\",\"Bristol-Myers Squibb\",\"$160,203\",\"$0\",\"$160,203\",\"2004\",\"20041226\",\"employment-related offenses\",\"wage and hour violation\",\"Fair Labor Standards Act\",\"\",\"federal\",\"agency action\",\"Labor Department Wage and Hour Division\",\"civil\",\"\",\"\",\"1379241\",\"\",\"\",\"New York\",\"Grand Island\",\"\",\"14072\",\"32541\",\"32541: Pharmaceutical and Medicine Manufacturing\",\"USA\",\"New York\",\"publicly traded\",\"BMY\",\"pharmaceuticals\",\"pharmaceuticals\",\"March 7, 2017 download of a dataset posted by the Wage and Hour Division at https://enforcedata.dol.gov/views/data_summary.php\",\"Date and year are the Findings End Date in the dataset posted by the Wage and Hour Division, which does not provide case opening or closing dates. The company name is the Legal Name provided by the dataset unless that field is blank, in which case the Trade Name is used. The dataset provides only one address and does not indicate whether it is the company headquarters address or the establishment address. The penalty amount is the total of civil monetary penalties and mandated back wages. The original dataset provides a breakdown.\"',\n '\"Amgen Inc.\",\"Amgen\",\"$762,000,000\",\"$0\",\"$762,000,000\",\"2012\",\"20121219\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"U.S. District Judge Sterling Johnson, Jr. accepted a guilty plea by American biotechnology giant Amgen Inc. for illegally introducing a misbranded drug into interstate commerce. The plea is part of a global settlement with the United States in which Amgen agreed to pay $762 million to resolve criminal and civil liability arising from its sale and promotion of certain drugs.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"California\",\"publicly traded\",\"AMGN\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/amgen-inc-pleads-guilty-federal-charge-brooklyn-ny-pays-762-million-resolve-criminal\",\"\"',\n '\"Amgen Inc.\",\"Amgen\",\"$24,900,000\",\"$0\",\"$24,900,000\",\"2013\",\"20130416\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"Amgen Inc. agreed to pay the United States $24.9 million to settle allegations that it violated the False Claims Act. The company was accused of paying kickbacks  to long-term care pharmacy providers Omnicare Inc., PharMerica Corporation and Kindred Healthcare Inc. in return for implementing \"\"therapeutic interchange\"\" programs that were designed to switch Medicare and Medicaid beneficiaries from a competitor drug to Amgen\\'s Aranesp.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"California\",\"publicly traded\",\"AMGN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/amgen-pay-us-249-million-resolve-false-claims-act-allegations\",\"\"',\n '\"Amgen, Inc.\",\"Amgen\",\"$40,000\",\"$0\",\"$40,000\",\"2011\",\"20110302\",\"employment-related offenses\",\"labor relations violation\",\"\",\"back pay award in unfair labor practices case\",\"federal\",\"agency action\",\"National Labor Relations Board\",\"civil\",\"\",\"\",\"14-CA-30273-001\",\"\",\"\",\"Missouri\",\"St. Louis\",\"\",\"63130\",\"541720\",\"541720: Research and Development in the Social Sciences and Humanities\",\"USA\",\"California\",\"publicly traded\",\"AMGN\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from an NLRB dataset covering 1999-2011 downloaded at https://catalog.data.gov/dataset/nlrb-cats-final-c-case-data-bulk-19990101-20110930-in-xml\",\"\"',\n '\"Amneal Pharmaceuticals of NY, LLC\",\"Amneal Pharmaceuticals\",\"$99,000\",\"$0\",\"$99,000\",\"2015\",\"20150930\",\"employment-related offenses\",\"employment discrimination\",\"\",\"\",\"federal\",\"agency action\",\"Office of Federal Contract Compliance Programs\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"AMRX\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.dol.gov/ofccp/foia/files/AmnealPharmaceuticalsCA_Redacted.pdf\",\"\"',\n '\"Astellas Pharma US Inc.\",\"Astellas Pharma\",\"$7,300,000\",\"$0\",\"$7,300,000\",\"2014\",\"20140416\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"off-label or unapproved promotion of medical products\",\"Astellas Pharma US Inc. agreed to pay $7.3 million to resolve allegations that it violated the False Claims Act in connection with its marketing and promotion of the drug Mycamine for pediatric use, which had not received FDA approval.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Japan\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/astellas-pharma-us-inc-pay-73-million-resolve-false-claims-act-allegations-relating-marketing\",\"\"',\n '\"AstraZeneca\",\"AstraZeneca\",\"$250,000\",\"$0\",\"$250,000\",\"2011\",\"20110606\",\"employment-related offenses\",\"employment discrimination\",\"\",\"AstraZeneca agreed to pay $250,000 to 124 women who allegedly were subjected to pay discrimination while working at the corporation\\'s Philadelphia Business Center in Wayne, Pa. The action resolved a lawsuit filed by the U.S. Department of Labor in May 2010 alleging that the company discriminated against female sales specialists by paying them salaries that were, on average, $1,700 less than their male counterparts. \",\"federal\",\"agency action\",\"Office of Federal Contract Compliance Programs\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Pennsylvania\",\"Wayne\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.dol.gov/opa/media/press/ofccp/OFCCP20110829.htm\",\"\"',\n '\"AstraZeneca LP\",\"AstraZeneca\",\"$520,000,000\",\"$0\",\"$520,000,000\",\"2010\",\"20100427\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"AstraZeneca LP and AstraZeneca Pharmaceuticals LP will pay $520 million to resolve allegations that AstraZeneca illegally marketed the anti-psychotic drug Seroquel for uses not approved as safe and effective by the Food and Drug Administration, the Departments of Justice and Health and Human Services\\' Health Care Fraud Enforcement Action Team.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/pharmaceutical-giant-astrazeneca-pay-520-million-label-drug-marketing\",\"\"',\n '\"AstraZeneca LP\",\"AstraZeneca\",\"$46,500,000\",\"$0\",\"$46,500,000\",\"2015\",\"20150706\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"AstraZeneca LP agreed to pay the United States and participating states a total of $46.5 million, plus interest, to resolve allegations that it knowingly underpaid rebates owed under the Medicaid Drug Rebate Program.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/astrazeneca-and-cephalon-pay-465-million-and-75-million-respectively-allegedly-underpaying\",\"\"',\n '\"AstraZeneca LP\",\"AstraZeneca\",\"$7,900,000\",\"$0\",\"$7,900,000\",\"2015\",\"20150211\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"AstraZeneca LP, a pharmaceutical manufacturer based in Delaware, agreed to pay the government $7.9 million to settle allegations that it engaged in a kickback scheme in violation of the False Claims Act.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/astrazeneca-pay-79-million-resolve-kickback-allegations\",\"\"',\n '\"AstraZeneca Pharmaceuticals\",\"AstraZeneca\",\"$2,600,000\",\"$0\",\"$2,600,000\",\"2009\",\"20091019\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Mylan Pharmaceuticals, UDL Laboratories, AstraZeneca Pharmaceuticals and Ortho McNeil Pharmaceutical entered into settlement agreements for a total of $124 million to resolve claims that they violated the False Claims Act by failing to pay appropriate rebates to state Medicaid programs for drugs paid for by those programs.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/four-pharmaceutical-companies-pay-124-million-submission-false-claims-medicaid\",\"\"',\n '\"AstraZeneca Pharmaceuticals LP\",\"AstraZeneca\",\"$354,900,000\",\"$0\",\"$354,900,000\",\"2003\",\"20030620\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"AstraZeneca Pharmaceuticals LP pleaded guilty in federal district court in Wilmington, Delaware and agreed to pay $354.9 million to resolve criminal charges and civil liabilities in connection with its drug pricing and marketing practices with regard to Zoladex, a drug used primarily for the treatment of prostate cancer. AstraZeneca agreed to pay a criminal fine of $63.9 million as part of pleaded guilty to conspiring to violate the Prescription Drug Marketing Act by causing to be submitted claims for payment for the prescription of Zoladex which had been provided as free samples to urologists. AstraZeneca agreed to settle its federal civil False Claim Act liabilities and to pay the U.S. government $266.1 million to resolve allegations it caused false and fraudulent claims to be filed with the Medicare; another $24.9 million was to be paid to states to resolve similar claims concerning Medicaid.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/archive/opa/pr/2003/June/03_civ_371.htm\",\"\"',\n '\"AstraZeneca PLC\",\"AstraZeneca\",\"$5,522,000\",\"$0\",\"$5,522,000\",\"2016\",\"20160830\",\"competition-related offenses\",\"kickbacks and bribery\",\"\",\"\",\"federal\",\"agency action\",\"Securities and Exchange Commission\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.sec.gov/litigation/admin/2016/34-78730.pdf\",\"\"',\n '\"Aventis Pharmaceutical Inc.\",\"Sanofi\",\"$95,500,000\",\"$0\",\"$95,500,000\",\"2009\",\"20090528\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Aventis Pharmaceutical Inc. agreed to pay the United States $95.5 million to settle allegations that it violated the False Claims Act by misreporting drug prices in order to reduce its Medicaid Drug Rebate obligations.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"France\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/aventis-pharmaceutical-pay-us-955-million-settle-false-claims-act-allegations\",\"\"',\n '\"Aventis Pharmaceuticals Inc.\",\"Sanofi\",\"$190,000,000\",\"$0\",\"$190,000,000\",\"2007\",\"20070910\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"fraud\",\"Aventis Pharmaceuticals Inc. paid the United States and a number of states, as well as the District of Columbia, over $190 million to resolve allegations that the company caused false claims to be filed with Medicare and other federal health programs as a result of the company\\'s alleged fraudulent pricing and marketing of drugs. Aventis, which changed its name to Sanofi-Aventis,  agreed to settle False Claims Act allegations concerning its pricing and marketing of Anzemet, an antiemetic drug used primarily in conjunction with oncology and radiation treatment to prevent nausea and vomiting. \",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"France\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/archive/opa/pr/2007/September/07_civ_694.html\",\"\"',\n '\"AVEO Pharmaceuticals Inc.\",\"AVEO Pharmaceuticals\",\"$4,000,000\",\"$0\",\"$4,000,000\",\"2016\",\"20160329\",\"financial offenses\",\"investor protection violation\",\"\",\"The SEC announced fraud charges against a Massachusetts-based biotech company and three former executives for misleading investors about the company\\'s efforts to obtain Food and Drug Administration approval for its flagship developmental drug to treat kidney cancer. The SEC alleged that AVEO Pharmaceuticals Inc. concealed the FDA\\'s level of concern about Tivozanib in public statements to investors by omitting the critical fact that FDA staff had recommended a second clinical trial to address their concerns about patient death rates during the first clinical trial.  When the FDA made public months later that it had recommended an additional\n\n*** WARNING: max output size exceeded, skipping output. ***\n\nodt\",\"$7,499\",\"$0\",\"$7,499\",\"2014\",\"20140502\",\"environment-related offenses\",\"environmental violation\",\"\",\"\",\"state\",\"agency action\",\"New York Department of Environmental Conservation\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"New York\",\"Hobart\",\"\",\"\",\"\",\"\",\"Ireland\",\"\",\"publicly traded\",\"MNK\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://web.archive.org/web/20201128041726/https://www.dec.ny.gov/docs/regions_pdf/mallinckrodt.pdf\",\"\"',\n '\"EMD Chemicals Inc.\",\"Merck KGaA (EMD)\",\"$30,700\",\"$0\",\"$30,700\",\"2008\",\"20080717\",\"environment-related offenses\",\"environmental violation\",\"\",\"\",\"state\",\"agency action\",\"Ohio Environmental Protection Agency\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Ohio\",\"Cincinnati\",\"\",\"\",\"\",\"\",\"Germany\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://edocpub.epa.ohio.gov/publicportal/ViewDocument.aspx?docid=52149\",\"Penalty listed includes a $6,140 Supplemental Environmental Project.\"',\n '\"EMD Chemicals Inc.\",\"Merck KGaA (EMD)\",\"$32,000\",\"$0\",\"$32,000\",\"2005\",\"20050721\",\"environment-related offenses\",\"environmental violation\",\"\",\"\",\"state\",\"agency action\",\"Ohio Environmental Protection Agency\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Ohio\",\"Cincinnati\",\"\",\"\",\"\",\"\",\"Germany\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://edocpub.epa.ohio.gov/publicportal/ViewDocument.aspx?docid=295488\",\"\"',\n '\"PHIBRO-TECH, INC\",\"Phibro Animal Health\",\"$15,000\",\"$0\",\"$15,000\",\"2011\",\"20110216\",\"environment-related offenses\",\"environmental violation\",\"\",\"hazardous waste violation\",\"state\",\"agency action\",\"South Carolina Department of Health and Environmental Control\",\"civil\",\"\",\"\",\"11-04-HW\",\"\",\"\",\"South Carolina\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"PAHC\",\"pharmaceuticals\",\"animal health products\",\"Contained in data received from the agency on October 22, 2020 in response to an open records request.\",\"\"',\n '\"PHIBRO-TECH\",\"Phibro Animal Health\",\"$7,500\",\"$0\",\"$7,500\",\"2004\",\"20040730\",\"environment-related offenses\",\"environmental violation\",\"\",\"air quality violation\",\"state\",\"agency action\",\"South Carolina Department of Health and Environmental Control\",\"civil\",\"\",\"\",\"04-046-A\",\"\",\"\",\"South Carolina\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"PAHC\",\"pharmaceuticals\",\"animal health products\",\"Contained in data received from the agency on October 22, 2020 in response to an open records request.\",\"\"',\n '\"Merck Sharp & Dohme Corp.\",\"Merck\",\"$20,925\",\"$0\",\"$20,925\",\"2020\",\"20200325\",\"environment-related offenses\",\"environmental violation\",\"\",\"\",\"state\",\"agency action\",\"Virginia Department of Environmental Quality\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Virginia\",\"Elkton\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"MRK\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.deq.virginia.gov/permits-regulations/enforcement/final-orders\",\"\"',\n '\"Merck Sharp & Dohme Corp.\",\"Merck\",\"$17,290\",\"$0\",\"$17,290\",\"2019\",\"20190822\",\"environment-related offenses\",\"environmental violation\",\"\",\"\",\"state\",\"agency action\",\"Virginia Department of Environmental Quality\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Virginia\",\"Elkton\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"MRK\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.deq.virginia.gov/permits-regulations/enforcement/final-orders\",\"\"',\n '\"Indivior plc\",\"Indivior Inc.\",\"$300,000,000\",\"$0\",\"$300,000,000\",\"2021\",\"20210427\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Indivior agreed to pay over $300 million to state governments to resolve allegations that it falsely and aggressively marketed Suboxone, resulting in improper use of state Medicaid funds. Suboxone is a drug product approved for use by recovering opioid addicts to avoid or reduce withdrawal symptoms while they undergo treatment. \",\"state\",\"agency action\",\"Multistate Attorneys General Case\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Virginia\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.oag.ca.gov/news/press-releases/attorney-general-bonta-announces-300-million-settlement-against-indivior\",\"\"',\n '\"CSL Behring, LLC\",\"CSL Limited\",\"$527,144\",\"$0\",\"$527,144\",\"2021\",\"20210504\",\"environment-related offenses\",\"environmental violation\",\"\",\"Clean Air Act\",\"federal\",\"agency action\",\"Environmental Protection Agency referral to the Justice Department\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Illinois\",\"\",\"\",\"\",\"\",\"\",\"Australia\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.epa.gov/newsreleases/epa-reaches-settlement-csl-behring-illinois-improve-risk-management-program\",\"\"',\n '\"Incyte Corporation\",\"Incyte Corp.\",\"$12,600,000\",\"$0\",\"$12,600,000\",\"2021\",\"20210504\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"The settlement resolved allegations that, from November 2011 through December 2014, Incyte Corporation purportedly used an independent foundation as a conduit to pay the copays of certain federal beneficiaries taking Incyte\\' drug Jakafi, which was approved to treat myleofibrosis in 2011. Specifically, Incyte was the sole donor to a fund that was opened in November 2011 to assist only myleofibrosis patients. After the fund opened, the government alleges that Incyte used the fund to pay the copays of federal beneficiaries taking Jakafi who were ineligible for assistance from the fund because they did not have myleofibrosis. Incyte managers pressured the foundation, through phone calls and emails, to provide economic assistance to these ineligible patients, and Incyte\\'s contractor helped ineligible patients to complete applications submitted to the fund for assistance. The government alleges that through this conduct, Incyte caused false claims for Jakafi to be submitted to Medicare and TRICARE.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Delaware\",\"publicly traded\",\"INCY\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/incyte-corporation-pay-126-million-resolve-false-claims-act-allegations-paying-kickbacks\",\"\"',\n '\"Bristol-Myers Squibb\",\"Bristol-Myers Squibb\",\"$75,000,000\",\"$0\",\"$75,000,000\",\"2021\",\"20210401\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Bristol-Myers Squibb agreed to pay the United States and participating states a total of $75 million, plus interest, to resolve allegations that it knowingly underpaid rebates owed under the Medicaid Drug Rebate Program. Of that amount, BMS will pay approximately $41 million, plus interest, to the United States, and the remainder to states participating in the settlement.\",\"federal\",\"agency action\",\"U.S. Attorney-Eastern District of Pennsylvania\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New York\",\"publicly traded\",\"BMY\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/usao-edpa/pr/bristol-myers-squibb-pay-75-million-resolve-false-claims-act-allegations-underpayment\",\"\"',\n '\"Morton Grove Pharmaceuticals, Inc.\",\"Wockhardt Limited\",\"$9,000\",\"$0\",\"$9,000\",\"2007\",\"20070829\",\"miscellaneous offenses\",\"campaign finance violation\",\"\",\"\",\"federal\",\"agency action\",\"Federal Election Commission\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"India\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.fec.gov/data/legal/matter-under-review/5784/\",\"\"',\n '\"BAUSCH AND LOMB PHARMACEUTICALS, INC.\",\"Bausch Health\",\"$7,000\",\"$0\",\"$7,000\",\"2000\",\"20000321\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Florida\",\"TAMPA\",\"8500 HIDDEN RIVER PARKWAY\",\"33637\",\"000000\",\"\",\"Canada\",\"\",\"publicly traded\",\"BHC\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"MALLINCKRODT INC.\",\"Mallinckrodt\",\"$7,000\",\"$0\",\"$7,000\",\"2000\",\"20000607\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Missouri\",\"ST. LOUIS\",\"MALLINCKRODT & SECOND STREETS Z-4\",\"63147\",\"000000\",\"\",\"Ireland\",\"\",\"publicly traded\",\"MNK\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"DURAMED PHARMACEUTICALS, INC.\",\"Teva Pharmaceutical Industries\",\"$7,000\",\"$0\",\"$7,000\",\"2001\",\"20010823\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Ohio\",\"CINCINNATI\",\"5040 DURAMED ROAD\",\"45213\",\"000000\",\"\",\"Israel\",\"\",\"publicly traded\",\"TEVA\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"TEVA PHARMACEUTICALS INC.\",\"Teva Pharmaceutical Industries\",\"$15,300\",\"$0\",\"$15,300\",\"2002\",\"20020828\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Missouri\",\"MEXICO\",\"5000 SNYDER DRIVE\",\"65265\",\"325412\",\"325412: Pharmaceutical Preparation Manufacturing\",\"Israel\",\"\",\"publicly traded\",\"TEVA\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"K V PHARMACEUTICAL\",\"KV Pharmaceutical\",\"$9,000\",\"$0\",\"$9,000\",\"2000\",\"20000120\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Missouri\",\"ST. LOUIS\",\"2303 SCHUETZ\",\"63146\",\"000000\",\"\",\"USA\",\"Missouri\",\"out of business\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"IMPAX LABORATORIES, INC\",\"Amneal Pharmaceuticals\",\"$18,000\",\"$0\",\"$18,000\",\"2004\",\"20040617\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"HAYWARD\",\"30831 HUNTWOOD AVE\",\"94544\",\"325412\",\"325412: Pharmaceutical Preparation Manufacturing\",\"USA\",\"New Jersey\",\"publicly traded\",\"AMRX\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"ALPHARMA ANIMAL HEALTH COMPANY\",\"Zoetis\",\"$18,300\",\"$0\",\"$18,300\",\"2001\",\"20010925\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Arkansas\",\"LOWELL\",\"415 BLOOMINGTON\",\"72745\",\"000000\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"ZTS\",\"pharmaceuticals\",\"animal health products\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"GILEAD SCIENCES\",\"Gilead Sciences\",\"$5,700\",\"$0\",\"$5,700\",\"2000\",\"20000128\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"FOSTER CITY\",\"333 LAKESIDE DRIVE\",\"94404\",\"000000\",\"\",\"USA\",\"California\",\"publicly traded\",\"GILD\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"CHIRON CORPORATION\",\"Novartis\",\"$90,140\",\"$0\",\"$90,140\",\"2000\",\"20000607\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"EMERYVILLE\",\"6455 CHRISTIE AVE\",\"94608\",\"000000\",\"\",\"Switzerland\",\"\",\"publicly traded\",\"NYSE: NVS\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"PHIBRO-TECH INC.\",\"Phibro Animal Health\",\"$31,600\",\"$0\",\"$31,600\",\"2000\",\"20000711\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"UNION CITY\",\"34400 ZWISSIG WAY\",\"94587\",\"000000\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"PAHC\",\"pharmaceuticals\",\"animal health products\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"TEVA SICOR\",\"Teva Pharmaceutical Industries\",\"$5,000\",\"$0\",\"$5,000\",\"2005\",\"20051212\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"IRVINE\",\"19 HUGHES\",\"92618\",\"325412\",\"325412: Pharmaceutical Preparation Manufacturing\",\"Israel\",\"\",\"publicly traded\",\"TEVA\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"PHARMAVITE CORP\",\"Otsuka Pharmaceutical\",\"$18,300\",\"$0\",\"$18,300\",\"2001\",\"20011115\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"SAN FERNANDO\",\"1150 AVIATION PLACE\",\"91340\",\"000000\",\"\",\"Japan\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"PHARMAVITE\",\"Otsuka Pharmaceutical\",\"$20,055\",\"$0\",\"$20,055\",\"2005\",\"20050503\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"SAN FERNANADO\",\"1150 AVIATION PLACE\",\"91342\",\"325412\",\"325412: Pharmaceutical Preparation Manufacturing\",\"Japan\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"GENENTECH\",\"Roche\",\"$11,240\",\"$0\",\"$11,240\",\"2003\",\"20030116\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"SOUTH SAN FRANCISCO\",\"1 DNA WAY, BLDG. #5 STABILITY LABS\",\"94080\",\"325412\",\"325412: Pharmaceutical Preparation Manufacturing\",\"Switzerland\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"ELAN PHARMACEUTICALS INC.\",\"Perrigo\",\"$7,125\",\"$0\",\"$7,125\",\"2003\",\"20030910\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"SOUTH SAN FRANCISCO\",\"800 GATEWAY BLVD.\",\"94080\",\"325412\",\"325412: Pharmaceutical Preparation Manufacturing\",\"Ireland\",\"\",\"publicly traded\",\"PRGO\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"ELAN PHARMACEUTICALS INC.\",\"Perrigo\",\"$18,225\",\"$0\",\"$18,225\",\"2004\",\"20040809\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"SOUTH SAN FRANCISCO\",\"800 GATEWAY BLVD.\",\"94080\",\"325412\",\"325412: Pharmaceutical Preparation Manufacturing\",\"Ireland\",\"\",\"publicly traded\",\"PRGO\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"AMPHASTAR PHARMACEUTICALS INC\",\"Amphastar Pharmaceuticals\",\"$18,500\",\"$0\",\"$18,500\",\"2002\",\"20021011\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"RANCHO CUCAMONGA\",\"11570 6TH ST\",\"91730\",\"325412\",\"325412: Pharmaceutical Preparation Manufacturing\",\"USA\",\"California\",\"publicly traded\",\"AMPH\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"BAXTER HEALTHCARE CORP DBA BAXTER BIOSCIENCE\",\"Takeda Pharmaceutical\",\"$195,000\",\"$0\",\"$195,000\",\"2011\",\"20110121\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"LOS ANGELES\",\"4501 COLORADO BLVD.\",\"90039\",\"325412\",\"325412: Pharmaceutical Preparation Manufacturing\",\"Japan\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"ROCHE MOLECULAR SYSTEMS INC\",\"Roche\",\"$9,225\",\"$0\",\"$9,225\",\"2002\",\"20021105\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"ALAMEDA\",\"1145 ATLANTIC AVE\",\"94501\",\"000000\",\"\",\"Switzerland\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"PHIBRO-TECH, INC.\",\"Phibro Animal Health\",\"$10,950\",\"$0\",\"$10,950\",\"2000\",\"20000912\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"South Carolina\",\"SUMTER\",\"2395 CAINS MILL RD.\",\"29151\",\"000000\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"PAHC\",\"pharmaceuticals\",\"animal health products\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"TEVA PHARMACEUTICAL\",\"Teva Pharmaceutical Industries\",\"$5,000\",\"$0\",\"$5,000\",\"2000\",\"20000809\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"New Jersey\",\"ELMWOOD PARK\",\"92 ROUTE 46 EAST\",\"07407\",\"000000\",\"\",\"Israel\",\"\",\"publicly traded\",\"TEVA\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"St. Jude Medical Inc.\",\"Abbott Laboratories\",\"$27,000,000\",\"$0\",\"$27,000,000\",\"2021\",\"20210708\",\"safety-related offenses\",\"drug or medical equipment safety violation\",\"False Claims Act and related\",\"St. Jude Medical Inc. agreed to pay $27 million to settle allegations under the False Claims Act that, between November 2014 and October 2016, it knowingly sold defective heart devices to health care facilities that, in turn, implanted the devices into patients insured by federal health care programs.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/st-jude-agrees-pay-27-million-allegedly-selling-defective-heart-devices\",\"\"',\n '\"Alere Inc.\",\"Abbott Laboratories\",\"$38,750,000\",\"$0\",\"$38,750,000\",\"2021\",\"20210708\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"drug or medical equipment safety violation\",\"Medical device manufacturers Alere Inc. and Alere San Diego Inc. agreed to pay $38.75 million to resolve allegations that the companies violated the False Claims Act by billing, and causing others to bill, the Medicare program for defective rapid point-of-care testing devices.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/medical-device-companies-alere-inc-and-alere-san-diego-inc-agree-pay-3875-million-settle\",\"\"',\n '\"GlaxoSmithKline, LLC\",\"GlaxoSmithKline\",\"$15,000,000\",\"$0\",\"$15,000,000\",\"2013\",\"20131217\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"False Claims Act and related\",\"The Maryland Attorney announced the state had recovered $15 million from GlaxoSmithKline, LLC, resolving allegations that the company engaged in improper marketing of the prescription drugs Avandia, Avandamet and Avandaryl, all of which are used to treat diabetes.\",\"state\",\"agency action\",\"Maryland Attorney General\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Maryland\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: GSK\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.marylandattorneygeneral.gov/press/2013/121713a.pdf\",\"\"',\n '\"Purdue Pharma\",\"Purdue Pharma\",\"$10,000,000,000\",\"$0\",\"$10,000,000,000\",\"2021\",\"20210901\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"A federal bankruptcy judge approved a deal worth an estimated $10 billion between Purdue Pharma and state governments (and others) that had sued the company over its role in causing and perpetuating the opioid crisis. The settlement included a plan under which Purdue Pharma would be converted into a trust with responsibility for distributing funds for treatment programs. The settlement included payment of $4.3 billion by the Sackler family, which has controlled the company and which grew enormously wealthy from its operations. In exchange, the family was granted immunity from opioid lawsuits. \",\"state\",\"agency action\",\"Multistate Attorneys General Case\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Connecticut\",\"out of business\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.washingtonpost.com/business/2021/09/01/purdue-pharma-bankruptcy-judge-ruling/\",\"\"',\n '\"Bristol Myers Squibb Co.\",\"Bristol-Myers Squibb\",\"$75,000,000\",\"$0\",\"$75,000,000\",\"2021\",\"20210817\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Bristol Myers Squibb agreed to pay a total of $75 million in settlement of allegations it overcharged state Medicaid programs for drugs.\",\"state\",\"agency action\",\"Multistate Attorneys General Case\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New York\",\"publicly traded\",\"BMY\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://portal.ct.gov/AG/Press-Releases/2021-Press-Releases/AG-Tong-Announces-75-Million-Settlement-with-Bristol-Myers-Squibb-over-Medicaid-Charges\",\"\"',\n '\"Johnson & Johnson\",\"Johnson & Johnson\",\"$5,000,000,000\",\"$0\",\"$5,000,000,000\",\"2021\",\"20210721\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Johnson & Johnson, the parent company of Janssen Pharmaceuticals, reached an agreement with a group of states under which it would pay $5 billion to resolve Janssen\\'s involvement in litigation alleging improper sale of pain medications, contributing to the national opioid epidemic.\",\"state\",\"agency action\",\"Multistate Attorneys General Case\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"JNJ\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://ncdoj.gov/attorney-general-josh-stein-announces-26-billion-agreement-with-opioid-distributors-manufacturer/\",\"\"',\n '\"Endo Health Solutions\",\"Endo International\",\"$50,000,000\",\"$0\",\"$50,000,000\",\"2021\",\"20210910\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"settlement with drug manufacturer in multi-company opioid litigation\",\"state\",\"agency action\",\"New York Attorney General\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"New York\",\"\",\"\",\"\",\"\",\"\",\"Ireland\",\"\",\"publicly traded\",\"ENDP\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://ag.ny.gov/press-release/2021/attorney-general-james-secures-50-million-opioid-abatement-drug-manufacturer-endo\",\"\"',\n '\"Perrigo Company\",\"Perrigo\",\"$20,000\",\"$0\",\"$20,000\",\"2021\",\"20210501\",\"employment-related offenses\",\"employment discrimination\",\"\",\"\",\"local\",\"agency action\",\"New York City Commission on Human Rights\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"New York\",\"\",\"\",\"\",\"\",\"\",\"Ireland\",\"\",\"publicly traded\",\"PRGO\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www1.nyc.gov/site/cchr/enforcement/2021-settlements.page\",\"\"']","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[39]: ['\"Abbott Laboratories\",\"Abbott Laboratories\",\"$5,475,000\",\"$0\",\"$5,475,000\",\"2013\",\"20131227\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"Abbott Laboratories agreed to $5.475 million to resolve allegations that it violated the False Claims Act by paying kickbacks to induce doctors to implant the company\\'s carotid, biliary and peripheral vascular products.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/abbott-laboratories-pays-us-5475-million-settle-claims-company-paid-kickbacks-physicians\",\"\"',\n '\"Abbott Laboratories Inc.\",\"AbbVie\",\"$1,500,000,000\",\"$0\",\"$1,500,000,000\",\"2012\",\"20120507\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Global Health Care Company Abbott Laboratories Inc. has pleaded guilty and agreed to pay $1.5 billion to resolve its criminal and civil liability arising from the company\\'s unlawful promotion of the prescription drug Depakote for uses not approved as safe and effective by the Food and Drug Administration. The resolution - the second largest payment by a drug company - includes a criminal fine and forfeiture totaling $700 million and civil settlements with the federal government and the states totaling $800 million. Abbott also will be subject to court-supervised probation and reporting obligations for Abbotts CEO and Board of Directors.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABBV\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/abbott-labs-pay-15-billion-resolve-criminal-civil-investigations-label-promotion-depakote\",\"\"',\n '\"Abbott Laboratories Inc.\",\"AbbVie\",\"$126,500,000\",\"$0\",\"$126,500,000\",\"2010\",\"20101207\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Abbott Laboratories Inc., B. Braun Medical Inc. and Roxane Laboratories Inc. n/k/a Boehringer Ingelheim Roxane Inc. and affiliated entities agreed to pay $421 million to settle False Claims Act allegations, that they engaged in a scheme to report false and inflated prices for numerous pharmaceutical products knowing that federal healthcare programs relied on those reported prices to set payment rates.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABBV\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/pharmaceutical-manufacturers-pay-4212-million-settle-false-claims-act-cases\",\"\"',\n '\"Abbott Laboratories Puerto Rico, Inc.\",\"Abbott Laboratories\",\"$49,045\",\"$0\",\"$49,045\",\"2009\",\"20090305\",\"employment-related offenses\",\"wage and hour violation\",\"Fair Labor Standards Act\",\"\",\"federal\",\"agency action\",\"Labor Department Wage and Hour Division\",\"civil\",\"\",\"\",\"1527129\",\"\",\"\",\"Puerto Rico\",\"San Juan\",\"\",\"\",\"423450\",\"423450: Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"March 7, 2017 download of a dataset posted by the Wage and Hour Division at https://enforcedata.dol.gov/views/data_summary.php\",\"Date and year are the Findings End Date in the dataset posted by the Wage and Hour Division, which does not provide case opening or closing dates. The company name is the Legal Name provided by the dataset unless that field is blank, in which case the Trade Name is used. The dataset provides only one address and does not indicate whether it is the company headquarters address or the establishment address. The penalty amount is the total of civil monetary penalties and mandated back wages. The original dataset provides a breakdown.\"',\n '\"Acclarent Inc.\",\"Johnson & Johnson\",\"$18,000,000\",\"$0\",\"$18,000,000\",\"2016\",\"20160722\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"California-based medical device manufacturer Acclarent Inc., a subsidiary of Johnson & Johnson, agreed to pay $18 million to resolve allegations that the company caused health care providers to submit false claims to Medicare and other federal health care programs by marketing and distributing its sinus spacer product for use as a drug delivery device without Food and Drug Administration approval.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"JNJ\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/johnson-johnson-subsidiary-acclarent-inc-pays-government-18-million-settle-false-claims-act\",\"\"',\n '\"Advanced Medical Optics\",\"Abbott Laboratories\",\"$16,800\",\"$0\",\"$16,800\",\"2004\",\"20040412\",\"employment-related offenses\",\"labor relations violation\",\"\",\"back pay award in unfair labor practices case\",\"federal\",\"agency action\",\"National Labor Relations Board\",\"civil\",\"\",\"\",\"21-CA-36104-001\",\"\",\"\",\"California\",\"Irvine\",\"\",\"92606\",\"333314\",\"333314: Optical Instrument and Lens Manufacturing\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from an NLRB dataset covering 1999-2011 downloaded at https://catalog.data.gov/dataset/nlrb-cats-final-c-case-data-bulk-19990101-20110930-in-xml\",\"\"',\n '\"Advanced Neuromodulation Systems, Inc.\",\"Abbott Laboratories\",\"$2,950,000\",\"$0\",\"$2,950,000\",\"2007\",\"20070702\",\"healthcare-related offenses\",\"HHS civil monetary penalties\",\"kickbacks and bribery\",\"The HHS Inspector General announced that Advanced Neuromodulation Systems, Inc.,  a medical device manufacturer specializing in spinal cord stimulation used for pain management, agreed to pay $2.95 million to settle allegations that it paid kickbacks to physicians in violation of the Civil Monetary Penalties Law (CMPL). The company also entered into a 3-year Corporate Integrity Agreement.\",\"federal\",\"agency action\",\"Health & Human Services Department Office of Inspector General\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://oig.hhs.gov/publications/docs/press/2007/ANS%20Press%20Release.pdf\",\"\"',\n '\"Advanced Sterilization Products\",\"Johnson & Johnson\",\"$136,800\",\"$0\",\"$136,800\",\"2014\",\"20140520\",\"environment-related offenses\",\"environmental violation\",\"\",\"The U.S. Environmental Protection Agency announced that an Irvine, Calif. company, Advanced Sterilization Products, has agreed to pay a $136,800 penalty for the sale and distribution of unregistered and misbranded pesticides to veterinary clinics and laboratories nationwide.\",\"federal\",\"agency action\",\"Environmental Protection Agency\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"Irvine\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"JNJ\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://archive.epa.gov/epapages/newsroom_archive/newsreleases/8e820317c86e4c5685257cde00717855.html\",\"\"',\n '\"Advanced Sterilization Products, a division of Ethicon Inc.\",\"Johnson & Johnson\",\"$1,200,000\",\"$0\",\"$1,200,000\",\"2013\",\"20131204\",\"safety-related offenses\",\"drug or medical equipment safety violation\",\"\",\"Settlement of a civil money penalty action against Advanced Sterilization Products, a division of Ethicon Inc., a Johnson & Johnson company, and two of ASP\\'s executives alleging that ASP manufactured and distributed adulterated and misbranded sterilization monitoring products.\",\"federal\",\"agency action\",\"Food and Drug Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"Irvine\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"JNJ\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm377588.htm\",\"\"',\n '\"Alere San Diego Inc.\",\"Abbott Laboratories\",\"$10,572\",\"$0\",\"$10,572\",\"2017\",\"20170309\",\"employment-related offenses\",\"wage and hour violation\",\"Fair Labor Standards Act\",\"\",\"federal\",\"agency action\",\"Labor Department Wage and Hour Division\",\"civil\",\"\",\"\",\"1813371\",\"\",\"\",\"California\",\"Pomona\",\"828 Towne Center Dr.\",\"91767\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"July 23, 2017 download of a dataset posted by the Wage and Hour Division at https://enforcedata.dol.gov/views/data_summary.php\",\"Date and year are the Findings End Date in the dataset posted by the Wage and Hour Division, which does not provide case opening or closing dates. The company name is the Legal Name provided by the dataset unless that field is blank, in which case the Trade Name is used. The dataset provides only one address and does not indicate whether it is the company headquarters address or the establishment address. The penalty amount is the total of civil monetary penalties and mandated back wages. The original dataset provides a breakdown.\"',\n '\"Allergan Inc.\",\"AbbVie\",\"$600,000,000\",\"$0\",\"$600,000,000\",\"2010\",\"20100901\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"American pharmaceutical manufacturer Allergan Inc. has agreed to plead guilty and pay $600 million to resolve its criminal and civil liability arising from the company\\'s unlawful promotion of its biological product, Botox Therapeutic, for uses not approved as safe and effective by the Food and Drug Administration. The resolution included a criminal fine and forfeiture totaling $375 million and a civil settlement with the federal government and the states of $225 million.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABBV\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/allergan-agrees-plead-guilty-and-pay-600-million-resolve-allegations-label-promotion-botox\",\"\"',\n '\"Allergan Inc.\",\"AbbVie\",\"$15,000,000\",\"$0\",\"$15,000,000\",\"2017\",\"20170117\",\"financial offenses\",\"investor protection violation\",\"\",\"Allergan Inc. admitted securities law violations and agreed to pay a $15 million penalty for disclosure failures in the wake of a hostile takeover bid.\",\"federal\",\"agency action\",\"Securities and Exchange Commission\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABBV\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.sec.gov/news/pressrelease/2017-16.html\",\"\"',\n '\"Alpharma Inc.\",\"Pfizer\",\"$42,500,000\",\"$0\",\"$42,500,000\",\"2010\",\"20100316\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"Alpharma Inc. agreed to pay $42.5 million to resolve False Claims Act allegations in connection with the marketing of the morphine-based drug Kadian. The settlement resolved allegations that between January 1, 2000 and December 29, 2008 Alpharma paid health care providers to induce them to promote or prescribe Kadian, and made misrepresentations about the safety and efficacy of the drug. \",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New York\",\"publicly traded\",\"PFE\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/alpharma-pay-425-million-resolve-false-claims-act-allegations-connection-promotion-drug\",\"\"',\n '\"Alpharma, Inc.\",\"Pfizer\",\"$2,500,000\",\"$0\",\"$2,500,000\",\"2004\",\"20040812\",\"competition-related offenses\",\"price-fixing or anti-competitive practices\",\"consumer protection violation\",\"Generic drug manufacturers Alpharma Inc. and Perrigo Company agreed to give up a total of $6.25 million in illegal profits to settle Federal Trade Commission allegations that their agreement to limit competition for over-the-counter store-brand children\\'s liquid ibuprofen drove up prices and violated federal law.\",\"federal\",\"agency action\",\"Federal Trade Commission\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New York\",\"publicly traded\",\"PFE\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.ftc.gov/news-events/press-releases/2004/08/generic-drug-marketers-settle-ftc-charges\",\"\"',\n '\"American Pharmaceutical Partners, Inc.\",\"Bristol-Myers Squibb\",\"$160,203\",\"$0\",\"$160,203\",\"2004\",\"20041226\",\"employment-related offenses\",\"wage and hour violation\",\"Fair Labor Standards Act\",\"\",\"federal\",\"agency action\",\"Labor Department Wage and Hour Division\",\"civil\",\"\",\"\",\"1379241\",\"\",\"\",\"New York\",\"Grand Island\",\"\",\"14072\",\"32541\",\"32541: Pharmaceutical and Medicine Manufacturing\",\"USA\",\"New York\",\"publicly traded\",\"BMY\",\"pharmaceuticals\",\"pharmaceuticals\",\"March 7, 2017 download of a dataset posted by the Wage and Hour Division at https://enforcedata.dol.gov/views/data_summary.php\",\"Date and year are the Findings End Date in the dataset posted by the Wage and Hour Division, which does not provide case opening or closing dates. The company name is the Legal Name provided by the dataset unless that field is blank, in which case the Trade Name is used. The dataset provides only one address and does not indicate whether it is the company headquarters address or the establishment address. The penalty amount is the total of civil monetary penalties and mandated back wages. The original dataset provides a breakdown.\"',\n '\"Amgen Inc.\",\"Amgen\",\"$762,000,000\",\"$0\",\"$762,000,000\",\"2012\",\"20121219\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"U.S. District Judge Sterling Johnson, Jr. accepted a guilty plea by American biotechnology giant Amgen Inc. for illegally introducing a misbranded drug into interstate commerce. The plea is part of a global settlement with the United States in which Amgen agreed to pay $762 million to resolve criminal and civil liability arising from its sale and promotion of certain drugs.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"California\",\"publicly traded\",\"AMGN\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/amgen-inc-pleads-guilty-federal-charge-brooklyn-ny-pays-762-million-resolve-criminal\",\"\"',\n '\"Amgen Inc.\",\"Amgen\",\"$24,900,000\",\"$0\",\"$24,900,000\",\"2013\",\"20130416\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"Amgen Inc. agreed to pay the United States $24.9 million to settle allegations that it violated the False Claims Act. The company was accused of paying kickbacks  to long-term care pharmacy providers Omnicare Inc., PharMerica Corporation and Kindred Healthcare Inc. in return for implementing \"\"therapeutic interchange\"\" programs that were designed to switch Medicare and Medicaid beneficiaries from a competitor drug to Amgen\\'s Aranesp.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"California\",\"publicly traded\",\"AMGN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/amgen-pay-us-249-million-resolve-false-claims-act-allegations\",\"\"',\n '\"Amgen, Inc.\",\"Amgen\",\"$40,000\",\"$0\",\"$40,000\",\"2011\",\"20110302\",\"employment-related offenses\",\"labor relations violation\",\"\",\"back pay award in unfair labor practices case\",\"federal\",\"agency action\",\"National Labor Relations Board\",\"civil\",\"\",\"\",\"14-CA-30273-001\",\"\",\"\",\"Missouri\",\"St. Louis\",\"\",\"63130\",\"541720\",\"541720: Research and Development in the Social Sciences and Humanities\",\"USA\",\"California\",\"publicly traded\",\"AMGN\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from an NLRB dataset covering 1999-2011 downloaded at https://catalog.data.gov/dataset/nlrb-cats-final-c-case-data-bulk-19990101-20110930-in-xml\",\"\"',\n '\"Amneal Pharmaceuticals of NY, LLC\",\"Amneal Pharmaceuticals\",\"$99,000\",\"$0\",\"$99,000\",\"2015\",\"20150930\",\"employment-related offenses\",\"employment discrimination\",\"\",\"\",\"federal\",\"agency action\",\"Office of Federal Contract Compliance Programs\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"AMRX\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.dol.gov/ofccp/foia/files/AmnealPharmaceuticalsCA_Redacted.pdf\",\"\"',\n '\"Astellas Pharma US Inc.\",\"Astellas Pharma\",\"$7,300,000\",\"$0\",\"$7,300,000\",\"2014\",\"20140416\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"off-label or unapproved promotion of medical products\",\"Astellas Pharma US Inc. agreed to pay $7.3 million to resolve allegations that it violated the False Claims Act in connection with its marketing and promotion of the drug Mycamine for pediatric use, which had not received FDA approval.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Japan\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/astellas-pharma-us-inc-pay-73-million-resolve-false-claims-act-allegations-relating-marketing\",\"\"',\n '\"AstraZeneca\",\"AstraZeneca\",\"$250,000\",\"$0\",\"$250,000\",\"2011\",\"20110606\",\"employment-related offenses\",\"employment discrimination\",\"\",\"AstraZeneca agreed to pay $250,000 to 124 women who allegedly were subjected to pay discrimination while working at the corporation\\'s Philadelphia Business Center in Wayne, Pa. The action resolved a lawsuit filed by the U.S. Department of Labor in May 2010 alleging that the company discriminated against female sales specialists by paying them salaries that were, on average, $1,700 less than their male counterparts. \",\"federal\",\"agency action\",\"Office of Federal Contract Compliance Programs\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Pennsylvania\",\"Wayne\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.dol.gov/opa/media/press/ofccp/OFCCP20110829.htm\",\"\"',\n '\"AstraZeneca LP\",\"AstraZeneca\",\"$520,000,000\",\"$0\",\"$520,000,000\",\"2010\",\"20100427\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"AstraZeneca LP and AstraZeneca Pharmaceuticals LP will pay $520 million to resolve allegations that AstraZeneca illegally marketed the anti-psychotic drug Seroquel for uses not approved as safe and effective by the Food and Drug Administration, the Departments of Justice and Health and Human Services\\' Health Care Fraud Enforcement Action Team.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/pharmaceutical-giant-astrazeneca-pay-520-million-label-drug-marketing\",\"\"',\n '\"AstraZeneca LP\",\"AstraZeneca\",\"$46,500,000\",\"$0\",\"$46,500,000\",\"2015\",\"20150706\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"AstraZeneca LP agreed to pay the United States and participating states a total of $46.5 million, plus interest, to resolve allegations that it knowingly underpaid rebates owed under the Medicaid Drug Rebate Program.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/astrazeneca-and-cephalon-pay-465-million-and-75-million-respectively-allegedly-underpaying\",\"\"',\n '\"AstraZeneca LP\",\"AstraZeneca\",\"$7,900,000\",\"$0\",\"$7,900,000\",\"2015\",\"20150211\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"AstraZeneca LP, a pharmaceutical manufacturer based in Delaware, agreed to pay the government $7.9 million to settle allegations that it engaged in a kickback scheme in violation of the False Claims Act.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/astrazeneca-pay-79-million-resolve-kickback-allegations\",\"\"',\n '\"AstraZeneca Pharmaceuticals\",\"AstraZeneca\",\"$2,600,000\",\"$0\",\"$2,600,000\",\"2009\",\"20091019\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Mylan Pharmaceuticals, UDL Laboratories, AstraZeneca Pharmaceuticals and Ortho McNeil Pharmaceutical entered into settlement agreements for a total of $124 million to resolve claims that they violated the False Claims Act by failing to pay appropriate rebates to state Medicaid programs for drugs paid for by those programs.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/four-pharmaceutical-companies-pay-124-million-submission-false-claims-medicaid\",\"\"',\n '\"AstraZeneca Pharmaceuticals LP\",\"AstraZeneca\",\"$354,900,000\",\"$0\",\"$354,900,000\",\"2003\",\"20030620\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"AstraZeneca Pharmaceuticals LP pleaded guilty in federal district court in Wilmington, Delaware and agreed to pay $354.9 million to resolve criminal charges and civil liabilities in connection with its drug pricing and marketing practices with regard to Zoladex, a drug used primarily for the treatment of prostate cancer. AstraZeneca agreed to pay a criminal fine of $63.9 million as part of pleaded guilty to conspiring to violate the Prescription Drug Marketing Act by causing to be submitted claims for payment for the prescription of Zoladex which had been provided as free samples to urologists. AstraZeneca agreed to settle its federal civil False Claim Act liabilities and to pay the U.S. government $266.1 million to resolve allegations it caused false and fraudulent claims to be filed with the Medicare; another $24.9 million was to be paid to states to resolve similar claims concerning Medicaid.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/archive/opa/pr/2003/June/03_civ_371.htm\",\"\"',\n '\"AstraZeneca PLC\",\"AstraZeneca\",\"$5,522,000\",\"$0\",\"$5,522,000\",\"2016\",\"20160830\",\"competition-related offenses\",\"kickbacks and bribery\",\"\",\"\",\"federal\",\"agency action\",\"Securities and Exchange Commission\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.sec.gov/litigation/admin/2016/34-78730.pdf\",\"\"',\n '\"Aventis Pharmaceutical Inc.\",\"Sanofi\",\"$95,500,000\",\"$0\",\"$95,500,000\",\"2009\",\"20090528\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Aventis Pharmaceutical Inc. agreed to pay the United States $95.5 million to settle allegations that it violated the False Claims Act by misreporting drug prices in order to reduce its Medicaid Drug Rebate obligations.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"France\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/aventis-pharmaceutical-pay-us-955-million-settle-false-claims-act-allegations\",\"\"',\n '\"Aventis Pharmaceuticals Inc.\",\"Sanofi\",\"$190,000,000\",\"$0\",\"$190,000,000\",\"2007\",\"20070910\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"fraud\",\"Aventis Pharmaceuticals Inc. paid the United States and a number of states, as well as the District of Columbia, over $190 million to resolve allegations that the company caused false claims to be filed with Medicare and other federal health programs as a result of the company\\'s alleged fraudulent pricing and marketing of drugs. Aventis, which changed its name to Sanofi-Aventis,  agreed to settle False Claims Act allegations concerning its pricing and marketing of Anzemet, an antiemetic drug used primarily in conjunction with oncology and radiation treatment to prevent nausea and vomiting. \",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"France\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/archive/opa/pr/2007/September/07_civ_694.html\",\"\"',\n '\"AVEO Pharmaceuticals Inc.\",\"AVEO Pharmaceuticals\",\"$4,000,000\",\"$0\",\"$4,000,000\",\"2016\",\"20160329\",\"financial offenses\",\"investor protection violation\",\"\",\"The SEC announced fraud charges against a Massachusetts-based biotech company and three former executives for misleading investors about the company\\'s efforts to obtain Food and Drug Administration approval for its flagship developmental drug to treat kidney cancer. The SEC alleged that AVEO Pharmaceuticals Inc. concealed the FDA\\'s level of concern about Tivozanib in public statements to investors by omitting the critical fact that FDA staff had recommended a second clinical trial to address their concerns about patient death rates during the first clinical trial.  When the FDA made public months later that it had recommended an additional\n\n*** WARNING: max output size exceeded, skipping output. ***\n\nodt\",\"$7,499\",\"$0\",\"$7,499\",\"2014\",\"20140502\",\"environment-related offenses\",\"environmental violation\",\"\",\"\",\"state\",\"agency action\",\"New York Department of Environmental Conservation\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"New York\",\"Hobart\",\"\",\"\",\"\",\"\",\"Ireland\",\"\",\"publicly traded\",\"MNK\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://web.archive.org/web/20201128041726/https://www.dec.ny.gov/docs/regions_pdf/mallinckrodt.pdf\",\"\"',\n '\"EMD Chemicals Inc.\",\"Merck KGaA (EMD)\",\"$30,700\",\"$0\",\"$30,700\",\"2008\",\"20080717\",\"environment-related offenses\",\"environmental violation\",\"\",\"\",\"state\",\"agency action\",\"Ohio Environmental Protection Agency\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Ohio\",\"Cincinnati\",\"\",\"\",\"\",\"\",\"Germany\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://edocpub.epa.ohio.gov/publicportal/ViewDocument.aspx?docid=52149\",\"Penalty listed includes a $6,140 Supplemental Environmental Project.\"',\n '\"EMD Chemicals Inc.\",\"Merck KGaA (EMD)\",\"$32,000\",\"$0\",\"$32,000\",\"2005\",\"20050721\",\"environment-related offenses\",\"environmental violation\",\"\",\"\",\"state\",\"agency action\",\"Ohio Environmental Protection Agency\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Ohio\",\"Cincinnati\",\"\",\"\",\"\",\"\",\"Germany\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://edocpub.epa.ohio.gov/publicportal/ViewDocument.aspx?docid=295488\",\"\"',\n '\"PHIBRO-TECH, INC\",\"Phibro Animal Health\",\"$15,000\",\"$0\",\"$15,000\",\"2011\",\"20110216\",\"environment-related offenses\",\"environmental violation\",\"\",\"hazardous waste violation\",\"state\",\"agency action\",\"South Carolina Department of Health and Environmental Control\",\"civil\",\"\",\"\",\"11-04-HW\",\"\",\"\",\"South Carolina\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"PAHC\",\"pharmaceuticals\",\"animal health products\",\"Contained in data received from the agency on October 22, 2020 in response to an open records request.\",\"\"',\n '\"PHIBRO-TECH\",\"Phibro Animal Health\",\"$7,500\",\"$0\",\"$7,500\",\"2004\",\"20040730\",\"environment-related offenses\",\"environmental violation\",\"\",\"air quality violation\",\"state\",\"agency action\",\"South Carolina Department of Health and Environmental Control\",\"civil\",\"\",\"\",\"04-046-A\",\"\",\"\",\"South Carolina\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"PAHC\",\"pharmaceuticals\",\"animal health products\",\"Contained in data received from the agency on October 22, 2020 in response to an open records request.\",\"\"',\n '\"Merck Sharp & Dohme Corp.\",\"Merck\",\"$20,925\",\"$0\",\"$20,925\",\"2020\",\"20200325\",\"environment-related offenses\",\"environmental violation\",\"\",\"\",\"state\",\"agency action\",\"Virginia Department of Environmental Quality\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Virginia\",\"Elkton\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"MRK\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.deq.virginia.gov/permits-regulations/enforcement/final-orders\",\"\"',\n '\"Merck Sharp & Dohme Corp.\",\"Merck\",\"$17,290\",\"$0\",\"$17,290\",\"2019\",\"20190822\",\"environment-related offenses\",\"environmental violation\",\"\",\"\",\"state\",\"agency action\",\"Virginia Department of Environmental Quality\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Virginia\",\"Elkton\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"MRK\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.deq.virginia.gov/permits-regulations/enforcement/final-orders\",\"\"',\n '\"Indivior plc\",\"Indivior Inc.\",\"$300,000,000\",\"$0\",\"$300,000,000\",\"2021\",\"20210427\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Indivior agreed to pay over $300 million to state governments to resolve allegations that it falsely and aggressively marketed Suboxone, resulting in improper use of state Medicaid funds. Suboxone is a drug product approved for use by recovering opioid addicts to avoid or reduce withdrawal symptoms while they undergo treatment. \",\"state\",\"agency action\",\"Multistate Attorneys General Case\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Virginia\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.oag.ca.gov/news/press-releases/attorney-general-bonta-announces-300-million-settlement-against-indivior\",\"\"',\n '\"CSL Behring, LLC\",\"CSL Limited\",\"$527,144\",\"$0\",\"$527,144\",\"2021\",\"20210504\",\"environment-related offenses\",\"environmental violation\",\"\",\"Clean Air Act\",\"federal\",\"agency action\",\"Environmental Protection Agency referral to the Justice Department\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Illinois\",\"\",\"\",\"\",\"\",\"\",\"Australia\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.epa.gov/newsreleases/epa-reaches-settlement-csl-behring-illinois-improve-risk-management-program\",\"\"',\n '\"Incyte Corporation\",\"Incyte Corp.\",\"$12,600,000\",\"$0\",\"$12,600,000\",\"2021\",\"20210504\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"The settlement resolved allegations that, from November 2011 through December 2014, Incyte Corporation purportedly used an independent foundation as a conduit to pay the copays of certain federal beneficiaries taking Incyte\\' drug Jakafi, which was approved to treat myleofibrosis in 2011. Specifically, Incyte was the sole donor to a fund that was opened in November 2011 to assist only myleofibrosis patients. After the fund opened, the government alleges that Incyte used the fund to pay the copays of federal beneficiaries taking Jakafi who were ineligible for assistance from the fund because they did not have myleofibrosis. Incyte managers pressured the foundation, through phone calls and emails, to provide economic assistance to these ineligible patients, and Incyte\\'s contractor helped ineligible patients to complete applications submitted to the fund for assistance. The government alleges that through this conduct, Incyte caused false claims for Jakafi to be submitted to Medicare and TRICARE.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Delaware\",\"publicly traded\",\"INCY\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/incyte-corporation-pay-126-million-resolve-false-claims-act-allegations-paying-kickbacks\",\"\"',\n '\"Bristol-Myers Squibb\",\"Bristol-Myers Squibb\",\"$75,000,000\",\"$0\",\"$75,000,000\",\"2021\",\"20210401\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Bristol-Myers Squibb agreed to pay the United States and participating states a total of $75 million, plus interest, to resolve allegations that it knowingly underpaid rebates owed under the Medicaid Drug Rebate Program. Of that amount, BMS will pay approximately $41 million, plus interest, to the United States, and the remainder to states participating in the settlement.\",\"federal\",\"agency action\",\"U.S. Attorney-Eastern District of Pennsylvania\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New York\",\"publicly traded\",\"BMY\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/usao-edpa/pr/bristol-myers-squibb-pay-75-million-resolve-false-claims-act-allegations-underpayment\",\"\"',\n '\"Morton Grove Pharmaceuticals, Inc.\",\"Wockhardt Limited\",\"$9,000\",\"$0\",\"$9,000\",\"2007\",\"20070829\",\"miscellaneous offenses\",\"campaign finance violation\",\"\",\"\",\"federal\",\"agency action\",\"Federal Election Commission\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"India\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.fec.gov/data/legal/matter-under-review/5784/\",\"\"',\n '\"BAUSCH AND LOMB PHARMACEUTICALS, INC.\",\"Bausch Health\",\"$7,000\",\"$0\",\"$7,000\",\"2000\",\"20000321\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Florida\",\"TAMPA\",\"8500 HIDDEN RIVER PARKWAY\",\"33637\",\"000000\",\"\",\"Canada\",\"\",\"publicly traded\",\"BHC\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"MALLINCKRODT INC.\",\"Mallinckrodt\",\"$7,000\",\"$0\",\"$7,000\",\"2000\",\"20000607\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Missouri\",\"ST. LOUIS\",\"MALLINCKRODT & SECOND STREETS Z-4\",\"63147\",\"000000\",\"\",\"Ireland\",\"\",\"publicly traded\",\"MNK\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"DURAMED PHARMACEUTICALS, INC.\",\"Teva Pharmaceutical Industries\",\"$7,000\",\"$0\",\"$7,000\",\"2001\",\"20010823\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Ohio\",\"CINCINNATI\",\"5040 DURAMED ROAD\",\"45213\",\"000000\",\"\",\"Israel\",\"\",\"publicly traded\",\"TEVA\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"TEVA PHARMACEUTICALS INC.\",\"Teva Pharmaceutical Industries\",\"$15,300\",\"$0\",\"$15,300\",\"2002\",\"20020828\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Missouri\",\"MEXICO\",\"5000 SNYDER DRIVE\",\"65265\",\"325412\",\"325412: Pharmaceutical Preparation Manufacturing\",\"Israel\",\"\",\"publicly traded\",\"TEVA\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"K V PHARMACEUTICAL\",\"KV Pharmaceutical\",\"$9,000\",\"$0\",\"$9,000\",\"2000\",\"20000120\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Missouri\",\"ST. LOUIS\",\"2303 SCHUETZ\",\"63146\",\"000000\",\"\",\"USA\",\"Missouri\",\"out of business\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"IMPAX LABORATORIES, INC\",\"Amneal Pharmaceuticals\",\"$18,000\",\"$0\",\"$18,000\",\"2004\",\"20040617\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"HAYWARD\",\"30831 HUNTWOOD AVE\",\"94544\",\"325412\",\"325412: Pharmaceutical Preparation Manufacturing\",\"USA\",\"New Jersey\",\"publicly traded\",\"AMRX\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"ALPHARMA ANIMAL HEALTH COMPANY\",\"Zoetis\",\"$18,300\",\"$0\",\"$18,300\",\"2001\",\"20010925\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Arkansas\",\"LOWELL\",\"415 BLOOMINGTON\",\"72745\",\"000000\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"ZTS\",\"pharmaceuticals\",\"animal health products\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"GILEAD SCIENCES\",\"Gilead Sciences\",\"$5,700\",\"$0\",\"$5,700\",\"2000\",\"20000128\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"FOSTER CITY\",\"333 LAKESIDE DRIVE\",\"94404\",\"000000\",\"\",\"USA\",\"California\",\"publicly traded\",\"GILD\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"CHIRON CORPORATION\",\"Novartis\",\"$90,140\",\"$0\",\"$90,140\",\"2000\",\"20000607\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"EMERYVILLE\",\"6455 CHRISTIE AVE\",\"94608\",\"000000\",\"\",\"Switzerland\",\"\",\"publicly traded\",\"NYSE: NVS\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"PHIBRO-TECH INC.\",\"Phibro Animal Health\",\"$31,600\",\"$0\",\"$31,600\",\"2000\",\"20000711\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"UNION CITY\",\"34400 ZWISSIG WAY\",\"94587\",\"000000\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"PAHC\",\"pharmaceuticals\",\"animal health products\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"TEVA SICOR\",\"Teva Pharmaceutical Industries\",\"$5,000\",\"$0\",\"$5,000\",\"2005\",\"20051212\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"IRVINE\",\"19 HUGHES\",\"92618\",\"325412\",\"325412: Pharmaceutical Preparation Manufacturing\",\"Israel\",\"\",\"publicly traded\",\"TEVA\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"PHARMAVITE CORP\",\"Otsuka Pharmaceutical\",\"$18,300\",\"$0\",\"$18,300\",\"2001\",\"20011115\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"SAN FERNANDO\",\"1150 AVIATION PLACE\",\"91340\",\"000000\",\"\",\"Japan\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"PHARMAVITE\",\"Otsuka Pharmaceutical\",\"$20,055\",\"$0\",\"$20,055\",\"2005\",\"20050503\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"SAN FERNANADO\",\"1150 AVIATION PLACE\",\"91342\",\"325412\",\"325412: Pharmaceutical Preparation Manufacturing\",\"Japan\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"GENENTECH\",\"Roche\",\"$11,240\",\"$0\",\"$11,240\",\"2003\",\"20030116\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"SOUTH SAN FRANCISCO\",\"1 DNA WAY, BLDG. #5 STABILITY LABS\",\"94080\",\"325412\",\"325412: Pharmaceutical Preparation Manufacturing\",\"Switzerland\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"ELAN PHARMACEUTICALS INC.\",\"Perrigo\",\"$7,125\",\"$0\",\"$7,125\",\"2003\",\"20030910\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"SOUTH SAN FRANCISCO\",\"800 GATEWAY BLVD.\",\"94080\",\"325412\",\"325412: Pharmaceutical Preparation Manufacturing\",\"Ireland\",\"\",\"publicly traded\",\"PRGO\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"ELAN PHARMACEUTICALS INC.\",\"Perrigo\",\"$18,225\",\"$0\",\"$18,225\",\"2004\",\"20040809\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"SOUTH SAN FRANCISCO\",\"800 GATEWAY BLVD.\",\"94080\",\"325412\",\"325412: Pharmaceutical Preparation Manufacturing\",\"Ireland\",\"\",\"publicly traded\",\"PRGO\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"AMPHASTAR PHARMACEUTICALS INC\",\"Amphastar Pharmaceuticals\",\"$18,500\",\"$0\",\"$18,500\",\"2002\",\"20021011\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"RANCHO CUCAMONGA\",\"11570 6TH ST\",\"91730\",\"325412\",\"325412: Pharmaceutical Preparation Manufacturing\",\"USA\",\"California\",\"publicly traded\",\"AMPH\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"BAXTER HEALTHCARE CORP DBA BAXTER BIOSCIENCE\",\"Takeda Pharmaceutical\",\"$195,000\",\"$0\",\"$195,000\",\"2011\",\"20110121\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"LOS ANGELES\",\"4501 COLORADO BLVD.\",\"90039\",\"325412\",\"325412: Pharmaceutical Preparation Manufacturing\",\"Japan\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"ROCHE MOLECULAR SYSTEMS INC\",\"Roche\",\"$9,225\",\"$0\",\"$9,225\",\"2002\",\"20021105\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"ALAMEDA\",\"1145 ATLANTIC AVE\",\"94501\",\"000000\",\"\",\"Switzerland\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"PHIBRO-TECH, INC.\",\"Phibro Animal Health\",\"$10,950\",\"$0\",\"$10,950\",\"2000\",\"20000912\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"South Carolina\",\"SUMTER\",\"2395 CAINS MILL RD.\",\"29151\",\"000000\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"PAHC\",\"pharmaceuticals\",\"animal health products\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"TEVA PHARMACEUTICAL\",\"Teva Pharmaceutical Industries\",\"$5,000\",\"$0\",\"$5,000\",\"2000\",\"20000809\",\"safety-related offenses\",\"workplace safety or health violation\",\"\",\"\",\"federal\",\"agency action\",\"Occupational Safety & Health Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"New Jersey\",\"ELMWOOD PARK\",\"92 ROUTE 46 EAST\",\"07407\",\"000000\",\"\",\"Israel\",\"\",\"publicly traded\",\"TEVA\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from a download of OSHA\\'s Enforcment Data downloaded on 9/16/2021, available at https://enforcedata.dol.gov/views/data_catalogs.php\",\"\"',\n '\"St. Jude Medical Inc.\",\"Abbott Laboratories\",\"$27,000,000\",\"$0\",\"$27,000,000\",\"2021\",\"20210708\",\"safety-related offenses\",\"drug or medical equipment safety violation\",\"False Claims Act and related\",\"St. Jude Medical Inc. agreed to pay $27 million to settle allegations under the False Claims Act that, between November 2014 and October 2016, it knowingly sold defective heart devices to health care facilities that, in turn, implanted the devices into patients insured by federal health care programs.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/st-jude-agrees-pay-27-million-allegedly-selling-defective-heart-devices\",\"\"',\n '\"Alere Inc.\",\"Abbott Laboratories\",\"$38,750,000\",\"$0\",\"$38,750,000\",\"2021\",\"20210708\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"drug or medical equipment safety violation\",\"Medical device manufacturers Alere Inc. and Alere San Diego Inc. agreed to pay $38.75 million to resolve allegations that the companies violated the False Claims Act by billing, and causing others to bill, the Medicare program for defective rapid point-of-care testing devices.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/medical-device-companies-alere-inc-and-alere-san-diego-inc-agree-pay-3875-million-settle\",\"\"',\n '\"GlaxoSmithKline, LLC\",\"GlaxoSmithKline\",\"$15,000,000\",\"$0\",\"$15,000,000\",\"2013\",\"20131217\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"False Claims Act and related\",\"The Maryland Attorney announced the state had recovered $15 million from GlaxoSmithKline, LLC, resolving allegations that the company engaged in improper marketing of the prescription drugs Avandia, Avandamet and Avandaryl, all of which are used to treat diabetes.\",\"state\",\"agency action\",\"Maryland Attorney General\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Maryland\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: GSK\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.marylandattorneygeneral.gov/press/2013/121713a.pdf\",\"\"',\n '\"Purdue Pharma\",\"Purdue Pharma\",\"$10,000,000,000\",\"$0\",\"$10,000,000,000\",\"2021\",\"20210901\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"A federal bankruptcy judge approved a deal worth an estimated $10 billion between Purdue Pharma and state governments (and others) that had sued the company over its role in causing and perpetuating the opioid crisis. The settlement included a plan under which Purdue Pharma would be converted into a trust with responsibility for distributing funds for treatment programs. The settlement included payment of $4.3 billion by the Sackler family, which has controlled the company and which grew enormously wealthy from its operations. In exchange, the family was granted immunity from opioid lawsuits. \",\"state\",\"agency action\",\"Multistate Attorneys General Case\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Connecticut\",\"out of business\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.washingtonpost.com/business/2021/09/01/purdue-pharma-bankruptcy-judge-ruling/\",\"\"',\n '\"Bristol Myers Squibb Co.\",\"Bristol-Myers Squibb\",\"$75,000,000\",\"$0\",\"$75,000,000\",\"2021\",\"20210817\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Bristol Myers Squibb agreed to pay a total of $75 million in settlement of allegations it overcharged state Medicaid programs for drugs.\",\"state\",\"agency action\",\"Multistate Attorneys General Case\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New York\",\"publicly traded\",\"BMY\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://portal.ct.gov/AG/Press-Releases/2021-Press-Releases/AG-Tong-Announces-75-Million-Settlement-with-Bristol-Myers-Squibb-over-Medicaid-Charges\",\"\"',\n '\"Johnson & Johnson\",\"Johnson & Johnson\",\"$5,000,000,000\",\"$0\",\"$5,000,000,000\",\"2021\",\"20210721\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Johnson & Johnson, the parent company of Janssen Pharmaceuticals, reached an agreement with a group of states under which it would pay $5 billion to resolve Janssen\\'s involvement in litigation alleging improper sale of pain medications, contributing to the national opioid epidemic.\",\"state\",\"agency action\",\"Multistate Attorneys General Case\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"JNJ\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://ncdoj.gov/attorney-general-josh-stein-announces-26-billion-agreement-with-opioid-distributors-manufacturer/\",\"\"',\n '\"Endo Health Solutions\",\"Endo International\",\"$50,000,000\",\"$0\",\"$50,000,000\",\"2021\",\"20210910\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"settlement with drug manufacturer in multi-company opioid litigation\",\"state\",\"agency action\",\"New York Attorney General\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"New York\",\"\",\"\",\"\",\"\",\"\",\"Ireland\",\"\",\"publicly traded\",\"ENDP\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://ag.ny.gov/press-release/2021/attorney-general-james-secures-50-million-opioid-abatement-drug-manufacturer-endo\",\"\"',\n '\"Perrigo Company\",\"Perrigo\",\"$20,000\",\"$0\",\"$20,000\",\"2021\",\"20210501\",\"employment-related offenses\",\"employment discrimination\",\"\",\"\",\"local\",\"agency action\",\"New York City Commission on Human Rights\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"New York\",\"\",\"\",\"\",\"\",\"\",\"Ireland\",\"\",\"publicly traded\",\"PRGO\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www1.nyc.gov/site/cchr/enforcement/2021-settlements.page\",\"\"']"]}}],"execution_count":0},{"cell_type":"code","source":["splpharmardd= pharmardd1.map(lambda x: x.split(\",\")) #map() was used to apply lambda(transformation function) on every element of clinicrdd1 using by split () function used for splitting the string column on (\",\") delimeter\nsplpharmardd.take(10)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"04f66c27-7072-4b9a-b22a-09022f9087d6"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[40]: [['\"Abbott Laboratories\"',\n  '\"Abbott Laboratories\"',\n  '\"$5',\n  '475',\n  '000\"',\n  '\"$0\"',\n  '\"$5',\n  '475',\n  '000\"',\n  '\"2013\"',\n  '\"20131227\"',\n  '\"government-contracting-related offenses\"',\n  '\"False Claims Act and related\"',\n  '\"kickbacks and bribery\"',\n  '\"Abbott Laboratories agreed to $5.475 million to resolve allegations that it violated the False Claims Act by paying kickbacks to induce doctors to implant the company\\'s carotid',\n  ' biliary and peripheral vascular products.\"',\n  '\"federal\"',\n  '\"agency action\"',\n  '\"Justice Department Civil Division\"',\n  '\"civil\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"USA\"',\n  '\"Illinois\"',\n  '\"publicly traded\"',\n  '\"ABT\"',\n  '\"pharmaceuticals\"',\n  '\"pharmaceuticals\"',\n  '\"https://www.justice.gov/opa/pr/abbott-laboratories-pays-us-5475-million-settle-claims-company-paid-kickbacks-physicians\"',\n  '\"\"'],\n ['\"Abbott Laboratories Inc.\"',\n  '\"AbbVie\"',\n  '\"$1',\n  '500',\n  '000',\n  '000\"',\n  '\"$0\"',\n  '\"$1',\n  '500',\n  '000',\n  '000\"',\n  '\"2012\"',\n  '\"20120507\"',\n  '\"healthcare-related offenses\"',\n  '\"off-label or unapproved promotion of medical products\"',\n  '\"\"',\n  '\"Global Health Care Company Abbott Laboratories Inc. has pleaded guilty and agreed to pay $1.5 billion to resolve its criminal and civil liability arising from the company\\'s unlawful promotion of the prescription drug Depakote for uses not approved as safe and effective by the Food and Drug Administration. The resolution - the second largest payment by a drug company - includes a criminal fine and forfeiture totaling $700 million and civil settlements with the federal government and the states totaling $800 million. Abbott also will be subject to court-supervised probation and reporting obligations for Abbotts CEO and Board of Directors.\"',\n  '\"federal\"',\n  '\"agency action\"',\n  '\"Food and Drug Administration referral to the Justice Department\"',\n  '\"civil and criminal\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"USA\"',\n  '\"Illinois\"',\n  '\"publicly traded\"',\n  '\"ABBV\"',\n  '\"pharmaceuticals\"',\n  '\"pharmaceuticals\"',\n  '\"http://www.justice.gov/opa/pr/abbott-labs-pay-15-billion-resolve-criminal-civil-investigations-label-promotion-depakote\"',\n  '\"\"'],\n ['\"Abbott Laboratories Inc.\"',\n  '\"AbbVie\"',\n  '\"$126',\n  '500',\n  '000\"',\n  '\"$0\"',\n  '\"$126',\n  '500',\n  '000\"',\n  '\"2010\"',\n  '\"20101207\"',\n  '\"government-contracting-related offenses\"',\n  '\"False Claims Act and related\"',\n  '\"\"',\n  '\"Abbott Laboratories Inc.',\n  ' B. Braun Medical Inc. and Roxane Laboratories Inc. n/k/a Boehringer Ingelheim Roxane Inc. and affiliated entities agreed to pay $421 million to settle False Claims Act allegations',\n  ' that they engaged in a scheme to report false and inflated prices for numerous pharmaceutical products knowing that federal healthcare programs relied on those reported prices to set payment rates.\"',\n  '\"federal\"',\n  '\"agency action\"',\n  '\"Justice Department Civil Division\"',\n  '\"civil\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"USA\"',\n  '\"Illinois\"',\n  '\"publicly traded\"',\n  '\"ABBV\"',\n  '\"pharmaceuticals\"',\n  '\"pharmaceuticals\"',\n  '\"https://www.justice.gov/opa/pr/pharmaceutical-manufacturers-pay-4212-million-settle-false-claims-act-cases\"',\n  '\"\"'],\n ['\"Abbott Laboratories Puerto Rico',\n  ' Inc.\"',\n  '\"Abbott Laboratories\"',\n  '\"$49',\n  '045\"',\n  '\"$0\"',\n  '\"$49',\n  '045\"',\n  '\"2009\"',\n  '\"20090305\"',\n  '\"employment-related offenses\"',\n  '\"wage and hour violation\"',\n  '\"Fair Labor Standards Act\"',\n  '\"\"',\n  '\"federal\"',\n  '\"agency action\"',\n  '\"Labor Department Wage and Hour Division\"',\n  '\"civil\"',\n  '\"\"',\n  '\"\"',\n  '\"1527129\"',\n  '\"\"',\n  '\"\"',\n  '\"Puerto Rico\"',\n  '\"San Juan\"',\n  '\"\"',\n  '\"\"',\n  '\"423450\"',\n  '\"423450: Medical',\n  ' Dental',\n  ' and Hospital Equipment and Supplies Merchant Wholesalers\"',\n  '\"USA\"',\n  '\"Illinois\"',\n  '\"publicly traded\"',\n  '\"ABT\"',\n  '\"pharmaceuticals\"',\n  '\"pharmaceuticals\"',\n  '\"March 7',\n  ' 2017 download of a dataset posted by the Wage and Hour Division at https://enforcedata.dol.gov/views/data_summary.php\"',\n  '\"Date and year are the Findings End Date in the dataset posted by the Wage and Hour Division',\n  ' which does not provide case opening or closing dates. The company name is the Legal Name provided by the dataset unless that field is blank',\n  ' in which case the Trade Name is used. The dataset provides only one address and does not indicate whether it is the company headquarters address or the establishment address. The penalty amount is the total of civil monetary penalties and mandated back wages. The original dataset provides a breakdown.\"'],\n ['\"Acclarent Inc.\"',\n  '\"Johnson & Johnson\"',\n  '\"$18',\n  '000',\n  '000\"',\n  '\"$0\"',\n  '\"$18',\n  '000',\n  '000\"',\n  '\"2016\"',\n  '\"20160722\"',\n  '\"government-contracting-related offenses\"',\n  '\"False Claims Act and related\"',\n  '\"\"',\n  '\"California-based medical device manufacturer Acclarent Inc.',\n  ' a subsidiary of Johnson & Johnson',\n  ' agreed to pay $18 million to resolve allegations that the company caused health care providers to submit false claims to Medicare and other federal health care programs by marketing and distributing its sinus spacer product for use as a drug delivery device without Food and Drug Administration approval.\"',\n  '\"federal\"',\n  '\"agency action\"',\n  '\"Justice Department Civil Division\"',\n  '\"civil\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"USA\"',\n  '\"New Jersey\"',\n  '\"publicly traded\"',\n  '\"JNJ\"',\n  '\"pharmaceuticals\"',\n  '\"pharmaceuticals\"',\n  '\"https://www.justice.gov/opa/pr/johnson-johnson-subsidiary-acclarent-inc-pays-government-18-million-settle-false-claims-act\"',\n  '\"\"'],\n ['\"Advanced Medical Optics\"',\n  '\"Abbott Laboratories\"',\n  '\"$16',\n  '800\"',\n  '\"$0\"',\n  '\"$16',\n  '800\"',\n  '\"2004\"',\n  '\"20040412\"',\n  '\"employment-related offenses\"',\n  '\"labor relations violation\"',\n  '\"\"',\n  '\"back pay award in unfair labor practices case\"',\n  '\"federal\"',\n  '\"agency action\"',\n  '\"National Labor Relations Board\"',\n  '\"civil\"',\n  '\"\"',\n  '\"\"',\n  '\"21-CA-36104-001\"',\n  '\"\"',\n  '\"\"',\n  '\"California\"',\n  '\"Irvine\"',\n  '\"\"',\n  '\"92606\"',\n  '\"333314\"',\n  '\"333314: Optical Instrument and Lens Manufacturing\"',\n  '\"USA\"',\n  '\"Illinois\"',\n  '\"publicly traded\"',\n  '\"ABT\"',\n  '\"pharmaceuticals\"',\n  '\"pharmaceuticals\"',\n  '\"Extracted from an NLRB dataset covering 1999-2011 downloaded at https://catalog.data.gov/dataset/nlrb-cats-final-c-case-data-bulk-19990101-20110930-in-xml\"',\n  '\"\"'],\n ['\"Advanced Neuromodulation Systems',\n  ' Inc.\"',\n  '\"Abbott Laboratories\"',\n  '\"$2',\n  '950',\n  '000\"',\n  '\"$0\"',\n  '\"$2',\n  '950',\n  '000\"',\n  '\"2007\"',\n  '\"20070702\"',\n  '\"healthcare-related offenses\"',\n  '\"HHS civil monetary penalties\"',\n  '\"kickbacks and bribery\"',\n  '\"The HHS Inspector General announced that Advanced Neuromodulation Systems',\n  ' Inc.',\n  '  a medical device manufacturer specializing in spinal cord stimulation used for pain management',\n  ' agreed to pay $2.95 million to settle allegations that it paid kickbacks to physicians in violation of the Civil Monetary Penalties Law (CMPL). The company also entered into a 3-year Corporate Integrity Agreement.\"',\n  '\"federal\"',\n  '\"agency action\"',\n  '\"Health & Human Services Department Office of Inspector General\"',\n  '\"civil\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"USA\"',\n  '\"Illinois\"',\n  '\"publicly traded\"',\n  '\"ABT\"',\n  '\"pharmaceuticals\"',\n  '\"pharmaceuticals\"',\n  '\"https://oig.hhs.gov/publications/docs/press/2007/ANS%20Press%20Release.pdf\"',\n  '\"\"'],\n ['\"Advanced Sterilization Products\"',\n  '\"Johnson & Johnson\"',\n  '\"$136',\n  '800\"',\n  '\"$0\"',\n  '\"$136',\n  '800\"',\n  '\"2014\"',\n  '\"20140520\"',\n  '\"environment-related offenses\"',\n  '\"environmental violation\"',\n  '\"\"',\n  '\"The U.S. Environmental Protection Agency announced that an Irvine',\n  ' Calif. company',\n  ' Advanced Sterilization Products',\n  ' has agreed to pay a $136',\n  '800 penalty for the sale and distribution of unregistered and misbranded pesticides to veterinary clinics and laboratories nationwide.\"',\n  '\"federal\"',\n  '\"agency action\"',\n  '\"Environmental Protection Agency\"',\n  '\"civil\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"California\"',\n  '\"Irvine\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"USA\"',\n  '\"New Jersey\"',\n  '\"publicly traded\"',\n  '\"JNJ\"',\n  '\"pharmaceuticals\"',\n  '\"pharmaceuticals\"',\n  '\"https://archive.epa.gov/epapages/newsroom_archive/newsreleases/8e820317c86e4c5685257cde00717855.html\"',\n  '\"\"'],\n ['\"Advanced Sterilization Products',\n  ' a division of Ethicon Inc.\"',\n  '\"Johnson & Johnson\"',\n  '\"$1',\n  '200',\n  '000\"',\n  '\"$0\"',\n  '\"$1',\n  '200',\n  '000\"',\n  '\"2013\"',\n  '\"20131204\"',\n  '\"safety-related offenses\"',\n  '\"drug or medical equipment safety violation\"',\n  '\"\"',\n  '\"Settlement of a civil money penalty action against Advanced Sterilization Products',\n  ' a division of Ethicon Inc.',\n  ' a Johnson & Johnson company',\n  ' and two of ASP\\'s executives alleging that ASP manufactured and distributed adulterated and misbranded sterilization monitoring products.\"',\n  '\"federal\"',\n  '\"agency action\"',\n  '\"Food and Drug Administration\"',\n  '\"civil\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"California\"',\n  '\"Irvine\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"USA\"',\n  '\"New Jersey\"',\n  '\"publicly traded\"',\n  '\"JNJ\"',\n  '\"pharmaceuticals\"',\n  '\"pharmaceuticals\"',\n  '\"http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm377588.htm\"',\n  '\"\"'],\n ['\"Alere San Diego Inc.\"',\n  '\"Abbott Laboratories\"',\n  '\"$10',\n  '572\"',\n  '\"$0\"',\n  '\"$10',\n  '572\"',\n  '\"2017\"',\n  '\"20170309\"',\n  '\"employment-related offenses\"',\n  '\"wage and hour violation\"',\n  '\"Fair Labor Standards Act\"',\n  '\"\"',\n  '\"federal\"',\n  '\"agency action\"',\n  '\"Labor Department Wage and Hour Division\"',\n  '\"civil\"',\n  '\"\"',\n  '\"\"',\n  '\"1813371\"',\n  '\"\"',\n  '\"\"',\n  '\"California\"',\n  '\"Pomona\"',\n  '\"828 Towne Center Dr.\"',\n  '\"91767\"',\n  '\"\"',\n  '\"\"',\n  '\"USA\"',\n  '\"Illinois\"',\n  '\"publicly traded\"',\n  '\"ABT\"',\n  '\"pharmaceuticals\"',\n  '\"pharmaceuticals\"',\n  '\"July 23',\n  ' 2017 download of a dataset posted by the Wage and Hour Division at https://enforcedata.dol.gov/views/data_summary.php\"',\n  '\"Date and year are the Findings End Date in the dataset posted by the Wage and Hour Division',\n  ' which does not provide case opening or closing dates. The company name is the Legal Name provided by the dataset unless that field is blank',\n  ' in which case the Trade Name is used. The dataset provides only one address and does not indicate whether it is the company headquarters address or the establishment address. The penalty amount is the total of civil monetary penalties and mandated back wages. The original dataset provides a breakdown.\"']]","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[40]: [['\"Abbott Laboratories\"',\n  '\"Abbott Laboratories\"',\n  '\"$5',\n  '475',\n  '000\"',\n  '\"$0\"',\n  '\"$5',\n  '475',\n  '000\"',\n  '\"2013\"',\n  '\"20131227\"',\n  '\"government-contracting-related offenses\"',\n  '\"False Claims Act and related\"',\n  '\"kickbacks and bribery\"',\n  '\"Abbott Laboratories agreed to $5.475 million to resolve allegations that it violated the False Claims Act by paying kickbacks to induce doctors to implant the company\\'s carotid',\n  ' biliary and peripheral vascular products.\"',\n  '\"federal\"',\n  '\"agency action\"',\n  '\"Justice Department Civil Division\"',\n  '\"civil\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"USA\"',\n  '\"Illinois\"',\n  '\"publicly traded\"',\n  '\"ABT\"',\n  '\"pharmaceuticals\"',\n  '\"pharmaceuticals\"',\n  '\"https://www.justice.gov/opa/pr/abbott-laboratories-pays-us-5475-million-settle-claims-company-paid-kickbacks-physicians\"',\n  '\"\"'],\n ['\"Abbott Laboratories Inc.\"',\n  '\"AbbVie\"',\n  '\"$1',\n  '500',\n  '000',\n  '000\"',\n  '\"$0\"',\n  '\"$1',\n  '500',\n  '000',\n  '000\"',\n  '\"2012\"',\n  '\"20120507\"',\n  '\"healthcare-related offenses\"',\n  '\"off-label or unapproved promotion of medical products\"',\n  '\"\"',\n  '\"Global Health Care Company Abbott Laboratories Inc. has pleaded guilty and agreed to pay $1.5 billion to resolve its criminal and civil liability arising from the company\\'s unlawful promotion of the prescription drug Depakote for uses not approved as safe and effective by the Food and Drug Administration. The resolution - the second largest payment by a drug company - includes a criminal fine and forfeiture totaling $700 million and civil settlements with the federal government and the states totaling $800 million. Abbott also will be subject to court-supervised probation and reporting obligations for Abbotts CEO and Board of Directors.\"',\n  '\"federal\"',\n  '\"agency action\"',\n  '\"Food and Drug Administration referral to the Justice Department\"',\n  '\"civil and criminal\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"USA\"',\n  '\"Illinois\"',\n  '\"publicly traded\"',\n  '\"ABBV\"',\n  '\"pharmaceuticals\"',\n  '\"pharmaceuticals\"',\n  '\"http://www.justice.gov/opa/pr/abbott-labs-pay-15-billion-resolve-criminal-civil-investigations-label-promotion-depakote\"',\n  '\"\"'],\n ['\"Abbott Laboratories Inc.\"',\n  '\"AbbVie\"',\n  '\"$126',\n  '500',\n  '000\"',\n  '\"$0\"',\n  '\"$126',\n  '500',\n  '000\"',\n  '\"2010\"',\n  '\"20101207\"',\n  '\"government-contracting-related offenses\"',\n  '\"False Claims Act and related\"',\n  '\"\"',\n  '\"Abbott Laboratories Inc.',\n  ' B. Braun Medical Inc. and Roxane Laboratories Inc. n/k/a Boehringer Ingelheim Roxane Inc. and affiliated entities agreed to pay $421 million to settle False Claims Act allegations',\n  ' that they engaged in a scheme to report false and inflated prices for numerous pharmaceutical products knowing that federal healthcare programs relied on those reported prices to set payment rates.\"',\n  '\"federal\"',\n  '\"agency action\"',\n  '\"Justice Department Civil Division\"',\n  '\"civil\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"USA\"',\n  '\"Illinois\"',\n  '\"publicly traded\"',\n  '\"ABBV\"',\n  '\"pharmaceuticals\"',\n  '\"pharmaceuticals\"',\n  '\"https://www.justice.gov/opa/pr/pharmaceutical-manufacturers-pay-4212-million-settle-false-claims-act-cases\"',\n  '\"\"'],\n ['\"Abbott Laboratories Puerto Rico',\n  ' Inc.\"',\n  '\"Abbott Laboratories\"',\n  '\"$49',\n  '045\"',\n  '\"$0\"',\n  '\"$49',\n  '045\"',\n  '\"2009\"',\n  '\"20090305\"',\n  '\"employment-related offenses\"',\n  '\"wage and hour violation\"',\n  '\"Fair Labor Standards Act\"',\n  '\"\"',\n  '\"federal\"',\n  '\"agency action\"',\n  '\"Labor Department Wage and Hour Division\"',\n  '\"civil\"',\n  '\"\"',\n  '\"\"',\n  '\"1527129\"',\n  '\"\"',\n  '\"\"',\n  '\"Puerto Rico\"',\n  '\"San Juan\"',\n  '\"\"',\n  '\"\"',\n  '\"423450\"',\n  '\"423450: Medical',\n  ' Dental',\n  ' and Hospital Equipment and Supplies Merchant Wholesalers\"',\n  '\"USA\"',\n  '\"Illinois\"',\n  '\"publicly traded\"',\n  '\"ABT\"',\n  '\"pharmaceuticals\"',\n  '\"pharmaceuticals\"',\n  '\"March 7',\n  ' 2017 download of a dataset posted by the Wage and Hour Division at https://enforcedata.dol.gov/views/data_summary.php\"',\n  '\"Date and year are the Findings End Date in the dataset posted by the Wage and Hour Division',\n  ' which does not provide case opening or closing dates. The company name is the Legal Name provided by the dataset unless that field is blank',\n  ' in which case the Trade Name is used. The dataset provides only one address and does not indicate whether it is the company headquarters address or the establishment address. The penalty amount is the total of civil monetary penalties and mandated back wages. The original dataset provides a breakdown.\"'],\n ['\"Acclarent Inc.\"',\n  '\"Johnson & Johnson\"',\n  '\"$18',\n  '000',\n  '000\"',\n  '\"$0\"',\n  '\"$18',\n  '000',\n  '000\"',\n  '\"2016\"',\n  '\"20160722\"',\n  '\"government-contracting-related offenses\"',\n  '\"False Claims Act and related\"',\n  '\"\"',\n  '\"California-based medical device manufacturer Acclarent Inc.',\n  ' a subsidiary of Johnson & Johnson',\n  ' agreed to pay $18 million to resolve allegations that the company caused health care providers to submit false claims to Medicare and other federal health care programs by marketing and distributing its sinus spacer product for use as a drug delivery device without Food and Drug Administration approval.\"',\n  '\"federal\"',\n  '\"agency action\"',\n  '\"Justice Department Civil Division\"',\n  '\"civil\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"USA\"',\n  '\"New Jersey\"',\n  '\"publicly traded\"',\n  '\"JNJ\"',\n  '\"pharmaceuticals\"',\n  '\"pharmaceuticals\"',\n  '\"https://www.justice.gov/opa/pr/johnson-johnson-subsidiary-acclarent-inc-pays-government-18-million-settle-false-claims-act\"',\n  '\"\"'],\n ['\"Advanced Medical Optics\"',\n  '\"Abbott Laboratories\"',\n  '\"$16',\n  '800\"',\n  '\"$0\"',\n  '\"$16',\n  '800\"',\n  '\"2004\"',\n  '\"20040412\"',\n  '\"employment-related offenses\"',\n  '\"labor relations violation\"',\n  '\"\"',\n  '\"back pay award in unfair labor practices case\"',\n  '\"federal\"',\n  '\"agency action\"',\n  '\"National Labor Relations Board\"',\n  '\"civil\"',\n  '\"\"',\n  '\"\"',\n  '\"21-CA-36104-001\"',\n  '\"\"',\n  '\"\"',\n  '\"California\"',\n  '\"Irvine\"',\n  '\"\"',\n  '\"92606\"',\n  '\"333314\"',\n  '\"333314: Optical Instrument and Lens Manufacturing\"',\n  '\"USA\"',\n  '\"Illinois\"',\n  '\"publicly traded\"',\n  '\"ABT\"',\n  '\"pharmaceuticals\"',\n  '\"pharmaceuticals\"',\n  '\"Extracted from an NLRB dataset covering 1999-2011 downloaded at https://catalog.data.gov/dataset/nlrb-cats-final-c-case-data-bulk-19990101-20110930-in-xml\"',\n  '\"\"'],\n ['\"Advanced Neuromodulation Systems',\n  ' Inc.\"',\n  '\"Abbott Laboratories\"',\n  '\"$2',\n  '950',\n  '000\"',\n  '\"$0\"',\n  '\"$2',\n  '950',\n  '000\"',\n  '\"2007\"',\n  '\"20070702\"',\n  '\"healthcare-related offenses\"',\n  '\"HHS civil monetary penalties\"',\n  '\"kickbacks and bribery\"',\n  '\"The HHS Inspector General announced that Advanced Neuromodulation Systems',\n  ' Inc.',\n  '  a medical device manufacturer specializing in spinal cord stimulation used for pain management',\n  ' agreed to pay $2.95 million to settle allegations that it paid kickbacks to physicians in violation of the Civil Monetary Penalties Law (CMPL). The company also entered into a 3-year Corporate Integrity Agreement.\"',\n  '\"federal\"',\n  '\"agency action\"',\n  '\"Health & Human Services Department Office of Inspector General\"',\n  '\"civil\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"USA\"',\n  '\"Illinois\"',\n  '\"publicly traded\"',\n  '\"ABT\"',\n  '\"pharmaceuticals\"',\n  '\"pharmaceuticals\"',\n  '\"https://oig.hhs.gov/publications/docs/press/2007/ANS%20Press%20Release.pdf\"',\n  '\"\"'],\n ['\"Advanced Sterilization Products\"',\n  '\"Johnson & Johnson\"',\n  '\"$136',\n  '800\"',\n  '\"$0\"',\n  '\"$136',\n  '800\"',\n  '\"2014\"',\n  '\"20140520\"',\n  '\"environment-related offenses\"',\n  '\"environmental violation\"',\n  '\"\"',\n  '\"The U.S. Environmental Protection Agency announced that an Irvine',\n  ' Calif. company',\n  ' Advanced Sterilization Products',\n  ' has agreed to pay a $136',\n  '800 penalty for the sale and distribution of unregistered and misbranded pesticides to veterinary clinics and laboratories nationwide.\"',\n  '\"federal\"',\n  '\"agency action\"',\n  '\"Environmental Protection Agency\"',\n  '\"civil\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"California\"',\n  '\"Irvine\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"USA\"',\n  '\"New Jersey\"',\n  '\"publicly traded\"',\n  '\"JNJ\"',\n  '\"pharmaceuticals\"',\n  '\"pharmaceuticals\"',\n  '\"https://archive.epa.gov/epapages/newsroom_archive/newsreleases/8e820317c86e4c5685257cde00717855.html\"',\n  '\"\"'],\n ['\"Advanced Sterilization Products',\n  ' a division of Ethicon Inc.\"',\n  '\"Johnson & Johnson\"',\n  '\"$1',\n  '200',\n  '000\"',\n  '\"$0\"',\n  '\"$1',\n  '200',\n  '000\"',\n  '\"2013\"',\n  '\"20131204\"',\n  '\"safety-related offenses\"',\n  '\"drug or medical equipment safety violation\"',\n  '\"\"',\n  '\"Settlement of a civil money penalty action against Advanced Sterilization Products',\n  ' a division of Ethicon Inc.',\n  ' a Johnson & Johnson company',\n  ' and two of ASP\\'s executives alleging that ASP manufactured and distributed adulterated and misbranded sterilization monitoring products.\"',\n  '\"federal\"',\n  '\"agency action\"',\n  '\"Food and Drug Administration\"',\n  '\"civil\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"California\"',\n  '\"Irvine\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"\"',\n  '\"USA\"',\n  '\"New Jersey\"',\n  '\"publicly traded\"',\n  '\"JNJ\"',\n  '\"pharmaceuticals\"',\n  '\"pharmaceuticals\"',\n  '\"http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm377588.htm\"',\n  '\"\"'],\n ['\"Alere San Diego Inc.\"',\n  '\"Abbott Laboratories\"',\n  '\"$10',\n  '572\"',\n  '\"$0\"',\n  '\"$10',\n  '572\"',\n  '\"2017\"',\n  '\"20170309\"',\n  '\"employment-related offenses\"',\n  '\"wage and hour violation\"',\n  '\"Fair Labor Standards Act\"',\n  '\"\"',\n  '\"federal\"',\n  '\"agency action\"',\n  '\"Labor Department Wage and Hour Division\"',\n  '\"civil\"',\n  '\"\"',\n  '\"\"',\n  '\"1813371\"',\n  '\"\"',\n  '\"\"',\n  '\"California\"',\n  '\"Pomona\"',\n  '\"828 Towne Center Dr.\"',\n  '\"91767\"',\n  '\"\"',\n  '\"\"',\n  '\"USA\"',\n  '\"Illinois\"',\n  '\"publicly traded\"',\n  '\"ABT\"',\n  '\"pharmaceuticals\"',\n  '\"pharmaceuticals\"',\n  '\"July 23',\n  ' 2017 download of a dataset posted by the Wage and Hour Division at https://enforcedata.dol.gov/views/data_summary.php\"',\n  '\"Date and year are the Findings End Date in the dataset posted by the Wage and Hour Division',\n  ' which does not provide case opening or closing dates. The company name is the Legal Name provided by the dataset unless that field is blank',\n  ' in which case the Trade Name is used. The dataset provides only one address and does not indicate whether it is the company headquarters address or the establishment address. The penalty amount is the total of civil monetary penalties and mandated back wages. The original dataset provides a breakdown.\"']]"]}}],"execution_count":0},{"cell_type":"code","source":["print (\"The number of studies for clinicaltrial_2021 is\", clinicrdd1.count())"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"Task 1 - The total number of studies in the dataset","showTitle":true,"inputWidgets":{},"nuid":"ebd9199c-2f47-4578-9b56-5e528e08f5a2"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"The number of studies for clinicaltrial_2021 is 387261\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["The number of studies for clinicaltrial_2021 is 387261\n"]}}],"execution_count":0},{"cell_type":"code","source":["type2= splrdd.map(lambda x: (x[5],1)).reduceByKey(lambda x1,x2: x1+x2) \nType= type2.sortBy(lambda a: -a[1]) \nType.collect()\n"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"Task 2 - list of all the types of studies in the dataset ","showTitle":true,"inputWidgets":{},"nuid":"76a1cd3e-f7f6-4790-85b2-e096e8ada7f0"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[43]: [('Interventional', 301472),\n ('Observational', 77540),\n ('Observational [Patient Registry]', 8180),\n ('Expanded Access', 69)]","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[43]: [('Interventional', 301472),\n ('Observational', 77540),\n ('Observational [Patient Registry]', 8180),\n ('Expanded Access', 69)]"]}}],"execution_count":0},{"cell_type":"code","source":["conditionrdd= clinicrdd1.map(lambda x: x.split(\"|\")).map(lambda s: (s[7]).split(','))\nskipspace=[\" \", \"\"]\nremnull=conditionrdd.filter(lambda l:l not in skipspace)\ncondition=remnull.flatMap(lambda x:x).filter(lambda x:len(x)>0)  # flatMap() to output multiple elements for each input value, split on space\ncondition2= condition.map(lambda x: (x,1)) # Map a tuple and append int 1 for each word in words.txt\ncondition3=condition2.reduceByKey(lambda x1,x2: x1+x2) # Perform aggregation (sum) all the int values for each unique key\nTopconditions=condition3.sortBy(lambda ascend:-ascend[1])\nTopconditions.take(5)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"Task 3- The top 5 conditions with their frequencies.","showTitle":true,"inputWidgets":{},"nuid":"af6589ab-0061-4bd5-bf96-850325c84439"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[44]: [('Carcinoma', 13389),\n ('Diabetes Mellitus', 11080),\n ('Neoplasms', 9371),\n ('Breast Neoplasms', 8640),\n ('Syndrome', 8032)]","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[44]: [('Carcinoma', 13389),\n ('Diabetes Mellitus', 11080),\n ('Neoplasms', 9371),\n ('Breast Neoplasms', 8640),\n ('Syndrome', 8032)]"]}}],"execution_count":0},{"cell_type":"code","source":["splmesh=meshrdd1.map(lambda x:(x.split(\",\")[-1],x.split(',')[:-1]))\nsplmeshdata=splmesh.flatMapValues(lambda s:s)\\\n    .map(lambda s:(s[1],s[0].split(\".\")[0]))  # flatMap() to output multiple elements for each input value, split on (\".\")\nsplmeshdata.take(10)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"task 4-5 most frequent roots","showTitle":true,"inputWidgets":{},"nuid":"68fed341-c663-4a7a-a088-48f67d09a2fc"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[55]: [('Calcimycin', 'D03'),\n ('A-23187', 'D03'),\n ('Temefos', 'D02'),\n ('Temefos', 'D02'),\n ('Temefos', 'D02'),\n ('Abate', 'D02'),\n ('Abate', 'D02'),\n ('Abate', 'D02'),\n ('Difos', 'D02'),\n ('Difos', 'D02')]","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[55]: [('Calcimycin', 'D03'),\n ('A-23187', 'D03'),\n ('Temefos', 'D02'),\n ('Temefos', 'D02'),\n ('Temefos', 'D02'),\n ('Abate', 'D02'),\n ('Abate', 'D02'),\n ('Abate', 'D02'),\n ('Difos', 'D02'),\n ('Difos', 'D02')]"]}}],"execution_count":0},{"cell_type":"code","source":["splclinicalrdd=clinicrdd1.map(lambda s:s.split('|')).map(lambda s:(s[0],s[7].split(',')))\nflatsplclinicalrdd=splclinicalrdd.map(lambda x:(x[0],x[1]))\\\n    .flatMapValues(lambda x:x)\\\n    .map(lambda x:(x[1],x[0]))\\\n.filter(lambda x:(len(x[0])>0))\nflatsplclinicalrdd.take(10)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"07663b2a-4f42-45e9-8281-f659426f7513"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[54]: [('Autistic Disorder', 'NCT02751957'),\n ('Autism Spectrum Disorder', 'NCT02751957'),\n ('Diabetes Mellitus', 'NCT02758483'),\n ('Tuberculosis', 'NCT02759848'),\n ('Lung Diseases', 'NCT02759848'),\n ('Pulmonary Disease', 'NCT02759848'),\n ('Diverticular Diseases', 'NCT02758860'),\n ('Diverticulum', 'NCT02758860'),\n ('Diverticulosis', 'NCT02758860'),\n ('Asthma', 'NCT02757209')]","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[54]: [('Autistic Disorder', 'NCT02751957'),\n ('Autism Spectrum Disorder', 'NCT02751957'),\n ('Diabetes Mellitus', 'NCT02758483'),\n ('Tuberculosis', 'NCT02759848'),\n ('Lung Diseases', 'NCT02759848'),\n ('Pulmonary Disease', 'NCT02759848'),\n ('Diverticular Diseases', 'NCT02758860'),\n ('Diverticulum', 'NCT02758860'),\n ('Diverticulosis', 'NCT02758860'),\n ('Asthma', 'NCT02757209')]"]}}],"execution_count":0},{"cell_type":"code","source":["frequentroots =flatsplclinicalrdd.join(splmeshdata).values()\ntoproots = frequentroots.map(lambda s: (s[1],1))\\\n.reduceByKey( lambda v1,v2:v1+v2)\\\n.sortBy(lambda a: -a[1])\ntoproots.take(5)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"b450a7ff-3f4b-4851-824e-63e1307629ae"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[47]: [('C04', 143994),\n ('C23', 136079),\n ('C01', 106674),\n ('C14', 94523),\n ('C10', 92310)]","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[47]: [('C04', 143994),\n ('C23', 136079),\n ('C01', 106674),\n ('C14', 94523),\n ('C10', 92310)]"]}}],"execution_count":0},{"cell_type":"code","source":["splpharmardd= pharmardd1.map(lambda x:(x.split('\",\"')[1],1))\nclinicsponsor = clinicrdd1.map(lambda x: x.split(\"|\"))\\\n    .map(lambda x:(x[1],1))\nSponsors=clinicsponsor.subtract(splpharmardd)\\\n    .map(lambda x:(x[0],1))\\\n.reduceByKey(lambda x1,x2: x1+x2)\\\n.sortBy(lambda a:-a[1])\nSponsors.take(10)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"task 5- 10 most common sponsors","showTitle":true,"inputWidgets":{},"nuid":"8e62280a-5f7f-488c-8ecb-1c7ce917d7db"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[48]: [('National Cancer Institute (NCI)', 3218),\n ('M.D. Anderson Cancer Center', 2414),\n ('Assistance Publique - Hpitaux de Paris', 2369),\n ('Mayo Clinic', 2300),\n ('Merck Sharp & Dohme Corp.', 2243),\n ('Assiut University', 2154),\n ('Novartis Pharmaceuticals', 2088),\n ('Massachusetts General Hospital', 1971),\n ('Cairo University', 1928),\n ('Hoffmann-La Roche', 1828)]","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[48]: [('National Cancer Institute (NCI)', 3218),\n ('M.D. Anderson Cancer Center', 2414),\n ('Assistance Publique - Hpitaux de Paris', 2369),\n ('Mayo Clinic', 2300),\n ('Merck Sharp & Dohme Corp.', 2243),\n ('Assiut University', 2154),\n ('Novartis Pharmaceuticals', 2088),\n ('Massachusetts General Hospital', 1971),\n ('Cairo University', 1928),\n ('Hoffmann-La Roche', 1828)]"]}}],"execution_count":0},{"cell_type":"code","source":["completed = splrdd.map(lambda x:(x[2],x[4])).filter(lambda x:x[0]==\"Completed\")\ncompletion=completed.filter(lambda x:len(x[1])>0)\\\n    .filter(lambda x:x[1].split(\" \")[1]==\"2021\")\\\n    .map(lambda x:(x[1].split (\" \")[0],1))\\\n    .reduceByKey(lambda x1,x2:x1+x2)\ncompletion.sortByKey().collect()"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"task 6 -- Plot number of completed studies each month in a given year ","showTitle":true,"inputWidgets":{},"nuid":"0cf46352-7c70-4035-8604-edd85daab633"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[49]: [('Apr', 967),\n ('Aug', 700),\n ('Feb', 934),\n ('Jan', 1131),\n ('Jul', 819),\n ('Jun', 1094),\n ('Mar', 1227),\n ('May', 984),\n ('Oct', 187),\n ('Sep', 528)]","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[49]: [('Apr', 967),\n ('Aug', 700),\n ('Feb', 934),\n ('Jan', 1131),\n ('Jul', 819),\n ('Jun', 1094),\n ('Mar', 1227),\n ('May', 984),\n ('Oct', 187),\n ('Sep', 528)]"]}}],"execution_count":0},{"cell_type":"code","source":["import calendar\nc = {i:e for e,i in enumerate(calendar.month_abbr[1:],1)}\n\n#{'Jan': 1, 'Feb': 2, 'Mar': 3, 'Apr': 4, 'May': 5, 'Jun': 6, 'Jul': 7, \n#'Aug': 8, 'Sep': 9, 'Oct': 10, 'Nov': 11, 'Dec': 12}\n\nCompletion=completion.sortBy(keyfunc=lambda x: c.get(x[0]))\nCompletion.collect()"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"9617f663-8810-4064-acc2-da118194b293"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[50]: [('Jan', 1131),\n ('Feb', 934),\n ('Mar', 1227),\n ('Apr', 967),\n ('May', 984),\n ('Jun', 1094),\n ('Jul', 819),\n ('Aug', 700),\n ('Sep', 528),\n ('Oct', 187)]","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[50]: [('Jan', 1131),\n ('Feb', 934),\n ('Mar', 1227),\n ('Apr', 967),\n ('May', 984),\n ('Jun', 1094),\n ('Jul', 819),\n ('Aug', 700),\n ('Sep', 528),\n ('Oct', 187)]"]}}],"execution_count":0},{"cell_type":"code","source":["import matplotlib.pyplot as plt\n\n# x-coordinates of left sides of bars\nleft = ['Jan','Feb','Mar','Apr','May','Jun','Jul','Aug','Sep','Oct']\n\n# heights of bars\nheight = [1131,934,1227, 967,984,1094,819,700,528,187]\n\n# labels for bars\ntick_label = ['one', 'two', 'three', 'four', 'five']\n\n# plotting a bar chart\nplt.bar(left, height,\n\t\twidth = 0.8, color = ['orange', 'green'])\n\n# naming the x-axis\nplt.xlabel('Months')\n# naming the y-axis\nplt.ylabel('Count')\n# plot title\nplt.title('Studies Completion!')\n\n# function to show the plot\nplt.show()\n"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"5f520c7f-c349-49c9-b242-7f3492d8e192"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAYsAAAEWCAYAAACXGLsWAAAAOXRFWHRTb2Z0d2FyZQBNYXRwbG90bGliIHZlcnNpb24zLjQuMiwgaHR0cHM6Ly9tYXRwbG90bGliLm9yZy8rg+JYAAAACXBIWXMAAAsTAAALEwEAmpwYAAAbrklEQVR4nO3de7xldV3/8ddbEBQRRmB+hAw5pKOGhIojXrBCsQKiBg0R5IegGPXLa5iG2U+irJ+W9/LSJCgWgoQoJKQSF/1pggxIIDcZEWQQYbijiAp++mN9JzbHc2ad695nZl7Px+M8zlrf9d3r+13nnH3ee33X2t+dqkKSpLV52Kg7IEma/wwLSVIvw0KS1MuwkCT1MiwkSb0MC0lSL8NC670k5yV5VVs+OMkXR92nuZLksCRfmcHjL0+yx+z1SOsLw0Ijl+R5Sf4zyV1Jbk/y1STPbNtm9M9vrKo6oap+c7b2t0aS7ZIcm+SmJPckuSrJMUkeNdttzZYkH0/y9sGyqnpKVZ03S/uvJE+YjX1p9AwLjVSSLYDPAX8PbAVsDxwD/HiU/ZqKJFsBXwMeCTynqh4N/AawAHj8CLsmzRrDQqP2RICqOrGqHqiqH1XVF6vq0iS/DHwEeE6SHyS5Ex46rNTWH3L2keQ32iv7u5L8A5C11H1ykrPaGc3VSQ4Y2LZPkivamcKNSf5kgmM4ErgH+N9VdV07nhuq6vVVdWnb13OTXNj6dGGS5w60c16St7ezqx8k+bckWyc5Icndrf7igfqV5HVJrk1ya5K/SzLuc3mi40tyBHAw8OY1bbby65K8sC1vmuR9Sb7Xvt6XZNO2bY8kq5K8Mckt7YzqFRP8fLQeMCw0at8CHkhyfJK9kzxmzYaquhL4Q+BrVbV5VS3o21mSbYBTgT8HtgG+Dew+Qd1HAWcBnwT+F3Ag8KEkO7UqxwJ/0M4UdgbOmaDZFwKnVtXPJmhnK+AM4APA1sB7gDOSbD1Q7UDgELozq8fTnal8jO5s60rg6DG7fRGwFNgVWAa8cirHV1XLgROAv20/298Zp+tvBZ4NPA14KrAb3c91jV8Atmx9Phz44ODvT+sXw0IjVVV3A88DCvgnYHWS05NsO81d7gNcXlWnVNVPgfcB35+g7r7AdVX1saq6v6q+AXwaeEnb/lNgpyRbVNUdVXXxBPvZGrhpLX36beCaqvrn1s6JwFXA4D/oj1XVt6vqLuDfgW9X1X9U1f3AvwJPH7PPd1bV7VX13XaMB03j+PocDPxlVd1SVavphgcPGdj+07b9p1V1JvAD4EmT3LfWMYaFRq6qrqyqw6pqEd0r+MfS/QOcjscCNwzsuwbXx3gc8Kwkd675ovsH+Qtt++/Rhc/1Sb6U5DkT7Oc2YLuePl0/pux6ulfka9w8sPyjcdY3H/P4wWO6vrUxVt/x9Rnb77Ht3NbCbI17x+mn1hOGheaVqroK+DhdaEB3xjHWD4HNBtYH//ndBOywZiVJBtfHuAH4UlUtGPjavKr+T+vLhVW1jG4I57PAyRPs5z+AF0103QD4Ht0/7kG/CNw4Qf3JGDymX2xtjLXW42P8n+2gsf2eqJ1xVVWqauVk62t+Myw0Uu0C7BuTLGrrO9ANqZzfqtwMLEqyycDDLgFenGSzdmvm4QPbzgCekuTFSTYGXsfEr6Q/BzwxySFJHt6+npnkl5Nsku49GVu24ay7gXGvSdBdg9gCOD7J49pxbJ/kPUl2Ac5s7bwsycZJXgrs1NqfrjcleUz7eb0e+NRUjq9tvxn4pbW0cSLw50kWtmtBbwP+ZQZ91jrMsNCo3QM8C7ggyQ/pQuKbwBvb9nOAy4HvJ7m1lb0X+AndP7vj6S7UAlBVt9KNyb+DbnhoCfDV8RquqnuA36S78Ps9umsb7wQ2bVUOAa5LcjfdhfaDJ9jP7cBz6cbwL0hyD3A2cBewsqpuo7t+8MbWpzcD+7a+TtdpwEV0wXkG3cX4qR7fsXTXZO5M8tlx2ng7sAK4FLgMuLiVTUq7y2ptYaR1SPzwI2ndkqSAJQ7xaJg8s5Ak9TIsJEm9HIaSJPXyzEKS1GvjUXdgLmyzzTa1ePHiUXdDktYpF1100a1VtXC8betlWCxevJgVK1aMuhuStE5JMnamgf/hMJQkqZdhIUnqZVhIknoZFpKkXoaFJKmXYSFJ6mVYSJJ6GRaSpF6GhSSp13r5Dm5N0ycz9228zIkrpXXRnJ1ZJDkuyS1JvjlQ9ndJrkpyaZLPJFkwsO0tSVYmuTrJbw2U79XKViY5aq76K0ma2FwOQ30c2GtM2VnAzlW1C/At4C0ASXai++jHp7THfCjJRkk2Aj4I7E33mcUHtbqSpCGas7Coqi8Dt48p+2JV3d9WzwcWteVlwElV9eOq+g6wEtitfa2sqmur6ifASa2uJGmIRnmB+5XAv7fl7YEbBratamUTlf+cJEckWZFkxerVq+egu5K04RpJWCR5K3A/cMJs7bOqllfV0qpaunDhuNOxS5Kmaeh3QyU5DNgX2LMe/EzXG4EdBqotamWspVySNCRDPbNIshfwZuB3q+regU2nAwcm2TTJjsAS4OvAhcCSJDsm2YTuIvjpw+yzJGkOzyySnAjsAWyTZBVwNN3dT5sCZyUBOL+q/rCqLk9yMnAF3fDUq6vqgbaf1wBfADYCjquqy+eqz5Kk8c1ZWFTVQeMUH7uW+n8N/PU45WcCZ85i1yRJU+R0H5KkXoaFJKmXYSFJ6mVYSJJ6GRaSpF6GhSSpl59nMR4/10GSHsIzC0lSL8NCktTLsJAk9TIsJEm9DAtJUi/vhpJGKMfM/Z13dbR33mnmPLOQJPUyLCRJvQwLSVIvw0KS1MuwkCT1MiwkSb0MC0lSL8NCktTLsJAk9TIsJEm9DAtJUi/DQpLUa87CIslxSW5J8s2Bsq2SnJXkmvb9Ma08ST6QZGWSS5PsOvCYQ1v9a5IcOlf9lSRNbC7PLD4O7DWm7Cjg7KpaApzd1gH2Bpa0ryOAD0MXLsDRwLOA3YCj1wSMJGl45iwsqurLwO1jipcBx7fl44H9Bso/UZ3zgQVJtgN+Czirqm6vqjuAs/j5AJIkzbFhX7PYtqpuasvfB7Zty9sDNwzUW9XKJir/OUmOSLIiyYrVq1fPbq8laQM3sgvcVVXArH0qS1Utr6qlVbV04cKFs7VbSRLDD4ub2/AS7fstrfxGYIeBeota2UTlkqQhGvbHqp4OHAq8o30/baD8NUlOoruYfVdV3ZTkC8DfDFzU/k3gLUPus9Z3n5z7jzblZX60qdZtcxYWSU4E9gC2SbKK7q6mdwAnJzkcuB44oFU/E9gHWAncC7wCoKpuT/JXwIWt3l9W1diL5pKkOTZnYVFVB02wac9x6hbw6gn2cxxw3Cx2TZI0RcMehpLGlWPmfiiojnYoSJoup/uQJPUyLCRJvQwLSVIvw0KS1MsL3POMF3olzUeeWUiSehkWkqRehoUkqZdhIUnqZVhIknoZFpKkXoaFJKmXYSFJ6mVYSJJ6GRaSpF6GhSSpl2EhSeplWEiSehkWkqRehoUkqZdhIUnqZVhIknoZFpKkXoaFJKnXSD6DO8kfA68CCrgMeAWwHXASsDVwEXBIVf0kyabAJ4BnALcBL62q60bRb2m98sm5/7x3Xubnva8vhn5mkWR74HXA0qraGdgIOBB4J/DeqnoCcAdweHvI4cAdrfy9rZ4kaYhGNQy1MfDIJBsDmwE3AS8ATmnbjwf2a8vL2jpt+55JhvCSSJK0xtDDoqpuBN4FfJcuJO6iG3a6s6rub9VWAdu35e2BG9pj72/1tx673yRHJFmRZMXq1avn9iAkaQMzimGox9CdLewIPBZ4FLDXTPdbVcuramlVLV24cOFMdydJGjCKYagXAt+pqtVV9VPgVGB3YEEblgJYBNzYlm8EdgBo27eku9AtSRqSUYTFd4FnJ9msXXvYE7gCOBfYv9U5FDitLZ/e1mnbz6kqb7GQpCEaxTWLC+guVF9Md9vsw4DlwJ8CRyZZSXdN4tj2kGOBrVv5kcBRw+6zJG3oRvI+i6o6Gjh6TPG1wG7j1L0PeMkw+iVJGp/v4JYk9TIsJEm9DAtJUi/DQpLUy7CQJPUyLCRJvQwLSVIvw0KS1GtSYZFk98mUSZLWT5M9s/j7SZZJktZDa53uI8lzgOcCC5McObBpC7pPuJMkbQD65obaBNi81Xv0QPndPDhDrCRNSY6Z+w+7rKOdnHo2rTUsqupLwJeSfLyqrh9SnyRJ88xkZ53dNMlyYPHgY6rqBXPRKUnS/DLZsPhX4CPAR4EH5q47kqT5aLJhcX9VfXhOeyJJmrcme+vsvyX5oyTbJdlqzdec9kySNG9M9sxizWdgv2mgrIBfmt3uSJLmo0mFRVXtONcdkSTNX5MKiyQvH6+8qj4xu92RJM1Hkx2GeubA8iOAPYGLAcNCkjYAkx2Geu3gepIFwElz0SFJ0vwz3SnKfwh4HUOSNhCTvWbxb3R3P0E3geAvAyfPVackSfPLZK9ZvGtg+X7g+qpaNd1G2zDWR4Gd6ULolcDVwKfophS5Djigqu5IEuD9wD7AvcBhVXXxdNuWJE3dpIah2oSCV9HNPPsY4CczbPf9wOer6snAU4ErgaOAs6tqCXB2WwfYG1jSvo4AfCe5JA3ZZD8p7wDg68BLgAOAC5JMa4ryJFsCvwYcC1BVP6mqO4FlwPGt2vHAfm15GfCJ6pwPLEiy3XTaliRNz2SHod4KPLOqbgFIshD4D+CUabS5I7Aa+FiSpwIXAa8Htq2qm1qd7wPbtuXtgRsGHr+qld2EJGkoJns31MPWBEVz2xQeO9bGwK7Ah6vq6XR3Vh01WKGqigcvqE9KkiOSrEiyYvXq1dPsmiRpPJP9h//5JF9IcliSw4AzgDOn2eYqYFVVXdDWT6ELj5vXDC+172vC6UZgh4HHL2plD1FVy6tqaVUtXbhw4TS7Jkkaz1rDIskTkuxeVW8C/hHYpX19DVg+nQar6vvADUme1Ir2BK4ATufBCQsPBU5ry6cDL0/n2cBdA8NVkqQh6Ltm8T7gLQBVdSpwKkCSX2nbfmea7b4WOCHJJsC1wCvoguvkJIcD19NdSIfuDGYfYCXdrbOvmGabkqRp6guLbavqsrGFVXVZksXTbbSqLgGWjrNpz3HqFvDq6bYlSZq5vmsWC9ay7ZGz2A9J0jzWFxYrkvz+2MIkr6K75VWStAHoG4Z6A/CZJAfzYDgsBTYBXjSH/ZIkzSNrDYuquhl4bpLn083jBHBGVZ0z5z2TJM0bk/08i3OBc+e4L5KkeWq678KWJG1ADAtJUq/JTiQoSeuHT2bu23jZlKa2Wyd4ZiFJ6mVYSJJ6GRaSpF6GhSSpl2EhSeplWEiSehkWkqRehoUkqZdhIUnqZVhIknoZFpKkXoaFJKmXYSFJ6mVYSJJ6GRaSpF6GhSSpl2EhSeo1srBIslGSbyT5XFvfMckFSVYm+VSSTVr5pm19Zdu+eFR9lqQN1SjPLF4PXDmw/k7gvVX1BOAO4PBWfjhwRyt/b6snSRqikYRFkkXAbwMfbesBXgCc0qocD+zXlpe1ddr2PVt9SdKQjOrM4n3Am4GftfWtgTur6v62vgrYvi1vD9wA0Lbf1eo/RJIjkqxIsmL16tVz2HVJ2vAMPSyS7AvcUlUXzeZ+q2p5VS2tqqULFy6czV1L0gZv4xG0uTvwu0n2AR4BbAG8H1iQZON29rAIuLHVvxHYAViVZGNgS+C24XdbkjZcQz+zqKq3VNWiqloMHAicU1UHA+cC+7dqhwKnteXT2zpt+zlVVUPssiRt8ObT+yz+FDgyyUq6axLHtvJjga1b+ZHAUSPqnyRtsEYxDPU/quo84Ly2fC2w2zh17gNeMtSOSZIeYj6dWUiS5inDQpLUy7CQJPUyLCRJvQwLSVIvw0KS1MuwkCT1MiwkSb0MC0lSL8NCktTLsJAk9TIsJEm9DAtJUi/DQpLUy7CQJPUyLCRJvQwLSVIvw0KS1MuwkCT1MiwkSb0MC0lSL8NCktTLsJAk9TIsJEm9DAtJUq+hh0WSHZKcm+SKJJcneX0r3yrJWUmuad8f08qT5ANJVia5NMmuw+6zJG3oRnFmcT/wxqraCXg28OokOwFHAWdX1RLg7LYOsDewpH0dAXx4+F2WpA3b0MOiqm6qqovb8j3AlcD2wDLg+FbteGC/trwM+ER1zgcWJNluuL2WpA3bSK9ZJFkMPB24ANi2qm5qm74PbNuWtwduGHjYqlY2dl9HJFmRZMXq1avnrtOStAEaWVgk2Rz4NPCGqrp7cFtVFVBT2V9VLa+qpVW1dOHChbPYU0nSxqNoNMnD6YLihKo6tRXfnGS7qrqpDTPd0spvBHYYePiiViZJ65Qckzlvo46e0uvsSRvF3VABjgWurKr3DGw6HTi0LR8KnDZQ/vJ2V9SzgbsGhqskSUMwijOL3YFDgMuSXNLK/gx4B3ByksOB64ED2rYzgX2AlcC9wCuG2ltJ0vDDoqq+Akx0LrbnOPULePWcdkqStFa+g1uS1MuwkCT1MiwkSb0MC0lSL8NCktTLsJAk9TIsJEm9DAtJUi/DQpLUy7CQJPUyLCRJvQwLSVIvw0KS1MuwkCT1MiwkSb0MC0lSL8NCktTLsJAk9TIsJEm9DAtJUi/DQpLUy7CQJPUyLCRJvQwLSVIvw0KS1GudCYskeyW5OsnKJEeNuj+StCFZJ8IiyUbAB4G9gZ2Ag5LsNNpeSdKGY50IC2A3YGVVXVtVPwFOApaNuE+StMFIVY26D72S7A/sVVWvauuHAM+qqtcM1DkCOKKtPgm4eohd3Aa4dYjt2bZt2/aG0/4w235cVS0cb8PGQ+rAnKuq5cDyUbSdZEVVLbVt27bt9a/tUbc/6mNfY10ZhroR2GFgfVErkyQNwboSFhcCS5LsmGQT4EDg9BH3SZI2GOvEMFRV3Z/kNcAXgI2A46rq8hF3a9BIhr9s27Zte4Nof9THDqwjF7glSaO1rgxDSZJGyLCQJPUyLKYgyQ9G0OYDSS4Z+Fq8lrrnJZm1W+ySVJJ/GVjfOMnqJJ+brTYm0Yf9Wj+ePKT2Rn7Mrd2h/61NtQ9z8Pc21N/1mLbfmuTyJJe259mzhtz+oiSnJbkmybeTvL/dzDNR/Tck2WyYfTQs5r8fVdXTBr6uG2LbPwR2TvLItv4bTPGW5SQzvYniIOAr7ftU2t1omu3N+Jg1bdP6Xc9UkucA+wK7VtUuwAuBG4bYfoBTgc9W1RLgicDmwF+v5WFvAAyL+SzJ5knOTnJxksuSLGvli5NcmeSf2iuULw78w5ntPjwjyZeSXJTkC0m2G9h8SHtl9M0ku81Cc2cCv92WDwJOHOjHbkm+luQbSf4zyZNa+WFJTk9yDnD2dBtOsjnwPOBwutulSbJHki8nOaNNLPmRJA9r236Q5N1J/gt4znTbZXrH/OUkTxuo95UkT51BH9Yc6+cG1v8hyWFt+bokxwz8Hc7Jq/G19WGW25nodz3R8e+T5Kr2HPjADM/8tgNuraofA1TVrVX1vYmeZ+2M6v2z+Dx7AXBfVX2stf8A8MfAK5M8Ksm7WjuXJnltktcBjwXOTXLuDNueNMNi6u4DXlRVuwLPB97dXhkALAE+WFVPAe4Efm8W2ntkHhyC+kyShwN/D+xfVc8AjuOhr0A2q6qnAX/Uts3UScCBSR4B7AJcMLDtKuBXq+rpwNuAvxnYtmvr46/PoO1lwOer6lvAbUme0cp3A15LN6nk44EXt/JHARdU1VOr6iszaHc6x3wscBhAkicCj6iq/5pBHybj1vZ3+GHgT+a4rbk20e/657Tfyz8Ce7fnwLjTU0zBF4EdknwryYeS/PqQn2dPAS4aLKiqu4HvAq8CFgNPa2c9J1TVB4DvAc+vqufPsO1JWyfeZzHPBPibJL8G/AzYHti2bftOVV3Sli+i+yXP1I/aH2XXeLIzsDNwVsuojYCbBuqfCFBVX06yRZIFVXXndBuvqkvTXSc5iO4V96AtgeOTLAEKePjAtrOq6vbpttscBLy/LZ/U1j8HfL2qrgVIciLdK9JTgAeAT8+wzeke878C/zfJm4BXAh+faT8m4dT2/SIeDMx11US/6/E8Gbi2qr7T1k/kwXnhpqyqftDC6VfpXgB+Cng7Q3yercUewIeq6v7W3kyfU9NmWEzdwXSvZJ5RVT9Nch3wiLbtxwP1HgDmYhgqwOVVNdEwy9g3zszGG2lOB95F94e79UD5XwHnVtWL2j/X8wa2/XAmDSbZiu70/FeSFN2TtYAzmPgY72un8LNhSsdcVfcmOYvuFfIBwISvjKfgfh569v+IMdvX/L09wNw9l/v6MGNr+V2fNtdtr9H+bs4DzktyGfBqhvc8uwLYf7AgyRbALwLXzWC/s8phqKnbErilBcXzgccNuf2rgYXpLsqR5OFJnjKw/aWt/HnAXVV11yy0eRxwTFVdNqZ8Sx68+HvYLLQzaH/gn6vqcVW1uKp2AL5D9+pvt3RTvzyM7nhnMuQ0kekc80eBDwAXVtUds9CH64GdkmyaZAGw5yzscz72YaLf9cMmaPtq4Jfy4J2BL51J40me1M4U13gacCXDe56dDWyW5OVtnxsB76Y7O/0C8AdpN4q0YAW4B3j0DNqcMsNiktov68fACcDS9urj5XRj2EPTPs9jf+Cd7ULuJcBzB6rcl+QbwEfoLhbORpur2jjpWH8L/L/W3my/sj0I+MyYsk+38guBf6B7Qn9nnHozNp1jrqqLgLuBj82k7TV/a1V1A3Ay8M32/Rsz2e887sNEv+sDx2u7qn5Ed63g80kuovvHOZN/1pvTDS1ekeRSumthb2NIz7PqptF4EfCSJNcA36K7NvpndC9Avgtc2vrxsvaw5XTHP7QL3E73MUnp7mz5p6qajTuMNE1J9gD+pKr2HXFXfk6Sx9INZTy5qn42g/2M/G9tPvRhbZJs3q41hO5TNK+pqvcOqe3z6P4GVwyjvfnCM4tJSPKHdBe0/nzUfdH81IYQLgDeOsOgGPnf2nzowyT8fpJLgMvphgb/cbTdWf95ZiFJ6uWZhSSpl2EhSeplWEiSehkW0hRklmelTbIgyR8NrO8x3X1Jc8mwkKZmtmelXUD3ngFpXjMspKlb26y0WyX5bJsh9Pwku7Tyv0hyXLoZS69tM4cCvAN4fJso8u9a2eZJTkk3q+oJayaqTPKONW8cS/Ku4Ryq1HFuKGnqTgLe1oaLdqGbGuRX27ZjgG9U1X5JXgB8gm76COgmwHs+3TQNVyf5MHAUsPOaySLbmw6fTjcT6feArwK7J7mS7l2+T66qatNfSEPjmYU0RVV1Kd2MwuPNSvs84J9bvXOArdukcABnVNWPq+pW4BYenK14rK+36UZ+RjfNxGK66SzuA45N8mLg3lk7IGkSDAtpetbMSntiX8UBY2clnujM/ufqtSmqd6Obin1f4PNTaFeaMcNCmp6JZqX9/3TT2K8ZUrq1fZDNRCY1e2i6T5LbsqrOpPsUtRl9Cp80VV6zkKahqlbRTUc+1l8Ax7XZS+8FDu3Zz21Jvprkm8C/031ex3geDZyW7lPiAhw53b5L0+HcUJKkXg5DSZJ6GRaSpF6GhSSpl2EhSeplWEiSehkWkqRehoUkqdd/A3NdrMaBdl99AAAAAElFTkSuQmCC\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"image","arguments":{}}},"output_type":"display_data","data":{"image/png":"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\n"}}],"execution_count":0},{"cell_type":"code","source":[""],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"2403c3b5-1a72-440e-9077-3f5f694d320a"}},"outputs":[],"execution_count":0},{"cell_type":"code","source":[""],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"e0c5e8b9-0954-4743-82a7-4e1781aaefe2"}},"outputs":[],"execution_count":0}],"metadata":{"application/vnd.databricks.v1+notebook":{"notebookName":"main RDD","dashboards":[],"notebookMetadata":{"pythonIndentUnit":4},"language":"python","widgets":{},"notebookOrigID":1459409874689127}},"nbformat":4,"nbformat_minor":0}
